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Compared to other trauma types, rape is associated with a high risk of developing posttraumatic 
stress disorder (PTSD). Women are at increased risk of developing PTSD compared to men 
and are also more frequently victims of sexual assault. PTSD is a complex, multifactorial 
disorder and an array of demographic, trauma-related, psychological and genetic putative risk 
and protective factors mediate or contribute to the development and course of the disorder.  
Few studies have comprehensively investigated demographic and psychological risk 
and protective factors for PTSD in a longitudinal prospective design, especially beyond the 3-
month post-rape period and in low- to medium-income countries. There are currently no known 
epigenome-wide association studies (EWASs) investigating differential methylation in relation 
to PTSD in (1) an African population and (2) a sample of rape-exposed women exclusively. 
There are also no known studies investigating longitudinal change in the hypothalamic-
pituitary-adrenal (HPA) axis associated candidate gene FK506 binding protein (FKBP5) in 
relation to PTSD in a sample of rape-exposed women exclusively. 
In this study we investigated the demographic, rape/assault-related, psychological, 
genetic (FKBP5) and epigenetic (epigenome-wide differential methylation) risk and protective 
factors associated with the development and course of PTSD symptoms over six months. Self-
report measures and specimen collection was completed at baseline (within 20 day after the 
rape), 3-months and 6-months post-rape as part of the Rape Impact Cohort Evaluation (RICE) 
study. The RICE sample consisted of 852 Black African rape-exposed women, between the 
ages of 16 and 40 years and from a low socio-economic background.  
 We found that baseline demographic, rape/assault-related and psychological protective 
factors were not significant predictors of PTSD symptoms over time. Baseline depression and 
rape stigma were significant psychological risk factors for the development and course of PTSD 
post-rape. We also identified one intergenic CpG site (cg01700569) that was differentially 
methylated in relation to PTSD status at 3-months post-rape on a genome-wide level. Thirty-
four differentially methylated regions were identified and included a region in the HPA-axis-
associated adenylate cyclase activating polypeptide 1 (ADCYAP1) gene and the 
neuroendocrine-associated brain-specific serine/threonine-protein kinase 2 (BRSK2) gene. 
Decreased BRSK2 and ADCYAP1 methylation at 3-months and 6-months post-rape was 
associated with increased PTSD symptom scores at the same time-points. Decreased FKBP5 
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methylation was a predictor of increased PTSD symptom scores at 3-months and 6-months 
post-rape. High childhood trauma and the CC genotype of FKBP5 rs1360780 resulted in 
decreased FKBP5 methylation and increased PTSD scores at baseline. 
 The study builds on existing literature, highlighting the psychological risk factors for 
the development and course of PTSD in rape-exposed women. Methylation findings also build 
on the existing literature regarding the role of epigenetics in PTSD, although the genome-wide 
finding implicating differential methylation of BRSK2 in the development of PTSD is a novel 
finding in human studies. The study provides evidence that both psychological and biological 
factors have an impact on the symptom trajectory of PTSD and that both should be considered 




















Verkragting word geassosieer met ‘n hoë risiko vir die ontwikkeling van posttraumatiese 
stresversteuring (PTSV) in vergelyking met ander tipes trauma. Vroue loop ‘n verhoogde risiko 
om PTSV te ontwikkel in vergelyking met mans en is ook meer gereeld slagoffers van seksuele 
aanranding in vergelyking met mans. PTSV is ‘n komplekse, multifaktoriese versteuring en ‘n 
verskeidenheid demografiese, trauma-verwante, sielkundige en genetiese vermeende risiko en 
beskermende faktore bemiddel of dra by tot die ontwikkeling en verloop van die versteuring.  
 Min studies ondersoek die demografiese en sielkundige risiko en beskermingsfaktore 
vir PTSV op ‘n omvattende manier deur gebruik te maak van ‘n voornemende longitudinale 
ontwerp, veral buite die periode van 3 maande na die verkragting en in lae- to middel-inkomste 
lande. Daar is huidig geen epigenoom-wye assosiasie studies (EWAS’s) wat die verhouding 
tussen PTSV en differensiële metilering ondersoek in (1) ‘n Afrika-bevolking en (2) uitsluitlik 
vroue wat aan verkragting blootgesel was nie. Daar is ook huidig geen studies wat die 
longitudinale veranderinge in die hipotalamus-pituïtêre-adrenale (HPA) as geassosieerde 
kandidaat geen FK506-bindingsproteïen (FKBP5) in verhouding met PTSV in ‘n steekproef 
van vroue wat uitsluitlik aan verkragting blootgestel was, bestudeer nie.  
In hierdie studie het ons die demografiese, verkragtings-/aanrandingsverwante, 
sielkundige, genetiese (FKBP5) en epigenetiese (epigenoom-wye differensiële metilering) 
risiko en beskermende faktore in verwant met die ontwikkeling en verloop van PTSV-
simptome oor ses maande bestudeer. Selfrapporteringskale en versameling van monsters was 
by basislyn (binne 20 dae na die verkragting), 3 maande en 6 maande na die verkragting voltooi, 
as deel van die verkragtingsimpak kohort evaluering (VIKE) studie. Die VIKE steekproef het 
bestaan uit 852 Swart vroue wat aan verkragting blootgestel was, wat tussen die ouderdom van 
16 en 40 jaar was en wat vanuit ‘n lae sosio-ekonomiese agtergrond gekom. het  
Ons het gevind dat demografiese, verkragtings/aanrandingsverwante en sielkundige 
beskermende faktore op basislyn nie PTSV-simptome beduidend voorspel het nie. Depressie 
en verkragtingsstigma op basislyn was wel beduidende sielkundige risikofaktore vir die 
ontwikkeling en verloop van PTSV na verkragting. Een CpG (cg01700569) wat op ‘n 
genoomwye vlak differensieel gemetileer was in verhouding met PTSV-status 3 maande na die 
verkragting was ook geïdentifiseer. Vier en dertig differensieel gemetileerde streke was 
geïdentifiseer en het ‘n streek in die HPA-as geassosieerde adenilaat-siklase-aktiveerende-
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polipeptied (ADCYAP1) geen en ‘n streek in die neuro-edokriene geassosieerde 
berinspesifieke-serine-drieonien-proteïen-kinase 2 (BRSK2) geen ingesluit.  
‘n Afname in BRSK2 en ADCYAP1 metilering by 3 maande en 6 maande na die 
verkragting was geassosieer met ‘n toename in PTSV-simptoomtelling by dieselfde tydpunte. 
‘n Afname in FKBP5 metilering het ‘n toename in PTSV-simptoomtelling 3 maande en 6 
maande na verkragting voorspel. Hoë kindertrauma en die CC genotipe van rs1360780 het gelei 
tot ‘n afname in FKBP5 metilering en ‘n toename in PTSV-simptoomtelling by basislyn.  
 Die studie bou voort op die bestaande literatuur en beklemtoon die risikofaktore vir 
PTSV in vroue wat aan verkragting blootgestel is. Die metilering bevindinge bou ook voort op 
die bestaande literatuur, alhoewel die genoomwye bevinding dat differensiële metilering van 
BRSK2 verband hou met die ontwikkeling van PTSV ‘n nuwe bevinding in menslike studies is. 
Die studie bewys dat sielkundige en biologiese faktore ‘n impak het op die verloop van PTSV-
simptome en dat beide oorweeg moet word wanneer intervensies vir die behandeling van PTSV 
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1.1.  INTRODUCTION 
This chapter provides an overview of trauma exposure, PTSD prevalence and rape in South 
Africa, followed by a review of the literature related to socio-demographic, psychological and 
biological factors associated with PTSD. Risk and protective factors are discussed and 
contextualized using the biopsychosocial model as theoretical framework. Risk and protective 
factors are grouped into pre-trauma, peri-trauma and post-trauma factors. The literature review 
is followed by a brief description of the methods applied in the parent study from which this 
sub-study originates and the rationale, aim and objectives of this dissertation are explained.  
 
1.1.1. Trauma exposure and PTSD prevalence in South Africa 
A nationally representative study investigating the prevalence of trauma and psychiatric 
disorders in South Africa found that 73.8% of adult South Africans have been exposed to at 
least one traumatic event in their lifetime, with an average of 4.3 traumatic events experienced 
per participant in the sample as a whole 1,2. The most commonly reported traumatic event was 
the unexpected death of a loved one (39.2%) followed by physical violence (37.6%), accidents 
(31.9%), witnessing death or atrocities (29.5%), a family member expose to trauma (14.1%), 
war events (12.2%) and sexual violence (7.6%) 1. The prevalence of trauma exposure in South 
Africa is at the higher end of the range of trauma prevalence rates (41.5%-80.7%) reported in 
a review of nationally representative studies across 24 low- to high-income countries 3. It is 
also higher than the average trauma exposure rate of 67.1% reported in the same review 3. 
One of the psychiatric disorders most commonly associated with trauma exposure, 
especially traumas involving death, threatened death, serious injury and sexual assault, is 
posttraumatic stress disorder (PTSD) 4–6. PTSD is characterized by trauma-related intrusion 
symptoms (upsetting memories, nightmares, flashbacks, emotional distress and physical 
reactivity), avoidance symptoms (thoughts/feelings, external reminders), negative alterations 
in cognitions and mood (inability to recall features of the trauma, negative thoughts, blame of 
self and others, negative affect, decreased interest in activities, feeling isolated, difficulty 
experiencing positive affect) and alterations in arousal and reactivity (irritability, aggression, 
destructive behavior, hypervigilance, heightened startle response, difficulty concentrating and 
sleeping) 7. A diagnosis of PTSD is dependent on the presence of the symptoms for at least one 
month following the traumatic event as well as significant emotional distress and functional 
impairment 7. Depression and substance use disorders also often co-occur with PTSD 8,9. 
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The South African 12-month and lifetime prevalence of PTSD following one of many 
possible traumatic events was reported as 0.6% and 2.3%, respectively 2. Exceptionally higher 
prevalence rates varying between 24%-65% have been reported among survivors of rape and 
sexual abuse 10–12. Rape is associated with a higher conditional risk for the development of 
PTSD compared to other trauma types and PTSD symptoms are often present for more than a 
year following the event 13. Identifying the social, psychological and biological risk and 
protective factors associated with PTSD following rape is of particular importance for early 
intervention and prevention of PTSD, given the high risk for PTSD associated with rape and 
the significant emotional and functional impairment associated with PTSD 14,15. 
 
1.1.2. Definition, prevalence and reporting of rape in South Africa 
According to the South African Sexual Offences and Related Matters Amendment Act 32 of 
2007, rape is defined as: “…Any person ('A') who unlawfully and intentionally commits an act 
of sexual penetration with a complainant ('B'), without the consent of B, is guilty of the offence 
of rape…sexual penetration is defined as any act which causes penetration to any extent 
whatsoever by - (i) the genital organs of one person into or beyond the genital organs, anus, or 
mouth of another person; (ii) any other part of the body of one person or, any object, including 
any part of the body of an animal, into or beyond the genital organs or anus of another person; 
or (iii) the genital organs of an animal, into or beyond the mouth of another person… it is not 
a valid defense for the accused person to contend that a marital or other relationship exists or 
existed between him or her and the complainant”  16. According to the act, adult rape can take 
on many forms e.g. acquaintance rape also known as date rape (perpetrator is known to the 
victim), stranger rape (perpetrator not known to victim), spousal rape (perpetrator is a marital 
partner), compelled rape (when the perpetrator forces the victims to have sex with each other), 
gang rape (multiple perpetrators) and corrective rape (rape as punishment for homosexuality) 
16. The underlying theme of rape, and what defines it as a criminal offence, is that the rape 
survivor did not consent to the act 16.  
 Nationally, 41,583 cases of rape were reported to the South African Police Service in 
the past year (2018-2019) and the national prevalence of rape is estimated to be 2.1% 1,17. 
However, rape statistics as reflected by the number of cases reported to the South African police 
service and are not considered indicative of the actual number of rapes occurring in a given 
year since underreporting of rape is very common 18,19. It is estimated that between 76% and 
97.9% of rape survivors do not report the offence to the police, which results in skewed 
prevalence rates and many non-convicted perpetrators 18,19. Barriers to reporting rape include  
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fear of being accused of lying; shame, guilt and embarrassment; feeling pity or love towards 
the perpetrator; fear of retaliation; fear of the stigma associated with rape and being ostracised; 
fear of loss of income provided by the perpetrator; structural challenges in accessing police 
services, lack of trust in police and the justice system and fear of secondary victimisation 20.  
 Reporting rape and regaining a sense of safety, control and belief in the justice system 
is further complicated by the low conviction rate of perpetrators 21. A South African regional 
study found that only half of reported rapes (n = 2000) resulted in arrests, 43% resulted in 
criminal charges, 17% went to trial and only 4% resulted in convictions 22. The low conviction 
rate is, in part, due to an overburdened criminal justice system but also due to 
limited/incomplete evidence provided by medical, laboratory and legal personnel 21,22. 
Disbelieving attitudes may further contribute to under-reporting and low conviction rates and 
is likely rooted in stigmatising attitudes towards rape (e.g. the victim should have done more 
to prevent the rape, was provoking the perpetrator, did not do enough to resist the rape etc.) 21. 
 A concerted effort to reduce the prevalence of rape and increase the prosecution and 
conviction of offenders was made by the National Prosecuting Authority (NPA) when the 
Sexual Offences and Community Affairs (SOCA) unit  launched the Thuthuzela project and 
opened the first Thuthuzela Care Center (TCC) in 2006 23,24. TCCs offer comprehensive care 
to rape survivors including a medical examination, prophylactic medication, a statement taken 
by a police officer, psychological counselling and general non-judgemental support 23,25. There 
are currently 54 TCCs across the nine provinces of South Africa and participants for this study 
were recruited from four of these TCCs in and around the city of Durban in KwaZulu Natal, 
South Africa 24. Although TCCs have made a vital contribution to addressing the needs of rape 
survivors, rape prevalence and its associated diseases (e.g. HIV and other sexually transmitted 
infection) and disorders (e.g. PTSD, depression, anxiety, alcohol abuse) remain a significant 
public health concern 26,27.  
 
1.1.3. The biopsychosocial model and the history of PTSD 
Several accounts of PTSD-related symptomatology are recorded in early English literature 
dating back as far as 440 BC, but the disorder was first recognized by psychiatrists when 
physically unharmed World War I soldiers displayed extreme anxiety and fear when facing 
reminders of mutilated or deceased soldiers who perished in combat 28. The number of soldiers 
displaying psychiatric symptoms far outweighed the number of soldiers being treated for 
physical injuries which indicated that the trauma associated with combat exposure had a 
significant impact on the health of the soldiers 29. The term ‘shell shock’ was used to describe 
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the emotional shock, fear, dissociation, amnesia, muteness and catatonic behavior often 
observed in soldiers 28. Although there were no know effective treatment for shell shock at the 
time, psychiatrists did experiment with electrotherapy and psychotherapy which indicates that 
it was believed that the disorder was rooted in both psychological and physical abnormalities 
30.  
 World War II differed from World War I since military attacks were no longer targeted 
at soldiers only but also at civilian populations e.g. bombings, mass executions and 
detaining/torturing civilians in concentration camps 28. This led to the discovery that emotional 
disturbances following combat exposure was not limited to soldiers since civilians also 
displayed distressing symptoms 29. It was also during this time that a distinction between the 
symptoms associated with traumatic stress or acute stress reactions and posttraumatic stress 
disorder started to emerge 28. The importance of early intervention and elements of exposure 
therapy was also discovered since soldiers treated at the battleground showed higher recovery 
rates (measured by their ability to return to battle) compared to those sent away from the 
battleground 31. Some psychiatrists at the time believed that the symptoms of distress originated 
from cardiovascular and vasomotor abnormalities, while others followed a psychoanalytical 
approach in explaining the symptoms 29.  
The end of World War II was followed by decades of research on the etiology, 
presentation and course of posttraumatic stress and many studies reported chronic 
posttraumatic stress symptoms in military and civilian samples 28,29. The emotional distress 
observed in soldiers exposed to the Vietnam war further emphasized that the symptoms 
experienced by war veterans were distinct from other known psychiatric disorders 32. PTSD 
was finally recognized as a distinct disorder that developed following trauma exposure when it 
was included as a diagnostic category in the DSM-III in 1980 33. 
In the same year that PTSD was officially recognized as a distinct disorder, the 
biopsychosocial model gained popularity when the American psychiatrist George Engel called 
for a move away from disease-orientated medicine and towards patient-orientated medicine 34. 
Patient-orientated medicine would not only consider physical symptoms, but also the 
interaction of basic biological aspects of disease (changes in body chemistry and biomarkers of 
health) in conjunction with psychological aspects (learning, thoughts, mood, thinking, 
personality, trauma exposure, etc.) and the social/environmental/demographical context (socio-
economic status, gender, social support, impact of behavior of significant others, access to 
healthcare etc.) of the patient 34. Evidence linking psychological and social factors to the 
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diagnosis and recovery from disease lead to the mainstream adoption of the biopsychosocial 
model 34–37.  
The biopsychosocial model, compared to the earlier biomedical model, was of 
particular importance in psychiatry since the field had been devalued by many physicians 
because the origin of disorders could not be traced back to cellular and molecular irregularities 
38. This view changed to some degree with the discovery of the first antipsychotic 
(chlorpromazine) and tricyclic anti-depressant (iproniazid) in the 1950’s 39. Today there is a 
growing body of literature linking physical abnormalities to symptoms of PTSD, mostly due to 
technological advances in imaging techniques and in neuropsychiatric genetics 40–42. Although 
substantial evidence exists linking psychiatric symptoms to neurological functions, some 
remnants of the biomedical model remain today in the form of stigma surrounding psychiatric 
disorders 43. 
In addition to biological factors associated with PTSD, various social and psychological 
risk and protective factors have been linked to the onset and duration of PTSD 40–42. These 
factors can be grouped into pre-trauma, peri-trauma and post-trauma social, psychological and 
biological factors 44. Those most consistently associated with PTSD in the context of rape and 
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1.2.  PRE-TRAUMA FACTORS ASSOCIATED WITH PTSD 
Various pre-trauma socio-demographic, psychological and biological factors have been 
associated with PTSD risk. These risk factors are discussed below.  
 
1.2.1. Pre-trauma socio-demographic factors 
The demographic factors most commonly investigated as risk/protective factors for the 
development of PTSD are age, gender, relationship status, education and income/employment 
44,45. Studies investigating large samples and systematic reviews have generally found that 
lower education, lower income and being single, divorced or widowed are associated with 
increased PTSD symptom severity 41,44–46. The association between lower education/income 
and PTSD is most likely due to decreased availability of resources to cope with the trauma and 
an environment where trauma and violence occur more frequently 47. Being single, divorced or 
widowed may decrease social support as a positive coping mechanism following trauma 45. 
Findings related to age as a predictor of PTSD symptom severity are inconsistent 41,46. Some 
studies report that lower age is associated with increased risk for PTSD 46 while a study 
comparing urban and rural samples found that older age was associated with PTSD in both the 
urban and rural groups 41.  
 By far the most consistent finding, although contested by some, is the association 
between female gender and PTSD 44,45. Some studies report a two-fold increase in PTSD 
severity in women while others report as much as a seven-fold increase 41,44,45,48. Whether 
women are more likely to develop PTSD following trauma exposure or are just more likely to 
disclose the trauma and seek help, remains unclear 49. It has also been found that women are at 
increased risk for PTSD but only when exposed to specific trauma types such as physical and 
sexual assault 45. Gender-specific characteristics of the central nervous system and the 
endocrine system may further confer risk for PTSD in women and are discussed in the section 
dedicated to post-trauma risk factors 50,51. 
 
1.2.2. Pre-trauma psychological factors 
Childhood trauma and especially multiple, chronic and repeated trauma is significantly 
associated with adult revictimization and PTSD 52–57. Childhood sexual abuse has been 
associated with adult sexual and physical abuse and an increased likelihood to develop PTSD 
following revictimization in a female rape-exposed sample 58. Childhood abuse has also been 
associated with more complex and severe PTSD symptoms following revictimization 59,60. 
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Children exposed to chronic abuse are likely to display disturbances in affective and 
interpersonal self-regulation 60, e.g. inability to form safe and appropriate boundaries with 
others, low self-esteem and more tolerance towards abuse 58,59,61–63. Emotional development 
during childhood is therefore negatively affected by abuse and the consequential maladaptive 
coping, social and emotional skills predispose child abuse victims to adult revictimization 64,65.   
Cumulative lifetime trauma may involve multiple exposures to the same trauma type or 
exposure to several different trauma types e.g. natural disasters, fire or explosion, transport 
accidents, other serious accidents, exposure to toxic substances, physical assault, assault with 
a weapon, sexual assault, unwanted sexual experiences, combat/war exposure, captivity, severe 
human suffering, sudden violent death, sudden accidental death and serious injury, harm or 
death 7,66. Increased exposure to lifetime trauma has been associated with greater PTSD 
symptom severity and complexity in studies investigating participants exposed to various 
trauma types and those investigating sexual assault and rape only 61,67–69. Cumulative lifetime 
trauma may result in distrust of others and a view of the world as a dangerous place 61,62,68,69. 
This association me be strengthened with every additional trauma exposure and may decrease 
positive coping styles and increase risk for PTSD and other psychiatric disorders 62,68.  
 
1.2.3. Pre-trauma biological factors and disease 
A genetic predisposition may increase vulnerability to PTSD as well as pre-existing medical 
conditions interacting with biological mechanisms implicated in PTSD (e.g.  hypothalamic-
pituitary-adrenal axis functioning and neurocircuitry) 40,70–72. Various diseases may also have 
an impact on quality of life and indirectly affect mental health 73. Chronic diseases in particular, 
may increase stress through persistent fears and worries about the long-term impact of the 
disease, fear of dying, fear of medical procedures, long-term adverse side-effects of chronic 
medication use and an inability to come to terms with a diagnosis 74. HIV is of particular 
concern in the context of rape given that it is sexually transmitted 75. It is also of particular 
concern in the South African context given the high prevalence rate in the country 76. 
Heritability, genetic variation and HIV infection as risk factors for the development of PTSD 
are discussed below.  
 
1.2.3.1. Heritability of PTSD and genetic variation 
A number of twin studies have investigated the heritability of PTSD using an overlapping 
sample of male, predominately Caucasian, North American Vietnam veterans 40. These studies 
have reported a heritability rate of between 23% and 30% for PTSD and a 62.5% heritability 
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rate for PTSD-depression comorbidity 77–79. Another study investigating the same Vietnam 
veteran sample reported a 41% heritability rate for internalizing disorders (depression, 
dysthymia, generalized anxiety disorder, panic disorder and PTSD) and a 69% heritability rate 
for externalizing disorders (antisocial personality disorder, alcohol abuse/dependence, drug 
abuse/dependence and PTSD) 80. Only one study has investigated a mixed gender sample and 
reported a 38% heritability rate for PTSD 81. Heritability in a North American female sample 
was investigated in one study and a much larger heritability rate, compared to male studies, of 
71% was reported in this study 82. The higher heritability rate may be explained by the age of 
participants since trauma exposure was measured when participants were between 12 and 19 
years old and PTSD was measured when participants were 21.7 years old 83. Childhood and 
adolescent trauma exposure are associated with an increased risk for PTSD likely due to 
heightened brain plasticity during these developmental periods 83,84. Prior twin studies included 
older participants (30-53 years old) with trauma exposure predominately measured in 
adulthood 77–79.  However, this increased heritability rate in the female sample also corresponds 
to a prior finding indicating that women have a two to three-fold increased risk for developing 
PTSD following trauma exposure compared to men 50,85.  
 Although twin studies provide evidence of the general heritability of PTSD by 
comparing PTSD prevalence in monozygotic twins and dizygotic twins, they do not provide 
evidence for the specific genes conferring risk for PTSD 77. Single nucleotide polymorphism 
(SNP) heritability studies investigate the proportion of common, genome-wide SNPs associated 
with PTSD in unrelated individuals 86. The first large SNP heritability study in PTSD (N = 
20 070), which comprised seven African American, nine European American, one Hispanic 
American and two South African samples, reported a statistically significant 29% SNP 
heritability rate for PTSD in female participants 87. Heritability among male participants was 
7% but this finding did not reach statistical significance 87. They also investigated single gene 
variants and gene pathways as predictors of PTSD, but none of the gene variants or pathways 
investigated reached genome-wide significance 87. This study was expanded upon to include 
data from 60 ancestrally diverse populations (n = 206 665) 88. A SNP heritability rate ranging 
between 5% and 20% was observed, with this effect being driven by female participants 88. 
Five SNPs, annotated to zinc finger DHHC-type palmitoyltransferase 14 (ZDHHC14), parkin 
RBR E3 ubiquitin protein ligase (PARK2), kazrin periplakin interacting protein (KAZN), 
transmembrane protein 51 antisense RNA 1 (TMEM51-AS1) and zinc finger protein 813 
(ZNF813) reached genome-wide significance in the European ethnicity subset, while five 
SNPs, annotated to long intergenic non-protein coding RNA 2335 (LINC02335), 
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microRNA5007 (MIR5007), transcribed ultra-conserved region 338 (TUC338), long intergenic 
non-protein coding RNA 2571 (LINC02571) and human leukocyte antigen B (HLA-B), reached 
genome-wide significance in the African ethnicity subset 88. The two large genome-wide 
association studies (GWASs) expanded on the evidence implicating heritability in the etiology 
of PTSD specifically in females, but also indicates that several SNPs may be involved in the 
development of PTSD and risk alleles may differ depending on ethnicity 87. 
 
1.2.3.2. HIV infection 
Living with HIV may have an impact on various significant domains of life e.g. affordability 
and access to healthcare, being healthy enough to earn an income, being ostracized by the 
community, the prospect of having children and intimate partners, etc 89. The fear of being 
infected with HIV following rape may cause significant distress to rape survivors which may 
add to the adverse effects of rape on mental health 90. Living with HIV has also been associated 
with a significant increase in PTSD in a study investigating samples from South Africa, Nigeria, 
Australia, Sweden and the USA 91–93There are several shared underlying risk factors that may 
explain the relationship between PTSD and HIV e.g. both PTSD and HIV are associated with: 
an increased prevalence of sexual abuse, physical abuse,  intimate partner violence, 94 and risk 
behavior 91; stigma and reduced social support 95; neuroinflammation, altered hippocampal 
morphology, disruption in dopamine transmission, and altered hypothalamic-pituitary-adrenal 
(HPA) axis functioning 96. Considering HIV status is therefore important when investigating 
the etiology and trajectory of PTSD, given the distress it may cause and the shared risk factors 
between the two conditions.  
 
1.3.  PERI-TRAUMA FACTORS ASSOCIATED WITH PTSD 
Various trauma-related risk factors for PTSD have been investigated in general community 
samples and rape-exposed samples with most studies report non-significant or inconsistent 
findings. Trauma-related factors that have been consistently found to be associated with PTSD  
include perceived life threat during the exposure 44,45,48,97, length of the event 97 and malicious 
intent to cause harm 45,48. Malicious intent to cause harm is also associated with chronic PTSD 
and less spontaneous recovery 45. Sexual assault and rape in itself is also a risk factor for the 
development of PTSD compared to other trauma types such as accidents, sudden death of a 
loved one, physical assault, robbery and bereavement 98–100.  
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1.4.  POST-TRAUMA FACTORS ASSOCIATED WITH PTSD 
Various post-trauma psychosocial (social support, stigma, resilience, perceived stress, alcohol 
use, depression) and biological risk and protective factors have been associated with PTSD. 
Biological studies have predominately focused on the nervous system, endocrine system and 
immune system. These risk and protective factors are discussed below. It should be noted that 
some of the post-trauma risk and protective factors discussed could serve as both pre-trauma 
and post-trauma factors but longitudinal studies proving causality are needed to elucidate the 
relationship between these factors (especially epigenetic risk factors) and their role in the 
etiology and trajectory of PTSD following rape.  
 
1.4.1. Post-trauma psychosocial risk and protective factors 
Although women exposed to rape are at high risk of developing PTSD not all will go on to 
develop the disorder 10–12. This suggests that variables other than the traumatic event are 
involved in the development of PTSD. Various psychosocial risk and protective factors have 
been associated with PTSD in multiple studies investigating various trauma types 101. Post-
trauma psychosocial risk factors include: perceived stress 102; stigma 103; alcohol use 8,9; and 
depression 104–106. Psychosocial protective factors include: social support 101,107,108; and 
resilience 109,110. These psychosocial risk and protective factors are discussed below. 
 
1.4.1.1. Perceived stress 
Perceived stress can be defined as a subjective appraisal of common situations in life as either 
stressful or not 102. Women report significantly higher levels of perceived chronic stress and 
daily stressors compared to men 111. Higher levels of perceived stress are associated with 
increased PTSD symptom severity and greater vulnerability for the development of PTSD 102. 
Early childhood trauma and insecure attachment is also associated with a higher tendency to 
appraise events as stressful 112. 
 
1.4.1.2. Rape stigma 
Rape and sexual assault is often characterised by stigmatising belief  and attitudes e.g. some 
may belief that the victim could have done more to prevent the rape or that the victim provoked 
the perpetrator 62,113–116. Victim blaming, self-blaming, shame, embarrassment and decreased 
respect for victims are also forms of rape stigma and has consistently been found to be 
associated with PTSD in rape and sexual assault studies 61,114–116. Knowing the perpetrator is 
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especially linked to rape stigma and victim blaming from family members and friends 62,113–116. 
Less severe physical injuries has also been linked to stigmatising beliefs from health-care 
providers, police officials and legal representatives 59,62,69,117,118. Not only is stigma linked to 
decreased mental health treatment-seeking but it is also linked to decreased physical health 
treatment-seeking and access to post-exposure prophylaxis for the prevention of HIV 26.  
 
1.4.1.3. Alcohol use 
A 25.3% PTSD prevalence rate has been found among treatment-seeking participants with 
alcohol or drug abuse/dependency 119. Elevated PTSD symptom trajectories have also been 
linked to alcohol use disorders in rape and sexual assault survivors 120 and childhood trauma 
has been identified as a risk factor for alcohol or substance abuse/dependence in adulthood 121. 
It has been hypothesized that substance abuse increases susceptibility to PTSD following 
trauma exposure, that individuals with comorbid PTSD and substance abuse/dependence are 
psychologically vulnerable for mental health disorders, and that substance abuse or dependence 
is a form of self-medication in the aftermath of trauma  122,123. Sexual assault victims who 
receive more negative social reactions are also more likely to develop PTSD and alcohol 
abuse/dependence problems 115.  
 
1.4.1.4. Depression 
Depression is often diagnosed among individuals who have experienced trauma 104–106. PTSD 
and depression comorbidity is common among survivors of trauma, with 36% to 51% of those 
diagnosed with PTSD also meeting diagnostic criteria for depression 104–106. Individuals with 
both PTSD and depression experience more severe psychological symptoms 104,105, are more 
likely to have a history of trauma 105 and have lower levels of social support 104. Rape, 
interpersonal violence and sexual violence have been identified as risk factors for comorbid 
PTSD and depression 59,69,101,118,124,125. Women survivors of sexual assault are four to five times 
more likely to suffer from depression and anxiety 125 and women with a history of sexual assault 
are more likely to attempt suicide during their lifetime 126. 
 
1.4.1.5. Social support  
Lower levels of social support are often associated with higher PTSD symptom severity 
101,107,108. Social support is viewed as a stress management or coping strategy and 
perceived/actual social support from significant others play a significant role in reducing PTSD 
symptom severity 107. Lower social support is also linked to increased victim blaming/shaming 
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and the use of avoidant coping strategies 127. Women are more likely to receive negative 
responses from family and friends following a traumatic event compared to men 128 and 
negative social reactions are linked to increased PTSD symptom severity 61,128. Social support 
is also important in re-establishing trust in others and viewing the world as a safe and reliable 
place following trauma exposure, especially following interpersonal and sexual traumas 59. 
 
1.4.1.6. Resilience 
Resilience can be defined as intrinsic, possibly modifiable, biological and psychological 
characteristics that protect survivors of trauma against the development of psychiatric disorders 
129. Lower levels of resilience are often associated with higher levels of PTSD symptom severity 
109,110. Protective factors against the development of PTSD have been identified and include: 
strong religious beliefs 130–132; having a sense of humour 130; having patience and tolerance 130, 
disclosure of trauma to others and bonding with fellow survivors 130,133; positive coping styles 
61,134; self-efficacy, self-confidence and self-esteem 131,133,134; parental affection and secure 
attachment 130,135; and a high internal locus of control 134. Individuals with higher levels of 
resilience may also avoid adverse coping mechanisms such as alcohol use and negative 
appraisal of the trauma and may find it easier to access social support and find meaning in the 
event 59,61,136,137,68,69,107,115,118,120,132,133. 
 
1.4.2. Post-trauma biological factors 
There is a growing body of evidence implicating biological processes in the aetiology and 
trajectory of PTSD, especially changes occurring in the nervous system, endocrine system and 
the immune system 42,138–140. Epigenetics is the study of heritable phenotypic changes that do 
not involve modification of the genetic code 141. In the last decade, there has also been 
increasing evidence suggesting that epigenetic factors potentially mediate the impact of 
environmental trauma exposure and gene expression resulting in altered neurological, 
endocrine and immune processes 138,139. Epigenetic changes occur mainly through DNA 
methylation, histone modification and mechanisms involving non-coding ribonucleic acids 
(ncRNAs) 142. Although evidence exists linking diseases and psychiatric disorders to histone 
modification and ncRNAs, DNA methylation changes remains the most widely studied 
epigenetic mechanism 142. This is most likely due to: (1) the role of DNA methylation in 
regulating cell differentiation during embryogenesis, gametogenesis and development, but 
remaining relatively stable once differentiation has occurred; (2) DNA methylation patterns, 
although relatively stable, can change in response to changing environmental conditions and; 
Stellenbosch University  https://scholar.sun.ac.za
39 
 
(3) the technological advancements made in the study and replication of epigenetic findings in 
recent year 138,141,143. 
 
1.4.2.1. Brief overview of DNA methylation 
DNA methylation refers to the addition of a methyl group (CH3) predominantly to cytosine 
nucleotides142. CpG islands are of specific interest in methylation studies since: (1) more than 
50% of the nucleotide sequence consists of CpG sites; (2) CpG islands are often unmethylated; 
and (3) CpG island are usually located in the promoter regions of genes 138,144. Promoter regions 
are located close to transcription start sites (TSS) and binding of transcription factors to the 
TSS is essential for DNA expression 145,146. Methylation of promoter regions is generally 
associated with decreased gene expression and silencing of genes 145,146. DNA methylation and 
associated binding proteins may also result in histone deacetylase which condenses chromatin 
and inhibits transcription factors from binding to DNA and thereby further reduces expression 
of the gene 147. Concordant methylation is important in regulating and differentiating cells, and 
also for long-term environmental adaptation and evolution, but when gene methylation profiles 
are discordant, they may  result in increased risk for diseases such as autoimmune disorders, 











Figure 2: DNA methylation as a regulator of gene expression. Addition of a methyl group 
(CH3) to CpG sites in the promoter region of a gene results in decreased expression of the gene. 
DNA methylation and histone deacetylase condense chromatin and further inhibits 
transcription of genes since RNA polymerase II (RNA pol II) is unable to bind to DNA and 
transcribe messenger RNA. Reprinted from “Insects as models to study epigenetic basis of 
disease” by K Mukherjee, RM Twyman, A Vilcinskas, 2015, Progress in Biophysics and 
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1.4.2.2. Methods to investigate DNA methylation 
Earlier studies investigating DNA methylation in relation to PTSD mainly relied on hypothesis-
driven studies investigating differential methylation at CpG sites in single genes, which were  
selected based on evidence linking the protein coded by the gene (e.g. cortisol, serotonin, 
epinephrine) to PTSD 150. These studies relied on laboratory methods such as 
immunoprecipitation, bisulfite conversion and pyrosequencing 138. Many studies investigating 
candidate genes reported significant associations between DNA methylation and PTSD 
status/severity which resulted in valuable insights into the role of methylation as a potential 
mediator of psychiatric symptoms (see Table 1 for details) 151. However, CpG site-specific 
findings identified in this way have rarely been replicated 152,153. Candidate gene studies also 
come with unavoidable limitation, e.g. they are based on a priori knowledge and genes not 
expected to be related to the biology of the disorder of interest are overlooked; the gene 
investigated may be relevant to PTSD but the effect may be driven by genes upstream or 
downstream of the gene under investigation; the selected CpG sites usually represents a small 
section of the gene only and are usually located in the promoter region of the gene while 
methylation of other regions in the gene may also contribute to the phenotype of interest; most 
candidate gene studies are underpowered and heterogeneity in terms of trauma exposure, socio-
economic status, age, ethnicity etc. dilutes the findings since the aforementioned factors may 
be related to differential methylation in and of themselves  154–156.  
 The alternative to candidate gene designs are hypothesis-free, data-driven methods 
investigating methylation across the entire genome 157. While technologies such as whole-
genome bisulfite sequencing exist, it is questionable if and when large enough PTSD cohorts 
will exist in order to truly have adequate statistical power to apply these methods 157,158. High-
density microarray chips are considered representative of the genome and are currently the 
preferred method for investigating genome-wide differentially methylated genes 138. 
Microarray chips can investigate close to a million sites across the genome and stringent criteria 
(e.g. p < 5 × 10-8) are used to determine genome-wide statistical significance 159. Genome-wide 
studies are not confined by prior knowledge and may result in identification of novel genes and 
pathways involved in the aetiology of PTSD 138,158. Secondary analyses using laboratory 
techniques previously employed to investigate candidate genes can further substantiate the 
finding resulting from genome-wide studies and may also expand the findings by investigating 
additional CpG sites not represented on microarray chips 138,158. However, genome-wide studies 
are not without limitations and have been criticised for producing small effect sizes and non-
replicable results 138. To date, only twelve studies investigating methylation in relation to PTSD 
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have followed a genome-wide approach 160,161,170–173,162–169. While most genome-wide studies 
have reported valuable and significant finding, few have replicated findings, and only two have 
followed a longitudinal design 162,163. Similar to candidate gene studies, the discrepancies in 
findings is most likely due to small sample sizes and heterogeneity related to trauma exposure, 
PTSD measure, socio-economic status, age, ethnicity etc, within and between studies 159.  
 The findings of candidate gene and genome-wide studies investigating differential 
methylation in relation to PTSD are discussed below (for a detailed review of genome-wide 
studies see chapter 4). The differentially methylated genes previously identified are group into 
findings related to: (1) the central nervous system; (2) the endocrine system and; (3) the immune 
system. A summary of the methodology and finding of candidate gene studies investigating the 
relationship between PTSD and methylation is presented in Table 1.  
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load in group with 
PTSD. 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
46 
 
and 77 without 
PTSD  
American (14%), 
7 other (7%). 
(60%); 45.32 
years 
          









PTSD and 321 
without PTSD 
War exposed Bosnian 
civilians  












↑ Methylation in 
group with PTSD at 
CpG 3 & 12. 
 











30 with current or 
life-time PTSD 






traumas as motor 
vehicle accidents, 
participation in a 
peacekeeping 
mission, assault with 
a weapon, physical 
and/or sexual abuse 























↓ Exon 1B 
methylation across 29 
CpG sites in group 
with PTSD; ↓ 
methylation at CpG 
2-4, 11 & 14 in group 
with PTSD. 
 
↓ Exon 1C 
methylation across 54 
CpG sites in group 
with PTSD; ↓ 
methylation at CpG 
40-41 and ↑ 
methylation at CpG 
51. 









28 with PTSD 
17 without PTSD 
Community members 
and treatment seeking 
women exposed to 
intimate partner 
violence 












↓ Mean methylation 




          
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
47 
 
























Not significant across 
52 CpG sites. No site-
specific finding.  




























↓ Methylation at 
CpG3 ↑ PTSD 
symptom severity. 
          











9 Vietnam veterans 
and 7 veterans 
returning from Iraq or 
Afghanistan – all 
veterans were 




















↑ Methylation (across 
39 CpG sites) ↓ 
PTSD symptom 
severity.  









61 with PTSD 
61 without PTSD 



















↓ Methylation in 
group with PTSD 
across 39 CpG sites. 
↓ Methylation in 
group with PTSD at 
CpG23 & 39. 




















Not significant across 
26 CpG sites. No site-
specific findings. 
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1 Identified using the GENECODE database; 2 identified using the Human Genome 19 (HG19) build from the Genome Reference Consortium 
 
Abbreviations:  
PTSD Symptom Scale (PSS); pituitary adenylate cyclase-activating polypeptide 1 receptor 1 (ADCYAP1R1); transcription start site (TSS); not 
otherwise specified (NOSP); not specified (NS); posttraumatic stress disorder (PTSD); pituitary adenylate cyclase-activating polypeptide 1 
(ADCYAP1); Clinician-Administered PTSD Scale (CAPS); absent in melanoma 2 (AIM2); PTSD Checklist (PCL); brain-derived neurotropic 
factor (BDNF); catechol-O-methyltransferase (COMT); FK506 binding protein (FKBP5); 5-hydroxytryptamine receptor 3A (HTR3A); 
interleukin 12B (IL12B); mannosidase, alpha class 2c member 1 (MAN2C1); Mini International Neuropsychiatric Interview (MINI); monoamine 
oxidase A (MAOA); nuclear receptor subfamily 3, group C (NR3C1); Self-Report Inventory for PTSD (SRIP); Post-Traumatic Diagnostic Scale 
(PDS); oxytocin receptor (OXTR); spindle and kinetochore-associated protein 2 (SKA2); 3’ Untranslated Region (3’UTR); solute carrier family 
6, member 3 (SLC6A3); solute carrier family 6, member 4 (SLC6A4). 
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1.4.2.3. The central nervous system  
Since many PTSD symptoms are rooted in cognitive functions (e.g. memory, learning, fear) it 
is likely that brain regions and neurotransmitters controlling these functions are altered in PTSD 
198. Neuro-imaging studies and successful pharmacological treatment of PTSD with 
pharmaceuticals targeting neurotransmission, provides further evidence implicating 
neurological systems in the aetiology and trajectory of PTSD 42,198. The neurocircuitry of 
PTSD, evidence from neuro-imaging studies, neurotransmitters (catecholamines, serotonin and 
oxytocin), and differentially methylated genes associated with PTSD are discussed below. 
 
1.4.2.3.1. Neurocircuitry and PTSD 
Advancements in structural and functional magnetic resonance imaging (MRI) technology have 
contributed greatly to understanding the neurocircuitry of PTSD and affected brain regions in 
recent decades 198. The brain regions most consistently identified as being altered in PTSD 
include the hippocampus, amygdala, hypothalamus and prefrontal cortex 198,199. The 
hippocampus is involved in processing, interpreting, organising, categorising and 
contextualising memories 200. Memories stored in the hippocampus are largely coherent and 
placed in sequential time-dependent order 201. When faced with a threat, the hippocampus is 
supressed and the amygdala is activated 200. The amygdala forms part of the limbic system and 
is involved in the processing of fearful emotions and initiating the fight-or-flight response via 
the hypothalamus 199. When facing a threat, the hippocampus is not able to process and 
contextualise memories as it would under normal circumstances and environmental cues 
(including visual, auditory, olfactory, tactile and gustatory cues) previously identified as non-
threatening may be recoded in memory as threatening cues 202. This may result in ongoing 
activation of the amygdala and the fight-or-flight response when presented with a trauma cue, 
but in the absence of the actual threat 202.  
Intrusive thoughts and memories of the event may resurface when the hippocampus 
attempts to consolidate previous non-threatening memories connected to environmental cues 
and the newly formed threatening memories connected to the same environmental cues 200. 
Avoiding trauma cues and the resulting memories may strengthen the negative emotions 
association with these cues while at the same time diminishing the neutral non-threatening 
memories previously associated with these cues 201. Engaging with a trauma memory, in the 
absence of an actual threat, may facilitate reconsolidation of the memory and may decrease the 
intensity of the emotional response associated with that memory 203. This process may 
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eventually result in fear extinction, where the cue is no longer associated with fear and 
activation of the amygdala and the fight-or-flight response 200. The prefrontal cortex (involved 
in higher order brain functioning) is the brain region where fear and response to fear is learned 
(fear conditioning) and can be unlearned (fear extinction) 198. The prefrontal cortex is connected 
to the amygdala and mediates the fear response by inhibiting the fight-or-flight response when 
a trauma cue is present, but a real threat does not follow 198. The prefrontal cortex and 
hippocampus are also closely connected, the hippocampus stores and recalls memories and the 
prefrontal cortex plays out the memories in the conscious mind where one is able to think, 
organise, plan, restructure and modify memories  42,202. Metacognitive functions such as reality 
testing is also governed by the prefrontal cortex and can become impaired in PTSD e.g. a 
flashback or trauma memory may be relived and perceived as playing out in real-time rather 
than being interpreted as a past event or memory 204.  
 
1.4.2.3.2. Neuroanatomical alteration and differential methylation in PTSD 
The majority of studies investigating structural neuroanatomical differences between 
individuals with and without PTSD have found an association between reduced hippocampal 
volume and PTSD status/symptom severity 205–213. Functional MRI studies on hippocampal 
activation have produced mixed results, with some showing increased activation of the 
hippocampus when presented with fearful stimuli, while others show decreased activation 
210,213–217.  
 Inconsistent findings related to amygdala volume have also been reported in structural 
MRI studies with some studies reporting increased volume 210,213,218–221 and others reporting 
decreased volume related to PTSD 213,222–224 On the other hand, functional MRI studies have 
generally reported consistent results linking increased amygdala activity to PTSD status when 
presented with trauma-related stimuli 213,214,230,215,217,219,225–229  
 Studies investigating structural and functional differences in the prefrontal cortex in 
relation to PTSD are less common and are complicated by the various sub-fields of the 
prefrontal cortex and their associated functions 231. In general, PTSD has been associated with 
decreased volume in the prefrontal cortex 210,213,232–235 and with decreased activation when 
presented with fearful stimuli 210,213,240,214,218,219,229,236–239.  
 The mechanisms through which brain regions are affected in PTSD are not clearly 
understood, but it is thought that increased exposure to catecholamines and glucocorticoids 
may result in neuronal damage and degeneration, specifically in the hippocampus 241. Increased 
methylation of  brain-derived neurotropic factor (BDNF, chr11:27744279-27744292, exon1, 
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promoter region), which supports neuronal differentiation, maturation and survival, has been 
associated with PTSD in one study 177,242 and decreased expression of BDNF have been 
reported in many neurodegenerative diseases, such as Parkinson’s disease, multiple sclerosis 
and Huntington’s disease 243 as well as psychiatric disorders including PTSD 244, obsessive-
compulsive disorder 245–247 and panic disorder 248,249. BDNF also contains a common functional 
SNP (rs6265, exon 4) which has been associated with PTSD in several studies 250. Substitution 
of the G allele with the A allele in rs6265 results in the conversion of the amino acid valine 
(Val) to methionine (Met) at the 66th amino acid position in the gene, and hence the name 
Val66Met as it is commonly referred to 251. The Met66 allele is associated with decreased 
secretion of BDNF compared to the Val66 allele, and the Met66 allele has been found to be a 
risk factor for the development of PTSD 252–257. Reduced expression of BDNF is associated 
with hippocampal atrophy which adversely affects hippocampal driven memory functions and 
fear extinction and prolongs PTSD recovery 250,258–262. 
Differential methylation of several other genes associated with neuronal development 
growth and maintenance have also been associated with PTSD 163,164. Epigenome-wide 
decreased methylation of the nerve growth factor (NGF; chr1:115844232, 5’UTR) 164, ninjurin 
(NINJ2; chr12:739980 and 740100, promoter associated), myelin transcription factor 1 like 
(MYT1L; chr2:1817351, body/opensea), paired box 8 (PAX8; chr2:113992921, 
TSS200/TSS1500/3'UTR/5'UTR) and ring finger protein 39 (RNF39; chr6:30039403, 
30039432, 30039435 and 30039466, island in body) genes was found to be associated with 
PTSD in veteran studies 163.  
NGF regulates growth and survival of sympathetic and sensory neurons and differential 
methylation of the gene may enhanced the sensitivity of the sympathetic nervous system (SNS) 
263–265. NINJ2 is involved in axonal regeneration following injury and may represent neuronal 
compensation in brain regions affected by accelerated apoptosis 266–270. The NINJ2 gene has 
also been linked to the development of Alzheimer’s disease and borderline personality disorder 
in previous studies 270,271.   
Less is known about the function of MYT1L, PAX8 and RNF39, although MYT1L and 
PAX8 have been associated with central nervous system development 272,273 and RNF39 has 
been associated with increases long-term neuronal potentiation in animal studies 274,275. SNPs 
in MYT1L have been linked to the development of depression and schizophrenia 270,276 and 
SNPs in PAX8 have been implicated in sleep disturbances, schizophrenia and PTSD in prior 
studies 171,277,278. Differential methylation of BDNF, NGF, NINJ2, MYT1L, PAX8 and RNF39 
potentially mediates the functional and structural neuroanatomical differences observed in 
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PTSD although further research (specifically neuroimaging genetics studies) is needed to 
provide insight into the association between differential methylation and altered brain regions 
279. 
Differential methylation of genes involved in providing the neuronal structure for 
neurotransmission may further add to altered neuronal development 198. Epigenome-wide 
decreased methylation of brain-specific serine/threonine-protein kinase 1 (BRSK1; 
chr19:55813339, North shore of island in the promoter region) was associated with PTSD in a 
study on North American veterans 164. BRSK1 is highly expressed in the brain, specifically in 
the cerebellum, hippocampus and hypothalamus, and is involved in neuronal polarity and 
synaptic development 280. BRSK1 is thought to be involved in mediating the release of 
neurotransmitters into the synaptic cleft via exocytosis of synaptic vesicles 281. Differential 
methylation and expression of BRSK1 may therefore disrupt synaptic development and result 
in uncoordinated release of neurotransmitters which may also increase the risk for PTSD and 
other psychiatric disorders 198,282. 
 
1.4.2.3.3.  Brain structural and functional changes and differential methylation in PTSD 
Neurotransmitters are involved in stimulating or inhibiting an action between brain regions and 
downstream physiological and behavioural outcomes 283. Neurotransmitters most commonly 
implicated in PTSD include catecholamines (norepinephrine, epinephrine and dopamine), 
serotonin and oxytocin 282. The neurological functioning of catecholamines, serotonin and 
oxytocin and their relation to differentially methylated genes are discussed below.  
 
Norepinephrine and epinephrine 
Norepinephrine (NE) functions both as a neurotransmitter and a hormone 282. NE, when 
functioning as a neurotransmitter, is a regulator of the fight-or-flight response (see Figure 3) 
199. NE neurons originate predominantly from the locus coeruleus (LC) in the brain stem and 
projects to various brain regions including the amygdala, hippocampus, hypothalamus and 
prefrontal cortex 198. When NE neurotransmitters stimulate the hypothalamus, the 
hypothalamus signals the adrenal cortex (through postganglionic fibres) to release the 
hormones, epinephrine and NE into the bloodstream 42. In the bloodstream, NE and epinephrine 
mediate the activation of the SNS 42. Epinephrine stimulates blood flow to the heart, muscles, 
brain and other vital organs 284. It also enhances the senses, increases oxygen supply in the 
lungs and triggers the release of glucose and lipids to increase energy supply 284. NE inhibits 
blood flow to the gastrointestinal tract and suppresses the immune system in an effort to 
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conserve energy use by these systems which are considered non-essential when facing an 
immediate threat 42,199.  
 In a study investigating cerebrospinal fluid and plasma NE levels in male combat 
veterans with PTSD compared to healthy controls it was reported that: (1) cerebrospinal fluid 
NE concentrations were significantly higher in the group of men with PTSD 285. Another study 
investigating urinary catecholamine levels in a group of children admitted to hospital following 
traumatic injuries found that higher levels of epinephrine upon admission were associated with 
increased PTSD symptom severity at six weeks post-trauma 286. Increased levels of NE and 
epinephrine may indicate enhanced activation of the stress response and, based on the 
aforementioned studies, may increase the risk of developing PTSD following trauma exposure  
42,284–286.  
 Differential methylation of the genes coding two enzymes involved in the metabolism 
of catecholamines, monoamine oxidase A (MAOA) and catechol-O-methyltransferase (COMT), 
have been linked to PTSD in prior studies 178,186. MAOA is predominately involved in the 
metabolism of NE and serotonin and is found throughout the brain 42 while COMT is involved 
in the metabolism of all catecholamine neurotransmitters and is predominately expressed in the 
prefrontal cortex and hippocampus (Kaur & Singh, 2017, Almli, 2014). Increased methylation 
of MAOA (chrX: 43515613-43515840, exon1/intron1) 186 and COMT (chr22:19950040, 
promoter associated) 178 was associated with PTSD in two separate studies. Increased 
methylation of these genes may result in less enzyme activity, increased levels of 
catecholamines, increased alertness, mood instability and susceptibility to psychiatric disorders 
288–290. The relationship between COMT and PTSD may also be explained by the common 
functional rs4680 SNP, also known as Val158Met, in exon 3 of the COMT gene 288. Similar to 
the BDNF Val66Met SNP, substitution of the G allele with the A allele at position 158 in the 
COMT gene results in the conversion of the amino acid valine to methionine 288,291. Those 
carrying the Val/Val genotype have higher enzyme activity and increased stress resiliency 288,289 
while Met/Met carriers have 35-50% less enzyme activity and lower stress resiliency 288–290.  
 
Dopamine 
While less is known about the function of dopamine in relation to PTSD, dopaminergic 
dysfunction has been linked to psychotic symptoms which is sometimes present in severe forms 
of PTSD 292. Dopamine is both an excitatory and inhibitory neurotransmitter, and is associated 
with behaviour, sleep, concentration, learning, mood and immune function 287. It is also thought 
to play a role in hyperarousal, irritability and hypervigilance in PTSD 42. Studies have reported 
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increased urinary and plasma dopamine levels in individuals diagnosed with PTSD compared 
to controls 293,294. NE is also thought to interacts with dopamine by stimulating the release of 
dopamine in the adrenal cortex and dopamine uptake, in turn, is increased in the prefrontal 
cortex when binding to NE transporter 282. The interaction between dopamine and NE in the 
prefrontal cortex may adversely affect the recall and reconsolidation of trauma memories and 
increase the risk for PTSD 282.  
One methylation study did not find a relationship between solute carrier family 6, 
member 3 (SLC6A3 or DAT; chr5:1446443, CpG island in promoter region) gene methylation 
and PTSD, but they did find that individuals with the 9-repeat allele (17.7%) of a 40 base pair 
(bp) variable number of tandem repeats polymorphism (VNTR) in the 3’UTR region of the 
SLC6A3 gene showed a two-fold increased risk for meeting PTSD criteria compared to carriers 
of the 10-repeat allele (75.4%) 196. The interaction between the VNTR and methylation also 
significantly predicted PTSD 196. Individuals possessing the 9-repeat allele and showing 
increased methylation were at increased risk for PTSD 196. Those possessing the 9-repeat allele 
and showing increased SLC6A3 promoter methylation may have a ‘double hit’ risk for 
developing PTSD following trauma exposure 196. The 9- and 10-repeat alleles also vary in 
repeat motifs and often contain SNPs, which may, in turn, influence methylation levels if the 
number of cytosines differ between motifs295,296. Increased methylation may result in reduced 
expression of SLC6A3 and increased dopamine in the synaptic cleft as well as decreased 
absorption of dopamine by the postsynaptic neuron, thereby increasing the risk for PTSD 293,294. 
 
Serotonin 
Serotonergic neurons originate predominantly in the raphe nuclei of the brainstem and are 
generally associated with regulating mood, anxiety, emotions, sleep, appetite and temperature 
287. Serotonergic neurons project to various areas of the brain including the amygdala, 
hypothalamus, hippocampus and prefrontal cortex 202. While the exact mechanism of 
interacting with neurocircuits involved in PTSD is not yet fully understood, a potential 
mechanism of action may be the interaction between the raphe nucleus and the locus coeruleus 
42. Neurons projecting from the raphe nucleus to the locus coeruleus may inhibit the function 
of NE neurons and their signalling to the amygdala which may decrease the activation of the 
SNS responsible for the fight-or-flight response 42,198,202.  
A significant decline in PTSD symptoms following treatment with selective serotonin 
reuptake inhibitors (SSRIs) provides further evidence for the role of serotonin in the aetiology 
and trajectory of PTSD 42,297. SSRIs inhibits the functioning of serotonin transporter which 
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removes unabsorbed serotonin from the synaptic cleft and transports it back to the button of the 
presynaptic neuron, thereby terminating absorption of serotonin by the postsynaptic neuron 
197,198. Inhibiting serotonin reuptake will therefore result in increased absorption of serotonin 
by the postsynaptic neuron and potentially decreased activation of NE 197,198. Furthermore, 
longitudinal studies investigating neuroimaging in relation to SSRI treatment and PTSD have 
also reported an increase in hippocampal volumes, increased activation of the of the left medial 
prefrontal cortex and decreased activation of the amygdala in those receiving SSRI treatment 
42,297–299.  
 One methylation study also found that increased trauma exposure interacted with 
decreased methylation of the serotonin transporter - solute carrier family 6, member 4 (SLC6A4; 
chr17:28562220, island in promoter region) gene to predict PTSD status and PTSD symptom 
severity 197. Another methylation study investigating the 5-hydroxytryptamine receptor 3A 
(HTR3A) found that women with PTSD showed decreased methylation at one CpG site 
(chr11:113846004, 5’UTR, promoter associated) and increased methylation at two other CpG 
sites (chr11:113846044 and 113846077, promoter associated)  compared to women without 
PTSD 183. The HTR3A gene has been associated with childhood trauma, bipolar disorder, 
attention deficit hyperactivity disorder (ADHD) and borderline personality disorder in previous 
studies 183,300–304. Although strong evidence exists linking serotonin to PTSD symptoms 
(including hypervigilance, impulsivity and the frequency of intrusive memories), more studies 
are needed to delineate the role of serotonin in PTSD, especially given that fifteen different 
serotonin receptors have been identified to date and each receptor may exhibit unique and/or 
overlapping functions 305. 
 
Oxytocin 
Oxytocin functions both as a neuropeptide and a hormone, and is produced in the 
paraventricular nucleus and the supraoptic nucleus of the hypothalamus 306,307. The 
hypothalamus contains various oxytocin receptors and projects oxytocinergic neurons to the 
hippocampus 307. The release of oxytocin in the hippocampus has been shown to protect 
hippocampal neurons from neuronal degeneration caused by increased levels of glucocorticoids 
in periods of prolonged stress 306,307. Oxytocin receptors are also found in the amygdala and the 
prefrontal cortex, where it may mediate the stress response 308,309. Oxytocin is therefore 
considered to be involved in neurogenesis and to have anxiolytic properties 307,309.  
 When oxytocin is released in the bloodstream by the posterior pituitary gland, it 
functions as a hormone that is primarily involved in contraction of the uterus during childbirth 
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and in lactation 307,309. Oxytocin has also been implicated as a regulator of social behaviour, 
including social recognition, trust and mother-infant bonding 306,307,309.  
One study investigating oxytocin concentration in saliva samples of a group of male 
and female police officers with and without PTSD found that men with PTSD showed lower 
oxytocin concentrations compared to those without PTSD, but no significant difference in 
oxytocin levels was found between women with and without PTSD 310. A functional MRI study 
investigating an overlapping sample of police officers (mixed gender) investigated in Koch et 
al. (2016) found that police officers with PTSD showed reduced amygdala reactivity in 
response to emotional faces after intranasal administration of oxytocin compared to the 
amygdala reactivity reported when a intranasal placebo was administered 311. Another study 
investigated intranasal administration of oxytocin as an early intervention for the prevention of 
PTSD in a group of adults (mixed gender) presenting to an emergency department following 
trauma exposure 312. They found that those with high baseline PTSD symptom severity 
receiving intranasal oxytocin treatment showed a significant decline in PTSD symptom severity 
at 45 days post-trauma compared to those who received the placebo 312. A study investigating 
a large male military cohort did not find a significant relationship between oxytocin levels and 
the development of PTSD over time 313. A recent meta-analysis investigating blood, urine, 
saliva and cerebrospinal fluid oxytocin concentrations also did not find a significant difference 
between those with and without PTSD 308.  
 One methylation study found that increased methylation of the oxytocin receptor 
(OXTR, chr3:8809437 and chr3:8809413, CpG island in exon 3) gene was associated with 
PTSD in females, but not in males 314. While evidence suggest that oxytocin plays a significant 
role in neuronal pathways associated with PTSD, less is known about the role of peripheral 
oxytocin in relation to PTSD and the mediating role of methylation. Further evidence using 
gender-stratified samples are also needed given the aforementioned gender specific findings 
reported in studies investigating the role of oxytocin in PTSD 310,314. 
 
1.4.2.4. The central nervous system and the endocrine system  
The HPA-axis is one of the main systems involved in the regulation of the stress response in 
mammals 315. It involves a coordinated effort between the central nervous system and the 
endocrine system which has downstream effects on nearly all vital physiological systems 316–
318. The pituitary adenylate cyclase activating peptide (PACAP) has been identified as a master 
regulator of the HPA-axis and PACAP receptor (PACR1) is abundantly expressed in the 
paraventricular nucleus (PVN) of the hypothalamus 316. When PACAP binds to PACR1 in the 
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hypothalamus, it triggers the release of corticotrophin-releasing hormone (CRH) and the 
activation of the stress response 316,319,320. CRH stimulates the pituitary gland to release 
adrenocorticotropic hormone (ACTH) which signals the release of cortisol from the adrenal 
cortex 316,321. Cortisol, in turn, reduces CRH secretion in the hypothalamus and ACTH secretion 
in the pituitary gland which creates a negative feedback loop 321–323. 
 PACAP binding in the hypothalamus also signals the release of NE via the locus 
coeruleus to the effector organs of the Splanchnic nerve (stomach, liver, pancreas, intestines, 
adrenal gland) 324. The adrenal medulla, as part of the adrenal hormone system, releases NE 
and epinephrine in the bloodstream to sustain the SNS response (see Figure 3) 316,325. One 
methylation study found that increased methylation of the PACR1 gene called ADCYAP1R1 
(chr7:31091718, CpG island in TSS1500) was associated with increased PTSD symptom 
severity 174. The CC genotype of the rs2267735 SNP in ADCYAP1R1 has also been associated 
with increased PTSD symptom severity, decreased ADCYAP1R1 mRNA expression and 
increased amygdala and hippocampal activity 174,326. ADCYAP1R1 polymorphisms and 
differential methylation of ADCYAP1R1 may result in a dysregulated HPA-axis and increased 
systemic stress which may increase the risk for PTSD and comorbid physiological disorders 
such as cardiovascular disease 315,327. 
 Cortisol, as part of the stress response, acts mainly through glucocorticoid receptors in 
the hypothalamus which activates the negative feedback loop and returns the body to 
homeostasis following exposure to a stressor 321. Glucocorticoid receptors are also found on 
various cell-types and does not only have an effect on neurons 328. When cortisol binds to 
intracellular glucocorticoid receptors and other co-regulators, it is able to enter the nucleus, 
where it can upregulate or downregulated gene transcription 321,328. Several methylation studies 
have investigated an overlapping region in the glucocorticoid receptor nuclear receptor 
subfamily 3 (NR3C1) gene (chr5:142783936-142783531, island in exon 1F promoter) 182,188–
192. The majority of the studies found that decreased methylation across several CpG sites was 
associated with increased PTSD symptom severity 182,188,191. Differential methylation of NR3C1 
may contribute to the dysregulated negative feedback loop of the HPA-axis associated with 
PTSD and may also be involved in regulating transcription of genes containing glucocorticoid 
response elements (GREs). 
Spindle and kinetochore-associated protein 2 (SKA2) has been implicated in 
glucocorticoid receptor transactivation with increased expression of SKA2 resulting in 
increased glucocorticoid translocation to the nucleus 329. Two methylation studies have 
investigated methylation of the SKA2 gene at the same CpG site (chr17:57187728, 3’UTR) in 
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relation to PTSD with one study reporting an association between decreased SKA2 methylation 
and PTSD 195 and the other reporting an association between increased SKA2 methylation and 
PTSD 194. Further studies are needed to elucidate the role of SKA2 methylation in the 
development of PTSD, given the conflicting findings reported in these two studies 329.  
 FK506 binding protein (FKBP5) is another important functional regulator of the 
glucocorticoid receptor 330,331. Intracellularly, cortisol binds to glucocorticoid receptors in the 
cytoplasm and enters the cell nucleus where it binds to glucocorticoid response elements 
located on the FKBP5 gene (promoter region, intron 2, 5 and 7) 332,333. Binding of 
glucocorticoid receptor to GREs upregulates FKBP5 transcription 332,333. FKBP5, in turn, binds 
to glucocorticoid receptors in the cytoplasm and inhibits glucocorticoid receptor translocation 
to the nucleus thereby creating an ultra-short intracellular negative feedback loop and 
increasing cortisol resistance 334,335.  
The T allele of the rs1360780 SNP of the FKBP5 gene has been linked to increased 
FKBP5 transcription, both in the absence and presence of glucocorticoid receptor binding to 
GREs, compared to the CC genotype 336. Increased expression most likely occurs as a result of 
the T risk allele and it adjacent alleles forming a TATA box which often represents the 
transcription start site in promoters 337. Transcription is normally initiated when RNA 
polymerase 2 (RNA Pol II) and TATA binding protein (TBP) binds to the TATA sequence 
333,337. Binding of TBP causes the DNA strands to bend at the binding site and a three-
dimensional chromatin loop is formed resulting in the GRE of intron 7 coming into direct 
contact with the GRE of intron 2 and RNA Pol II, thereby further enhancing transcription of 
FKBP5 336,337. An attention bias towards threat stimuli, increased hippocampal activation and 
increased risk for the development of PTSD was also associated with the T allele in prior studies 
333,338.  
 Methylation studies investigating FKBP5 have reported conflicting findings, with some 
showing that decreased FKBP5 methylation (chr6:35558513 and 35558710,  intron 7) is 
associated with PTSD 179,180, while others showed that increased FKBP5 methylation 
(chr6:35558488, 35558513, 35558710 intron 7 & chr6: 35656916-35656633, exon 1 promoter 
associated) is associated with PTSD  180,181. The conflicting findings reported in FKBP5 
methylation studies may be explained by the differential expression of cortisol among 
psychiatric disorders which is further complicated by comorbidities 315,321,339.  
 Mood disorders, specifically major depressive disorder and bipolar disorder, have been 
linked to elevated cortisol levels, while anxiety disorders and trauma-related disorders 
(including PTSD) have been linked to reduced urinary, blood and saliva cortisol levels 339,340. 
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Some studies report an initial increase in circulating cortisol levels shortly after trauma 
exposure, followed by lasting decreased cortisol levels 341,342. Although PTSD has been linked 
to reduced cortisol levels, the exact mechanisms through which lowered cortisol, and changes 
in glucocorticoid receptor activity, links to PTSD symptoms remains to be fully understood 321. 
It has been hypothesised that: (1) HPA-axis underactivity and/or increased activation of the 
negative feedback loop results in decreased cortisol secretion, but this theory does not 
accurately reflect the hyper-aroused state associated with PTSD and other anxiety disorders; 
(2) endocrine glands downstream of the hypothalamus may be downregulated i.e. they may 
exhibit decreased sensitivity to the upstream signalling of the HPA-axis (starting in the 
hypothalamus) indicating that the HPA-axis is reprogrammed in response to chronic stress; and 
(3) intracellular metabolism of cortisol mediated by tissue specific changes in enzyme 
expression (needed to activate ligand binding for access to the cell nucleus and gene expression 
changes) may also be altered by chronic stress and HPA-axis activity 321,328,343.  



































Figure 3: Hypothalamic-pituitary-adrenal (HPA) axis regulation of the stress response. The 
pituitary adenylate cyclase-activating polypeptide (PACAP) binds to PACAP receptor in the 
paraventricular nucleus (PVN) of the hypothalamus. The hypothalamus releases corticotropin-
releasing hormone (CRH) which signals the pituitary gland to secrete adrenocorticotropic 
hormone (ACTH) and the adrenal cortex to release cortisol (CORT). Cortisol binds to 
glucocorticoid receptors in the hypothalamus and reduces CRH and ACTH secretion as part of 
the negative feedback loop of the HPA-axis. PACAP binding in the hypothalamus also signals 
the release of norepinephrine (NE) via the locus coeruleus (LC) to the effector organs of the 
Splanchnic nerve. The adrenal medulla, as part of the adrenal hormone system (AHS), releases 
NE and epinephrine in the bloodstream to sustain the sympathetic nervous system (SNS) 
response. Reprinted from “Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP): A 
Master Regulator in Central and Peripheral Stress Responses” by T Mustafa, 2013, Advances 
in Pharmacology, 68, p. 447, Copyright 2013 by Elsevier Incorporated 344. 
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1.4.2.5. The central nervous, endocrine and immune systems 
Several studies have reported a link between PTSD and comorbid metabolic, cardiovascular, 
respiratory, gastrointestinal, inflammatory and autoimmune disease 140,345–352. The relationship 
between PTSD and comorbid disease may in part be explained by alterations to the immune 
system 96. A recent review of proinflammatory responses in PTSD found that interleukin 1 beta 
(IL-1B), interleukin 6 (IL-6), tumour necrosis factor alpha (TNF-a) and C-reactive protein 
(CRP) blood levels are generally increased in participants with PTSD compared to controls 353. 
One prospective study found that CRP increased in relation to PTSD symptoms in male 
veterans 354. Cross-sectional studies have found that there are no differences in 
proinflammatory markers between participants who recovered from PTSD and healthy 
controls, suggesting that proinflammatory markers covary with PTSD symptoms 355,356. Other 
studies have shown that pre-existing alterations to the immune response and increased 
inflammation (due to genetic disposition, pre-existing disease, lifestyle factors, childhood 
trauma etc.) may be a risk factor for the development of PTSD following trauma exposure in 
adulthood 140,357–359. 
The inflammatory response reported in PTSD studies is thought to be driven by the 
synthesis and secretion of proinflammatory cytokines 360. Proinflammatory cytokines are 
secreted by various cells (e.g. macrophages, lymphocytes, endothelial cells, microglia, 
astrocytes and neurons) and is responsible for protection against pathogens by regulating 
systemic inflammation, fever and cell death 361,362. However, upregulation of proinflammatory 
cytokines in the absence of infection may result in damage to healthy peripheral tissue and 
damage to neurons and ganglia in the central nervous system  363.  
Cortisol is an immunosuppressant and downregulates nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB), a transcription factor involved in the synthesis of 
cytokines 364. The decreased levels of cortisol observed in PTSD studies may explain the 
increased synthesis of proinflammatory cytokines and the inflammatory state observed in 
PTSD studies 353,365. A hyperactive SNS may further enhance cytokine synthesis and 
neuroinflammation 353,366 since NE released form the adrenal medulla upregulates NF-kB and 
the release of proinflammatory cytokines in the peripheral system 140,357. Cytokine syntheses 
from microglia and astrocytes in brain regions (including the hypothalamus) with NE neuronal 
projections may result in neuroinflammation, neuronal damage and neuronal death (see Figure 
4) 353,367.  
One methylation study found that veterans with PTSD showed significantly decreased 
methylation levels (chr5:159314783-159330473, promoter region) of the gene coding the 
Stellenbosch University  https://scholar.sun.ac.za
63 
 
proinflammatory cytokine interleukin 12 (IL12), compared to a group of healthy controls not 
exposed to combat trauma 184. Another study found that veterans with PTSD showed a 
significant increase in methylation of the proinflammatory cytokine interleukin 18 (IL18) from 
pre- to post-deployment 368. Decreased methylation of the interferon-inducible protein / absent 
in melanoma 2 (AIM2) gene (chr1:159046973, TSS1500, promoter associated) has been 
associated with increased AIM2 expression 369, increased CRP 175,369 and increased PTSD 
symptom severity in a veteran sample (Miller et al., 2018). AIM2 is involved in tumour 
reversion, control of cell proliferation and activation of the immune response and is mediated 
by the release of proinflammatory cytokines 175,369.  
Differential methylation of genes involved in apoptosis and programmed cell death e.g. 
toll like receptor 8 (TLR8; chrX:12924783, not otherwise specified) 168; mannosidase alpha 
class 2c member 1 (MAN2C1; chr15:75661449, island in promoter region) 185 and C-type lectin 
domain containing 9A (CLEC9A; chr12:10183364, not otherwise specified) 168 have also been 
associated with PTSD. TLR8 recognises the microbial structure of pathogens and promotes 
apoptosis of infected cells 370,371. Decreased expression of MAN2C1 by compromised cells 
signal the binding of cytotoxic T lymphocytes which initiates programmed cell death 372. 
CLEC9A detects compromised cells marked for early cell death and regulates adaptive 
immunity to the pathogen that triggered cell death 373,374. 
Dedicator of cytokinesis 2 (DOCK2) is a neurological immune regulator of phagocytes 
and its function is mediated by cytokines released from microglia 375. One study found that 
decreased methylation (chr5:169068404, 5’UTR, promoter associated) of DOCK2 was 
associated PTSD in a veteran sample 164. Decreased methylation was also associated with 
increased expression of the gene in the same sample 164. Increased DOCK2 expression may 
result in neuroinflammation and toxicity (as is the case in Alzheimer’s disease) 376 and may 
explain the previously identified link between PTSD and increased lifetime risk of early 
cognitive decline and dementia 164,377,378. 
 
 




Figure 4: Interaction between the hypothalamic-pituitary-adrenal (HPA) axis, sympathetic 
nervous system and the immune system. The hypothalamus releases corticotropin-releasing 
hormone (CRH) which signals the pituitary gland to secrete adrenocorticotropic hormone 
(ACTH) and the adrenal cortex to release cortisol. A dysregulated HPA-axis results in reduced 
cortisol secretion in posttraumatic stress disorder (PTSD). Reduced binding of cortisol to 
glucocorticoid receptors (GRs) in the hypothalamus and pituitary gland disrupts the negative 
feedback loop of the HPA-axis. Reduced cortisol (an immunosuppressant) increases nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB) activity and synthesis of 
proinflammatory cytokines e.g. interleukin 1, interleukin 6, tumour necrosis factor-α (TNFα). 
Increased release of norepinephrine (NE) from the adrenal medulla also upregulates NF-kB. 
NE neuronal projection (originating from the locus coeruleus) to brain regions associated with 
the HPA-axis increases cytokine synthesis from microglia and astrocytes resulting in 
neuroinflammation, neuronal damage and neuronal death. Reprinted from “Inflammation and 
post-traumatic stress disorder” by H Hori, Y Kim, 2019, Psychiatric and Clinical 
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The neuroendocrinological characteristics of PTSD overlap to a large degree with those 
of metabolic syndrome (MetS) and cardiovascular disease 350,379. PTSD, MetS and 
cardiovascular disease also share common metabolic characteristics that can be traced back to 
HPA-axis dysregulation (e.g. altered cortisol secretion, insulin resistance, glucose intolerance, 
hypertriglyceridemia, increased visceral adipose tissue, altered adipose hormone secretion) and 
altered SNS functioning (e.g. increased heart rate, hypertension, increased circulating NE) 
350,353. The overlap between PTSD, MetS and cardiovascular disease may be explained by 
underlying immune and inflammatory mechanisms such as chronic low-grade inflammation 
caused by increased synthesis of proinflammatory cytokines 380,381. Differential methylation of 
genes related to central nervous system, endocrine system and immune system functioning 
likely modulate the phenotypic presentation of PTSD and associated diseases, although further 
research is needed to uncover the shared epigenetic alterations in PTSD, MetS and 
cardiovascular disease  138,164,167,170,174. 
 
1.4.2.6. Confounding factors in methylation studies 
Various environmental and biological factors, including age, shared ethnicity, gender, cell type 
composition, pharmaceuticals, toxins, metabolic disease, HIV infection and childhood trauma 
have been associated with differential methylation382,383. These confounding factors are 
discussed below and will be controlled for in all analyses related to methylation outcomes in 
the chapters to follow (details provided under section 1.5 – rationale and objectives).  
 
1.4.2.6.1. Age 
Chronological age has been linked to differentially methylated genes in various genome-wide 
studies which may explain the phenotypic presentation of aging and age associated increased 
risk for diseases 384–389. Aging has been associated with decreased global methylation as well 
as differential methylation of genes associated with cell proliferation, tumour promoters and 
tumour suppressors 390. Controlling for the effect of age in relation to methylation changes is 
therefore important in PTSD studies to distinguish between methylation changes associated 
with age and those associated with PTSD 390. 
 
1.4.2.6.2. Shared ethnicity  
Shared ethnicity has been linked to differential global methylation levels and distinct 
epigenome-wide profiles 391,392. This may be due to inherited genetic and epigenetic alteration 
or due to shared environmental exposures such as air pollution, tobacco smoke, poverty etc. 
Stellenbosch University  https://scholar.sun.ac.za
66 
 
392,393. Methylation profiles may also explain the ethnicity-related increased risk for specific 




Significant differences in brain morphology, neurochemical activity and cognitive functions 
have been identified between men and women and may explain the increased risk for PTSD in 
women 395,396. These differences may be due to epigenetic differences governing sexual 
differentiation (e.g. testosterone, oestrogen, steroid receptors, binding proteins) and their 
impact on neurological and endocrine functioning 395,397. Similarly, female-specific 
methylation changes related to pregnancy and lactation have been reported and should be 
considered when investigating methylation profiles in relation to disease 398.   
 
1.4.2.6.4. Cell type composition 
Methylation also mediates cell differentiation and functional specialisation by activating tissue-
specific genes and their expression 399. The majority of human epigenetic studies investigating 
PTSD aetiology have relied on blood samples to identify differentially methylated genes, given 
that the procedure is minimally invasive and neuronal tissue is inaccessible in living 
participants 138. However, methylation levels in blood may not be representative of methylation 
levels in brain tissue 400,401. Some studies have reported a high correlation between overall 
average methylation at CpG sites in blood vs brain tissue, but the correlation becomes 
increasingly smaller when investigating specific genomic regions or individual CpG sites 400,402. 
One review study found that the position of a CpG site in the gene is relatively important when 
investigating methylation levels given that blood methylation levels in CpG islands were 
generally highly correlated with methylation levels in brain tissue 401. However, the long-term 
aim of epigenetic studies is generally to collate findings and identify potential blood biomarkers 
(since brain tissue cannot be used to assess risk) of psychiatric disorders and using this 
information to prioritise and individualise treatment according to individual risk profiles 403. 
There are also studies that have assessed the correlation between blood and brain methylation 
and created online tools that can be used to support the relevance of CpG site-specific 
differential methylation findings in blood in relation to differentially methylation brain tissue 
400,402,404,405.  
Compared to other sample types (e.g. saliva and buccal mucosa), blood samples reflect 
brain methylation levels more accurately 402. However, whole blood in itself is not homogenous 
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in cell type composition. It contains varying numbers of neutrophils, lymphocytes, monocytes, 
eosinophils and basophils each with different methylation profiles 406,407. Using laboratory 
techniques such as flow cytometry can be implemented to identify and count specific blood cell 
types in induvial samples, and this can be controlled for in the methylation analysis 408.  As an 
alternative, cell type composition can be controlled for using reference-based methods i.e. 
based on prior findings and characteristics of the study participants 409. The Houseman 
algorithm is a popular referenced-based method used in methylation studies to control for the 
heterogeneity of methylation levels across cell types 410. Cell type composition can compromise 
the findings in methylation studies and controlling for variation in cell type is therefore 
important 409. 
 
1.4.2.6.5. Pharmaceuticals  
Various common pharmaceuticals have been found to exert their effects through alterations in 
DNA methylation, chromatin structure, transcription factor activity and receptor expression 411. 
Pharmaceuticals with known epigenetic interactions include those related to cardiovascular 
disease (hydralazine, procainamide, beta-blockers and statins); seizures and psychiatric 
disorders (valproic acid, neuroleptics, SSRIs, methylphenidate); skin disorders and cancer 
(methotrexate, thalidomide, isotretinoin, chemotherapeutics); antimalarials (chloroquine); 
general anaesthetics and hormone contraceptives 411. Pharmaceutical confounding should be 
considered when investigating differential methylation in relation to disease. The inclusion of 
drug-naïve participants can overcome the confounding effects of pharmaceuticals.  
 
1.4.2.6.6. Toxins  
Cigarette smoke has been linked to reduced global methylation as well as genome-wide 
differentially methylated genes related to the metabolism of toxins 412. Similarly, exposure to 
persistent organic pollutants such as insecticides, pesticides and by-products of industrial 
production processes have been linked to reduced global methylation and disruption of 
neurological, endocrine and intracellular pathways 413. Alcohol dependence has also been 
associated with decreased global methylation levels and genome-wide differential methylation 
of genes associated with the dopaminergic system, neurotransmitters and inflammation 414,415. 
The confounding effect of exposure to toxins should therefore be considered when investigating 
methylation in relation to PTSD.  
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1.4.2.6.7. Metabolic disease 
Several previous studies have linked PTSD to an increased risk for metabolic disease including 
obesity, type 2 diabetes, hypertension, increased triglycerides and decreased HDL cholesterol 
350,416. The link between PTSD and metabolic disease is likely due to differential methylation 
of genes involved in mitochondrial function, metabolic and endocrine processes shared by both 
conditions 417. Body mass index (BMI) as a measure of obesity has also been linked to genome-
wide differentially methylated genes predominately linked to metabolic functions 418.  
 
1.4.2.6.8. HIV infection  
HIV infection is associated with increased risk for cardiovascular disease, cancers, diabetes and 
increased levels of triglycerides 419,420. The relationship between HIV and increased risk for 
comorbid diseases is possibly mediated by epigenetic mechanisms 421. Differential methylation 
of genes associated with transcription factors, chromatin remodelling, viral binding and viral 
transport have been associated with HIV infection as well as genes associated with the immune, 
metabolic and endocrine system 420,422–424. Increased methylation age (5-14 years) have also 
been reported in HIV infected samples 389,420,425,426. Differential methylation may also be a 
mechanism implemented by the virus in order to increase its survival and replication rate 420. 
Controlling for the effect of HIV infection on methylation levels is therefore important when 
investigating diseases and disorders in populations with high HIV prevalence rates.   
 
1.4.2.6.9. Childhood trauma  
Exposure to childhood trauma is a risk factor for PTSD and various other psychiatric disorders 
427,428. The increased risk for psychiatric disorders is possibly mediated by epigenetic changes 
during critical periods of development as a result of childhood exposed to trauma 429. Studies 
investigating healthy adults have reported significant differences in genome-wide DNA 
methylation profiles between those with and without childhood trauma 430 as well as differences 
in candidate genes associated with the nervous system and the endocrine system 431–437.  
One study investigating genome-wide differential expression of genes in participants 
with PTSD and childhood trauma compared to those with PTSD without childhood trauma 
found that the gene expression profiles of these groups were almost completely unique with 
only 2% overlap 169.  Differential expression of NR3C1 has also been reported between those 
with PTSD and childhood trauma compared to those with PTSD without childhood trauma 188. 
Substantial evidence therefore links childhood trauma to differential methylation and 
controlling for the effect of childhood trauma when investigating methylation in relation to 
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psychiatric disorders is important given the effect of childhood trauma on the epigenome 427,428. 
See Chapter 2 for a review of childhood trauma and differential methylation in healthy adults 
and adults with depression, PTSD, borderline personality disorder, bipolar disorder, generalised 
anxiety disorder, alcohol dependence, schizophrenia and suicide completers 438.  
 
1.5. RATIONALE, AIM AND OBJECTIVES 
The overarching aim of this study is to investigate the pre-, peri- and post-trauma risk and 
protective factors related to socio-demographic, psychological and epigenetic mechanisms in 
the aetiology and trajectory of PTSD following rape-exposure. The parent study, the Rape 
Impact Cohort Evaluation (RICE), from which the  study participants and samples were drawn, 
included 852 rape-exposed women between 16 and 40 years of age 439. Baseline assessments 
(including self-report questionnaires, physical examination and specimen collection) were 
completed within 20 days following the rape and were repeated at 3-months, 6-months, 12-
months, 18-months, 24-months and 36-months post-rape. The sub-aims of the study which are 
elaborated as objectives below include (1) differential methylation associated with childhood 
trauma and adult mental health outcomes; (2) the psychosocial risk and protective factors 
associated with PTSD symptom trajectory; (3.1) epigenome-wide differentially methylated 
genes associated with PTSD; (3.2) differentially methylated candidate genes associated with 
PTSD; and (4) FKBP5 intron 7 methylation and the trajectory of PTSD symptoms. Each 
objective is addressed in a separate chapter in the dissertation and presented in manuscript 
format. The rationale and approach used are included under each objective below. 
 
Objective 1: Epigenetic alterations associated with childhood trauma and adult mental 
health outcomes: A systematic review 
Childhood trauma is an established risk factor for the development of a range of adult 
psychiatric disorders, but less is known about the epigenetic mechanisms potentially mediating 
the relationship between childhood trauma and adult mental health outcomes 27,440–445.  
Identifying the differentially methylated genes that originated from exposure to childhood 
trauma and increased the risk for adult psychiatric disorders may provide insight into the 
underlying biological pathways affected and may aid in identifying epigenetic differences or 
similarities across disorders 139.    
 A systematic review of studies investigating differentially methylated genes in relation 
to childhood trauma was conducted to address this objective. Studies investigating healthy 
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adults and adults diagnosed with depression, PTSD, borderline personality disorder, bipolar 
disorder, generalised anxiety disorder, alcohol dependence, schizophrenia and suicide 
completers were included in the final pool of articles meeting inclusion/exclusion criteria. The 
article was published online in The World Journal of Biological Psychiatry in April 2019 and 
is presented in Chapter 2 of the dissertation 438. 
 
Objective 2: Risk and protective factors affecting the symptom trajectory of 
posttraumatic stress disorder post-rape 
The majority of studies investigating psychosocial risk and protective factors for PTSD have 
followed a cross-sectional retrospective design which limits causal inference and may be 
tainted by recall bias 446. Few studies to date have investigated mental health outcomes in rape-
exposed women using a longitudinal prospective design and those that have tend to pool 
attempted rape, completed rape and sexual assault together. Baseline pre-assault (age, 
education, employment, relationship status, HIV status, childhood trauma, cumulative lifetime 
trauma), assault (rape context e.g. number of perpetrators, relationship to perpetrator, coercion, 
use of a weapon, physical force, threatened murder, perceived death, repeat perpetrator, number 
of sexual acts, rape reported to police), and post-assault (perceived stress, rape stigma, alcohol 
use, depression, resilience, social support) psychosocial risk and protective factors were 
investigated in relation to change in PTSD symptom severity over time. Baseline, 3-month and 
6-month post-rape self-report measures were used to address this objective. Participants 
meeting the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) 7  
criteria for PTSD at baseline related to a trauma other than the rape were excluded (n = 215). 
Six hundred thirty-nine participants were retained and included in the analysis. The results are 
presented in Chapter 3 of the dissertation. 
 
Objective 3.1: Genome-wide differentially methylated genes associated with 
posttraumatic stress disorder and longitudinal change in methylation in rape survivors 
Twelve epigenome-wide association studies (EWASs) investigating PTSD as outcome have 
been published to date 160,161,170–173,162–169. The majority of EWASs have investigated North 
American war veteran samples 160–162,165. Those investigating civilian samples have included 
participants with a mixture of trauma types and  most have not stratified their analysis by 
gender167–170,173. No EWAS to date has investigated PTSD symptoms in a rape-exposed female 
only cohort. The procedure followed to address Objective 3.1 was divided into two phases. 
Firstly, 48 participants (24 with PTSD and 24 without PTSD) at the 3-month post-rape 
Stellenbosch University  https://scholar.sun.ac.za
71 
 
timepoint were matched on HIV status, age, education, income, childhood trauma, cumulative 
lifetime trauma, BMI and smoking status. All participants were female and of African ethnicity. 
Participants meeting baseline criteria for PTSD i.e. PTSD due to a trauma other than the rape 
were excluded as well as participants who were currently pregnant, lactating or participants 
who HIV seroconverted at any timepoint. The 48 samples were analysed using the 
HumanMethylation EPIC BeadChip 447 at the University of South California (USC) Epigenome 
Centre. The sample was limited to 48 participants given the prohibitively high cost of EWAS 
laboratory procedures.  
 Secondly, selected significant findings from the EWAS were investigated in the same 
sample of participants included in the EWAS study, using EpiTYPER analysis, in order to 
validate the results. To replicate the results, we included an additional 49 participants, 
independent of the participants included in the validation set, and investigated the selected 
significant EWAS findings, using the same method applied in the validation. We then 
combined the samples used in the validation and replication analyses and included methylation 
data from the baseline and 6-months post-rape timepoints to investigate methylation changes 
in relation to change in PTSD scores over time, in the combined set. The laboratory procedures 
were completed at Inqaba Biotec in South Africa using EpiTYPER Sequenom MassARRAY 
technology. The results of the EWAS, validation, replication and longitudinal findings are 
presented in Chapter 4 of the dissertation.  
 
Objective 3.2: Replication of findings from prior epigenome-wide association studies and 
candidate gene studies investigating differentially methylated genes associated with PTSD  
Various CpG sites within genes and in intergenic regions have been associated with PTSD in 
EWAS and candidate gene studies, but few studies have been able to replicate prior findings 
with the exception of some HPA-axis related genes e.g. NR3C1 and FKBP5 138,279,448. The 
variation in findings is likely due to the vast differences in sample size, gender ratio, age, 
ethnicity, cellular heterogeneity, study design, PTSD measures, adjusting for confounding 
variables and molecular technology used between studies 138,149. Reporting significant and non-
significant findings resulting from an EWAS and relating to genes investigated in prior studies 
may provide insight into the substantial, nominal, or negligible contribution of these genes in 
predicting risk for PTSD in a specific population and may guide future research. The results 
are presented in Chapter 4. 
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Objective 4: FKBP5 intron 7 methylation and the trajectory of PTSD symptoms in rape-
exposed women 
Dysfunction of the HPA-axis has been implicated in the aetiology and trajectory of PTSD 
following trauma since it is the core system involved in the regulation of the stress response 
138,139,448,449. One of the most commonly investigated HPA-axis genes is the FKBP5 gene 138. 
FKBP5 is a co-chaperone and important functional regulator of the glucocorticoid receptor 
330,332. Intron 7 of the gene contains several know GREs and prior studies have reported 
differential methylation at some of these GREs in relation to PTSD 180,181,336,450. Differential 
methylation of GREs in FKBP5 may result in altered FKBP5 expression and may have adverse 
effects on HPA-axis functioning and increase the risk for PTSD 336,451 138. We investigated a 
467 bp region in intron 7 of the FKBP5 gene which overlaps with the region investigated in 
prior studies 180,181,336,450. The region includes eight CpG site, two of which are located in two 
separate GREs 336. Only one of the CpG sites in this region is included on the 
HumanMethylation EPIC BeadChip (cg22363520) and this site is not located in a GRE 447. 
FKBP5 intron 7 methylation was investigated in the same sample of 96 participants described 
in objective 3. Longitudinal FKBP5 methylation levels were investigated using the baseline, 3-
month and 6-month post-rape timepoints. Longitudinal methylation levels were determined 
using EpiTYPER Sequenom MassARRAY technology. 
 A SNP in intron 2 of the FKBP5 gene (rs1360780; 400pb from a GRE)  has also been 
associated with altered HPA-axis functioning especially when considering the interaction 
between the T allele of the SNP and childhood trauma 336,449,452–456. The T allele of rs1360780 
increases FKBP5 transcription, both in the absence and presence of glucocorticoid binding to 
GREs 336. Increased expression likely occur as a result of the T allele and its adjacent alleles 
forming a TATA box, which acts as a transcription start site 337. Binding of transcription factors 
in intron 2 results in the formation of a three-dimensional chromatin loop which brings the 
GREs of intron 2 and intron 7 into close contact and further enhances transcription of FKBP5 
336,337. We therefore included rs1360780 genotype and childhood trauma, in addition to FKBP5 
intron 7 methylation levels, as predictors of longitudinal change in PTSD symptoms scores. 
Genotyping was completed using matrix-assisted laser desorption ionization time-of-flight 
(MALDI-TOF) mass spectrometry. No studies to date have investigated childhood trauma, 
rs1360980 genotype, FKBP5 intron 7 methylation and PTSD in rape-exposed women of 
African ethnicity exclusively, and only one study has investigated the relationship between 
FKBP5 intron 7 methylation and PTSD longitudinally 450. The results of this objective are 
presented in Chapter 5 of the dissertation. 




This chapter provided a comprehensive review of the pre-trauma, peri-trauma and post-trauma 
risk and protective factors associated with the etiology and trajectory of PTSD and 
contextualized the aim and objectives of this study in the current literature. The chapters that 
follow cover the background, methodology, results and a discussion related to each of the 
aforementioned objectives. In the final chapter (Chapter 6), the findings of the study objectives 
are integrated to address the overarching aim of the study. Study limitations, clinical 
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EPIGENETIC ALTERATIONS ASSOCIATED WITH 
CHILDHOOD TRAUMA AND ADULT MENTAL HEALTH 




This chapter presents the findings of a published systematic review on epigenetic alterations 
associated with childhood trauma and adult mental health outcome. The literature search was 
completed in March 2018. At the time there were a number of reviews investigating 
differential methylation in relation in psychiatric disorders, but none investigating childhood 
trauma, methylation and adult-onset psychiatric disorders. A number of new publications 
investigating childhood trauma and methylation have since been published, predominantly 
investigating glucocorticoid receptor nuclear receptor subfamily 3 (NR3C1) gene and 
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 Table 1. Summary of epigenetic studies investigating childhood trauma and adult mental health outcomes. 
 
Reference 


















(Wankerl Physical abuse, sexual abuse, 63 females, Case–control; Healthy adults n.a. German-Caucasian; SLC6A4 Blood; bisulfite No significant effect of child- 
et al. 2014) emotional abuse, emotional 70 Males community   23.8 years  pyrosequencing hood trauma on SLC6A4 
 neglect, physical neglect;        methylation levels. 
 Childhood Trauma         
 Questionnaire         
(Duman and Physical abuse, sexual abuse, 105 males Case–control; Healthy adults n.a. Caucasian-American; SLC6A4 Blood; EpiTYPER No association between child- 
Canli 2015) emotional abuse, emotional  community   28.5 years  MassArray hood trauma and SLC6A4 
 neglect, physical neglect;        methylation levels. 




















aIncreased methylation at the 
et al. 2012) abuse, sexual abuse, emo- 41 males community   otherwise speci-  pyrosequencing NGF1-A site in the NR3C1 
 tional abuse, physical neg-     fied); 27.3 years   promoter region was associ- 
 lect, emotional neglect;        ated with increased levels  




















aWomen with childhood phys- 
et al. 2016) abuse; Items from the     53.9 years  pyrosequencing ical and sexual abuse 
 Conflict Tactics Scale and        showed significantly 




















aDecreased maternal care was 
et al. 2015) Parental 18 males community   27.3 years  MassArray associated with significantly 
 Bonding Instrument        increased methylation in 




















aChildhood trauma was associ- 
et al. 2017) Childhood Abuse Index 23 females    27 years  pyrosequencing ated with increased methy- 
         lation at one CpG site in 
         the promoter of the OXTR 
         gene, but the association 
         did not hold after correc- 
         tion for multiple testing. 
(Janusek 





et al. 2014) 
Physical abuse, sexual abuse, 
emotional abuse, emotional 
neglect, physical neglect; 
Childhood Trauma 
Questionnaire 
Verbal, emotional, physical and 
sexual abuse; binary 






















decreased methylation of 
IL-6. 
 
aThere were 311 hypermethy- 
lated and 686 hypomethy- 
lated gene promoter cites 




































34 males Case–control; Healthy adults n.a. African-American; IL-6 Blood; sodium bisul- aIncreased childhood trauma 
 community   20.2 years  phite mapping was associated with 
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Table 1. Continued. 
 
Reference 


















(Booij Physical abuse, sexual abuse 44 females, Case–control; clinic Depression Structured Irish, 37.8 years SLC6A4 Blood; bisulfite aIncreased levels of childhood 
et al. 2015) and emotional abuse; 25 males   Clinical   pyrosequencing abuse were significantly 
 Childhood Trauma    Interview for    associated with increased 
 Questionnaire    DSM-    SLC6A4 methylation. 
     IV Disorders     
(Kang Parental loss, financial hard- 81 females, Cohort; clinic Depression Structured Korean, 54.9 years SLC6A4 Blood; bisulfite aParental loss, physical abuse, 
et al. 2013) ship, physical and sexual 21 males   Clinical   pyrosequencing sexual abuse and child 
 abuse; binary response to    Interview for    adversity in general were 
 individual questions    DSM    associated with significantly 




















aChildhood trauma was associ- 
et al. 2013) divorce, financial problems  community  Depression (median age)  EpiTYPER ated with significantly 
 and other familial con-    Inventory   MassArray increased NR3C1 methyla- 
 straints; binary response to        tion. 
 four individual questions        Childhood adversity was 



















of MAO-A methylation. 
aChildhood trauma predicted 
et al. 2016)1 and emotional abuse; items 56 males community  Questionnaire American;  pyrosequencing significantly increased 
 from the Conflict Tactics     49.6 years   methylation in 4 CpG sites 




















aChildhood trauma was not 
et al. 2016)2 and emotional abuse; 118 males   Depression 41 years  450K BeadChip associated with OXTR 
 Childhood Trauma    Inventory    methylation. The interaction 
 Questionnaire        between childhood trauma 
         and methylation predicted 


















Blood; Illumina 450K 
tom severity. 
aChildhood trauma was associ- 
et al. 2016) to one question   (postpartum) for current American;  BeadChip followed ated with significantly 
     Major 30.6 years  by bisulphite increased OXTR methylation 
     Depressive   pyrosequencing levels in women without 
     Episode    postpartum depression, but 
         not in woman with postpar- 
         tum depression. 
(Bustamante Physical abuse, sexual abuse 62 females, Case–control; Depression Patient Health Mostly African- FKBP5 Blood; bisulfite Childhood trauma did not sig- 
et al. 2018)1 and emotional abuse; items 50 males community  Questionnaire American;  pyrosequencing nificantly predict FKBP5 
 from the Conflict Tactics     50.7 years   methylation across the pro- 
 Scale and the Childhood        moter or at introns 2 and 7. 
 Trauma Questionnaire         
(Tozzi Physical abuse, sexual abuse, 66 female, Case–control; not Depression Patient Health Irish; 37.6 years FKBP5 Blood; bisulfite Childhood trauma was not a 
et al. 2018) emotional abuse, emotional 40 male otherwise  Questionnaire   pyrosequencing significant predictor of 
 neglect, physical neglect;  specified  & Beck    FKBP5 methylation at 
 Childhood Trauma    Depression    intron 7. 
 Questionnaire    Inventory     
         (continued) 
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 Table 1. Continued. 
 Childhood trauma type Sample size Design  Diagnostic Ethnicity and  Tissue type  
Reference and measure and gender and setting Population assessment mean age Gene and technique Main findings 
(Khulan 
et al. 2014) 
Separated from parents due to 
World War II- 
related conditions 





Finnish; 70.2 years Genome-wide Blood; Illumina 450K 
Array followed by 
bisulphite 
pyrosequencing 
No significant differences in 
methylation profiles 
between those separated 
from their parents in child- 
hood compared to those 
not separated from 
their parents. 
(McGowan 














et al. 2012a)4 
Sexual abuse, physical abuse, 
and severe neglect; 
Childhood Experience of 
Care and Abuse 
 
Sexual abuse, physical abuse, 
and severe neglect; 
Childhood Experience of 




Sexual abuse, physical abuse, 
and severe neglect; 
Childhood Experience of 
Care and Abuse 
Sexual abuse, physical abuse, 
and severe neglect; 
Childhood Experience of 
Care and Abuse 












































































aSignificant increased NR3C1 
methylation across pro- 
moter sites in suicide com- 
pleters with 
childhood abuse. 
aNo significant difference in 
methylation levels across 
exon 1B and 1C. 
Significantly decreased 
methylation across exon 1H 
in abused sui- 
cide completers. 
aSignificant increased methyla- 
tion throughout the rRNA 
promoter region in abused 
suicide completers. 
aSignificant increased methy- 
lation in 248 promoters and 
significant decreased 
methylation in 114 pro- 
moters of abuse sui- 
cide completers. 
(Kaminsky 
et al. 2015)2 
Physical abuse, sexual abuse 


















aIncreased SKA2 methylation 
interacted with increased 
childhood trauma scores to 
predict suicide attempts. 
(Murphy 
et al. 2013) 
Physical abuse and sexual 
abuse; documentation of a 




Case–control; clinic Suicide (history 
of attempts) 
Documentation 
of a history 
of a com- 
pleted act of 
self-harm 
Irish; 37.2 years Global Blood; Methylflash 
methylated DNA 
quantification kit 
History of childhood abuse was 
not a  significant  predictor 
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Table 1. Continued. 
 
Reference 


















(Yehuda Physical abuse, sexual abuse, 24 females, Case–control; Posttraumatic Clinician-admin- Jewish-American; FKBP5 Blood; bisulfite Childhood trauma was not 
et al. 2016) emotional abuse, emotional 7 males Jewish cohort stress istered PTSD 46.5 years  pyrosequencing associated with FKBP5 
 neglect, physical neglect;   disorder Scale for    methylation in the offspring 
 Childhood Trauma    DSM-    of parents exposed and not 
 Questionnaire    IV disorders    exposed to the Holocaust. 
(Boks General trauma, physical abuse, 93 males Case–control; mili- Posttraumatic Self-Report European-Caucasian; SKA2 Blood; Illumina Childhood trauma was not sig- 
et al. 2016) sexual abuse and emotional  tary cohort stress Inventory 27.5 years  450K BeadChip nificantly associated with a 
 abuse; Early   disorder for PTSD    change in SKA2 methyla- 
 Trauma Inventory        tion levels. 
(Smith Physical abuse, sexual abuse 40 females Case–control; Posttraumatic Clinician-admin- Mostly African- Genome-wide Blood; Illumina There were no significant dif- 
et al. 2011b)2 and emotional abuse; 64 males community stress istered PTSD American;  27 BeadChip ferences in methylation pro- 
 Childhood Trauma   disorder Scale for 42.7 years   files of those with and 


















Blood; Illumina 450K 
 
aParticipants with childhood 
et al. 2013)2 and emotional abuse; 18 males  stress istered PTSD American;  BeadChip followed trauma had only 2% over- 
 Childhood Trauma   disorder Scale for 41.63 years  by lap in gene expression pro- 



















without childhood trauma. 
aIncreased exposure to child- 
et al. 2011)3 emotional abuse, emotional 45 males  sonality Clinical   pyrosequencing hood trauma was associated 
 neglect, physical neglect;   disorder Interview for    with significantly increased 




















aIncreased childhood trauma 
et al. 2013)3 emotional abuse, emotional 35 males  sonality Clinical   melt assay was associated with signifi- 
 neglect, physical neglect;   disorder Interview for    cantly increased BDNF 


















Blood; Illumina 450K 
 
aChildhood trauma and border- 
et al. 2015)3 emotional abuse, emotional 42 males  sonality Clinical   BeadChip followed line personality disorder 
 neglect, physical neglect;   disorder Interview for   by bisulphite was associated with differ- 
 Childhood Trauma    DSM-   pyrosequencing entially methylated genes 
 Questionnaire    IV Disorders    related to inflammation 
         processes; regulators of 
         gene expression; neuronal 



















tioning and maintenance. 
aIncreased levels of emotional 
et al. 2016)3 emotional abuse, emotional 145 males   Genetics 38.1 years  pyrosequencing abuse, sexual abuse, phys- 
 neglect, physical neglect;    Studies for    ical abuse and physical neg- 
 Childhood Trauma    DSM-    lect were associated with 
 Questionnaire    IV disorders    significantly decreased lev- 
         els of methylation in one 
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to CT in an African-American sample (n = 34) (Janusek   et 
al. 2017). Higher levels of CT were associated with 
decreased methylation of IL-6, suggesting  that  CT  may be 
linked to  a  proinflammatory  phenotype  that  is often 
associated with mood and anxiety disorders in adulthood 
(Danesh et al. 2008;  Hoge  et  al.  2008;  Slopen et al. 2010; 
Janusek et al. 2017). 
 
1.1.1. Genome-wide studies 
One genome-wide study reported increased methyla-  tion 
in 311 promoters and  decreased  methylation  in 686  
promoters  in  British-Caucasian   participants   with (n = 
12) and without (n = 28) CT (Suderman  et  al. 2014). The 
differentially methylated genes were predominantly 
related to Wingless-type mouse mammary tumour virus 
(Wnt) signalling pathways, chromatin modification, 
histone modification, transcription factor binding, 
multicellular organism development and cell surface 
receptor-linked signal transduction. Increased methylation 
of 31 microRNAs and decreased methyla- tion of eight 
microRNAs were also associated with CT (Suderman et al. 
2014). Increased levels of CT were positively associated 
with M20 domain-containing pro- tein 1 (PM20D1) (energy 
homeostasis regulator) methylation across several CpG 
sites (Suderman et al. 2014). Increased methylation of 
PM20D1 has previously been linked to obesity, but little is 
known about its function in relation  to  psychiatric  
disorders  (Feinberg  et al. 2011; Suderman et al. 2014). 
The aforementioned studies illustrate that CT may 
alter epigenetic profiles and ultimately gene and pro- 
tein expression. In the section that follows, we discuss 
how these alterations in the context of CT can be linked 
to mental health outcomes. 
 
1.2. Depression 
Nine studies investigated the relationship between CT 
and differential methylation in adults with depression. 
SLC6A4, NR3C1, OXTR and FK506 binding protein 
(FKBP5) genes were investigated in more than one 
study, monoamine oxidase A (MAO-A) gene was inves- 
tigated in one study only, and one study investigated 
genome-wide methylation profiles. 
 
1.2.1. Serotonin transporter 
Differential methylation was investigated in an over- 
lapping regulating region of SLC6A4 in two studies  of  Irish 
(n = 69) and Korean (n = 102) samples with clinical 
depression (Kang et al. 2013; Booij et al. 2015). Greater 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































RISK AND PROTECTIVE FACTORS AFFECTING THE 



































Introduction: The prevalence of posttraumatic stress disorder (PTSD) in rape 
survivors is considerably higher than the prevalence in non-sexual trauma survivors. Few 
studies have investigated risk and protective factors in survivors early-after-rape in a 
prospective longitudinal design. Methods: Baseline data from a sample of 639 rape-exposed 
women assessed within 20 days of rape were analysed as putative predictors of PTSD symptom 
severity scores up to 6-months post-rape. Results: The incidence of PTSD at 3-months and at 
6-months post-rape was 48.5% and 25.4%, respectively. Post-assault experience of rape stigma 
and depression were significant predictors of PTSD symptom scores in mixed linear regression 
models. Higher levels of depression and rape stigma at baseline (measured in quartile ranges) 
were associated with higher PTSD scores at all timepoints. Conclusion: Addressing rape 
stigma and the misattributions of rape in women who present to rape clinics may reduce the 
long-term adverse effects on mental health outcomes, such as PTSD. Rape survivors who 
present with high levels of depression soon after a rape should be carefully monitored and 
























In South Africa approximately 114 rape cases are reported to police every day with a total of 
41,583 cases reported in the 2018/2019 financial year 1. Crime statistics indicate that an average 
of 70.5 cases of rape are reported per 100 000 South African nationals 1,2. There are no 
nationally representative studies on the under-reporting of rape, but regional survey data 
indicate that between 2.1% and 15.2% of women who have been raped report the incident to 
the police 3,4. This suggests that the true prevalence of rape may be much higher than reflected 
in South African crime statistics 3,4.   
Acute stress reactions are a normal response to interpersonal violence; however,  
symptoms reduce in severity and duration within the first four weeks following the event 5–7. 
For some survivors of interpersonal violence, and specifically women exposed to sexual 
assault, traumatic stress responses may be sustained with high trauma symptomatology beyond 
1-month post-exposure presenting as posttraumatic stress disorder (PTSD) 8–16. Prospective 
studies investigating PTSD in sexual assault survivors have reported prevalence rates between 
35% and 45% at 3-months post-rape 9,17–19 which are considerably higher than prevalence rates 
reported in general community samples that have investigated a mixture of trauma types 20–22. 
Few studies to date have investigated rape and/or sexual assault beyond 3-months, but one 
study investigating a North American sample (n=126) of rape-exposed women reported a 
prevalence of 7.1% at 4-months post-assault 19 and another investigating a Swedish sample of 
rape-exposed women (n=317) reported a prevalence of 38.6% at 6-months post-rape 18. 
Risk and protective factors for PTSD in sexual assault survivors, including rape, have 
been found to differ from those associated with non-sexual trauma types 9,23. Prior studies have 
generally grouped risk and protective factors into pre-assault factors and post-assault factors 
23,24. Pre-assault factors include demographic factors (age, education, employment, relationship 
status, HIV status) and prior traumatic experiences (childhood trauma and lifetime trauma). 
The pre-assault factors: age 8,9,25, relationship status 18,25,26, education 8,26 and 
employment/income 8,18,25 have generally been found not to be associated with PTSD status 
and/or PTSD symptom severity across studies investigating sexual assault survivors. In some 
studies, however, younger age 26, being single 8 a lower level of education 25  and lower income 
27 were associated with risk for developing PTSD. Studies also report a significant association 
between childhood trauma exposure 26–28, adult cumulative lifetime trauma 9,18,26, HIV status29 
and PTSD, while others have not replicated these finding 8,18.  
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Post-assault risk (perceived stress, rape stigma, alcohol use, depression) and protective 
factors (resilience, social support) may also contribute to PTSD symptom severity 
8,9,18,26,27,30,31. Higher levels of perceived stress 5,32 have been found to predict PTSD symptom 
severity following trauma exposure. Negative social reactions and rape stigma (e.g. victim 
blaming, self-blaming, shame, embarrassment, downplaying the severity of the rape, treating 
the victim differently) have also been associated with PTSD symptom severity in a number of 
studies 10,25,26,31. Lower levels of social support have been associated with higher PTSD 
symptom severity in one cross-sectional rape study 33 while others did not replicate this finding 
8,9. Factors associated with low resilience such as negative affectivity (general negative 
perspective on the world and oneself), avoidance coping (disengagement, denial and self-
distraction), loss of control (related to emotional recovery and future victimisation) and 
negative beliefs about personal characteristics (being careless, unlucky, too trusting and a 
victim type) have generally been associated with increased PTSD symptom severity across 
rape studies 9,26,31. 
Although depression and alcohol use are referred to as post-assault risk factors in this 
study, they can be both pre-assault and post-assault risk factors for PTSD. Increased alcohol 
use and depression severity has been found to covary/predict PTSD status/symptom severity 
post-rape 8,18,27,34–39, but depression and alcohol use have also been associated with an increased 
risk for sexual assault exposure 34–36,40,41. Pre-existing depression has been associated with a 
three-fold increased risk for PTSD following trauma exposure while a 2.8-fold increased risk 
for first onset depression has been reported in participants exposed to interpersonal violence 
(including sexual assault) and with PTSD compared to those who did not develop PTSD 
following trauma exposure 34. A history of sexual assault and increased risk for the 
development of PTSD have been associated with problematic alcohol use prior to the assault 
and at the time of the assault 35,37,38. One study found that 26.3% of sexual assault survivors 
showed problematic alcohol use prior to the assault, 17.5% showed problematic alcohol use at 
the same age at which the sexual assault occurred and 56.1% developed problematic alcohol 
use following the assault 35.   
Pre-assault and post-assault factors may play a considerable role in the risk of 
developing PTSD 1-month post-rape, but may also have long-term effects on the trajectory of 
PTSD symptomatology 5,7,23. Trauma type itself may influence the trajectory of PTSD e.g. 
traumas involving intentional injury or harm have been found to result in higher PTSD 
prevalence at 1-month, 3-months, 6-months and 12-months post-rape compared to trauma 
associated with non-intentional injury 7. Limited access to mental health resources as a result 
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of poverty 42; the adverse effects of childhood trauma or cumulative lifetime trauma 42–44; 
negative coping mechanisms such as social isolation and alcohol abuse 43–45; stigmatising views 
on rape 8,10,18,27,31,45–48 and predisposition to anxiety and depression 43–45 may sustain PTSD 
symptoms and result in an upward PTSD symptom trajectory and chronicity.   
Fewer studies have investigated factors associated with the assault itself. Assault-
factors such as the severity of the rape and specific contextual factors related to the rape may 
influence the degree of fear, horror and life threat experienced by rape survivors 18,25,26,30,48. 
Multiple perpetrators 18, multiple sexual acts 18, physical injury inflicted during the rape 18,25 
and a longer duration of assault 30 have generally been found to be associated with PTSD. 
However, other studies have not found a significant relationship between the number of 
perpetrators 9, physical injury inflicted 8,26 and general assault severity 26. Relationship with the 
perpetrator (e.g. family member, partner, friend, acquaintance, stranger) has been found not to 
be associated with PTSD symptom severity or status 8,9,18,25. Some studies reported a significant 
association between perceived life threat during the assault and PTSD symptom severity 25,26,30 
while one study did not 18. 
Across studies investigating sexual violence, findings in relation to risk and protective 
factors have been inconsistent. Few studies have comprehensively investigated pre- and post-
assault risk and protective factors for PTSD in a longitudinal prospective design, especially 
beyond the 3-month post-rape period and in low- to medium-income countries 18,23. In this 
study we sought to investigate: (1) the relationship between baseline (within 20 days post-rape) 
pre- and post-assault factors in relation to PTSD symptom severity at 6-months post-rape in a 
cohort of rape-exposed women residing in a low-income region of South Africa; (2)  the 
interaction between baseline pre- and post-assault variables and PTSD symptom scores over 
time (baseline, 3-months and 6-months post-rape) and; (3) the association between assault 
related variables and PTSD symptom severity at baseline, 3-month and 6-months post-rape in 




Participants and setting 
Rape-exposed participants  (n = 782) were recruited for the parent study “Rape Impact Cohort 
Evaluation (RICE)”, a study investigating the impact of rape on women’s health and their use 
of health services in South Africa 49. Female survivors of rape were recruited from four rape 
centres in and around the city of Durban located in the South African province of KwaZulu-
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Natal. The rape centres provide comprehensive emergency care, including access to police, 
counselling, medical and forensic care. Rape survivors who presented to one of four rape 
clinics were informed of the study after they had received post-rape care and had the initial 
clinical and forensic assessment. Interested participants were invited to the study site to obtain 
more information and to enrol in the study. 
 Recruitment was restricted to female participants between 16 and 40 years of age who 
had reported a rape in the past 20 days. Participants were excluded if they were severely 
distressed or in need of urgent psychological or psychiatric attention/hospitalisation (in which 
case they were supported and/or referred by the counsellor at the rape centre where the rape 
was initially reported); intellectually disabled; or more than 14 weeks pregnant. In order to 
investigate predictors of PTSD associated with rape, we excluded participants who met criteria 
for PTSD at baseline due to traumatic events other than the current rape (n=143).  
 
Study procedures  
Study procedures were explained to participants and informed consent was obtained by 
research assistants trained in research ethics and conducting research in vulnerable populations. 
At the baseline visit (within 20 days post-rape), participants completed a demographic 
questionnaire; a psychiatric interview; self-report questionnaires to gather data on the rape 
incident, childhood and lifetime trauma, resilience, social support, perceived stress, rape 
stigma, alcohol use, depression and PTSD (participants were asked to endorse PTSD symptoms 
in relation to the rape on the PTSD measure). The aforementioned measures are described in 
Table 1 along with the Cronbach alpha test statistic obtained from the data in this study and 
variables used in the analyses. A rapid HIV antibody blood spot test and a human chorionic 
gonadotropin (hCG) urine pregnancy test was also completed at baseline. The demographic 
questionnaire and self-report measures were administered by research assistants. The 
psychiatric interview was also administered by research assistants under the supervision of a 
registered trauma counsellor or nurse. The medical procedures were administered by a 
registered nurse. All assessments were completed face-to-face and responses to the 
demographic questionnaire and self-report measures were electronically recorded and captured 
in real-time. All mental health assessments, except for the time-independent demographic and 
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Ethical considerations  
The study was introduced to potential participants as the ‘Women’s Health and wellbeing 
study’ in order to protect them from being identified as someone who has been raped. 
Participants were informed that participation is voluntary and that they were allowed to 
withdraw from the study at any time. All data gathered in the study were deidentified by 
replacing any identifiable information with a study number. The study staff received training 
in ethical and legal issues associated rape. A counsellor specialising in trauma counselling was 
onsite to assist participants who exhibited signs of distress and to refer participants in need of 
specialised psychological or psychiatric care. Ethical approval to conduct the RICE study was 
obtained from the South African Medical Research Council Ethics Committee (SAMRC; 
EC019-10/2013) and approval to conduct the sub-study was obtained from the Health Research 
Ethics Committee at Stellenbosch University (HREC; S16/08/146). 
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Table 1: Description of measures and variables used in the study 




Variable/s Source of 
Measure 
      
Demographic 
questionnaire 
Six items with diverse response options depending on 
individual items 
Baseline  (1) Age, (2) education, (3) 
employment, (4) relationship status, 
(5) HIV status 
(Jewkes et al., 
2006)50 




7.0.0 (MINI) – PTSD 
module 
Twenty-one DSM-5 symptoms. Subscales include criterion 
A (stressor), criterion B (intrusion symptoms), criterion C 
(avoidance), criterion D (negative alterations in cognitions 
and mood), criterion E (alterations in arousal and 
reactivity). Responses are recorded as 0 (‘no’) or 1 (‘yes’) 
for presenting with a symptom. One or more symptoms 
endorsed in criterion A, B and C respectively and 2 or more 
symptoms endorsed in criterion D and E respectively 
constitutes a PTSD diagnosis.  
Baseline  PTSD status (Sheehan et 
al., 2014)51  
      
Childhood Trauma 
Questionnaire - Short 
Form (CTQ-SF)¹ 
Fourteen items e.g. ‘before I reached 18, I was beaten so 
hard at home that it left a mark or bruise’. Subscales include 
sexual abuse, physical abuse, emotional abuse, neglect and 
domestic violence. Responses recorded on a 4-point Likert 
scale ranging from 1 (‘never’) to 4 (‘very often’). Total 
score rage between14 and 56. 
Baseline .80 Childhood trauma (Bernstein & 
Fink, 1998)52  
      
Life Events Checklist 
(LEC)¹ 
Ten items e.g. ‘Have you ever experienced the murder of a 
family or friend?’. Responses recorded as 0 (‘no’) or 1 
(‘yes’). Total score rage between 0 and 10. 
Baseline  Lifetime cumulative trauma: 
(1) imprisonment, (2) civil 
unrest/war, (3) serious injury, (4) 
being close to death, (5) murder of 
family or friend, (6) unnatural death 
of family or friend, (7) murder of 
stranger, (8) robbed at gunpoint/ 
knifepoint (9) kid-napping, (10) 
sexual assault 
(Weathers et 
al., 2013)53  
      
Davidson Trauma 
Scale (DTS) 
Seventeen items e.g. ‘have you been upset by something 
which reminded you of the event?’. Subscales include 




.95 PTSD symptom score (Davidson et 
al., 1997)54  
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recorded on a 5-point Likert scale for symptom frequency 
ranging from 0 (‘not at all’) to 4 (‘every day’) and symptom 
severity ranging from 0 (‘not at all distressing’) to 4 
(‘extremely distressing’). Total score range between 0 and 
136. A cut-off of 40 indicates clinically significant PTSD 
symptoms. 




Twenty-five items e.g. ‘I am able to adapt when changes 
occur’. Responses recorded on a 4-point Likert scale 
ranging from 1 (‘strongly disagree’) to (4 ‘strongly agree’)². 




.89 Resilience  (Connor & 
Davidson, 
2003)55  
      
      
Multidimensional 
Scale of Perceived 
Social Support 
(MSPSS) 
Twelve items e.g. ‘There is a special person who is around 
when I am in need’. Responses recorded on a 4-point Likert 
scale ranging from 1 (‘strongly disagree’) to 4 (‘strongly 








      
Perceived Stress 
Scale (PSS) 
Ten items e.g. ‘In the last month, how often have you found 
that you could not cope with all the things that you had to 
do?’. Responses recorded on a 4-point Likert scale ranging 
from 1 (‘strongly disagree’) to (4 ‘strongly agree’)². Total 








      
Rape Stigma Scale 
(RSS)¹ 
Nine items e.g. ‘I have been concerned about people 
respecting me less if they were to find out what happened?’. 
Responses recorded on a 4-point Likert scale ranging from 
1 (‘never’) to 4 (‘many times’). Total score range between 




.85 Rape stigma  (Kalichman et 
al., 2005)58  
      
Alcohol Use 
Disorders 
Identification Test – 
Consumption 
Subscale (AUDIT-C) 
Three items e.g. ‘How many drinks containing alcohol do 
you have on a typical day when you are drinking?’. 
Responses recorded on a 5-point Likert scale with diverse 
response options dependent on the individual item. Total 
score range between 0 and 12. A score of 3 or more indicates 




.71 Alcohol consumption (Saunders, 
Aasland, 
Babor, De La 
Fuente & 
Grant, 1993)59  
      
Center for 
Epidemiologic 
Twenty items e.g. ‘I felt that I could not shake off the blues 
even with the help from my family or friends’. Responses 
Baseline 
3-months 
.88 Depression (Radloff, 
1977)60  
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recorded on a 4-point Likert scale ranging from 0 (‘rarely or 
none of the time’) to 3 (‘most or all of the time’). Total score 
range between 0 and 60. 
6-months 
      
Context of Rape 
Questionnaire (CRQ) 
Ten items e.g. ‘How many men were involved in the rape?’. 






 (1) Number of men involved in the 
rape, (2) perpetrator known, (3) use 
of coercion, (4) perpetrator used a 
weapon, (5) bodily physical 
force/assault used,  
(6) perpetrator threatened to kill the 
survivor, (7) rape survivor thought 
they would be killed,  
(8) prior rape by the same 
perpetrator, (9) number of sexual acts 
(vaginal, anal, oral, digital or object 
penetration, forced observed 
masturbation), (10) rape reported to 
the police 
(Jewkes et al., 
2009)61  
      
¹Modified version of the original measure. ²Response options were modified to reduce test fatigue and response errors by using a uniform 
response method across several measures.  
 
Abbreviations: posttraumatic stress disorder (PTSD)
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Pre-assault and post-assault variables 
Most variables did not conform to a normal distribution and non-parametric statistics were 
therefore used in the univariate analyses prior to imputing missing values. Spearman’s 
correlation coefficients were used to investigate the relationship between continuous variables 
and PTSD symptom total scores. Kruskal-Wallis, Mann-Whitney U and chi-square statistics 
were used to investigate the relationship between categorical variables and PTSD symptom 
scores. 
Two sets of independent variables were included in the regression analysis to determine 
their relationship with the dependent variable ‘PTSD symptom scores’. The first set of 
variables were defined as ‘pre-assault variables’ and were treated as time-independent 
variables. The pre-assault variables were further divided into pre-assault demographic factors 
and pre-assault trauma factors. Pre-assault demographic factors included the continuous 
variable age and the categorical variables education (secondary education completed vs not 
completed), employment status (employed vs unemployed), relationship status (in a 
relationship vs widowed/separated/divorced vs single) and HIV status (positive vs negative). 
Pre-assault trauma factors included the continuous variables childhood trauma and lifetime 
trauma.  
The second set of variables were defined as ‘post-assault variables’ and were treated as 
time-dependent variables in the analysis. All post-assault variables were continuous variables 
and were further divided into protective factors and risk factors. Post-assault protective factors 
included resilience and social support and post-assault risk factors included perceived stress, 
rape stigma, alcohol use and depression. Alcohol scores were assessed in relation to the four 
weeks preceding the baseline visit, the time between the baseline visit and the 3-month visit 
and the time between the 3-month visit and the 6-month visits. Depression scores were assessed 
in relation to the week preceding the baseline, 3-month and 6-month visit.  
 
Missing data and multiple imputation model 
Six hundred and thirty-nine participants completed the baseline interview and 274 (42.9%) 
completed all three visits.  Of the 639 participants, 368 (57.6%) completed the 3-month visit 
and 325 (50.9%) the 6-month visit. Two hundred and twenty-five participants (35.2%) 
completed the baseline visit only and as such did not have 3-month and 6-month data. One 
hundred and forty participants (21.9%) either missed the 3-month visit or 6-month visit. 
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Recording responses to the measures electronically ensured that there were no missing values 
at item level, given that the interviewer could not continue with the interview if responses were 
missing. However, an uploading error resulted in missing value sets for the symptom severity 
subscale of the DTS which was corrected once it was identified. There were no missing values 
for the DTS frequency subscale but 52.9% (n = 338) of the DTS symptom severity scores were 
missing at baseline, 46.2% (n = 127) were missing at 3-months post-rape and 43.4% (n = 141) 
were missing at 6-months post-rape. Missing DTS symptom severity values were imputed 
using a multiple imputation model while maintaining the multivariate normal distribution.  
A comparison of participants who completed all visits, participants who had missed 
visits and those who only completed the baseline visit revealed significant group differences 
on baseline measures of childhood trauma (p = .026), resilience (p = .042), perceived stress (p 
= .002) and alcohol consumption (p = .003) (see Supplementary Table 1 for details). Missing 
values were treated as missing at random (MAR) and imputation of missing data was 
undertaken to reduce the bias introduced by data MAR 62.  
Out of a potential 1917 observations (i.e. 639 completed interviews at baseline, 3-month 
and 6-month), 585 observations were missing (30.5%). A multiple imputation model using the 
Markov Chain Monte Carlo (MCMC) method was used to impute missing values at 3-months 
and 6-months post-rape for the dependent variable PTSD symptom total score and the time-
dependent post-assault continuous variables. The missing values were imputed as a function of 
baseline scores for resilience, social support, perceived stress, rape stigma, alcohol use and 
depression as well as baseline demographic characteristics (age, education, relationship status, 
employment status, HIV status) and the baseline measure of childhood trauma and lifetime 
trauma.  Thirty imputations were conducted, each time randomly selecting a data subset with 
complete values to predict the values of missing data while maintaining the participant specific 
correlation coefficient between the baseline time-independent and time-dependent measures 
and the time-dependent post-assault variables and PTSD symptom total score at 3-months and 
6-months post-rape. The estimates of the 30 imputations were then pooled and the average 
value was used to impute the missing data. Imputed values were bounded according to the 
lowest and highest possible score in the range of the original measure. 
 
Pre-assault and post-assault predictors of PTSD symptom severity and trajectory 
We followed four steps to determine predictors of PTSD symptom scores and trajectory 
(visually presented in Figure 1). In all four steps we conducted the analysis based on imputed 
missing values. Firstly, we investigated baseline pre-assault variables, post-assault variables 
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and time (baseline, 3-months and 6-months) as predictors of PTSD symptom scores at 6-
months post-rape in Model 1, using a mixed linear regression model.  
Secondly, we again investigated time and the pre-assault and post-assault variables 
investigated in Model 1 but converted the pre-assault trauma variables and the post-assault risk 
and protective variables into categorical variables in Model 2, for ease of interpretation. 
Childhood trauma (physical/sexual/emotional abuse, neglect, domestic violence) scores were 
converted into four categories ranging from 1 (‘no childhood trauma type endorsed’) to 4 
(‘three or more childhood traumas types endorsed’). Lifetime trauma exposure was converted 
into five categories ranging from 1 (‘no trauma endorsed’) to 5 (‘four or more traumas 
endorsed’). Alcohol consumption was converted into three categories, namely 1 (‘no 
consumption’), 2 (‘some consumption’) and 3 (‘hazardous consumption’). Resilience, social 
support, perceived stress, rape stigma and depression scores were divided into four quartiles 
each (see Table 2 for sub-group sizes and interquartile ranges).  
 Thirdly, we investigated the interaction between time (baseline, 3-months and 6-months 
post-rape) and the significant predictors of PTSD symptom scores resulting from Model 1 and 
Model 2. A mixed linear model was again used in this step (Model 3). 
 Fourthly, the least squares mean method was used to determine PTSD symptom scores 
at baseline, 3-months and 6-months post-rape while adjusting for the means of the significant 
predictor variables at baseline resulting from Model 1-3. The interaction between different 
quartile levels of the significant predictors and PTSD symptom scores at the three different 
timepoints were then plotted to visually present the effect of different levels of baseline 
predictors on PTSD symptom trajectory. 




Figure 1: Pre- and post-assault variables by time as predictors of PTSD. Pre-assault and post-assault baseline 
predictors of PTSD were investigated in mixed linear regression Model 1 & Model 2. The interaction between 
baseline post-assault predictor variables and time in relation to PTSD symptom scores were investigated in mixed 
linear regression Model 3.  
 
 
Assault variables and PTSD symptom scores 
Assault variables included the number of men involved in the rape, perpetrator known to the 
rape survivor, use of coercion, perpetrator used a weapon, physical force or assault used, rape 
survivor threatened with death, rape survivor thought she would die, prior rape by the same 
perpetrator, number of different sexual acts and rape reported to the police (see Figure 2 for a 
detailed description of assault variables). All assault variables were categorical variables and 
were treated as time-dependent variables.  
In the RICE study participants were followed-up beyond 6-months and assault variables 
were measured at any one of several timepoints (i.e. 3-, 6-, 12- or 18-months post-rape). The 
research team was advised by the police and the National Prosecuting Authority (NPA) not to 
ask questions pertaining to the rape if a participant had an ongoing legal case as disclosing 
information might influence the rape survivors testimony, compromise the case and reduce the 
likelihood of a successful conviction. This resulted in the availability of assault related data for 
a smaller subset of participants (n=168). We therefore did not include these variables in the 
mixed linear regression models but ran univariate analyses (Kruskal-Wallis, Mann-Whitney U 
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and chi-square statistics) to investigate the relationship between these variables and PTSD 
symptom scores at baseline, 3-months and 6-months post-rape (visually presented and 




Figure 2: The relationship between assault variables and PTSD. Definition of assault variables: (1) the number of 
perpetrators and accomplices involved in the rape including those who had sexual contact with the rape survivor 
and/or lured, abducted, physically assaulted or verbally threatened the rape survivor or participated in any other 
way in the rape; (2) if the perpetrator was known to the rape survivor (acquaintance, friend, boyfriend, husband, 
family member, employer, teacher, priest, policemen etc.) or was a stranger; (3) if the rape survivor was abducted, 
lured somewhere under false pretences (e.g. a job offer, providing directions, offering transport etc.) or not; (4) if 
a weapon was used by the perpetrator (e.g. firearm, knife, sharp tool/instrument, blunt object, rope, wire, chain) 
or not; (5) if bodily physical force/assault was used by the perpetrator (e.g. strangulation, hit with fists/hands, 
kicked, held very tight or physical pressure use, hand used to cover mouth or nose) or not; (6) if the perpetrator 
or accomplice threatened to kill the rape survivor or not; (7) if the rape survivor thought she would be killed or 
not; (8) if the same perpetrator/s had raped the same survivor on a previous occasion/s; (9) the number of different 
sexual acts that occurred during the rape (vaginal/anal/oral/digital/object penetration, forced or observed 















PTSD symptom scores and incidence 
Different timepoint mean (M) PTSD symptom scores and standard deviation (SD) were as 
follows: baseline (M = 68.1, SD = 24.7), 3-months (M = 39.3, SD = 24.1) and 6-months (M = 
31.7, SD = 22.6). The incidence of PTSD at 3-months post-rape was 48.5% and 25.4% at 6-
months post-rape (using a score of 40 or more on the DTS as indicative of the clinical threshold 
for PTSD). 
 
Descriptive statistics of pre-assault and post-assault variables 
Table 2 presents the descriptive statistics of the pre-assault and post-assault variables measured 
at baseline (n = 639). For pre-assault baseline demographic factors, the mean age of participants 
was 24.7 years (range 16-40), the majority of participants were married or in a relationship 
(80.8%), 57.6% completed secondary school (12 years of basic education), 78.4% were 
unemployed and 46.5% were HIV positive. For pre-assault trauma factors the mean number of 
childhood traumas reported was 1.3 (range 0-5) and the mean number of cumulative lifetime 
trauma exposures reported was 2.4 (range 0-10). For post-assault risk and protective factors at 
baseline, the mean scores were as follows: resilience (M = 74.5, SD = 6.3), social support (M 
= 35.0, SD = 5.0), perceived stress (M = 23.1, SD = 5.6), rape stigma (M = 20.7, SD = 6.9), 
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Pre-assault demographic factors     
     
Age  639 100 24.7(5.3) 16-40 
     
Secondary education completed  639 100   
     No 271 42.4   
     Yes 368 57.6   
     
Relationship status 639 100   
      In a relationship 516 80.8   
      Widowed/separated/divorced 1 0.2   
      Single 122 19.1   
     
Employment status 639 100   
      Employed 138 21.6   
      Unemployed 501 78.4   
     
HIV status 639 100   
      Positive 297 46.5   
      Negative 342 53.5   
     
Pre-assault trauma factors     
     
Number of childhood traumas (CTQ-SF)¹ 639 100 1.3(1.3) 0-5 
      No childhood trauma 244 38.2   
      1 childhood trauma 155 24.3   
      2 childhood traumas 121 18.9   
      3 or more childhood traumas 119 18.6   
           
Number of lifetime traumas (LEC)¹ 639 100 2.4(1.5) 1-10 
      No lifetime trauma 119 18.6   
      1 lifetime trauma 139 21.8   
      2 lifetime traumas 161 25.2   
      3 lifetime traumas 123 19.2   
      4 or more lifetime traumas 97 15.2   
     
Post-assault protective factors     
     
Resilience (CD-RISC)² 639 100 74.5(6.3) 51-100 
      1st quartile 157 24.6 68.1(3.4) 0-71 
      2nd quartile 127 19.9 72.7(0.5) 72-73 
      3rd quartile 86 13.4 74.0(0.0) 74 
      4th quartile 269 42.1 79.3(6.2) 75-100 
     
Social Support (MSPSS)² 639 100 35.0(5.0) 12-48 
       1st quartile 113 17.7 27.6(3.2) 0-31 
       2nd/3rd quartile 194 30.4 33.5(1.3) 32-35 
       4th quartile 332 52.9 38.3(3.6) 36-48 
     
Post-assault risk factors     
     
Perceived stress (PSS)² 639 100 23.1(5.6) 10-40 
        1st quartile 148 23.2 15.4(2.1) 1-18 
        2nd quartile 136 21.3 21.0(1.1) 19-22 
        3rd quartile 193 30.2 24.7(1.1) 23-26 
        4th quartile 162 25.3 30.0(2.9) 27-40 
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Rape Stigma (RSS) 639 100 20.7(6.9) 9-36 
         1st quartile 136 21.3 11.0(1.9) 0-14 
         2nd quartile 162 25.4 17.5(1.8) 15-20 
         3rd quartile 172 26.9 23.0(1.4) 21-25 
         4th quartile 169 26.4 29.3(3.0) 26-36 
     
Alcohol Use (AUDIT-C) 639 100 2.1(2.5) 0-12 
          No consumption 269 42.1 0.0(0.0) 0-0 
          Some consumption 152 23.8 1.5(0.5) 1-2 
          Hazardous consumption 218 34.1 2.0(0.1) 3-12 
     
Depression (CES-D) 639 100 33.0(12.6) 0-60 
          1st quartile 154 24.1 15.5(6.6) 0-24 
          2nd quartile 165 25.8 29.7(2.9) 25-34 
          3rd quartile 155 24.3 38.0(2.1) 35-41 
          4th quartile 165 25.8 48.0(4.3) 42-60 
     
1Modified version ²Modified response option  
Abbreviations: Mean (M); Standard Deviation (SD); Childhood Trauma Questionnaire Short 
Form (CTQ-SF); Life Events Checklist (LEC); The Connor-Davidson Resilience Scale (CD-
RISC); Multidimensional Scale of Perceived Social Support (MSPSS); Perceived Stress Scale 
(PSS); Rape Stigma Scale (RSS); Alcohol Use Disorders Identification Test - Consumption 
(AUDIT-C); Center for Epidemiologic Studies Depression Scale (CES-D) 
 
 
Univariate associations between PTSD and pre- and post-assault factors 
PTSD symptom scores at one or more timepoint were associated with the pre-assault 
demographic variables employment and HIV status as well as the pre-assault trauma variables 
childhood trauma and lifetime trauma. Individual childhood trauma types associated with 
PTSD scores included neglect, domestic violence, emotional abuse, physical abuse and sexual 
abuse. Individual lifetime trauma types associated with PTSD scores included civil unrest/war, 
serious injury, being close to death, murder of a family member or friend and murder of a 
stranger. PTSD symptom scores at one or more timepoint were also associated with social 
support (putative protective factor post-assault) and perceived stress, rape stigma, alcohol use 
and depression (putative risk factors post-assault). See Supplementary Tables 2-4.  
 
Baseline pre- and post-assault predictors of PTSD at 6-months post-rape 
Table 3 presents the summary statistics of Model 1 investigating baseline pre-assault and post-
assault factors as predictors of PTSD symptom severity at 6-months post-rape. The shared 
variance between the predictor variables significantly explained PTSD symptom severity at 6-
months post-rape F(16, 5020) = 42.2, p <.000. PTSD symptom severity decreased significantly 
by 28.7 points from baseline to 3-months post-rape (p <.001) and by 36.4 points from baseline 
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to 6-months post-rape (p <.001). Baseline age, education, employment, relationship status, HIV 
status, childhood trauma, lifetime trauma, social support, resilience, perceived stress and 
alcohol use were not significant predictors of PTSD symptom severity at 6-months post-rape. 
Rape stigma (ß = 0.72, p <.001) and depression (ß = 0.63, p <.001) were the only significant 
predictors of PTSD symptom severity in this model. Model 2 followed the same design as 
Model 1, but the pre-assault trauma and post-assault putative risk and protective variables (i.e. 
continuous variables) were replaced by categorical variables. Rape stigma and depression were 
again the only variables significantly associated with PTSD symptom severity (see 
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Table 3: Summary statistics of the mixed linear regression model for investigating baseline 
pre-assault and post-assault predictors of PTSD at 6-months post-rape 
 ß Std 
error 
t p 95% CI 
Lower          Upper  
      
Time (baseline)¹       
     3-months post-rape -28.74 1.88 -15.31 .000** -32.46 -25.02 
     6-months post-rape -36.37 1.85 -19.63 .000** -40.02 -32.72 
       
Age -0.14 0.17 -0.80 .427 -.48 0.20 
       
Basic education - not completed¹       
      Completed  0.21 1.66 0.12 .901 -3.60 3.47 
       
Employment - unemployed¹       
      Employed  -1.57 2.01 -0.78 .436 -5.51 2.38 
       
Relationship status - in a 
relationship¹ 
      
      Separated/divorced/widow  -0.59 3.45 -0.17 .864 -7.38 6.19 
      Single  -1.44 2.04 -0.70 .483 -5.45 2.58 
       
HIV status – negative¹       
      Positive 1.86 1.81 1.03 .304 -1.70 5.42 
       
Childhood trauma (CTQ-SF)² 0.22 0.25 0.85 .393 -0.28 0.72 
Lifetime trauma (LEC)²  0.61 0.48 1.29 .198 -0.32 1.55 
Resilience (CD-RISC)³ 0.06 0.15 0.41 .679 -.23 0.35 
Social support (MSPSS)³ 0.19 0.18 1.07 .285 -0.16 0.54 
Perceived stress (PSS)³ 0.11 0.16 0.70 .485 -0.21 0.43 
Rape stigma (RSS) 0.72 0.14 5.30 .000** 0.45 0.99 
Alcohol use (AUDIT-C) 0.15 0.34 0.45 .652 -0.52 0.82 
Depression (CES-D) 0.63 0.07 8.84 .000** 0.49 0.77 
       
1 Reference categories in regression model ²Modified version ³Modified response options 
 Abbreviations: Childhood Trauma Questionnaire Short Form (CTQ-SF); Life Events 
Checklist (LEC); The Connor-Davidson Resilience Scale (CD-RISC); Multidimensional Scale 
of Perceived Social Support (MSPSS); Perceived Stress Scale (PSS); Rape Stigma Scale 
(RSS); Alcohol Use Disorders Identification Test – Consumption (AUDIT); Center for 
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Interaction between baseline depression, baseline rape stigma and PTSD symptom scores 
across time 
Table 4 presents the summary statistics of Model 3 investigating the interaction effects for time 
x depression and time x rape stigma (significant predictors identified from Model 1 and Model 
2) on PTSD symptom scores. The shared variance from the predictor variables and their 
interaction with time significantly explained PTSD symptom severity F(20, 4969) = 35.6, p < 
.000 in the model as a whole. The interaction between time (for all timepoints) and rape stigma 
was not significant F(6, 1367) = 1.61, p =.140. However, when investigating individual 
timepoints participants with baseline rape stigma scores falling in the 3rd (ß = -11.18, p =.029) 
and 4th (ß = -15.36, p =.004) quartiles did show significantly increased PTSD symptom scores 
at 6-months post-rape compared to those with scores in the 1st quartile.  
 There was a significant interaction between time (for all timepoints) and depression 
F(6, 1798) = 5.66, p <.000. Participants with baseline depression scores falling in the 3rd (ß = 
-17.81, p <.000) and 4th (ß = -19.61, p <.000) quartiles had significantly increased PTSD 
symptom severity scores at 3-months post-rape compared to those falling in the 1st quartile. 
Participants with baseline depression scores falling in the 3rd (ß = -19.01, p <.000) and 4th (ß = 
-22.08, p <.000) quartile also had significantly increased PTSD symptom severity scores at 6-
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Table 4:  Summary statistics of the mixed linear regression model investigating the 
interaction between time and baseline pre- and post-assault factors  
 ß Std 
error 
t p 95% CI 
Lower          Upper 
      
Time (Baseline)       
      3-months -15.94 4.07 -3.91 .000** -23.95 -7.93 
      6-months -15.92 4.44 -3.58 .000** -24.66 -7.18 
       
Rape stigma (RSS) - 1st quartile¹       
      2nd quartile 8.62 3.17 2.72 .007** 2.39 14.84 
      3rd quartile 13.58 3.31 4.11 .000** 7.08 20.08 
      4th quartile 20.62 3.50 5.90 .000** 13.74 27.50 
       
Rape stigma x Time - 1st quartile x 
baseline¹ 
      
      2nd quartile x 3-months -0.99 4.49 -0.22 .825 -9.81 7.83 
      2nd quartile x 6-months -6.65 5.05 -1.32 .189 -16.60 3.30 
      3rd quartile x 3-months   -2.34 4.51 -0.52 .604 -11.22 6.53 
      3rd quartile x 6-months -11.18 5.09 -2.20 .029* -21.19 -1.16 
      4th quartile x 3-months -5.16 5.14 -1.00 .317 -15.32 4.99 
      4th quartile x 6-months -15.36 5.35 -2.87 .004** -25.91 -4.82 
       
Depression (CES-D) - 1st quartile¹       
       2nd quartile 11.93 3.15 3.79 .000** 5.74 18.12 
       3rd quartile 25.36 3.09 8.21 .000** 19.30 31.42 
       4th quartile 33.07 3.24 10.20 .000** 26.71 39.44 
       
Depression x Time - 1st quartile x baseline¹       
      2nd quartile x 3-months -4.62 4.20 -1.10 .271 -12.86 3.62 
      2nd quartile x 6-months -5.43 4.71 -1.15 .250 -14.68 3.83 
      3rd quartile x 3-months   -17.81 4.34 -4.10 .000** -26.33 -9.29 
      3rd quartile x 6-months -19.01 4.88 -3.89 .000** -28.62 -9.41 
      4th quartile x 3-months -19.61 4.63 -4.24 .000** -28.71 -10.50 
      4th quartile x 6-months -22.08 4.87 -4.54 .000** -31.64 -12.52 
       
¹ Reference categories in regression model  
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Trajectories of depression, rape stigma and PTSD symptoms  
Figure 3 illustrates the estimated mean PTSD symptom scores when considering the interaction 
between time and the depression quartiles at baseline (see Supplementary Table 6 for details). 
The PTSD symptom trajectories followed a similar pattern over time with a decline in PTSD 
symptoms visible for all depression quartiles. An upward shift in PTSD symptom severity over 
time corresponded to an upward shift in depression quartiles. Figures 4a-4d illustrate the 
estimated additive effect of falling in a higher rape stigma quartile at baseline on PTSD 




Figure 3: Time-specific effects of different depression quartiles at baseline on estimated PTSD 
symptom score trajectories. The x-axis presents time passed since the rape occurred, with baseline 
representing 0-20 days post-rape. The y-axis presents the PTSD symptom score measured with the 
Davidson Trauma Scale (DTS). The grey dotted line represents the DTS cut-off of 40 and the solid grey 
line represents the estimated mean PTSD symptom scores when not considering the interaction between 
time and depression quartiles. 

























Figure 4: Time-specific effects of different depression quartiles with the added effect of different rape stigma quartiles at baseline on estimated 
PTSD symptom scores. The estimated mean PTSD trajectories when considering the 1st, 2nd, 3rd and 4th depression quartiles and the additional 
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effect of the rape stigma quartiles are consecutively presented in Figures 4a-4d. The x-axis presents the time passed since the rape occurred with 
baseline representing 0-20 days post-rape. The y-axis presents the PTSD symptom score measured with the Davidson Trauma Scale (DTS). The 
grey dotted line represents the DTS cut-off of 40 and the solid grey line represents the estimated mean PTSD symptom trajectory when not 
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Assault factors and PTSD symptom scores  
Table 5 shows findings from the subset of participants who disclosed assault characterist ics. 
None of the assault variables were significantly associated with PTSD symptom scores at any 
timepoint, with the exception of the number of men involved in the rape which was associated 
with PTSD symptom scores at 3-months post-rape (p = .032). Rape survivors reporting a single 
perpetrator had higher PTSD scores at 3-months post-rape (M = 43.9, SD = 29.4) compared to 
those who reported multiple perpetrators (M = 36.9, SD = 29.5).  
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Table 5: Assault factors in relation to PTSD symptom scores over time 
 
 
n(%) M(SD) Baseline PTSD score 
       M(SD)                  p 
3-month PTSD score 
       M(SD)                 p 
6-month PTSD score 
        M(SD)                 p 
         
Number of men involved in the rape 152(100) 1.3(1.0)  .676  .032*  .833 
      1 perpetrator  138(90.8)  70.9(25.2)  43.9(29.4)  31.0(28.8)  
      More than 1 perpetrator 14(9.2)  68.0(21.6)  36.9(29.5)  30.3(24.3)  
         
Relationship to perpetrator 165(100)   .838  .559  .600 
      Known 114(69.1)  69.9(26.2)  41.8(29.1)  29.7(27.8)  
      Not known  51(30.9)  71.4(21.5)  44.5(30.8)  30.9(27.6)  
         
Use of coercion  167(100)   .495  .116  .290 
      Abducted 55(32.9)  73.5(20.5)  36.5(26.8)  27.3(27.2)  
      Lured under false pretences 26(15.6)  67.6(21.0)  50.4(32.1)  37.1(31.4)  
      Not abducted 86(51.5)  69.1(27.8)  44.9(30.0)  30.3(27.8)  
         
Perpetrator used a weapon  168(100)   .363  .718  .526 
       Yes 51(30.4)  73.6(20.4)  41.3(27.6)  30.5(28.6)  
       No 85(50.6)  69.5(26.5)  42.8(30.2)  29.2(27.6)  
       Unsure 32(19.0)  66.3(25.3)  46.8(31.2)  34.7(28.6)  
         
Bodily physical force/assault used 160(100)   .674  .492  .441 
       Yes 134(83.8)  70.0(23.3)  43.1(29.6)  30.4(29.1)  
       No 26(16.2)  68.4(31.0)  37.8(26.1)  31.7(23.5)  
         
Perpetrator threatened to kill the survivor 163(100)   .397  .932  .699 
       Yes 75(46.0)  72.7(21.0)  42.6(32.0)  28.3(26.0)  
       No 88(54.0)  68.6(27.6)  41.6(26.3)  31.4(29.4)  
         
Rape survivor thought she would be killed  164(100)   .763  .127  .175 
       Yes 114(69.5)  71.2(23.1)  44.8(30.5)  24.4(22.1)  
       No 50(30.5)  69.0(28.4)  36.3(24.2)  33.2(29.9)  
         
Prior rape by the same perpetrator  168(100)   .699  .332  .905 
       Yes 15(8.9)  68.9(20.6)  34.9(23.3)  27.7(20.1)  
       No 153(91.1)  70.3(25.0)  43.9(30.0)  30.9(28.7)  
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Number of sexual acts (vaginal, anal, oral, 
digital or object penetration, forced or 
observed masturbation) 
160(100) 1.9(1.6)  .253  .226  .272 
       1 act 97(60.6)  68.0(26.0)  40.3(29.2)  29.3(29.4)  
       2 or more acts  63(39.4)  72.8(22.1)  46.0(29.5)  30.6(28.6)  
         
Reported to police 169(100)   .199  .716  .753 
       Yes 139(82.3)  71.6(22.9)  42.6(29.3)  30.8(28.8)  
       No 30(17.7)  64.1(30.8)  45.1(30.5)  30.3(24.2)  
         
Abbreviations: Mean (M), Standard Deviation (SD)
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Consistent with previous longitudinal studies, we found a high incidence of PTSD at 3-months 
post-rape. Previous studies reported that 35% - 45% of rape and/or sexual assault survivors met 
criteria for PTSD at 3-months post-rape, we found that 48,5% of the sample scored above the 
clinical cut-off for PTSD in this sample 9,17–19. We also found that 25.4% of participants 
remained above the clinical cut-off for PTSD at 6-months post-rape which is consistent with 
literature highlighting the long-term adverse effects of rape on mental health 18,19,23  
Pre-assault demographic factors age, education, employment, relationship status, HIV 
status, childhood trauma exposure and cumulative lifetime trauma exposure were not 
significant predictors of PTSD in the multivariate analyses. Most previous studies of risk 
factors for PTSD after rape have also not found a significant association between socio-
demographic factors and PTSD 9,18,26,28,33,63. Pre-assault childhood trauma and cumulative 
lifetime trauma were found to be strong predictors of PTSD in samples of participants with a 
mix of index trauma types 44,46,64 but inconsistent findings have been reported for rape and 
sexual assault and some support the non-significant findings found in the multivariate analyses 
in our study  9,18,26–28,63.  
Depression and rape stigma post-assault were the only significant predictors of PTSD, 
with depression being the strongest predictor. Previous studies on rape and sexual assault have 
also reported a link between higher baseline depression scores and increased PTSD symptom 
scores over time 18,27,63. Depression may be viewed as a comorbid condition that emerges 
following trauma exposure as many individuals with PTSD are likely to meet criteria for 
depression as well 65–67. One longitudinal study investigating sexual assault survivors found 
that PTSD symptom severity fully mediated the relationship between depression symptom 
severity and the effect of time 19. The study therefore suggests that a decrease in depression 
symptoms over time is directly linked to a decrease in PTSD symptoms and that depression 
likely develops secondary to PTSD following sexual assault 19. Some of the symptoms of 
depression also overlaps with the symptoms of PTSD (e.g. negative alterations in cognitions 
and mood and alteration in arousal and reactivity)68. This overlap may partly explain the 
significant association between PTSD symptom scores and depression scores reported in this 
study 65–67. A higher rate of lifetime depression has also been associated with PTSD in two 
longitudinal sexual assault studies and suggests that premorbid depression may be a risk factor 
for the development of PTSD following sexual assault 18,34. We are not able to deduce from 
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our findings that high depression scores post-rape were the result of rape since we did not take 
a prior history of depression into account in the analysis.  
    The significant relationship between rape stigma and PTSD corresponds to findings of 
several prior studies investigating sexual assault where negative social reactions were 
associated with increased PTSD symptom severity 10,25,26,31. Rape stigma, in this study and 
previous studies, is mostly defined by negative, morally rooted emotions such as self-blame, 
embarrassment and shame, disrespect and avoidance from others and the belief that the victim 
should have done more to prevent the rape 10,69,70. Rape stigma and social support seem to be 
closely interrelated with increased rape stigma associated with a decreased ability to access and 
rely on social support 10,45,69. Since rape is a violation at an interpersonal level, it is plausible 
that victims  develop a sense of distrust in others and when this distrust is not repaired over 
time through positive supportive responses, this may result in more severe emotional distress 
9,27. Decreased social support and increased self-blaming is also likely to hinder treatment 
seeking and long-term recovery 9. The majority of rape survivors in this study were acquainted 
with the perpetrator. This has also been found to contribute to others blaming the victim and 
holding the victim responsible for the event; this is especially true when the perpetrator is a 
family member or a respected member of the community 10,25,31,45,47. 
It has been suggested that the aggressive act of rape and its intrusive nature can result 
in such severe distress that it overrides the risk and protective factors that are generally 
associated with PTSD 9,71,72. This may explain the non-significant relationship found between 
resilience, social support and PTSD in the multivariate analyses in this study. Depression and 
rape stigma may also inhibit the role of protective factors such as resilience and social support 
to such a degree that the variance explained by the latter may be masked by the variance 
explained by the former.  
Similar to the findings of a recent longitudinal study in survivors of completed and 
attempted rape, we did not find that alcohol consumption significantly contributed to PTSD 
scores 18. Perceived stress was also not associated with PTSD. It should be noted that the 
majority of longitudinal sexual assault studies  have investigated sexual assault in general and 
not rape or completed rape exclusively 9,18,19,38. In this study we investigated survivors of rape 
only.  Rape compared to non-penetrative sexual assault may have further exacerbated 
emotional distress especially if it was accompanied by physical violence or threats of violence 
18,25,26,30. Differences in the type of sexual assault investigated in previous studies may explain 
inconsistencies between our finding and prior findings. 
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None of the assault-related factors were associated with PTSD at any timepoint, with 
the exception of number of perpetrators/accomplices involved in the rape. Previous studies 
investigating assault-related variables have reported inconsistent findings 9,18,25,26,63. Some 
studies have found a significant relationship between PTSD and multiple perpetrators 18, 
multiple sexual acts 18, physical injury inflicted during the rape 18,25 longer duration of assault 
30 and perceived life threat 25,26,30 while other studies did not 9,63. We found that rape involving 
a single perpetrator was associated with higher PTSD scores at 3-months post-rape compared 
to rape involving multiple perpetrators. This finding is counterintuitive and should be 
interpreted with caution given that (1) the assault-related variables was investigated using 
univariate analysis only and the findings were not corrected for multiple testing and (2) only a 
sub-sample of participants disclosed this information and the reasons for non-disclosure (e.g. 
emotionally unable to disclose, ongoing legal case) may themselves be associated with PTSD 
symptom scores and may have introduced bias.  
In conclusion, we found that depression and rape-stigma had a significant adverse 
impact on the PTSD recovery trajectory following rape. Identifying risk factors present before 
trauma exposure and manifesting soon after a traumatic event could potentially guide early 
interventions and reduce the number of PTSD cases resulting from rape and sexual violence 
18,23. Targeted early interventions are especially important in low- and middle-income countries 
characterised by limited resources and overburdened mental health care facilities since 
treatment of severe psychopathology is more resource intensive (e.g. longer duration of 
treatment, medical interventions, hospitalisation, management of comorbid disorders) with 
higher costs and burden for the healthcare system 73,74. Brief interventions, including 
psychoeducation, targeting cognitive distortions and stigma around rape, could be delivered by 
trained counsellors attending to those reporting the rape for the first time. Depression should 
also be assessed in rape survivors and those presenting with high levels of depression at rape 
crisis centres and/or hospitals should be appropriately referred and managed accordingly. 
  
Strengths and limitations 
Some limitations were unavoidable in this study and deserve mention. All participants 
disclosed the rape since they all sought help from rape crisis centres before enrolling in the 
study. As such, we could not assess risk and protective factors associated with PTSD in non-
disclosing rape survivors. Fear of contracting HIV may have contributed to emotional distress, 
but this was not considered in the analyses. Some participants received counselling at the rape 
crisis centres at which they presented and/or at the study site. We could not include counselling 
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as a predictor of PTSD scores in the multivariate analyses since we did not have this 
information for those who were lost to follow-up. Current psychotropic and psychotherapeutic 
interventions which may influence PTSD symptom severity were not considered as covariates. 
We could not include assault-related variables in the multivariate analyses since they were 
reported by a small sub-set of participants only. Lastly, the self-report measure of perceived 
stress showed poor reliability in the sample and the results related to this measure should be 
interpreted with caution. 
This study also had several strengths. First, the longitudinal design permitted causal 
and consequential inferences about risk and protective factors for PTSD in a large cohort of 
rape-exposed women to be made. Second, all women in this study were exposed to a 
homogenous trauma (i.e. rape), in contrast to most previous longitudinal studies that have 
lumped sexual assault, rape and attempted rape together. Third, the study was adequately 
powered to investigate a variety of risk and protective factors that have previously been 
documented to be associated with PTSD in mixed trauma samples. Finally, we did not exclude 
participants with missing data but imputed missing values using a multiple imputation model 
which limits bias caused by drop-out and other associated factors. We also used a mixed linear 
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Introduction: Rape is associated with a high risk for posttraumatic stress disorder (PTSD). 
DNA methylation changes may confer risk or protection for PTSD following rape by regulating 
expression of genes implicated in pathways affected by PTSD. We aimed to: (1) identify 
epigenome-wide differences in methylation profiles between rape-exposed women with and 
without PTSD at 3-months post-rape, in  a demographically and ethnically similar group, drawn 
from a low-income setting; (2) validating and replicate the findings resulting from the 
epigenome-wide analysis in selected genes (BRSK2 and ADCYAP1) at 3-months post-rape; and 
(3) investigate baseline and longitudinal changes in BRSK2 and ADCYAP1 methylation over 
six months in relation to change in PTSD symptom scores over 6 months, in the combined set. 
Methods: Rape-exposed women (n = 852) were recruited from rape clinics in the Rape Impact 
Cohort Evaluation (RICE) umbrella study. Epigenome-wide differentially methylated CpG 
sites between rape-exposed women with (n = 24) and without (n = 24) PTSD at 3-months post-
rape were investigated using the Illumina MethylationEpic BeadChip, in a discovery cohort (n 
= 48). Validation (n = 48) and replication (n = 49) of the findings related to BRSK2 and 
ADCYAP1 methylation were investigated using EpiTYPER technology. Longitudinal change 
in BRSK2 and ADCYAP1 were also investigated using EpiTYPER technology in the combined 
set (n = 96). Results: One differentially methylated CpG site (chr10: 61385771/ cg01700569, 
adjusted for multiple comparisons p = .049) and thirty-four differentially methylated regions 
were associated with PTSD status at 3-months post-rape, in the discovery set. Decreased 
BRSK2 CpG3 methylation at 3-months post-rape was associated with increased PTSD scores 
at 3-months post-rape. Conclusion: Decreased methylation of BRSK2 may result in abnormal 
neuronal polarisation, synaptic development, vesicle formation and disrupted 
neurotransmission in individuals with PTSD at 3-months post-rape. PTSD symptoms may also 
be mediated by differential methylation of the ADCYAP1 gene, which is involved in regulating 
the stress response. Replication of these findings are required to provide support for ADCYAP1 










Rape and sexual assault are associated with a high risk for the development of posttraumatic 
stress disorder (PTSD) compared to other trauma types 1,2. Prospective studies have reported 
PTSD prevalence rates ranging between 35% and 45% at 3-months post-rape, with many 
survivors of sexual assault continuing to experience PTSD symptoms at 6- and 12-months post-
rape 3–6. PTSD is a complex, multifactorial disorder and an array of environmental and genetic 
putative risk and protective factors mediate or contribute to the development of the disorder 
3,5,7. Epigenetic mechanisms, including DNA methylation, are known to respond to 
environmental exposures such as trauma, leading to stable changes in gene expression 8,9. DNA 
methylation responses may confer risk or protection for PTSD, as they may alter the ability to 
adapt to traumatic events on a molecular level 10. Using a hypothesis-neutral, genome-wide 
approach to study epigenome-wide signatures (while accounting for potential environmental 
and biological confounding factors) and validating and replicating these findings, may bring 
us closer to uncovering the complexity of the disorder 10.  
 To date, twelve epigenome-wide association studies (EWASs) of blood DNA 
methylation differences in PTSD cases and controls have been published (see Table 1 for 
details). In sum, the majority of genes identified as differentially methylated in  PTSD are 
linked to central nervous system functioning (e.g. neuron development, axonal outgrowth, 
synaptic connectivity, neurotransmitter release, neuroinflammation and apoptosis) 11–17 and the 
immune response (T-cell expression, cytokine and interferon release, phagocytosis) 13,14,18,19. 
A meta-analysis of three North American mixed-gender civilian EWASs 13,17,18,20 found 
that PTSD was associated with the neuregulin1 (NRG1) and hepatocyte growth factor-regulated 
tyrosine kinase substrate (HGS), both of which are related to central nervous system 
functioning 21. The largest EWAS meta-analysis to date included 796 participants with PTSD 
and 1100 healthy controls 22. North American and European male and female participants 
drawn from three civilian cohorts 13,17,18,20 and seven combat-exposed cohorts 15,16 were 
included. Associations with PTSD were observed at four CpG sites of the human aryl 
hydrocarbon receptor repressor (AHRR) gene, which has been linked to both pro- and anti-
inflammatory immune regulation 22,23. Ring finger protein 6 (RNF6), also associated with 
immune function; ATPase phospholipid transporting 9A (ATP9A), associated with glucose 
metabolism; family with sequence similarity 75, member D1 (FLJ46321), associated with cell 
regulation; the microRNA 3170 (MIR3170); and the long intergenic non-protein coding RNA 
599 (LINC00599) genes were also associated with PTSD 22. 
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None of the gene-specific findings have been replicated across EWASs. Heterogeneity 
between and within EWASs may explain the lack of consistent findings. The majority of 
EWASs (including those in the meta-analyses) have been cross-sectional studies 11–15,17–
20,22,24,25 and investigated differential methylation in combat-exposed populations and first 
responders 12,14–16,20,24,25. PTSD symptoms often present differently in combat-exposed samples 
(increased hypervigilance and compulsive behaviour) compared to civilian samples 26,27. PTSD 
symptom presentation, severity and recovery rates also differ between civilian trauma types 
26,28,29. Civilian EWASs have investigated a mixture of trauma types and none have investigated 
rape exclusively 30. Civilian EWASs have also been predominantly conducted in mixed-gender 
11,13,18,19,25,31, North American samples 11–13,17–20,25.  
Ethnicity- and sex-specific characteristic may influence methylation profiles 32–34. 
Women have a two-fold increased risk of developing PTSD compared to men 34. Increased risk 
for PTSD in women may be X-chromosome linked, given that PTSD heritability is 
considerably higher among women compared to men 35,36. Sex-specific expression of 
reproductive genes may also mediate the increased risk for PTSD in women e.g. estrogen levels 
have been associated with an altered hypothalamic-pituitary-adrenal (HPA) axis stress 
response in women 17,37,38 and differential methylation of estrogen response elements (EREs) 
in genes associated with HPA-axis functioning has been reported 17,39. 
We sought to address the design shortcomings and demographic differences in prior 
EWASs by conducting a cross-sectional EWAS study, complemented by a candidate gene 
validation, replication and longitudinal investigation study of a demographically similar 
group of rape-exposed African black women in a low-income setting. Specific aims were to: 
(1) identify genome-wide differentially methylated CpG sites/regions associated with PTSD 
status at 3-months post-rape using an EWAS approach in a discovery set; (2) validating the 
findings resulting from the EWAS in selected genes at 3-months post-rape in a validation set; 
(3) replicate the findings in selected genes at 3-months post-rape in a replication set; (4) 
investigate if baseline methylation levels of selected genes predict PTSD status change over 
6-months, in the combined set; (5) investigate if methylation changes in selected genes 
covary in relations to PTSD symptom scores over 6 months, in the combined set.
Stellenbosch University  https://scholar.sun.ac.za
180 
 
Table 1: Summary of epigenome-wide association studies in PTSD 
Reference Array and 
Tissue Type 






        





23 PTSD cases 
77 trauma exposed controls 
Civilians from the 
DNHS cohort; mixture 
of trauma types 
79 African American, 
14 Caucasian,  










Functional annotation clustering 
of differentially methylated genes 
implicated genes associated with 
the immune system in the 
development of PTSD. 
        





51 PTSD cases 
53 trauma exposed controls  
Civilians from the GTP 
cohort; mixture of 
trauma types  









differences in methylation at CpG 
sites in the APC5, TLR8, TPR, 
CLEC9A, ANXA2. 
        





32 PTSD cases with CT 
29 PTSD cases without CT 
 
Civilian; mixture of 
trauma types  
150 African American, 









Pathways affected by PTSD were 
related to apoptosis and cellular 
growth rate. Pathways uniquely 
affected in those with PTSD and 
CT were related to nervous 
system development and tolerance 
induction. 









12 PTSD cases 
12 trauma exposed controls 
Civilian; index 
traumas: 8 childhood 
physical or sexual 
abuse (33.3%); 3 
sexual assault (12.5%); 
9 violent crime 
(37.5%); 2 IPV (8.3%); 
2 witnessed violent 
death (8.3%) 









No genome-wide significant 
differences in methylation levels. 
Expression of genes associated 
with olfactory receptors, immune 
activation, GABAA receptor and 
vitamin D synthesis were 
upregulated in PTSD cases. 
        
Hammamieh 




79 PTSD cases 




deployed to Iraq or 
Afghanistan. 
159 American ethnically 
matched participants (not 







Functional enrichment analysis of 
differentially methylated genes 
implicated genes related to 
nervous system 
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complications and endocrine 
signalling in the development of 
PTSD. 
        







171 current PTSD cases 
100 past PTSD cases 
202 trauma exposed controls 
Civilian responders to 
the September 11th 
World Trade Centre 












No genome-wide significant 
differences in methylation levels. 
Differential methylation at CpG 
sites in the ZDHHC11, CSMD2, 
COL9A3, PDCD6IP, TBC1D24 
and FAM164A genes were 
associated with current PTSD at a 
nominal level. 
        





48 PTSD cases 
48 combat exposed controls 
Treatment seeking 
Vietnam veterans 










differences in methylation at CpG 
sites in the BRSK1, NGF, LCN8, 
DOCK2 genes and at an 
intergenic site (closest gene 
LRRC3B). 






34 PTSD cases 
39 trauma exposed controls 







No genome-wide significant 
differences in methylation levels. 
        





109 PTSD cases, 
169 trauma exposed controls  
Civilians from the GTP 











difference in methylation at one 
CpG sites in HDAC4. 
        








32 high PTSD, high trauma 
29 low PTSD, high trauma 
32 low PTSD, low trauma 
Replication dataset: 
longitudinal; 
35 with PTSD 
Military soldiers pre- 
and post-deployment 
(minimum of 4 
months) to Afghanistan 
from the PRISMO 
cohort. 
Marines pre- and post-
deployment to Iraq or 
93 Dutch Caucasian 
soldiers and 98 North 












Longitudinal changes in PTSD 
symptoms were associated with 
differential methylation at CpG 
sites in the DUSP22, NINJ2, 
HOOK2, SDK1, MYT1L, PAX8, 
COL1A2 and HIST1H2APS2 
genes in the PRISMO cohort. The 
finding related to HIST1H2APS2 
was replicated in the MRS cohort. 
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63 controls with combat 
exposure 
Afghanistan from the 
MRS cohort. 
        






198 with PTSD 
347 trauma exposed controls 
Civilians from the 
DNHS, GTP and WTC 
cohorts; mixture of 
trauma types. 
343 African American, 
164 Caucasian 
American,  










differences in methylation of CpG 
sites in the NRG1 and HGS genes. 
        





378 PTSD cases 
135 trauma exposed controls 
 
War veterans exposed 
to combat trauma in 
Iraq and/or 
Afghanistan form the 
TRACTS cohorts and 
veterans recruited from 
TBI-VA-Boston. 
 
513 American veterans 










difference in methylation of a 
CpG site in the G0S2 gene. 
        





123 PTSD cases 
143 war exposed controls 
Military (marine and 
army) combat exposed 
personnel from the 
MRS, STARRS and 
PRISMO cohorts. 
Deployed to Iraq or 





78 Caucasian American 
army soldiers, 












differences in methylation of CpG 
sites in the SPRY4, SDK1, CTRC, 
CDH15, MAD1L1, HEXDC 
genes.  
        






878 PTSD cases 
1018 trauma exposed 
controls 
Three civilian samples 
and seven combat 
samples all exposed to 
trauma including 
combat and various 
civilian traumas. 









777 African American, 
57 Hispanic, 

















differences in methylation of CpG 
sites in the AHRR, RNF6, 
MIR3170, ATP9A, AC011899.9, 
FLJ46321 and LINC00599 genes. 
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Abbreviations:  
HumanMethylation27 BeadChip (HM27); posttraumatic stress disorder (PTSD); Detroit Neighborhood Health Study (DNHS); PTSD Checklist – 
Civilian Version (PCL-C); Grady Trauma Project (GTP); Clinician-Administered PTSD Scale (CAPS); acid phosphatase 5, tartrate resistant (APC5); 
toll-like receptor 8 (TLR8); translocated promoter region (TPR); C-type lectin domain family 9, member A (CLEC9A); annexin A2 (ANXA2); 
HumanMethylation 450K BeadChip (450K); childhood trauma (CT); PTSD Symptom Scale (PSS); intimate partner violence (IPV); gamma-
aminobutyris acid A (GABAA); World Trade Centre 9/11 responders study (WTC); Structured Clinical Interview for DSM Disorders (SCID); zinc 
finger DHHC-type containing 11 (ZDHHC11); CUB and sushi domain-containing protein (2CSMD2); collagen type IX alpha 3 chai (COL9A3); 
programmed cell death 6 interacting protein (PDCD6IP); TBC1 domain family member 24 (TBC1D24); family with sequence similarity 164, member 
A (FAM164A); MethylationEPIC BeadChip (EPIC); brain-specific serine/threonine-protein kinase 1 (BRSK1); nerve growth factor (NGF); lipocalin 8 
(LCN8); dedicator of cytokinesis 2 (DOCK2); leucine rich repeat containing 3B (LRRC3B); histone deacetylase 4 (HDAC4); Prospective Research in 
Stress-related Military Operations (PRISMO); Marine Resiliency Study (MRS); Self-Rating Inventory for PTSD (SRIP); dual specificity phosphatase 
22 (DUSP22); ninjurin 2 (NINJ2); hook microtubule tethering protein 2 (HOOK2); sidekick cell adhesion molecule 1 (SDK1); myelin transcription 
factor 1 like (MYT1L); paired box 8 (PAX8); collagen type I alpha 2 chain (COL1A2); H2A histone family, member T, pseudogene (HIST1H2APS2); 
neuregulin 1 (NRG1); hepatocyte growth factor-regulated tyrosine kinase substrate (HGS); Translational Research Centre for TBI and Stress Disorders 
(TRACTS); Department of Veterans Affairs Rehabilitation Research and Development (VA-RR&D); Traumatic Brain Injury Centre of Excellence – 
Veteran Affairs Boston Healthcare System (TBI-VA-Boston); G0/G1 switch 2 (G0S2); Study to Assess Risk and Resiliency in Servicemembers 
(STARRS); Composite International Diagnostic Interview – Screening Scales (CIDI-SC); sprouty RTK signalling antagonist 4 (SPRY4); sidekick cell 
adhesion molecule 1 (SDK1); chymotrypsin C (CTRC); cadherin 15 (CDH15); mitotic arrest deficient 1 like 1 (MAD1L1); hexosaminidase glycosyl 
hydrolase family 20 catalytic domain containing (HEXDC); Injury and Traumatic Stress Study (INTRusST); Mid-Atlantic Mental Illness Research 
Education and Clinical Center PTSD Study European American cohort (VA-M-EA) and African American cohort (VA-M-AA); Boston Veterans 
Affairs National Center for PTSD (VA-NCPTSD); Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV); Mini-International 
Neuropsychiatric Interview (MINI); human aryl hydrocarbon receptor repressor (AHRR); ring finger protein 6 (RNF6); microRNA 3170 (MIR3170); 
ATPase phospholipid transporting 9A (ATP9A); family with sequence similarity 75, member D1 (FLJ46321); long intergenic non-protein coding RNA 
599 (LINC00599).
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Participant recruitment and setting 
Samples and data were analysed from a discovery set (n = 48), a validation set (n = 48), a 
replication set (n = 49) and the combined validation and replication set (n = 96). The 
Participants were recruited through the Rape Impact Cohort Evaluation (RICE) study 
conducted in South Africa (n = 852). A detailed description of the methods of the RICE study 
has been published elsewhere 40. In short, female survivors of rape were recruited from rape 
clinics. Interested participants were invited to the study site to enrol in the study following 
informed consent procedures. Recruitment was restricted to female participants between 18 
and 40 years who reported a rape in the preceding 20 days of the baseline visit. In the current 
study, we excluded women who: (1) were pregnant or lactating during the course of the study; 
(2) met criteria for PTSD at the baseline visit, indicative of  PTSD due to a past traumatic event 
other than the rape; and (3) had HIV-seroconverted.  
 Ethical approval for RICE was obtained from the Human Research Ethics Committee 
at the South African Medical Research Council (SAMRC; EC019-10/2013) and approval to 
conduct the sub-study was obtained from the Health Research Ethics Committee at 
Stellenbosch University (S16/08/146). 
 
Clinical measures  
At the baseline visit, a research assistant supervised by a registered trauma counsellor or 
registered nurse assessed for PTSD  (in relation to prior criterion A traumas other than the rape) 
on the Mini International Neuropsychiatric Interview (MINI) version 7.0.0 41. An HIV rapid 
test, pregnancy test, blood collection for DNA analysis and assessment of body mass index 
(BMI) were undertaken by a nurse at all timepoints (baseline, 3-months and 6-months post-
rape). 
 A research assistant administered a demographic questionnaire, a modified version of 
the Childhood Trauma Questionnaire - Short Form (CTQ-SF) 42 and a modified version of the 
Life Events Checklist (LEC) 43,44 at baseline. The Davidson Trauma Scale (DTS) 45, the 
Alcohol Use Disorders Identification Test, alcohol consumption subscale (AUDIT-C) 46 and 
the Center for Epidemiologic Studies Depression Scale (CES-D) 47 was administered at all 
timepoints. The DTS was used to measure PTSD symptoms with a cut-off score of forty or 
more considered indicative of PTSD 45. This cut-off was used to group participants into PTSD 
cases and controls at 3-months post-rape (see supplementary material for more details) 45. All 
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assessments were completed face-to-face and responses were recorded and electronically 
captured in real-time on a secure server. Item-level missing values were imputed using a 
multiple imputation model while maintaining a multivariate normal distribution. 
 
Demographic and clinical characteristics of the sample 
The baseline demographic and clinical characteristics of the sample were investigated using 
descriptive statistics. Differences in baseline demographic and clinical characteristics between 
the discovery/validation set and the replication set were investigated using non-parametric 
tests, since most of the variables did not conform to a normal distribution. Mann-Whitney U 
tests were used to compare differences between the groups for the continuous variables, i.e., 
age, body mass index (BMI), childhood trauma score, number of childhood traumas endorsed, 
number of lifetime traumas endorsed, alcohol use and depression symptom scores. Chi-square 
statistics were used to compare differences between the groups on several categorical variables 
(completed secondary education, relationship status, smoking status, HIV status, medication 
use, childhood neglect, witnessed domestic violence in childhood home, childhood emotional 
abuse, childhood physical abuse, childhood sexual abuse, imprisonment, civil unrest or war, 
serious injury, being close to death, murder of a family member or friend, unnatural death of a 
family member or friend, murder of a stranger, robbed at gun/knife point, kidnapped, hazardous 
alcohol use and depression status).   
The same variables and methods used to investigate baseline demographic and clinical 
differences between the discovery/validation and replication sets were used to investigate 
differences between those with and without PTSD at 3-months post-rape. 
 
Cross-sectional analyses (3 months post-rape) 
Discovery set 
Forty-eight participants, 24 with PTSD and 24 without PTSD at 3-months post-rape, were 
included in the discovery set. We implemented a cross-sectional, case-control EWAS design 
to identify genome-wide differentially methylated positions (DMPs) and differentially 
methylated regions (DMRs) between those with and without PTSD. Consecutive cases of 
PTSD at 3-months post-rape were identified until the target number was reached. Controls were 
perfectly matched to cases based on HIV status and as closely as possible (in descending 
hierarchical order of importance) on age, childhood trauma scores, lifetime trauma exposure, 
BMI, smoking, education and income. DNA was extracted from peripheral blood samples and 
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assayed using the Human MethylationEPIC BeadChip array (Illumina, California, United 
States).  
Raw probe intensity data (iDAT) files produced by Illumina GenomeStudio were 
decompressed and parsed into text format using the meffil R package 49 in R statistics version 
3.6.2 50. All EWAS analyses, including quality control measures and beta normalisation, were 
completed using the meffil R package 49.  
 No samples were excluded from the analysis, given that all samples passed the quality 
control checks (see Supplementary Material and Supplementary Figures 1, 2, 4 and 5). Probes 
not passing the quality control checks (n = 29936) were excluded from the downstream 
analyses (see Supplementary Material and Supplementary Figure 2 and 5). Previously 
identified cross-reactive probes for 43254 CpG sites were also excluded 51. Probes targeting 
CpG sites on the X chromosome were retained since all participants included in the study were 
female.  
The percentage of methylated alleles for each CpG site in each sample was calculated 
as β = M / (M + U +100) where M and U symbolises raw probe fluorescent intensities for 
methylated and unmethylated signals, respectively 52. Technical bias and batch effects were 
corrected for using functional normalisation (Supplementary Material, Supplementary Figure 
7-11, Supplementary Tables 1 and 2) 53. Any residual effects were handled by including 
surrogate variables as covariates in the EWAS models. These were estimated following 
functional normalisation using surrogate variable analysis (SVA) 54. Cell type composition was 
estimated by applying the Houseman algorithm to the normalized DNA methylation profiles 
and a publicly available blood cell type reference dataset (Gene Expression Omnibus accession 
number GSE35069) 55. Cell type composition was included in the final EWAS models 
(Supplementary Figure 12). Epigenome-wide associations were investigated using logistic 
regression models to identify DMPs associated with PTSD status. Benjamini-Hochberg 
correction was applied to correct for multiple testing with an adjusted p-value < .01 indicating 
genome-wide significance 56.  
The dmrff R package was applied to EWAS summary statistics  to identify DMRs 57. 
DMRs were defined as a region covering two or more CpG sites with less than 100 bp between 
consecutive sites showing the same direction of effect with an uncorrected p-value < .05 (see 
supplementary material for more details) 57. A DMR was considered significant on an 
epigenome-wide level if a Bonferroni-adjusted p < 0.05 was observed.  Coordinates resulting 
from the DMP and DMR analyses were annotated using the MethylationEPIC_v-1-0_B4 
manifest 52. Co-variation in methylation levels between blood and brain tissue was explored 
Stellenbosch University  https://scholar.sun.ac.za
187 
 
using the online Blood Brain DNA Methylation Comparison Tool 58. Prior findings reporting 
a link between any exposure or phenotype and the CpG sites identified from the EWAS were 
identified using the Medical Research Council Integrative Epidemiology Unit (MRC-IEU) 
catalogue of epigenome-wide association studies59 and the China National Center for 
Bioinformation National Genomics Data Center epigenome-wide association studies (EWAS) 
atlas60. All genomic coordinates reported in this study is in reference to the Hg19/GRCh37 




A candidate gene approach was used to validate the findings of the EWAS. The same sample 
included in the discovery set were investigated in the validation set. Samples were assayed 
using EpiTYPER Sequenom MassARRAY technology (Agena Bioscience, California, United 
States). DNA methylation was investigated at CpG sites in two selected regions at 3-months 
post-rape. Brain-specific serine/threonine-protein kinase 2 (BRSK2) and adenylate cyclase 
activating polypeptide 1 (ADCYAP1) were selected as candidate genes since they were the only 
genes that reached statistical significance as DMPs in the EWAS, prior to correction for 
multiple testing, and reached statistical significance at a genome-wide level as DMRs. BRSK1, 
a paralog of BRSK2 was identified as a DMP in a prior PTSD EWAS study 14. ADCYAP1 
receptor 1 (ADCYAP1R1) has been linked to the development of PTSD in several prior studies 
14,61–63.  
DNA methylation percentages were exported using the EpiTYPER Analyzer software 
(see Supplementary Material for more details). The validation analyses were completed using 
IBM SPSS Statistics 27.0. Logistic regression models were used to determine if differential 
methylation of BRSK2 and ADCYAP1 at 3-months post-rape was associated with PTSD status 
at 3-months post-rape.  
The relationship between baseline confounding variables, PTSD status at 3-months 
post-rape, BRSK2 methylation at 3-months post-rape and ADCYAP1 methylation at 3-months 
post-rape were investigated using Mann-Whitney U tests, Chi-square and Spearman’s 
correlations. Potential confounders included the continuous variables age, BMI, childhood 
trauma score, number of lifetime traumas endorsed, alcohol use and depression, and the 
categorical variables HIV status, smoking and medication use. Confounding variables 
significantly associated with PTSD or BRSK2/ADCYAP1 methylation were entered in the 
logistic regression models as covariates, in a stepwise manner. 
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Replication set  
Forty-nine additional, consecutively selected, participants from the RICE study were 
investigated in the replication set. Participants included in this replication set were not matched 
on PTSD status or potential methylation covariates. Samples were assayed using EpiTYPER 
Sequenom MassARRAY technology (Agena Bioscience, California, United States). 
Logistic regression models, including potential confounding variables, were used to 
determine if differential methylation of BRSK2 and ADCYAP1 at 3-months post-rape was 
associated with PTSD status at 3-months post-rape in the replication set, following the same 
procedure applied in the validation set.  
 
Comparison of previous findings from candidate gene studies and EWASs 
Candidate gene studies and EWASs investigating the relationship between methylation and 
PTSD were identified from published literature. For EWASs, the Illumina CpG identification 
number for significant findings was manually recorded and cross-checked against the findings 
of the current EWAS. For candidate gene studies, the genomic coordinates of the sites were 
identified from the publications and converted to H19/GRCh37 positions using the BLAT 
function of the UCSC genome browser (if not already indicated as H19/GrCh37 positions). 
The genomic locations were manually recorded and cross-checked with the 
MethylationEPIC_v-1-0_B4 manifest to determine if the sites were included on the 
MethylationEPIC array. Significant CpG sites resulting from the current EWAS and 
corresponding to prior findings are reported in the results. 
 
Agreement between the MethylationEPIC array and EpiTYPER  
Spearman’s correlation coefficients were used to investigate the level of agreement between 
methylation levels resulting from the MethylaytionEPIC array at 3-months post-rape and 
methylation levels resulting from EpiTYPER at 3-months post-rape. 
 
Longitudinal investigation (baseline, 3-months and 6-months post-rape) 
Combined set 
The validation and replication sets were combined and methylation data from the baseline and 
6-month post-rape samples were added to the dataset, for the same combined group. The group 
consisted of 96 participants with methylation data at all timepoints (baseline, 3-months and 6-
months). The samples were assayed using EpiTYPER Sequenom MassARRAY technology 
(Agena Bioscience, California, United States). We investigated the same BRSK2 and 
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ADCYAP1 CpG sites investigated in the validation and replication sets but followed a 
longitudinal cohort design with PTSD symptom scores as outcome, instead of a cross-sectional 
case-control design with PTSD status at 3-months as outcome.  
The PTSD scores at each timepoint were compared between the discovery/validation 
set and the replication set using Mann-Whitney U tests. The relationship between PTSD, 
BRSK2 methylation, ADCYAP1 methylation (at all timepoints) and potential baseline 
confounders (age, BMI, childhood trauma, lifetime traumas, alcohol use, depression, HIV 
status, smoking and medication use) were investigated using Mann-Whitney U tests, Chi-
square and Spearman’s correlations.  
Baseline ADCYAP1 and BRSK2 methylation levels were investigated as predictors of 
change in PTSD symptom scores over six months, in the first set of mixed regression models. 
In the second set of mixed regression models, we investigated change in BRSK2 and ADCYAP1 
methylation levels over six months in relation to change in PTSD symptom scores over six 
months. Confounding variables significantly associated with PTSD or BRSK2/ADCYAP1 
methylation at any timepoint were entered in the mixed regression models as covariates, in a 




Baseline demographic and clinical characteristics of the sample 
Table 2 presents the baseline demographic and clinical characteristics of the 
discovery/validation and replication sets. The sets were similar in demographic and clinical 
characteristics. The only variable that differed between the sets was the prevalence of lifetime 
exposure to the murder of a family member or friend, which was more frequently endorsed in 
the discovery/validation set compared to the replication set (25.5% vs. 8.2%, respectively; χ2 = 
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Replication set  
(n=49) 
Comparison of 
Discovery/validation set to 
replication set 
 n (%) M (SD) n (%) M (SD) χ2 z p 
        
Age¹ 47(100) 25.9(5.4) 49(100) 24.6(5.5)  -1.3 .178 
Secondary education completed² 32(68.1)  25(51)  2.9  .089 
Employed² 13(27.7)  9(18.4)  1.2  .279 
In a relationship/married² 38(80.9)  38(77.6)  0.2  .691 
        
BMI¹ 47(100) 26.0(6.5) 49(100) 25.8(5.7)  -0.1 .956 
Smoker² 5(10.6)  7(14.3)  0.3  .589 
HIV positive² 27(57.4)  19(38.8)  3.4  .067 
On ARVs² 12(25.5)  14(28.6)  0.1  .738 
On medications for STI² 2(4.3)  2(4.1)  0.0  .966 
Other medication use²,3 1(2.1)  2(4.1)  0.3  .582 
        
Childhood trauma score¹ 47(100) 17.2(4.1) 49(100) 16.2(2.5)  -0.8 .410 
Neglect² 23(48.9)  18(36.7)  1.5  .227 
Domestic violence² 10(21.3)  8(16.3)  0.4  .534 
Emotional abuse² 12(25.5)  11(22.4)  0.1  .724 
Physical abuse² 18(38.3)  19(38.8)  0.0  .962 
Sexual abuse² 10(21.3)  11(22.4)  0.0  .890 
Number of childhood traumas¹ 47(100) 1.6(1.6) 49(100) 1.4(1.5)  -0.6 .530 
        
Number of lifetime traumas¹,4 47(100) 1.6(1.5) 49(100) 1.1(1.2)  -1.7 .092 
Imprisonment² 2(4.3)  1(2.0)  0.4  .533 
Civil unrest or war² 3(6.4)  1(2.0)  1.1  .287 
Serious injury² 8(17.0)  3(6.1)  2.8  .094 
Being close to death² 13(27.7)  14(28.6)  0.0  .921 
Murder of family/friend² 12(25.5)  4(8.2)  5.2  .022* 
Unnatural death family/friend² 9(19.1)  5(10.2)  1.5  .214 
Murder of stranger² 10(21.3)  5(10.2)  2.2  .135 
Robbed gun/knife used² 17(36.2)  18(36.7)  0.0  .954 
Kidnapped² 3(6.4)  4(8.2)  0.1  .737 
        
PTSD symptom score¹ 47(100) 67.1(21.7) 49(100) 65.7(18.6)  -0.8 .431 
Alcohol use severity¹ 47(100) 1.4(2.2) 49(100) 1.9(2.5)  -1.2 .242 
Hazardous alcohol use² 12(25.5)  15(30.6)  0.3  .580 
Depression symptom score¹ 47(100) 32.4(13.9) 49(100) 31.7(12.1)  -0.2 .854 
Depression status² 41(87.2)  45(91.8)  0.5  .461 
        
¹Continous variables; ²categorical variables; ³medication prescribed for chronic sinusitis (n=1) and 
hypertension (n=2); 4lifetime traumas refer to directly experiencing the trauma; *p < .05 
Abbreviations: Posttraumatic stress disorder (PTSD); mean (M); standard deviation (SD); body 
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Comparison of baseline demographic and clinical characteristics between the PTSD 
groups at 3-months post-rape 
Table 3 presents the findings of the PTSD status group comparisons (at 3-months post-rape) in 
the discovery/validation set and the replication set, consecutively. Participants with and 
without PTSD had similar baseline demographic and clinical characteristics in the 
discovery/validation and replication sets. However, in the discovery/validation set, those with 
PTSD were more likely to endorse being robbed with a gun or knife compared to those without 
PTSD (50% and 21.7%, respectively; z = 4.1, p = .044). In the replication set, those with PTSD 
endorsed less lifetime traumas (M = 0.5, SD = 0.7) compared to those without PTSD (M = 1.4, 
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Table 3: Baseline demographic and clinical characteristics of rape-exposed participants with and without PTSD in the discovery/validation and 
replication sets 
  
Discovery/validation set (n = 47) 
 
 
Replication set (n = 49) 
 With PTSD at 3-
months (n = 24) 
Without PTSD at 3-
months (n = 23) 
Group differences With PTSD at 3-
months (n = 15) 
Without PTSD at 3-
months (n = 34) 
Group differences 
 n (%) M(SD) n (%) M(SD) χ2 z p n (%) M(SD) n (%) M(SD) χ2 z p 
 
               
Age¹ 24(100) 25.1(5.3) 23(100) 26.7(5.5)  -1.0 .296 15(100) 24.7(4.7) 34(100) 24.5(5.9)  -0.5 .616 
Secondary education completed² 16(66.7)  16(69.6)  0.1  .831 10(66.7)  15(44.1)  2.1  .146 
Employed² 4(16.7)  9(39.1)  3.0  .085 1(6.7)  8(23.5)  2.0  .160 
In a relationship/married² 19(79.2)  19(82.6)  0.1  .764 11(77.3)  27(79.4)  0.2  .638 
               
BMI¹ 24(100) 24.8(5.4) 23(100) 27.2(7.4)  -1.1 .268 15(100) 25.3(4.8) 34(100) 26.0(6.1)  -0.3 .745 
Smoker² 3(12.5)  2(8.6)  0.2  .672 2(13.3)  5(14.7)  0.0  .899 
HIV positive² 14(58.3)  13(56.5)  0.0  .900 7(46.7)  12(35.3)  0.6  .451 
On ARVs² 6(25.0)  6(26.1)  0.0  .932 4(26.7)  10(29.4)  0.0  .845 
On medications for STI² 1(4.2)  1(4.3)  0.0  .975 0(0.0)  2(5.9)  0.9  .338 
Other medication use²,3 0(0.0)  1(4.3)  1.1  .302 0(0.0)  2(5.9)  0.9  .338 
               
Childhood trauma score¹ 24(100) 18.2(4.6) 23(100) 16.2(3.3)  -1.7 .098 15(100) 15.7(2.5) 34(100) 16.4(2.6)  -1.0 .299 
Neglect² 13(54.2)  10(43.5)  0.5  .464 5(33.3)  13(38.2)  0.1  .743 
Domestic violence² 7(29.2)  3(13.0)  1.8  .177 3(20.0)  5(14.7)  0.2  .644 
Emotional abuse² 9(37.5)  3(13.0)  3.7  .055 3(20.0)  8(23.5)  0.1  .785 
Physical abuse² 10(41.7)  8(34.8)  0.2  .627 5(33.3)  14(41.2)  0.3  .604 
Sexual abuse² 7(29.2)  3(13.0)  1.8  .177 2(13.3)  9(26.5)  1.0  .310 
Number of childhood traumas¹ 24(100) 1.9(1.7) 23(100) 1.2(1.3)  -1.6 .120 15(100) 1.2(1.7) 34(100) 1.4(1.5)  -0.8 .430 
               
Number of lifetime traumas¹,4 24(100) 2.0(1.6) 23(100) 1.2(1.2)  -1.9 .063 15(100) 0.5(0.7) 34(100) 1.4(1.3)  -2.5 .014 
Imprisonment² 2(8.3)  0(0.0)  2.0  .157 0(0.0)  1(2.9)  0.5  .502 
Civil unrest or war² 2(8.3)  1(4.3)  0.3  .576 0(0.0)  1(2.9)  0.5  .502 
Serious injury² 6(25.0)  2(8.6)  2.2  .137 1(6.7)  2(5.9)  0.0  .916 
Being close to death² 7(29.2)  6(26.1)  0.1  .813 3(20.0)  11(32.4)  0.8  .378 
Murder of family/friend² 5(20.8)  7(30.4)  0.6  .450 0(0.0)  4(11.8)  1.9  .166 
Unnatural death family/friend² 5(20.8)  4(17.4)  0.1  .764 0(0.0)  5(14.7)  2.5  .117 
Murder of stranger² 7(29.2)  3(13.0)   1.8 .177 0(0.0)  5(14.7)  2.5  .117 
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Robbed gun/knife used² 12(50.0)  5(21.7)   4.1 .044 3(20.0)  15(44.1)  2.6  .107 
Kidnapped² 3(12.5)  0(0.0)   3.1 .080 1(6.7)  3(8.8)  0.1  .799 
               
PTSD symptom score¹ 24(100) 75.7(17.9) 23(100) 58.1(22.0)  -2.9 .004 15(100) 63.4(20.4) 34(100) 66.7(18.0) -0.1  .914 
Alcohol use severity¹ 24(100) 1.7(2.4) 23(100) 1.2(1.9)  -0.9 .394 15(100) 1.6(2.6) 34(100) 2.1(2.5)  -1.0 .299 
Hazardous alcohol use² 7(29.2)  5(21.7)   0.3 .559 4(26.7)  11(32.4)  0.2  .691 
Depression symptom score¹ 24(100) 35.1(12.9) 23(100) 29.5(14.7)  -1.4 .173 15(100) 28.4(13.5) 34(100) 33.1(11.4)  -1.4 .149 
Depression status² 22(91.7)  19(82.6)   0.9 .352 13(86.7)  32(94.1)  0.8  .380 
               
¹Continous variables; ²categorical variables; ³medication prescribed for chronic sinusitis (n=1) and hypertension (n=2); 4lifetime traumas refer to 
directly experiencing the trauma. 
Abbreviations: Posttraumatic stress disorder (PTSD); mean (M); standard deviation (SD); body mass index (BMI); antiretrovirals (ARV); sexually 
transmitted infection (STI).  
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Discovery set: genome-wide differentially methylated genes associated with PTSD status 
at 3-months post-rape 
Table 4 presents the findings of the top twenty DMPs that were associated with PTSD before 
correction for multiple comparisons (p < .05; see supplementary Figure 14 & 15 for more 
details). Only one DMP, cg01700569, remained significant after correcting for multiple testing 
(FDR adjusted p < .01). This intergenic site (cg01700569) is located 24 694 bases downstream 
of solute carrier family 16 member 9 (SLC16A9). Thirty-four DMRs were identified from the 
regional analysis after Bonferroni correction for multiple testing (adjusted p < .05; see 
supplementary Table 3 for details). Four regions were not attributed to a gene 
(chr1:153762201-153762244, chr17:72595585-72595587, chr1:153762359-153762434, 
chr1:153762201-153762244). The remaining regions were associated with leucine-rich repeat-
containing protein 34 (LRRC34; three regions), phospholipase D family member 6 (PLD6), 
solute carrier family 38 member 11 (SLC38A11), coiled-coil and C2 domain-containing protein 
2A (CC2D2A), endothelial cell specific molecule 1 (ESM1; two regions), sorbin and SH3 
domain-containing protein 2 (SORBS2), ankyrin repeat domain-containing protein 33 
(ANKRD33), collagen type XVIII alpha 1 chain (COL18A1), BRSK2, AC004895.4, spondin 1 
(SPON1), ADCYAP1, inositol polyphosphate-5-phosphatase A (INPP5A), chromosome 21 
open reading frame 62 (C21orf62), RP11-1085N6.3, thrombospondin type laminin G domain 
and EAR repeats antisense RNA 2 (TSPEAR-AS2), microRNA 125b-1 (MIR125B1), 
chromosome 5 open reading frame 66 antisense RNA (C5orf66AS1), fascin actin-bundling 
protein 2 (FSCN2), forkhead box J3 (FOXJ3), solute carrier family 39 member 13 (SLC39A13), 
tubulin polymerization promoting protein (TPPP), long intergenic non protein coding RNA 
1529 (LINC01529), chromosome 5 open reading frame 63 (C5orf63), hepatocellular 
carcinoma-associated gene 2 (HCCA2), oxytocin/neurophysin I prepropeptide (OXT) and zinc 
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Table 4: Genome-wide differentially methylated positions (DMPs) and regions (DMRs) associated with PTSD  




β SE t/z p Adj. p Other exposures/ 
phenotypes associated with the CpG 
site5 
           
Differentially methylated positions (DMPs)         
           
NA, SLC16A96  Chr10:61385771 cg01700569 OpenSea NSF 0.031 0.004 7.119 6.187e-08 0.049233 None 
 
NA, IRF46 Chr6:429318 cg06868375 OpenSea NSF -0.009 0.002 -5.846 2.067e-06 0.777284 None 
 
FEZ1 Chr11:125365803 cg06309855 Island 5'UTR 0.022 0.004 5.727 2.930e-06 0.777284 Gestational age 
 
CGLC Chr6:53371893 cg05277169 OpenSea Body 0.013 0.002 5.468 6.043e-06 0.999998 None 
 
 
BEGAIN Chr14:101036470 cg05730092 S_Shore TSS1500 0.032 0.006 5.401 7.352e-06 0.999998 Gestational age 
 
CRTC3-AS1 Chr15:91193536 cg16207883 OpenSea Body 0.021 0.004 5.233 1.183e-05 0.999998 None 
 
LINC01006 Chr7:156267149 cg01020356 OpenSea Body 0.025 0.005 5.224 1.216e-05 0.999998 Ethnicity; osteonecrosis of the 
femoral head 
 
EPB41L1 Chr20:34818105 cg20355257 OpenSea 3'UTR 0.017 0.003 5.204 1.286e-05 0.999998 Down syndrome 
 
ADCYAP1 Chr18:905177 cg22388954 Island 5'UTR; 
TSS200 
-0.025 0.005 -5.181 1.371e-05 0.999998 B acute lymphoblastic leukemia 
BRSK2 Chr11:1431833 cg09450823 Island Body 0.036 0.007 5.115 1.653e-05 0.999998 None 
 
NA, MIR42906 Chr9:92782655 cg04299914 OpenSea NSF -0.049 0.010 -5.091 1.769e-05 0.999998 None 
 
USP49 Chr6:41790313 cg11943190 OpenSea 5'UTR -0.010 0.002 -5.050 1.970e-05 0.999998 Rheumatoid arthritis; exercise 
 
DOK5 Chr20:53127455 cg01998039 OpenSea 5'UTR; 
Body 
0.040 0.008 5.049 1.994e-05 0.999998 Down syndrome; aging 
MCEE Chr2:71338735 cg08848660 OpenSea Body -0.011 0.002 -5.012 2.205e-05 0.999998 None 
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Chr7:44965393 cg01855601 OpenSea NSF 0.010 0.002 4.975 2.436e-05 0.999998 None 
PARD3 Chr10:35016204 cg18026072 OpenSea Body -0.009 0.002 -4.961 2.534e-05 0.999998 None 
 
NA, BRSK26 Chr11:1401914 cg22820726 N_Shelf NSF -0.063 0.013 -4.963 2.544e-05 0.999998 None 
 
TMEM52B Chr12:10322100 cg05617790 OpenSea Body; 
TSS1500 
0.015 0.003 4.953 2.619e-05 0.999998 None 
TRMO Chr9:100662939 cg13109115 OpenSea NSF -0.103 0.021 -4.915 2.915e-05 0.999998 None 
 
1 Identified using the GENECODE database; 2 identified using the Human Genome 19 (HG19) build from the Genome Reference Consortium; 3 
identified using the University of California Santa Cruz (UCSC) Genomic Institute/Genome Browser; 4 multiple listings indicate splice variants; 
5 identified using the Medical Research Council Integrative Epidemiology Unit (MRC-IEU) catalog of epigenome-wide association studies59 and 
the China National Center for Bioinformation National Genomics Data Center epigenome-wide association studies (EWAS) atlas60; 6 CpG sites 
located in a region not attributed to a gene, the gene closest to the CpG site is provided; 7 The site is associated with a promoter region - identified 
using the Methylation Consortium project. 
Abbreviations: Standard error (SE); adjusted (Adj); not applicable (NA); solute carrier family 16 member 9 (SLC16A9); not specified (NSF); 
interferon regulatory factor 4 (IRF4); fasciculation and elogation protein zeta 1 (FEZ1); 5’ untranslated region (5’UTR); glutamate-cysteine ligase 
catalytic subunit (GCLC); brain-enriched guanylate kinase-associated protein (BEGAIN); transcription start site 1500 (TSS1500); South shore 
(S_Shore); CRTC3 antisense RNA 1 (CRTC3-AS1); long intergenic non-protein coding RNA 1006 (LINC01006); erythrocyte membrane protein 
band 4.1 Like 1 (EPB41L1); 3’ untranslated region (3’UTR);  adenylate cyclase activating polypeptide 1 (ADCYAP1); transcription start site 200 
(TSS200); brain-specific serine/threonine-protein kinase 2 (BRSK2); microRNA 4290 (MIR4290); ubiquitin specific peptidase 49 (USP49); 
docking protein 5 (DOK5); methylmalonyl-CoA epimerase (MCEE); catenin alpha 3 (CTNNA3); novel transcript antisense to purine rich element 
binding protein B (AC004854.2); PAR-3 family cell polarity regulator (PARD3); North shelf (N_Shelf); transmembrane protein 52B (TMEM52B); 
TRNA methyltransferase O (TRMO). 
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Validation and replication set: differential methylation of BRSK2 in relation to PTSD 
status at 3-months post-rape 
The BRSK2 region (chr11:1463541-1463670; adjusted p < .05) identified from the EWAS 
included five CpG sites (CpG1 - cg12186219, CpG2 - cg14064268, CpG3 - cg10590925, CpG4 
- cg17429870, CpG5 - cg18651858) that showed decreased methylation in participants with 
PTSD (see Figure 1). Based on prior findings, DNA methylation of these CpG sites in blood 
was highly correlated with DNA methylation in the prefrontal cortex, superior temporal gyrus 
and the cerebellum (see Supplementary Figures 16a-16d) 58 Three of the five CpG sites (CpG3, 
CpG4 and CpG5) were investigated in the validation and replication set. We could not 
investigate CpG1 or CpG2, as the mass of CpG1 was too low to be measured by the EpiTYPER 
mass spectrometer, and CpG2 contained a silent peak that overlapped with the non-methylated 
peak for this site (see supplementary Table 4 for the genomic coordinates and sequence for 
CpG3, CpG4 and CpG5).  
Baseline age, HIV status, BMI, smoking status, childhood trauma score, lifetime 
trauma, alcohol use, depression and medication use were not associated with BRSK2 
methylation at 3-months post-rape in either the validation or replication sets. PTSD status at 3-
months post-rape was associated with lifetime trauma (z = -2.47, p = .014) in the replication 
set only (see supplementary Table 5 & 6).  
 In the validation set, methylation levels of BRSK2 CpG3 (β = -0.04, p =.050, OR 0.96) 
and CpG4 (β = -0.04, p =.052, OR 0.96) at 3-months post-rape were not significantly associated 
with PTSD status at 3-months post-rape. Decreased methylation of BRSK2 CpG5 (β = -0.04, p 
=.048, OR 0.96) at 3-months post-rape was significantly associated with a PTSD status at 3-
months post-rape, but the association was no longer significant when lifetime trauma was 
added as a covariate to the model (see supplementary Tables 7). In the replication set, 
methylation levels of BRSK2 CpG3 (β = -0.00, p =.889, OR 1.00), CpG4 (β = -0.01, p =.667, 
OR0.99) and CpG5 (β = 0.00, p =.866, OR 1.00) were not significantly associated with PTSD 
status at 3-months post-rape (see supplementary Table 8).  
 
 




Figure 1: Boxplots indicating methylation levels between participants with and without PTSD 
for the five CpG sites in the BRSK2 region found to be associated with PTSD at 3-months post-
rape in the epigenome-wide association study.  
 
Validation and replication sets: Differential methylation of ADCYAP1 in relation to PTSD 
status at 3-months post-rape  
The ADCYAP1 region (chr18:905177-905180) identified from the EWAS included only two 
differentially methylated CpG sites (CpG1 – cg22388954, CpG2 – cg11773720) which both 
showed increased methylation in participants with PTSD (see Figure 2). Based on prior 
findings, DNA methylation of these CpG sites in blood were not correlated with DNA 
methylation in brain tissue (Supplementary Figures 17a and 17b) 58. EpiTYPER signals for 
ADCYAP1 CpG1 and CpG2 were combined for analysis, due to their proximity to each other 
(see supplementary Table 9 for the genomic coordinates and sequence for CpG1 and CpG2). 
 Baseline age, HIV status, BMI, smoking status, childhood trauma score, lifetime 
trauma, alcohol use, depression and medication use were not associated with ADCYAP1 
methylation at 3-months post-rape in the validation or replication sets (see supplementary 
Tables 5 & 6). In the validation set, methylation levels of ADCYAP1 CpG1&2 (β = -0.09, p 
=.382, OR 0.92) was not significantly associated with PTSD status at 3-months post-rape (see 
supplementary Tables 7). In the replication set, methylation levels of ADCYAP1 CpG1&2 (β = 
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-0.06, p =.639, OR 0.94) was also not significantly associated with PTSD status at 3-months 
post-rape (see supplementary Table 8).  
 
 
Figure 2: Boxplots indicating methylation levels between participants with and without PTSD 
for the two CpG sites in the ADCYAP1 region found to be associated with PTSD in the 
epigenome-wide methylation study. 
 
Agreement between the MethylationEPIC array and EpiTYPER  
Large positive correlations were found when comparing the MethylationEPIC array and 
EpiTYPER methylation levels for BRSK2 CpG3 (r = .881, p < .000), CpG4 (r = .900, p < .000) 
and CpG5 (r = .831, p = .831) at 3-months post-rape. Small, non-significant correlations were 
found when comparing the MethylationEPIC array and EpiTYPER methylation levels for 
ADCYAP1 CpG1&2 (r = .254, p > .05; see Supplementary Tables 10 & 11). 
 
Replication of previous candidate gene and EWAS findings 
Differential methylation of five CpG sites previously investigated was replicated in this EWAS 
study, prior to correction for multiple testing (see Supplementary Table 12 and 13). These sites 
were located in the HTR3A (chr11:113846004, cg20621129, p = .028) 64, AHRR (two CpG 
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sites: chr5:373378, cg05575921, p = .033; chr5:377358, cg26703534, p = .031) 22, DUSP22 
(chr6:291882, cg21548813, p = .032) 15 and TPR (chr1:186344558, cg24577137, p = .0008) 
genes 13. Since decreased methylation of AHRR is strongly linked to smoking 22 we investigated 
the link between smoking and AHRR methylation (based on the values obtained from our 
EWAS) and found decreased AHRR methylation in smokers (M = 78.91, SD = 14.95, n = 5) 
compared to non-smokers (M = 93.88, SD = 1.45, n = 42) at cg05575921 (z = -2.92, p = .001).  
 
Longitudinal relationship between BRSK2, ADCYAP1, PTSD scores and confounding 
variables 
Baseline childhood trauma, alcohol use and depression were associated with PTSD scores at 
one or more timepoints. Baseline childhood trauma and lifetime trauma were associated with 
BRSK2 methylation at one or more timepoints. Baseline HIV status was associated with 
ADCYAP1 methylation at 3-months post-rape (see supplementary Table 14). 
 
Longitudinal change in PTSD symptom scores 
The mean PTSD scores at baseline, 3-months and 6-monhs, stratified by group 
(discovery/validation, replication, combined) are presented in Figure 3. There were no 
significant differences between the discovery/validation set and the replication set for baseline 
(z = -0.79, p = .431), 3-month (z = -1.37, p = .172) and 6-month (z = -0.15, p = .883) PTSD 
scores.  
 




Figure 3: PTSD symptom score trajectories over 6 months for the discovery/validation set, 
replication set and combined set 
 
Combined set: Baseline BRSK2 and ADCYAP1 methylation levels and longitudinal 
change in PTSD scores  
Table 5 presents the results of the mixed regression models investigating baseline BRSK2 and 
ADCYAP1 methylation as predictors of change in PTSD symptom scores over time. Decreased 
baseline BRSK2 CpG3, CpG4 and CpG5 methylation was a significant predictor of increased 
PTSD symptom scores at 3-months (CpG3 ß = -0.39, p <.001, CpG4 ß = -0.33, p =.005, CpG5 
ß = -0.27, p =.009) and 6-months (CpG3 ß = -0.49, p <.001, CpG4 ß = -0.44, p <.001, CpG5 ß 
= -0.38, p <.001) post-rape. However, the relationships between BRSK2 CpG3, CpG4 and 
CpG5 methylation and PTSD scores at 3-months and 6-months were no longer significant when 
covariates were added to the models.  
Increased baseline ADCYAP1 CpG1&2 methylation was a significant predictor of 
increased PTSD scores at baseline (ß = 5.34, p <.001) and decreased PTSD scores at 6-
months (ß = -3.52, p =.004) post-rape, but the associations were no longer significant when 





Combined 66,36 35,29 26,02
Discovery/Validation 67,09 40,64 25,21
Replication 65,67 30,16 26,8

















PTSD symptom score trajectory
Combined Discovery/Validation Replication PTSD cut-off
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Table 5:  Summary statistics of the mixed regression models investigating baseline BRSK2 and 
ADCYAP1 methylation as predictors of change in PTSD symptoms scores over time 
Model  ß Std 
error 
t p 95% CI 
Lower          Upper 
       
 Baseline BRSK2 CpG3 
methylation 
     
       
1A Baseline x CpG3 0.07 0.10 0.71 .482 -0.13 0.27 
 3-months x CpG3 -0.39 0.10 -3.81 .0002* -0.60 -0.19 
 6-months x CpG3 -0.49 0.10 -4.76 .000004* -0.70 -0.29 
        
1B Baseline x CpG3 -0.12 0.10 -1.17 .247 -0.33 0.08 
 3-months x CpG3 -0.16 0.15 -1.09 .276 -0.45 0.13 
 6-months x CpG3 -0.12 0.15 -0.81 .418 -0.41 0.17 
        
 Baseline x Childhood trauma 1.54 0.49 3.13 .002* 0.57 2.51 
 3-months x Childhood trauma 1.21 0.66 1.84 .069 -0.09 2.52 
 6-months x Childhood trauma -035 0.66 -0.53 .598 -1.65 0.96 
        
 Baseline x Alcohol consumption -1.36 0.76 -1.79 .077 -2.87 0.15 
 3-months x Alcohol consumption -0.96 1.23 -0.78 .438 -3.40 1.48 
 6-months x Alcohol consumption -1.65 1.23 -1.35 .181 -4.09 0.78 
        
 Baseline x Depression 0.73 0.14 5.29 .0000008* 0.46 1.01 
 3-months x Depression  0.00 0.22 0.00 1.00 -0.45 0.45 
 6-months x Depression 0.49 0.22 2.19 .031* 0.05 0.93 
        
1C Baseline x CpG3 -0.10 0.10 -1.01 .314 -0.31 0.10 
 3-months x CpG3 -0.15 0.15 -1.03 .305 -0.44 0.14 
 6-months x CpG3 -0.10 0.15 -0.68 .496 -0.39 0.19 
        
 Baseline x Childhood trauma 1.12 0.52 2.45 .016* 0.24 2.30 
 3-months x Childhood trauma 1.12 0.73 1.54 .126 -0.32 2.56 
 6-months x Childhood trauma -0.67 0.72 -0.93 .355 -2.10 0.76 
        
 Baseline x Alcohol consumption -1.40 0.76 -1.85 .067 -2.90 0.10 
 3-months x Alcohol consumption -0.98 1.24 -0.79 .432 -3.43 1.48 
 6-months x Alcohol consumption -1.70 1.23 -1.38 .170 -4.13 0.73 
        
 Baseline x Depression 0.77 0.14 5.50 .0000003* 0.49 1.04 
 3-months x Depression  0.01 0.23 0.06 .952 -0.44 0.47 
 6-months x Depression 0.53 0.23 2.35 .021* 0.08 0.98 
        
 Baseline x Lifetime trauma 2.06 1.36 1.51 .134 -0.65 4.76 
 3-months x Lifetime trauma 0.79 2.24 0.35 .727 -3.66 5.23 
 6-months x Lifetime trauma 2.47 2.22 1.11 .270 -1.95 6.88 
        
 Baseline BRSK2 CpG4 
methylation 
     
       
2A Baseline x CpG4 0.07 0.11 0.59 .558 -0.16 0.29 
 3-months x CpG4 -0.33 0.12 -2.85 .005* -0.56 -0.10 
 6-months x CpG4 -0.44 0.12 -3.83 .0002* -0.67 -0.21 
        
2B Baseline x CpG4 -0.08 0.12 -0.70 .486 -0.31 0.15 
 3-months x CpG4 -0.14 0.15 -0.93 .357 -0.44 0.16 
 6-months x CpG4 -0.19 0.15 -1.29 .201 -0.49 0.10 
        
 Baseline x Childhood trauma 1.44 0.51 2.84 .005* 0.43 2.44 
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 3-months x Childhood trauma 1.20 0.70 1.73 .086 -0.17 2.58 
 6-months x Childhood trauma -0.09 0.69 -0.12 .902 -1.45 1.28 
        
 Baseline x Alcohol consumption -1.41 0.77 -1.84 .069 -2.93 0.11 
 3-months x Alcohol consumption -1.00 1.23 -0.81 .421 -3.44 1.45 
 6-months x Alcohol consumption -1.60 1.22 -1.32 .191 -4.02 0.82 
        
 Baseline x Depression 0.71 0.14 5.08 .000002* 0.43 0.98 
 3-months x Depression  -0.01 0.23 -0.05 .963 -0.46 0.44 
 6-months x Depression 0.53 0.22 2.40 .018* 0.09 0.98 
        
2C Baseline x CpG4 -0.04 0.12 -0.36 .720 -0.27 0.19 
 3-months x CpG4 -0.12 0.16 -0.75 .458 -0.42 0.19 
 6-months x CpG4 -0.16 0.15 -1.01 .314 -0.46 0.15 
        
 Baseline x Childhood trauma 1.20 0.53 2.24 .027* 0.14 2.25 
 3-months x Childhood trauma 1.17 0.77 1.53 .130 -0.35 2.69 
 6-months x Childhood trauma -0.34 0.76 -0.45 .654 -1.84 1.16 
        
 Baseline x Alcohol consumption -1.47 0.76 -1.93 .056 -2.99 0.04 
 3-months x Alcohol consumption -1.03 1.24 -0.83 .407 -3.49 1.43 
 6-months x Alcohol consumption -1.67 1.22 -1.37 .175 -4.09 0.75 
        
 Baseline x Depression 0.74 0.14 5.28 .0000008 0.46 1.02 
 3-months x Depression  0.00 0.23 0.01 .996 -0.45 0.46 
 6-months x Depression 0.57 0.22 2.52 .013* 0.12 1.01 
        
 Baseline x Lifetime trauma 2.11 1.39 1.52 .132 -0.65 4.88 
 3-months x Lifetime trauma 0.71 2.27 0.32 .753 -3.79 5.22 
 6-months x Lifetime trauma 2.19 2.23 0.98 .329 -2.24 6.62 
        
 Baseline BRSK2 CpG5 
methylation 
     
       
3A Baseline x CpG5 0.16 0.10 1.60 .112 -0.04 0.35 
 3-months x CpG5 -0.27 0.10 -2.66 .009* -0.47 -0.07 
 6-months x CpG5 -0.38 0.10 -3.73 .0003* -0.58 -0.18 
        
3B Baseline x CpG5 -0.06 0.10 -0.57 .573 -0.25 0.14 
 3-months x CpG5 -0.12 0.14 -0.84 .405 -0.39 0.16 
 6-months x CpG5 -0.06 0.14 -0.44 .657 -0.33 0.21 
        
 Baseline x Childhood trauma 1.60 0.50 3.21 .002* 0.61 2.58 
 3-months x Childhood trauma 1.33 0.66 2.01 .047* 0.02 2.65 
 6-months x Childhood trauma -0.27 0.66 -0.41 .683 -1.58 1.04 
        
 Baseline x Alcohol consumption -1.44 0.77 -1.88 .064 -2.96 0.08 
 3-months x Alcohol consumption -1.01 1.23 -0.82 .412 -3.46 1.43 
 6-months x Alcohol consumption -1.72 1.23 -1.41 .163 -4.16 0.71 
        
 Baseline x Depression 0.72 0.14 5.13 .000002* 0.44 1.00 
 3-months x Depression  0.00 0.23 0.01 .991 -0.45 0.45 
 6-months x Depression 0.48 0.22 2.14 .035* 0.03 0.93 
        
3C Baseline x CpG5 -0.03 0.10 -0.29 .774 -0.23 0.17 
 3-months x CpG5 -0.10 0.14 -0.71 .477 -038 0.18 
 6-months x CpG5 -0.03 0.14 -0.22 .827 -0.31 0.25 
        
 Baseline x Childhood trauma 1.34 0.53 2.56 .012* 0.30 2.39 
 3-months x Childhood trauma 1.28 0.73 1.74 .085 -0.18 2.73 
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 6-months x Childhood trauma -0.58 0.73 -0.80 .425 -2.03 0.86 
        
 Baseline x Alcohol consumption -1.49 0.76 -1.96 .054 -3.01 0.02 
 3-months x Alcohol consumption -1.04 1.24 -0.84 .402 -3.50 1.41 
 6-months x Alcohol consumption -1.78 1.22 -1.46 .148 -4.21 0.65 
        
 Baseline x Depression 0.75 0.14 5.33 .0000007* 0.47 1.03 
 3-months x Depression  0.01 0.23 0.06 .950 -0.44 0.47 
 6-months x Depression 0.52 0.23 2.29 .024* 0.07 0.97 
        
 Baseline x Lifetime trauma 2.12 1.39 1.53 .129 -0.63 4.88 
 3-months x Lifetime trauma 0.74 2.26 0.33 0.75 -3.74 5.22 
 6-months x Lifetime trauma 2.52 2.23 1.13 .262 -1.92 6.96 
        
 Baseline ADCYAP1 CpG1&2 
methylation 
     
       
4A Baseline x CpG1&2 5.34 1.02 5.26 .0000009* 3.33 7.36 
 3-months x CpG1&2 -1.03 1.12 -0.92 .360 -3.25 1.19 
 6-months x CpG1&2 -3.52 1.18 -2.97 .004* -5.86 -1.17 
        
4B Baseline x CpG1&2 -0.73 0.88 -0.83 .407 -2.47 1.01 
 3-months x CpG1&2 2.75 1.39 1.98 .050 -0.00 5.50 
 6-months x CpG1&2 1.66 1.39 1.20 .235 -1.10 4.41 
        
 Baseline x Childhood trauma 1.84 0.47 3.95 .0001* 0.92 2.76 
 3-months x Childhood trauma 1.11 0.59 1.88 .062 -0.05 2.26 
 6-months x Childhood trauma -0.29 0.59 -0.49 .625 -1.45 0.87 
        
 Baseline x Alcohol consumption -1.48 0.77 -1.93 .057 -3.01 0.05 
 3-months x Alcohol consumption -1.43 1.22 -1.18 .242 -3.85 0.98 
 6-months x Alcohol consumption -1.91 1.21 -1.57 .120 -4.32 0.51 
        
 Baseline x Depression 0.73 0.14 5.29 .0000008* 0.46 1.01 
 3-months x Depression  -0.13 0.22 -0.59 .554 -0.56 0.30 
 6-months x Depression 0.42 0.22 1.96 .052 -0.00 0.85 
        
4C Baseline x CpG1&2 -0.54 0.89 -0.61 .541 -2.30 1.22 
 3-months x CpG1&2 2.76 1.42 1.95 .055 -0.05 5.57 
 6-months x CpG1&2 1.59 1.41 1.13 .263 -1.22 4.40 
        
 Baseline x Childhood trauma 1.87 0.47 4.01 .0001* 0.95 2.80 
 3-months x Childhood trauma 1.06 0.59 1.79 .076 -0.11 2.24 
 6-months x Childhood trauma -0.36 0.59 -0.60 .550 -1.53 0.82 
        
 Baseline x Alcohol consumption -1.44 0.76 -1.88 .063 -2.96 0.08 
 3-months x Alcohol consumption -1.43 1.22 -1.17 .247 -3.86 1.01 
 6-months x Alcohol consumption -1.91 1.22 -1.56 .121 -4.34 0.52 
        
 Baseline x Depression 0.74 0.14 5.33 .0000006* 0.46 1.01 
 3-months x Depression  -0.13 0.22 -0.61 .546 -0.56 0.30 
 6-months x Depression 0.42 0.22 1.92 .058 -0.01 0.85 
        
 Baseline x HIV status -4.51 3.54 -1.27 .206 -11.55 2.53 
 3-months x HIV status -0.39 5.65 -0.07 .945 -11.61 10.84 
 6-months x HIV status 1.24 5.65 0.22 .827 -9.99 12.46 
        
Abbreviations: confidence interval (CI); brain-specific serine/threonine-protein kinase 2 
(BRSK2); adenylate cyclase activating polypeptide 1 (ADCYAP1) 
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Combined set: longitudinal change in ADCYAP1 and BRSK2 methylation levels in relation 
to longitudinal change in PTSD scores 
Table 6 presents the results of the mixed regression models investigating change in BRSK2 and 
ADCYAP1 methylation over time as predictors of change in PTSD symptom scores over time. 
Decreased BRSK2 CpG3 (ß = -0.39, p < .001), CpG4 (ß = -0.36, p =.001) and CpG5 (ß = -0.32, 
p =.001) methylation at 3-months post-rape was associated with increased PTSD scores at 3-
months post-rape. Decreased BRSK2 CpG3 (ß = -0.49, p <.001), CpG4 (ß = -0.46, p <.001) and 
CpG5 (ß = -0.43, p <.001) methylation at 6-months post-rape was also associated with 
increased PTSD scores at 6-months post-rape. None of the associations remained significant 
after adding the covariates to the models, with the exception of BRSK2 CpG3 (ß = -0.30, p = 
.049).  
 Increase baseline ADCYAP1 CpG1&2 methylation was associated with increased 
PTSD scores at baseline (ß = 4.67, p <.001) while decreased ADCYAP1 CpG1&2 methylation 
at 3-months (ß = -2.61, p =.001) and 6-months (ß = -5.01, p <.001) was associated with 
increased PTSD scores at 3-months and 6-months post-rape, consecutively. The associations 
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Table 6:  Summary statistics of the mixed regression models investigating change in BRSK2 and 
ADCYAP1 methylation over time as predictors of change in PTSD symptoms scores over time 
Model  ß Std 
error 
t p 95% CI 
Lower          Upper 
       
 Baseline BRSK2 CpG3 
methylation 
     
       
1A Baseline x CpG3 0.07 0.10 0.71 .482 -0.13 0.27 
 3-months x CpG3 -0.39 0.10 -3.81 .0002* -0.60 -0.19 
 6-months x CpG3 -0.49 0.10 -4.76 .000004* -0.70 -0.29 
        
1B Baseline x CpG3 -0.16 0.10 -1.60 .111 -0.37 0.04 
 3-months x CpG3 -0.31 0.15 -2.06 .041* -0.60 -0.01 
 6-months x CpG3 -0.15 0.14 -1.02 .308 -0.44 0.14 
        
 Baseline x Childhood trauma 1.43 0.49 2.93 .004* 0.47 2.40 
 3-months x Childhood trauma 1.39 0.66 2.11 .037* 0.08 2.70 
 6-months x Childhood trauma -0.51 0.66 -0.78 .436 -1.81 0.78 
        
 Baseline x Alcohol consumption -1.31 0.76 -1.72 .088 -2.81 0.20 
 3-months x Alcohol consumption -0.86 1.22 -0.71 .481 -3.28 1.56 
 6-months x Alcohol consumption -1.60 1.24 -1.29 .199 -4.06 0.86 
        
 Baseline x Depression 0.74 0.14 5.34 .0000006* 0.46 1.01 
 3-months x Depression  0.06 0.22 0.26 .793 -0.38 0.50 
 6-months x Depression 0.50 0.23 2.16 .034* 0.04 0.97 
        
1C Baseline x CpG3 -0.15 0.10 -1.42 .157 -0.35 0.06 
 3-months x CpG3 -0.30 0.15 -1.99 .049* -0.60 -0.00 
 6-months x CpG3 -0.12 0.15 -0.80 .423 -0.41 0.17 
        
 Baseline x Childhood trauma 1.18 0.52 2.89 .024* 0.16 2.21 
 3-months x Childhood trauma 1.34 0.73 1.84 .068 -0.10 2.78 
 6-months x Childhood trauma -0.82 0.73 -1.12 .263 -2.25 0.62 
        
 Baseline x Alcohol consumption -1.35 0.75 -1.79 .077 -2.84 0.15 
 3-months x Alcohol consumption -0.88 1.23 -0.71 .477 -3.31 1.56 
 6-months x Alcohol consumption -1.66 1.24 -1.34 .184 -4.11 0.80 
        
 Baseline x Depression 0.77 0.14 5.55 .0000002* 0.49 1.05 
 3-months x Depression  0.07 0.23 0.31 .761 -0.38 0.52 
 6-months x Depression 0.53 0.23 2.27 .026* 0.07 1.00 
        
 Baseline x Lifetime trauma 2.02 1.36 1.48 .141 -0.68 4.72 
 3-months x Lifetime trauma 0.57 2.22 0.26 .797 -3.84 4.98 
 6-months x Lifetime trauma 2.28 2.27 1.01 .317 -2.23 6.79 
        
Model  ß Std 
error 
t p 95% CI 
Lower          Upper 
       
 Baseline BRSK2 CpG4 
methylation 
     
       
2A Baseline x CpG4 0.03 0.11 0.32 .749 -0.17 0.24 
 3-months x CpG4 -0.36 0.11 -3.40 .001* -0.57 -0.15 
 6-months x CpG4 -0.46 0.11 -4.92 .00003* -0.68 -0.25 
        
2B Baseline x CpG4 -0.13 0.11 -1.21 .230 -0.35 0.84 
 3-months x CpG4 -0.30 .15 -2.04 .043* -0.59 -0.01 
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 6-months x CpG4 -0.22 0.15 -1.49 .138 -0.51 0.07 
        
 Baseline x Childhood trauma 1.36 0.49 2.75 .007* 0.38 2.34 
 3-months x Childhood trauma 1.48 0.69 2.14 .034* 0.11 2.84 
 6-months x Childhood trauma -0.28 0.69 -0.40 .689 -1.64 1.09 
        
 Baseline x Alcohol consumption -1.35 0.76 -1.77 .080 -2.87 0.16 
 3-months x Alcohol consumption -0.85 1.22 -0.70 .488 -3.27 1.57 
 6-months x Alcohol consumption -1.59 1.22 -1.30 .197 -4.02 0.84 
        
 Baseline x Depression 0.72 0.14 5.15 .000001* 0.44 0.99 
 3-months x Depression  0.07 0.22 0.32 .751 -0.37 0.52 
 6-months x Depression 0.55 0.23 2.38 .020* 0.098 1.01 
        
2C Baseline x CpG4 -0.10 0.11 -0.88 .379 -0.32 0.12 
 3-months x CpG4 -0.28 0.15 -1.88 .062 -0.58 0.14 
 6-months x CpG4 -0.19 0.15 -1.25 .215 -0.48 0.11 
        
 Baseline x Childhood trauma 1.12 0.52 2.14 .035* 0.08 2.15 
 3-months x Childhood trauma 1.46 0.76 1.93 .056 -0.04 2.96 
 6-months x Childhood trauma -0.53 0.76 -0.70 .488 -2.03 0.97 
        
 Baseline x Alcohol consumption -1.41 0.76 -1.85 .067 -2.92 0.10 
 3-months x Alcohol consumption -0.87 1.23 -0.71 .478 -3.31 1.56 
 6-months x Alcohol consumption -1.64 1.22 -1.34 .183 -4.08 0.79 
        
 Baseline x Depression 0.75 0.14 5.34 .0000006* 0.47 1.02 
 3-months x Depression  0.79 0.23 0.35 .730 -0.37 0.53 
 6-months x Depression 0.58 0.23 2.48 .015* 0.12 1.04 
        
 Baseline x Lifetime trauma 2.00 1.39 1.44 .154 -0.76 4.75 
 3-months x Lifetime trauma 0.49 2.22 0.22 .826 -3.93 4.91 
 6-months x Lifetime trauma 2.12 2.25 0.95 .345 -2.33 6.59 
        
Model  ß Std 
error 
t p 95% CI 
Lower          Upper 
       
 Baseline BRSK2 CpG5 
methylation 
     
       
3A Baseline x CpG5 0.10 0.09 1.07 .285 -0.08 0.28 
 3-months x CpG5 -0.32 0.09 -3.40 .001* -0.51 -0.14 
 6-months x CpG5 -0.43 0.10 -4.42 .00002* -0.62 -0.24 
        
3B Baseline x CpG5 -0.11 0.10 -1.10 .275 -0.30 0.09 
 3-months x CpG5 -0.25 0.14 -1.81 .073 -0.53 0.02 
 6-months x CpG5 -0.15 0.13 -1.11 .269 -0.42 0.12 
        
 Baseline x Childhood trauma 1.43 0.49 2.91 .004* 0.46 2.40 
 3-months x Childhood trauma 1.46 0.67 2.17 .032* 0.13 2.78 
 6-months x Childhood trauma -0.35 0.66 -0.54 .593 -1.65 0.95 
        
 Baseline x Alcohol consumption -1.37 0.76 -1.79 .076 -2.88 0.15 
 3-months x Alcohol consumption -0.98 1.23 -0.80 .429 -3.41 1.46 
 6-months x Alcohol consumption -1.62 1.23 -1.32 .190 -4.06 0.82 
        
 Baseline x Depression 0.72 0.14 5.18 .000001* 0.45 1.00 
 3-months x Depression  0.05 0.22 0.21 .834 -0.40 0.49 
 6-months x Depression 0.52 0.23 2.26 .027* 0.06 0.98 
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3C Baseline x CpG5 -0.08 0.10 -0.81 .417 -0.27 0.11 
 3-months x CpG5 -0.24 0.14 -1.68 .095 -0.51 0.04 
 6-months x CpG5 -0.12 0.14 -0.86 .390 -0.39 0.15 
        
 Baseline x Childhood trauma 1.19 0.52 2.28 .024* 0.16 2.22 
 3-months x Childhood trauma 1.41 0.74 1.91 .058 -0.05 2.87 
 6-months x Childhood trauma -0.62 0.73 -0.86 .391 -2.06 0.81 
        
 Baseline x Alcohol consumption -1.42 0.76 -1.87 .065 -2.93 0.88 
 3-months x Alcohol consumption -0.99 1.23 -0.81 .423 -3.45 1.46 
 6-months x Alcohol consumption -1.68 1.23 -1.37 .175 -4.12 0.76 
        
 Baseline x Depression 0.75 0.14 5.37 .0000005* 0.48 1.03 
 3-months x Depression  0.06 0.23 0.26 .800 -0.40 0.51 
 6-months x Depression 0.55 0.23 2.36 .020* 0.09 1.01 
        
 Baseline x Lifetime trauma 2.03 1.38 1.47 .145 -0.71 4.77 
 3-months x Lifetime trauma 0.62 2.24 0.28 .781 -3.82 5.06 
 6-months x Lifetime trauma 2.23 2.26 0.98 .328 -2.27 6.72 
        
Model  ß Std 
error 
t p 95% CI 
Lower          Upper 
       
 Baseline ADCYAP1 CpG1&2 
methylation 
     
       
4A Baseline x CpG1&2 4.67 0.92 5.10 .000001* 2.86 6.49 
 3-months x CpG1&2 -2.61 0.80 -3.26 .001* -4.20 -1.02 
 6-months x CpG1&2 -5.01 1.12 -4.48 .00002* -7.23 -2.80 
        
4B Baseline x CpG1&2 -1.32 0.83 -1.16 .113 -2.97 0.32 
 3-months x CpG1&2 -1.46 0.92 -1.59 .116 -3.29 0.37 
 6-months x CpG1&2 -0.44 1.28 -0.34 .734 -2.97 2.10 
        
 Baseline x Childhood trauma 1.77 0.47 3.76 .0003* 0.84 2.70 
 3-months x Childhood trauma 1.44 0.61 2.37 .019* 0.24 2.63 
 6-months x Childhood trauma -0.19 0.60 -0.31 .757 -1.37 1.00 
        
 Baseline x Alcohol consumption -1.41 0.77 -1.84 .068 -2.93 0.11 
 3-months x Alcohol consumption -1.27 1.24 -1.02 .309 -3.73 1.19 
 6-months x Alcohol consumption -1.74 1.22 -1.42 .158 -4.17 0.69 
        
 Baseline x Depression 0.74 0.14 5.35 .0000006* 0.46 1.01 
 3-months x Depression  -0.03 0.22 -0.16 .876 -0.46 0.40 
 6-months x Depression 0.46 0.21 2.14 .035* 0.03 0.88 
        
4C Baseline x CpG1&2 -1.12 0.83 -1.35 .182 -2.78 0.54 
 3-months x CpG1&2 -1.54 0.93 -1.66 .100 -3.38 0.30 
 6-months x CpG1&2 -0.48 1.29 -0.37 .712 -3.03 2.08 
        
 Baseline x Childhood trauma 1.80 0.47 3.84 .0002* 0.87 2.73 
 3-months x Childhood trauma 1.37 0.61 2.23 .027* 0.16 2.58 
 6-months x Childhood trauma -0.26 0.61 -0.42 .675 -1.46 0.95 
        
 Baseline x Alcohol consumption -1.38 0.76 -1.81 .074 -2.90 0.17 
 3-months x Alcohol consumption -1.29 1.25 -1.04 .302 -3.77 1.18 
 6-months x Alcohol consumption -1.76 1.23 -1.43 .157 -4.21 0.69 
        
 Baseline x Depression 0.74 0.14 5.40 .0000005* 0.47 1.01 
 3-months x Depression  -0.04 0.22 -0.20 .844 -0.48 0.39 
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 6-months x Depression 0.45 0.22 2.08 .040* 0.02 0.88 
        
 Baseline x HIV status -4.28 3.53 -1.21 .229 -11.30 2.74 
 3-months x HIV status 2.16 5.78 0.37 .709 -9.32 13.65 
 6-months x HIV status 1.86 5.60 0.33 .740 -9.27 12.99 
        
Abbreviations: confidence interval (CI); brain-specific serine/threonine-protein kinase 2 



























In this study we identified one DMP (cg01700569) and thirty-four DMRs associated with PTSD 
at 3-months post-rape on an epigenome-wide level. We investigated two DMRs in the BRSK2 
and ADCYAP1 genes further. We were able to validate, but not replicate, the BRSK2 CpG5 
finding, which confirmed that participants with PTSD at 3-months post-rape showed decreased 
BRSK2 methylation compared to those without PTSD. We also found that decreased baseline 
BRSK2 CpG3, CpG4 and CpG5 methylation was associated with increased PTSD scores at 3- 
and 6-months post-rape. Decreased BRSK2 methylation at 3-months and 6-months post-rape 
was associated with increased PTSD scores at the same time-points. However, the relationship 
between decreased BRSK2 CpG3 methylation at 3-months post-rape and increased PTSD scores 
at 3-months post-rape was the only association that remained significant after covariates were 
added to the models.  
We were unable to validate or replicate the ADCYAP1 CpG1&2 findings. We found that 
decreased baseline ADCYAP1 CpG1&2 methylation was associated with increased PTSD 
scores at 6-months post-rape. Decreased ADCYAP1 methylation at 3-months and 6-months 
post-rape was also associated with increased PTSD scores at the same timepoints, while 
decreased baseline ADCYAP1 CpG1&2 methylation was associated with decreased PTSD 
scores at baseline. The findings did not remain significant after PTSD covariates were added to 
the models.  
Decreased methylation of the BRSK2 paralog,  BRSK165, has been associated with a 
PTSD diagnosis in a prior EWAS 14. BRSK1 and BRSK2 share a 68% overlap in genetic 
sequence, both are highly expressed in the brain and decreased expression of both has been 
linked to disorganised presynaptic vesicle formation, uncoordinated release and reuptake of 
neurotransmitters, altered axonal development and abnormal neuronal polarisation in animal 
studies 65–70. In human studies, a BRSK2 polymorphism (rs1881509) has been associated with 
heroin dependence 66 and functional variants of BRSK2 have been associated with autism 
spectrum disorder, cognitive impairment, intellectual disability and speech delays 71,72.  
 Genes BRSK1 and BRSK2 are expressed most strongly in the cerebellum and the 
hippocampus 66. The hippocampus is closely linked to PTSD since it is involved in memory 
consolidation 73. When memories are not consolidated into autobiographical memory networks, 
they may involuntarily resurface (e.g. flashbacks, intrusions, nightmares and dissociation) and 
activate the limbic system which induces the fight-or-flight response 74. Differential 
methylation and expression of BRSK2 may also alter the expression of neurotransmitters 
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previously found to be associated with PTSD (e,g. norepinephrine, epinephrine, dopamine and 
serotonin) through altered presynaptic vesicle and synaptic cleft development 75,76.  
In addition to its function in the brain, BRSK1 and BRSK2 have been linked to metabolic 
processes and glucose homeostasis 77,78. Animal studies have found increased expression of 
BRSK1 and BRSK2 in pancreatic cells and knockdown of BRSK2 resulted in a significant 
increase in serum insulin levels 77,78. In a human study, BRSK2 was found to be highly expressed 
in human pancreatic insulin producing B-cells and activation of BRSK2 was linked to reduced 
insulin secretion 78. An EWAS found that participants with type 1 diabetes and neuropathy 
showed decreased methylation at four CpG sites in the BRSK2 gene compared to participants 
with type 1 diabetes without neuropathy 79. 
 The BRSK2 CpG sites investigated in this study were located in intron 4 of the gene. 
The function of methylation in gene bodies is not well established, but methylation is abundant 
in these regions and is generally positively correlated with expression 80. Assuming the latter, 
we can hypothesise that decreased methylation of BRSK2 may contribute to adverse neuronal 
development, neuronal maintenance and dysregulated blood glucose levels which may explain 
the increased risk for diabetes and cardiovascular disease observed in prior PTSD studies 81,82.  
The relationship between BRSK2 methylation and adverse neuronal development and 
maintenance is further supported by prior findings of a high correlation between BRSK2 blood 
methylation and methylation in brain tissue 58.  
 We investigated ADCYAP1 since its protein product, PACAP, has been identified as a 
master regulator of the HPA-axis and the stress response 83. The highest concentration of 
PACAP in the brain is found in the hypothalamus 84. PACAP binding in the hypothalamus 
triggers the release of corticotrophin-releasing hormone (CRH) and signals the activation of the 
stress response 83. In the adrenal medulla, PACAP binding to PAC1R (product of ADCYAP1R1) 
stimulates the release of catecholamines as part of the sympathetic nervous system (SNS) 85. 
PACAP binding to PACR1 in preganglionic neurons triggers the release of 
phenylethanolamine-N-methyltransferase (PNMT) and tyrosine hydroxylase (TH) in effector 
organs of the SNS. PNMT and TH are catecholamine-synthesising enzymes and sustain the 
release of catecholamines in the effector organs during the stress response 85.  
Researchers investigating PACAP/ADCYAP1 and PACR1/ADCYAP1R1 in relation to 
PTSD in a predominantly African American sample with a mixture of trauma types found that, 
in women more than men, increased PACAP blood levels were associated with increased PTSD 
symptom severity and an increased acoustic startle reflex response 61,86. They also found that 
women carrying the ADCYAP1R1 rs2267735 CC genotype showed decreased ADCYAP1R1 
mRNA expression, increased PTSD symptom severity, increased dark-enhanced startle 
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response and increased amygdala and hippocampal activity in response to viewing threatening 
face stimuli 61–63,86. In both men and women, increased methylation of ADCYAP1R1 was 
associated with decreased cortical mRNA expression and increased PTSD symptom severity 
61,87. However, the functional effects of ADCYAP1 and ADCYAP1R1 seem to be more 
pronounced in women compared to men 61–63, due to the presence of several estrogen response 
elements (EREs) in the ADCYAP1R1 promoter. The CC genotype of rs2267735 has been 
associated with decreased binding of estrogen receptor alpha to the EREs and decreased 
expression of ADCYAP1R1 88. The role of estrogen in ADCYAP1R1 and HPA-axis activity may 
in part explain why women have an increased risk of PTSD compared to men 35,89.  
The two ADCYAP1 CpG sites investigated in this study are located in a CpG island 
spanning the 1st intron of the gene. Methylation in CpG islands and in the 1st intron of a gene is 
generally associated with decreased expression of the gene 90–92. Our longitudinal findings 
therefore correspond with prior findings since decreased methylation of ADCYAP1 is likely to 
result in increased expression of PACAP and increased PTSD symptom severity 62,63,88,93. 
Decreased PACAP is also likely to result in decreased binding to PAC1 and reduced activation 
of the HPA-axis 83,85.  
Based on prior findings, ADCYAP1 CpG1&2 DNA methylation in blood was not 
significantly correlated with DNA methylation at the same sites in brain tissue 58. However, the 
brain regions investigated did not specifically focus on the region where PACAP is most 
abundantly expressed i.e., the paraventricular nucleus of the hypothalamus and investigating 
blood-brain methylation in this region may show different results 37. It is also likely that 
expression of PACAP in the endocrine system has a more profound effect on the regulation of 
the HPA-axis compared to PACAP expression in the brain 37.  
In addition to the EWAS, the validation and the replication study, we investigate prior 
significant findings from published candidate gene studies and EWASs in relation to our 
findings. We found that, before correction for multiple testing, CpG sites in HTR3A 64, AHRR 
22, DUSP22 15 and TPR 13 were associated with PTSD. The results from our study are in line 
with recent results from the largest meta-analysis of PTSD published to date 22, where AHRR 
cg05575921 and cg26703534 were found to exhibit reduced DNA methylation in individuals 
with PTSD. Decreased AHRR methylation at these CpG sites were also associated with 
decreased kynurenine and kynurenic acid in the same study 22. Kynurenine ligand binding to 
aryl hydrocarbon receptors has been associated with the expression of anti-inflammatory genes 
which may be disrupted by decreased methylation of AHRR 22,25. This may result in increased 
levels of proinflammatory cytokines and the low-grade inflammatory state often observed in 
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PTSD 94,95. Upregulation in kynurenine to restore the imbalance between pro-inflammatory and 
anti-inflammatory cytokines may also result in reduced levels of serotonin since both 
kynurenine and serotonin are synthesised from tryptophan 96. A strong link between decreased 
AHRR methylation and smoking has also been reported in previous studies although some 
studies have reported a significant relationship between AHRR methylation and PTSD 
independent of the effect of smoking 22,97–99. 
Our findings should be interpreted in light of a number of limitations. First, the EWAS 
was conducted in a small sample of participants. However, the study was well designed to limit 
variation between groups. Second, we used DNA extracted from whole blood to measure 
methylation levels while differential methylation in brain tissue is a more direct approximation 
of PTSD pathophysiology. However, based on prior findings, we observed that blood-brain 
methylation was highly correlated in the BRSK2 CpG sites investigated in this study, but not 
the ADCYAP1 CpG sites. Blood is easily accessible and blood biomarkers of PTSD risk may 
be a more pragmatic approach for personalised treatment of individuals at high risk of 
developing PTSD following trauma exposure 100. Finally, DNA methylation in relation to gene 
expression and/or protein levels was not objectively measured and conclusions related to the 
functional effects of methylation are speculative. 
 The study has many strengths. First, all participants were rape-exposed women from 
similar sociodemographic backgrounds and from the same ethnicity group thus making the 
sample relatively homogenous. Second, the analyses were robust with a variety of confounding 
factors controlled for i.e. participants who were pregnant/lactating were excluded, none of the 
participants were on psychotropic medication and participants were of similar age. Baseline 
measures of age, HIV status, BMI, smoking, childhood trauma, lifetime trauma, alcohol use 
and depression were controlled for by matching participants on these variables in the cross-
sectional EWAS and including these factors as covariates/confounders in the longitudinal 
analysis. Third, we attempted to expand the findings of the EWAS by including longitudinal 
data which allowed us to investigate changes in methylation in relation to PTSD over time. 
Fourth, investigating the agreement between the results obtained from the two different 
laboratory methods used (MethylationEpic array and EpiTYPER) also allowed identification 
of potential bias/variation introduced by the different procedures involved in each method.  
 In summary, this study provides evidence that differential methylation of genes related 
to neurogenesis/development, glucose homeostasis and HPA-axis regulation are involved in 
PTSD development following rape. Our findings are supported by previous research 
implicating ADCYAP1/ADCYAP1R1 (especially in women) and BRSK1/BRSK2 in the 
development of PTSD. However, replication of our findings is needed to determine if the 
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differentially methylated regions identified in this study are consistently linked to the 
development of PTSD. Replication of findings may provide support for ADCYAP1 and BRSK2 
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FKBP5 INTRON 7 METHYLATION AND THE TRAJECTORY 























Background: Emotional distress and posttraumatic stress disorder (PTSD) are often reported 
following rape. Dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, a core regulator 
of the stress response, has been implicated in the aetiology and chronicity of PTSD. FK506 
binding protein (FKBP5) is a co-chaperone and functional regulator of the glucocorticoid 
receptor. No studies to date have investigated longitudinal methylation changes in the FKBP5 
gene in rape-exposed women. Aim: The overarching aim was to investigate the relationship 
between FKBP5 intron 7 methylation and PTSD symptoms over 6 months in a rape-exposed 
sample. We also investigated the interaction between childhood trauma, rs1360780 genotype 
and FKBP5 methylation in relation to PTSD scores over time. The baseline (0-20 days), 3-
month and 6-month post-rape data were used to investigate change over time. Method: Rape-
exposed women (n = 852) were recruited from rape clinics in the Rape Impact Cohort 
Evaluation (RICE) umbrella study. PTSD symptom scores were derived from the Davidson 
Trauma Scale (DTS) at baseline, 3-months and 6-months post-rape. Methylation levels at five 
FKBP5 intron 7 CpG sites (n = 96) were determined using EpiTYPER Sequenom MassArray 
technology. Genotyping of rs1360980 was completed using the Agena MassArray genotyping 
system. Mixed linear regression models were used to analyse the data. Results: Decreased 
FKBP5 methylation was a predictor of increased PTSD symptoms scores at 3-months and 6-
months post-rape. High childhood trauma and the CC genotype of rs1360780 resulted in 
decreased FKBP5 methylation and increased PTSD scores at baseline. Conclusion: This is the 
first study to investigate longitudinal changes in FKBP5 methylation in a relatively 
homogenous (in terms of demographic and trauma exposure) rape-exposed sample. The 
findings implicate FKBP5 methylation in the aetiology and course of PTSD in the aftermath of 















The prevalence of posttraumatic stress disorder (PTSD) in sexual assault survivors is higher 
than those associated with other trauma types 1–4. Women are at increased risk of developing 
PTSD compared to men and are also more frequently victims of sexual assault compared to 
men 2,5–12. The hypothalamic-pituitary-adrenal (HPA) axis is integral to the regulation of the 
stress response and returning the body to homeostasis 13,14. Dysfunction of the HPA-axis has 
been implicated in the aetiology and course of PTSD following trauma exposure 15–17. A 
growing body of literature suggests that genetic and epigenetic mechanisms, such as DNA 
methylation, may mediate the interplay between trauma and HPA-axis functioning 18,19. DNA 
methylation, which involves the addition of a methyl group to cytosine-guanine dinucleotides 
may mediate gene transcription by inhibiting binding of transcription factors of affected genes 
20,21. Decreased or increased expression of HPA-axis related genes in rape survivors may 
contribute to the phenotypic presentation of PTSD 18,22.  
Most epigenetic studies of PTSD have focused on genes that are directly or indirectly 
associated with regulation of the HPA-axis 23,24. One of the most commonly investigated genes 
is the FK506 binding protein gene (FKBP5) 23. FKBP5 is a co-chaperone and important 
functional regulator of the glucocorticoid receptor (GR) 25,26. Intracellularly, cortisol binds to a 
GR complex in the cytoplasm and enters the cell nucleus, where it binds to glucocorticoid 
response elements (GREs) 26,27. Binding of the GR complex to GREs upregulates FKBP5 
transcription 26,27. FKBP5, in turn, binds to GRs in the cytoplasm and inhibits GR translocation 
to the nucleus, thereby creating an ultra-short intracellular negative feedback loop 28,29. 
Prolonged stress and increased expression of FKBP5 may result in long-term methylation 
changes in HPA-axis genes and a dysregulated stress response. These changes may underlie the 
aetiology and trajectory of PTSD 23,24.  
Single-nucleotide polymorphisms (SNPs) may also contribute to dysfunction of the 
HPA-axis by adversely mediating dynamic methylation/demethylation of FKBP5 as part of the 
regulation of the ultra-short negative feedback loop 26. Several FKBP5 SNPs have been 
investigated in PTSD and childhood trauma studies, and many have delivered inconsistent 
results 19,30–32. One SNP, rs1360780 (intron 2, 400 bp from a GRE), has delivered more 
consistent results 30–36. The rs1360780 CT and TT genotypes have been linked to increased risk 
for developing PTSD 31,35, and increased FKBP5 transcription, both in the absence and presence 
of GR binding to GREs 35. Increased expression likely occurs as a result of the rs1360780 T 
allele and its adjacent alleles forming a TATA box, which often represents the transcription 
start site in promoters 37. Transcription is initiated when RNA polymerase 2 (Pol II) and TATA 
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binding protein (TBP) binds to the TATA sequence 27,37. Binding of TBP causes the DNA strand 
to bend at the binding site and a three-dimensional chromatin loop is formed, resulting in the 
GREs of intron 7 coming into direct contact with the GREs of intron 2 and PolII, thereby further 
enhancing transcription of FKBP5 35,37.  Increased transcription of FKBP5 promotes cortisol 
resistance, delays activation of the negative feedback loop of the HPA-axis and prolongs the 
fight-or-flight response 27,37.  
Childhood trauma is associated with an increased risk for PTSD 38–40 and a longer 
recovery period 3,41,42. The rs1360780 SNP has been found to moderate the association between 
childhood trauma and PTSD since it is believed that prolonged increased circulating cortisol 
subsequent to childhood trauma may result in neuroendocrinological changes underlying the 
functioning of the HPA-axis, especially in the presence of at least one rs1360780 T allele 
23,24,37,43,44. These changes may include methylation/demethylation of CpG sites in the FKBP5 
gene 15–17. 
Methylation studies have mainly focussed on an overlapping region in intron 7 of the 
FKBP5 gene since it contains several glucocorticoid response elements (GREs) 35,45. Studies 
investigating older participants (e.g. Korean Vietnam veterans and holocaust survivors) have 
found that increased methylation in intron 7 was associated with a history of trauma exposure 
46, carrying the T allele or CT/TT genotype of rs1360780 34 and with PTSD 34. Studies 
investigating methylation and the interaction between childhood trauma and rs1360780 
genotype in younger populations found that increased childhood trauma was associated with 
decreased methylation in T allele carriers in the offspring of holocaust survivors 46 and in 
German women of childbearing age 33. Increased childhood trauma also interacted with the 
rs1360780 T allele to predict increased PTSD symptom severity in a predominantly African 
American, mixed gender, civilian sample 35. Here, a 12.3% decrease in methylation in T allele 
carriers was observed, while the CC genotype carriers showed increased methylation in the 
same region 35.  
Only one study has investigated longitudinal change in FKBP5 intron 7 methylation in 
relation to change in PTSD symptom scores. The study investigated treatment responders and 
non-responders (Caucasian American veteran sample), following a nine-week mindfulness-
based stress reduction intervention and found that non-responders showed decreased 
methylation compared to responders who showed increased methylation in the same region 47. 
There were no significant differences in methylation levels between responders and non-
responders at baseline, and baseline PTSD symptom severity scores were not associated with 
methylation levels 47.  
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No studies to date have investigated the relationship between FKBP5 intron 7 
methylation and PTSD symptom scores over time in rape-exposed women of African ethnicity. 
Longitudinal studies are needed to determine if FKBP5 intron 7 methylation is associated with 
PTSD symptoms post-rape. In the present study, conducted in a South-African cohort of rape-
exposed women in a low-income setting, our overarching aim was to investigate the relationship 
between longitudinal FKBP5 intron 7 methylation and PTSD symptoms using baseline (0-20 
days post-rape), 3-months and 6-months post-rape data. We also aimed to investigate the main 
effect of rs1360780 genotype and baseline childhood trauma scores on longitudinal change in 
PTSD symptoms and to investigate the interaction between childhood trauma, rs1360780 




Design and setting 
The study followed a longitudinal, prospective follow-up design. Samples and data were 
analysed from a subset of rape-exposed women (n = 96) recruited from the RICE study, a cohort 
study investigating the impact of rape on women’s health and their use of health services in 
South Africa (n = 854). For a more detailed description of RICE’s study methods, see Abrahams 
et al., 2017 48. Survivors of rape were recruited from four rape centres in and around the city of 
Durban located in the KwaZulu Natal province of South Africa. The rape centres provide 
comprehensive emergency care, including access to police, counselling, medical and forensic 
care. Rape-exposed women were informed of the study after presenting to and receiving 




All participants were women who had been raped within 20 days of the baseline visit. All 
participants were between 18 and 40 years of age and of Black African ethnicity. In the parent 
study, participants were excluded if they were severely distressed or in urgent need of 
psychiatric treatment/hospitalisation, if they had an intellectually disability or were more than 
14 weeks pregnant at enrolment. Further exclusions were applied for this sub-study to control 
for factors that could influence methylation levels. Participants were excluded if they were 
pregnant or lactating (at any timepoint), if they had HIV seroconverted (at any timepoint) and 
if they met diagnostic criteria for PTSD as baseline due to a past traumatic event other than the 
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rape. Only participants with complete clinical datasets and blood samples with sufficient DNA 
at all timepoints were considered for inclusion.  
 
Procedure and ethical considerations 
Upon enrolment researchers explained the study procedure, obtained informed consent, and 
completed the baseline clinical interview and assessments with participants. Assessments 
included: a demographic questionnaire; self-report questionnaires measuring risk and protective 
factors for the development of PTSD; a rapid HIV antibody blood spot test; a human chorionic 
gonadotropin (hCG) urine pregnancy test; body mass index (BMI) assessment and; blood 
collection for DNA analysis. Nursing staff administered the HIV test, pregnancy tests, BMI 
assessment and blood collection. The nursing staff also recorded prescription medication use 
and smoking status at each timepoint. A research assistant administered the clinical interview 
(under supervision of a registered trauma counsellor or registered nurse) demographic 
questionnaire and self-report measures. Participants were invited back to the study site to 
complete a 3-month and 6-month follow-up visit where all assessments completed at baseline 
were repeated. The ninety-six participants were selected for the sub-study based on the quality 
of DNA that was available i.e. DNA concentration (>100 ng/μl) and purity (A260/A280 ration > 
1.8 and A260/A230 ration > 2.0) of blood samples. Ethical approved to conduct RICE was 
obtained from the ethics committee at the South African Medical Research Council (SAMRC; 
EC019-10/2013) and approval to conduct the sub-study was obtained from the Health Research 
Ethics Committee at Stellenbosch University (S16/08/146).  
 
Clinical measures 
The Mini International Neuropsychiatric Interview 
The Mini International Neuropsychiatric Interview (MINI) version 7.0.0 is a structured 
psychiatric interview that screens for 16 DSM-IV psychiatric disorders including mood 
disorders, anxiety disorders, alcohol and drug dependence, psychosis, eating disorders and 
personality disorders 49. The MINI was used at baseline to screen for PTSD based on prior 
traumas other than the rape. The MINI has shown good reliability and validity in various 
settings 50,51. 
 
Davidson Trauma Scale (DTS) 
The Davidson trauma scale (DTS) is a self-report questionnaire used to assess seventeen 
symptoms of PTSD 52. The DTS was administered at all timepoints and responses were 
measured on a 5-point Likert scale for symptom frequency ranging from 0 (‘not at all’) to 4 
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(‘every day’) and symptom severity ranging from 0 (‘not at all distressing’) to 4 (‘extremely 
distressing’). An uploading error resulted in missing value sets for the symptom severity 
subscale of the DTS which was corrected once it was identified. There were no missing values 
for the DTS frequency subscale. Missing DTS symptom severity values were imputed in the 
RICE study using a multiple imputation model while maintaining the multivariate normal 
distribution. The symptom frequency and severity scores were added together to produce a 
PTSD total score ranging between 0 and 136. A total score of 40 or more was considered 
indicative of PTSD. The DTS has shown excellent discriminating power for distinguishing 
between participants with and without PTSD at a cut-point of 40 52,53. The DTS showed 
excellent reliability in this study at each timepoint with a Cronbach alpha sore of .92 at baseline, 
.91 at 3-months and .93 at 6-months post-rape.  
 
Childhood Trauma Questionnaire Short Form (CTQ-SF) 
A modified version of the Childhood Trauma Questionnaire- Short Form (CTQ-SF) was used 
to measure exposure to childhood traumas before the age of 18 years, at the baseline visit 54,55. 
The 14 items measuring childhood trauma centres around sexual abuse, physical abuse, 
emotional abuse, parental neglect and domestic violence. Responses were measured on a 4-
point Likert scale ranging from 1 (‘never’) to 4 (‘very often’). The modified CTQ-SF showed 
acceptable reliability in this study with a Cronbach alpha score of .75 at baseline.  
 
Life Events Checklist (LEC) 
A modified version of the LEC was used to measure lifetime exposure to different trauma types 
at the baseline visit 56,57. The modified version of the LEC measures direct exposure to nine 
trauma types using a dichotomous ‘yes/no’ response. The trauma types measured were 
imprisonment, civil unrest/war, serious injury, being close to death, murder of a family member 
or friend, unnatural death of a family member or friend, murder of a stranger/s, robbed at 
gunpoint or knifepoint and kidnapped. The number of ‘yes’ responses were added together to 
yield a total score ranging from 0 to 9, indicating the cumulative lifetime trauma load of 
participants. 
 
Alcohol Use Disorders Identification Test (AUDIT) 
The Alcohol Use Disorders Identification Test-Consumption Scale (AUDIT-C) was used to 
measure hazardous alcohol use at baseline 58. The original AUDIT consists of 10-items with 
responses measured on a 5-point Likert scale and response options specific to each individual 
item. A score of three or more on the AUDIT-C (the first three items of the AUDIT) is 
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considered indicative of hazardous drinking in women 59. The AUDIT-C has shown good 
reliability and validity in various settings 60–66. The AUDIT-C showed good reliability in this 
study with a Cronbach alpha score of .83.  
 
Center for Epidemiologic Studies Depression Scale (CES-D) 
The Center for Epidemiologic Studies Depression Scale (CES-D) was used to measure 
depression in accordance with DSM-IV criteria at baseline 67. The CES-D is a twenty-item, 
self-report measure with responses measured on a 4-point Likert scale ranging from 0 (‘rarely 
or none of the time’) to 3 (‘most or all of the time’). The CESD has shown good reliability and 
validity in various settings 68–77. The CES-D showed good reliability in this study with a 
Cronbach alpha score of .89.  
 
Experimental procedure 
DNA was extracted from peripheral blood samples using the Gentra Puregene DNA extraction 
kit (Qiagen, Germany) and quantified by fluorimetry, using the Pico Green dsDNA quantitation 
reagent (ThermoFisher Scientific, Massachusetts, United States). Sample concentrations were 
normalised to 50 ng/ul and shipped on ice to Inqaba Biotec in Pretoria, South Africa for 
genotyping, busilfite conversion and methylation analysis.  
Genotyping was completed using the Agena MassArray genotyping system (Agena 
Bioscience, California, United States). Polymerase chain reaction (PCR) was followed by 
single base extension using dideoxynucleoside terminators of the SNP specific primer. Matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was then 
used to identify SNP genotype.  
Methylation analysis was completed using EpiTYPER Sequenom MassARRAY 
(Agena Bioscience, California, United States) technology. PCR primer design was completed 
using Sequenom Epidesigner software (www.epidesigner.com). The samples were randomly 
assigned to one of three plates i.e. 96 samples per plate, three plates to accommodate the 
samples collected at each timepoint. Samples were bisulfite-converted using the Zymo EZ DNA 
methylation kit (Zymo Research, California, United States). Bisulfite conversion was followed 
by PCR amplification of the target region using t7-promoter tagged primers (forward primer, 
5’-aggaagagagTTGTTTTTGGAATTTAAGGTAATTGA-3’ and reverse primer, 5’- 
cagtaatacgactcactatagggagaaggctCCTCCAACACTACTACTAAAAAAT AAAACA-3’). 
RNA transcription, base-specific RNA cleavage and finally DNA methylation quantification 
was completed using the SpectroCHIP array, MALDI-TOF mass spectrometry and EpiTYPER 
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software. Findings resulting from EpiTYPER technology has proven to be highly reproducible 
and has been found to detect methylation levels as low as 5% 78,79.  
We followed the same approach as Klengel et al. (2013) in selecting the FKBP5 intron 7 
CpG sites to investigate methylation differences. Of the six CpG sites (divided into 3 bins) 
investigated in Klengel et al. (2013), we investigated two CpG sites in bin1 (Bin1-CpG1 and 
Bin1-CpG2) and two sites in bin 2 (Bin2-CpG1 and Bin2-CpG2-GRE). We could not 
investigate Bin2-CpG3 since the mass of silent peaks in the surrounding area precluded 
detection of methylation levels in this CpG site. We could also not investigate Bin3-CpG1-GRE 
since its mass was too low to be detected. We included an additional CpG site located 2bp from 
the end of the GRE in Bin3. We labelled the five CpG sites investigated in this study as CpG1-
CpG5. Table1 presents the coordinates (chr6: 35558310-35558785) and sequences of the CpG 
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                          CpG2  
35558466 GGAGCCACAGTGCAGGCCTCTTCGTGACTCCTGTGAAG 
                         CpG3  
35558504 GGTACAATCCGTTCAGCTCTGAAAAGCTGCACCCCACT 









35558696 ACAAAATAAGAACACGGAGCTCCTTCGTTGTATATCAG  





Underlined sections present glucocorticoid response elements. CpG sites in large bold font 
indicate the sites investigated in this study. Genomic coordinates are based on the Human 















Most variables did not conform to a normal distribution and non-parametric statistics were 
therefore used in the univariate analyses. Descriptive statistics were calculated for baseline 
demographic and clinical characteristics of the sample. Baseline age, HIV status, BMI score, 
smoking status, lifetime trauma exposure and medication use were investigated as potential 
confounding variables in relation to PTSD, methylation, rs1360780 genotype and childhood 
trauma. Depression and alcohol use were investigated as covariates of PTSD. 
Confounding/covarying variables were identified using Spearman’s correlation coefficients, 
Chi square tests and Mann-Whitney U test statistics. The relationship between PTSD and 
rs1360780 genotype was investigated using Mann-Whitney U test statistics. An online 
calculator and Chi-squared test was used to determine if the observed rs1360780 genotype 
frequencies are consistent with Hardy-Weinberg equilibrium (http://www.dr-
petrek.eu/documents/HWE.xls). Rs1360780 was grouped into CC genotype carriers and CT/TT 
genotype carriers given that the T allele and its adjacent alleles forms a TATA box which has 
a functional effect on gene expression 37.  The dichotomised rs1360780 variable (CC vs CT/TT) 
was used in all univariate and multivariate analyses.  
Mixed linear regression models were used to investigate the main effect of methylation 
(baseline, 3-months and 6-months post-rape), rs1360780 genotype and childhood trauma on 
PTSD scores (baseline, 3-months and 6-months post-rape). Interaction effects between 
methylation, rs1360780 genotype and childhood trauma on PTSD scores were also investigated 
using mixed linear regression models. Childhood trauma scores were dichotomised using a 
median split to probe the significant interaction effects. Fisher’s Z tests were used to compare 
the correlations between methylation and PTSD scores in the high childhood trauma & CC 
genotype vs high childhood trauma and CT/TT genotype groups as well as the low childhood 
trauma & CC genotype vs low childhood trauma and CT/TT genotype groups. 
Confounding/covarying variables significantly associated with PTSD, methylation, rs1360780 
genotype and childhood trauma (resulting from the univariate analyses) were included in the 













Demographic and clinical characteristics of the sample 
The baseline demographic characteristics of the sample for age, education, employment, 
relationship status, HIV status, smoking status, medication use, BMI, childhood trauma 
exposure and lifetime trauma exposure are presented in Table 2. The rs1360780 genotype 
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Table 2: Baseline demographic and clinical characteristics of the sample 
 n % M SD Range 
      
Age  96 100 25.2 5.4 18-39 
      
Basic education completed 96 100    
     No 39 40.6    
     Yes 57 59.4    
      
Employed  96 100    
    No 74 77.1    
    Yes 22 22.9    
      
Relationship status 96 100    
     Single 20 20.8    
     In a relationship 76 79.2    
      
HIV status  96 100    
     Negative 50 52.1    
     Positive 46 47.9    
      
Smoker  96 100    
     No 84 87.5    
     Yes 12 12.5    
      
Medication use 96 100    
      No 64 66.7    
     Yes 32 33.3    
      
BMI 96 100 25.9 6.1 18.0 – 47.5 
      
Childhood trauma (CTQ-SF) 96 100 16.7 3.4 14-29 
     None 40 41.7    
     Sexual abuse  21 21.9    
     Physical abuse 37 38.5    
     Emotional abuse 23 24.0    
     Neglect 41 42.7    
     Domestic violence  18 18.8    
     Cumulative childhood trauma 96 100 1.5 1.5 0-5 
      
Lifetime trauma (LEC) 96 100    
     None 29 30.2    
     Imprisonment  3 3.1    
     Civil unrest or war 4 4.2    
     Serious injury 11 11.5    
     Close to death 27 28.1    
     Murder of family or friend 16 16.7    
     Unnatural death of family or friend 14 14.6    
     Murder of a stranger 15 15.6    
     Robbed at gun- or knifepoint 35 36.5    
     Kidnapped 7 7.3    
     Cumulative lifetime trauma 96 100 1.4 1.4 0-5 
      
Alcohol use (AUDIT-C) 96 100 1.7 2.4 0-10 
     Not Hazardous 69 71.9    
     Hazardous 27 28.1    
      
Depression (CES-D) 96 100 32.0 13.0 0-57 
      
rs1360980 genotype 95 100    
     CC 31 32.3    
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     CT 52 54.7    
     TT 12 12.6    
      
Abbreviations: 
Mean (M), standard deviation (SD), body mass index (BMI), Childhood Trauma Questionnaire 
Short Form (CTQ-SF), Life Events Checklist (LEC), Alcohol Use Disorders Identification Test 





The results of the univariate analyses are presented in Tables 3-5. Baseline depression (r = 0.50, 
p <.000) and baseline alcohol use (r = -0.20, p = .049) were correlated with PTSD. Baseline 
BMI score was correlated with CpG4 (r = 0.23, p = .033) and CpG5 (r = -0.24, p = .028) 
methylation. There was a significant difference in CpG5 methylation between participants who 
used prescription medication at baseline and those who did not (z = -2.03, p = .042). There were 
no differences between participants carrying the CC genotype and participant carrying the 
CT/TT genotype for any of the confounding/covarying variables. There was no significant 
difference in PTSD scores between CC and CT/TT genotype carriers. 
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Table 3: Baseline confounding/covarying variables related to PTSD symptom scores, FKBP5 methylation and childhood trauma 
*p < .05 












(no vs yes) 





(no vs yes) 
 r p z p r p z p r p r p r p z p 
                 
PTSD (baseline) -.199 .052 -1.07 .284 .077 .455 -0.49 .626 .062 .550 -.067 .514 .500 .000* -1.46 .144 
PTSD (3-months) -.118 .252 -0.14 .889 -.037 .720 0.00 1.00 .061 .552 -.047 .650 .059 .568 -1.08 .282 
PTSD (6-months) .110 .286 -0.14 .889 -.015 .884 -0.29 .773 .047 .646 -.202 .049* .222 .029* -0.51 .608 
                 
CpG1 (baseline) -.064 .566 -0.38 .702 .049 .658 -0.53 .598 .071 .524 .145 .188 -.071 .521 -1.28 .200 
CpG2 (baseline) -.200 .068 -0.02 .982 .082 .458 -1.06 .290 .007 .947 .065 .557 -.086 .438 -1.18 .239 
CpG3 (baseline) -.103 .353 -1.08 .282 .017 .876 -0.80 .423 .008 .941 .005 .966 -.062 .575 -0.01 .989 
CpG4 (baseline) .020 .859 -0.24 .811 .231 .033* -0.87 .384 -.087 .430 -.088 .423 -.007 .947 -0.44 .663 
CpG5 (baseline) -.202 .063 -0.77 .441 .047 .672 -1.35 .179 .028 .799 -.002 .984 -.073 .507 -0.65 .514 
                 
CpG1 (3-months) -.044 .689 -1.76 .079 -.074 .498 -1.02 .308 .180 .098 -.011 .917 -.104 .341 -0.38 .706 
CpG2 (3-months) -.060 .578 -1.41 .158 .005 .963 -1.93 .053 .092 .397 .005 .964 .063 .561 -1.15 .252 
CpG3 (3-months) .032 .766 -0.35 .728 .018 .866 -0.86 .392 .051 .638 -.024 .823 -.161 .134 -0.77 .440 
CpG4 (3-months) -.109 .319 -1.54 .124 .006 .956 -0.37 .712 .169 .121 .031 .780 -.006 .957 -1.24 .214 
CpG5 (3-months) .024 .827 -1.60 .109 .085 .432 -0.38 .706 -.004 .973 -.120 .266 -.119 .271 -0.32 .753 
                 
CpG1 (6-months) .060 .585 -0.68 .496 -.469 .125 -0.91 .362 -.072 .514 .070 .527 -.130 .238 -1.57 .118 
CpG2 (6-months) -.082 .461 -0.97 .331 -.095 .393 -0.07 .946 -.076 .494 -.086 .438 -.012 .881 -0.48 .630 
CpG3 (6-months) -.076 .493 -0.53 .594 -.122 .270 -0.80 .424 -.001 .995 -.011 .921 -.009 .935 -0.07 .942 
CpG4 (6-months) -.073 .513 -0.93 .350 .082 .459 -1.08 .280 .043 .699 -.056 .616 -.131 .238 -0.43 .664 
CpG5 (6-months) -.033 .768 -1.36 .174 -.239 .028* -0.48 .628 .073 .511 .137 .213 -.198 .071 -2.03 .042* 
                 
Childhood trauma 
(baseline) 
-.099 .338 -.156 .876 .005 .961 -1.08 .279 .316 .002* .196 .056 .193 .060 -.400 .689 
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Table 4: Univariate associations of baseline confounding/covarying variables with rs1360980 CC 




n = 31 
rs1360980 CT/TT 
n = 64 
Comparison by genotype 
grouping 
 M SD M SD n z p 
        
Age 25.29 6.10 25.23 5.13 95 -0.25 .802 
BMI 35.46 4.93 25.64 6.59 95 -1.50 .134 
Childhood trauma 17.00 3.86 16.56 3.24 95 -0.07 .941 
Lifetime trauma 1.39 1.56 1.38 1.28 95 -0.41 .680 
Alcohol use 1.61 2.36 1.73 2.39 95 -0.22 .827 
Depression 33.32 14.57 31.23 12.25 95 -1.06 .289 
        
 n % n % n χ2 p 
        
HIV positive 13 41.94 32 50.00 95 0.55 .460 
Smoker  4 12.90 8 12.50 95 0.00 .956 
Uses medication 9 29.03 23 35.94 95 0.45 .504 
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n = 31 
rs1360980 CT/TT 
n = 64 
Comparison by genotype 
grouping  
 M SD M SD n z p 
        
PTSD score (baseline) 70.95 22.03 63.88 18.87 95 -1.90 .058 
PTSD score (3-months) 34.65 27.86 36.08 27.65 95 -0.37 .712 
PTSD score (6-months) 21.76 28.35 27.95 28.02 95 -1.18 .240 
        
Abbreviations: posttraumatic stress disorder (PTSD) 
 
Main effect of methylation on PTSD 
The main effects of FKBP5 methylation as a predictor of PTSD are presented in Table 5 
(models 1A-5A). Decreased CpG1 methylation levels were associated with increased PTSD 
scores at 3-months  = -.59, t(-2.76), p = .007 and 6-months  = -.45, t(-2.58), p = .011  post-
rape. Decreased CpG2  = -.49, t(-2.19), p = .030  and CpG5  = -.57, t(-2.62), p = .010 
methylation levels were also associated with increased PTSD scores at 6-months post-rape.  
 Decreased CpG1 methylation remained a significant predictor of increased PTSD at 3-
months post-rape when adding baseline depression and alcohol as covariates  = -0.68, t(-2.14), 
p = .035 (see Supplementary Table 1). CpG1 and CpG2 methylation were no longer significant 
predictors of PTSD at 6-months post-rape, but increased baseline depression was a significant 
predictor of increased PTSD scores (see Supplementary Tables 2 and 3). CpG5 methylation 
remained a significant predictor of PTSD at 6-months post-rape when controlling for baseline 
BMI and baseline medication use  = -0.82, t(-2.29), p = .025 (see Supplementary Table 4). 
Baseline medication use was also a significant predictor of PTSD  = -14.12, t(-2.05), p = .044. 
When adding depression and alcohol use as covariates, CpG5 methylation was no longer a 
significant predictor of PTSD (see Supplementary Table 5). Baseline depression and alcohol 
use were not significant predictors of PTSD, but baseline medication use remained a significant 
predictor  = -14.06, t(-2.07), p = .042). 
 
Main effect of rs1360780 genotype on PTSD 
Rs1360780 genotype was not a significant predictor of PTSD in any of the models. The main 
effect of rs1360780 genotype as a predictor of PTSD is presented in Table 5 (models 1A-5A). 
 
Main effect of childhood trauma on PTSD 
The main effect of childhood trauma as a predictor of PTSD is presented in Table 5 (models 
1A-5A). Increased childhood trauma scores were associated with increased PTSD scores at 
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baseline in all models i.e. models containing CpG1  = 1.79, t(2.76), p = .008; CpG2  = 1.85, 
t(2.87), p = .006; CpG3  = 2.18, t(3.37), p = .001; CpG4  = 1.94, t(2.86), p = .007; and CpG5 
 = 1.78, t(2.77), p = .007. Increased childhood trauma remained a significant predictor of 
increased PTSD at baseline when including baseline depression and alcohol as covariates in all 
models (see Supplementary Tables 6-10). Increased baseline depression was also a significant 
predictor of increased baseline PTSD scores in all models i.e. models containing CpG1  = 
0.67, t(4.52), p < .000; CpG2  = 0.63, t(4.43), p < .000; CpG3  = 0.68, t(4.67), p < .000; 
CpG4  = 0.69, t(4.77), p < .000; and CpG5  = 0.68 t(4.62), p <.000 methylation. Decreased 
alcohol consumption at baseline was associated with increased PTSD scores at baseline for the 
models that included CpG1  = -1.68, t(-2.02), p = .047; CpG3  = -1.70, t(-2.09), p = .040; 
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Table 6:  Summary statistics of variables predicting PTSD symptom scores at baseline and over 
time using mixed linear regression models  
Model  ß Std 
error 
t p 95% CI 
Lower          Upper 
       
 FKBP5 CpG1 methylation      
       
1A Baseline*CpG1 -0.14 0.16 -0.90 .371 -0.45 0.18 
 3-months*CpG1 -0.59 0.21 -2.76 .007* -1.02 -0.17 
 6-months*CpG1 -0.45 0.18 -2.58 .011* -0.80 -0.11 
        
 Baseline*genotype -3.12 4.43 -0.70 .486 -12.07 5.84 
 3-months*genotype 6.76 6.29 1.07 .288 -5.87 19.39 
 6-months*genotype 7.08 5.59 1.27 .209 -4.03 18.19 
        
 Baseline*ChildT          1.79 0.65 2.76 .008* 0.49 3.09 
 3-months*ChildT 1.44 0.83 1.72 .090 -0.23 3.10 
 6-months*ChildT 0.04 0.64 0.06 .956 -1.24 1.31 
        
1B Baseline*CpG1*rs1360780 -0.02 0.04 -0.51 .609 -0.10 0.06 
 3-months*CpG1*rs1360780 -0.02 0.06 -0.39 .700 -0.13 0.09 
 6-months*CpG1*rs1360780 0.01 0.05 0.16 .875 -0.09 0.10 
        
 Baseline*ChildT 2.57 0.55 4.68 .000007* 1.48 3.65 
 3-months*ChildT 0.76 0.64 1.19 .235 -0.50 2.02 
 6-months*ChildT -0.11 0.55 -0.19 .848 -1.19 0.97 
        
1C Baseline*genotype -1.54 4.52 -0.34 .734 -10.52 7.44 
 3-months*genotype 0.93 5.89 0.16 .874 -10.75 12.62 
 6-months*genotype 0.64 6.21 0.10 .918 -11.70 12.98 
        
 Baseline*CpG1*ChildT 0.02 0.01 3.07 .003* 0.01 0.03 
 3-months*CpG1*ChildT -0.00 0.01 -0.49 .623 -0.02 0.01 
 6-months*CpG1*ChildT -0.01 0.01 -1.29 .201 -0.02 0.01 
        
1D Baseline*CpG1 -0.11 0.15 -0.79 .433 -0.40 0.17 
 3-months*CpG1 -0.55 0.16 -3.40 .001 -0.87 -0.23 
 6-months*CpG1 -0.60 0.15 -3.98 .0001 -0.90 -0.30 
        
 Baseline*rs1360780*ChildT 0.13 0.23 0.54 .591 -0.34 0.60 
 3-months* rs1360780*ChildT 0.50 0.30 1.65 .104 -0.11 1.11 
 6-months* rs1360780*ChildT 0.30 0.27 1.12 .267 -0.23 0.82 
        
1E Baseline*rs1360780*ChildT*CpG1 0.01 0.00 4.39 .00002* 0.00 0.01 
 3-months* rs1360780*ChildT*CpG1 -0.00 0.00 -1.35 .180 -0.01 0.00 
 6-months* rs1360780*ChildT*CpG1 -0.01 0.00 -3.29 .001* -0.01 -0.00 
        
 FKBP5 CpG2 methylation       
        
2A Baseline*CpG2 -0.10 0.21 -0.50 .621 -0.52 0.31 
 3-months*CpG2 -0.43 0.25 -1.74 .084 -0.92 0.06 
 6-months*CpG2 -0.49 0.23 -2.19 .030* -0.94 -0.05 
        
 Baseline*genotype -4.91 4.29 -1.15 .258 -13.54 3.73 
 3-months*genotype 2.84 6.19 0.46 .647 -9.43 15.11 
 6-months*genotype 5.75 5.38 1.07 .288 -4.93 16.43 
        
 Baseline*ChildT 1.85 0.65 2.87 .006* 0.56 3.15 
 3-months*ChildT 0.82 0.85 0.97 .336 -0.86 2.51 
 6-months*ChildT 0.23 0.68 0.34 .736 -1.12 1.58 
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2B Baseline*CpG2*rs1360780 -0.04 0.04 -0.93 .357 -0.13 0.05 
 3-months*CpG2*rs1360780 -0.01 0.06 -0.12 .908 -0.14 0.12 
 6-months*CpG2*rs1360780 0.01 0.06 0.15 .879 -0.10 0.12 
        
 Baseline*ChildT 2.53 0.53 4.75 .000006* 1.48 3.59 
 3-months*ChildT 0.46 0.63 0.73 .470 -0.80 1.71 
 6-months*ChildT -0.28 0.55 -0.51 .609 -1.36 0.80 
        
2C Baseline*genotype -1.90 3.97 -0.48 .633 -9.79 5.99 
 3-months*genotype -0.42 5.45 -0.08 .938 -11.33 10.48 
 6-months*genotype 0.34 4.81 0.07 .943 -9.19 9.88 
        
 Baseline*CpG2*ChildT 0.02 0.01 3.66 .0004* 0.01 0.03 
 3-months*CpG2*ChildT -0.00 0.01 -0.11 .916 -0.02 0.01 
 6-months*CpG2*ChildT -0.01 0.01 -1.38 .169 -0.02 0.00 
        
2D Baseline*CpG2 -0.03 0.19 -0.17 .869 -0.41 0.35 
 3-months*CpG2 -0.50 0.20 -2.48 .018 -0.91 -0.09 
 6-months*CpG2 -0.61 0.19 -3.19 .002 -1.00 -0.23 
        
 Baseline*rs1360780*ChildT 0.01 0.23 0.04 .972 -0.46 0.48 
 3-months* rs1360780*ChildT 0.30 0.30 1.00 .326 -0.32 0.93 
 6-months* rs1360780*ChildT 0.26 0.26 0.99 .327 -0.27 0.78 
        
2E Baseline*rs1360780*ChildT*CpG2 0.01 0.00 3.91 .0001* 0.00 0.01 
 3-months* rs1360780*ChildT*CpG2 -0.00 0.00 -1.69 .094 -0.01 0.00 
 6-months* rs1360780*ChildT*CpG2 -0.01 0.00 -3.70 .0002* -0.01 -0.00 
        
 FKBP5 CpG3 methylation       
        
3A Baseline*CpG3 0.02 0.16 0.10 .924 -0.31 0.34 
 3-months*CpG3 -0.10 0.21 -0.48 .630 -0.52 0.32 
 6-months*CpG3 -0.26 0.22 -1.17 .244 -0.69 0.18 
        
 Baseline*genotype -2.21 4.20 -0.53 .600 -10.54 6.13 
 3-months*genotype 1.20 6.28 0.19 .849 -11.34 13.74 
 6-months*genotype 5.11 5.46 0.94 .351 -5.71 15.93 
        
 Baseline*ChildT 2.18 0.65 3.37 .001* 0.90 3.46 
 3-months*ChildT 0.65 0.84 0.77 .444 -1.03 2.33 
 6-months*ChildT 0.47 0.75 0.63 .528 -1.01 1.95 
        
3B Baseline*CpG3*rs1360780 -0.02 0.04 -0.39 .698 -0.09 0.06 
 3-months*CpG3*rs1360780 0.01 0.06 0.17 .866 -0.10 0.12 
 6-months*CpG3*rs1360780 0.03 0.05 0.50 .617 -0.08 0.13 
        
 Baseline*ChildT 2.60 0.53 4.91 .000002* 1.56 3.65 
 3-months*ChildT 0.58 0.63 0.91 .362 -0.67 1.82 
 6-months*ChildT -0.17 0.56 -0.31 .759 -1.27 0.93 
        
3C Baseline*genotype 1.55 4.03 0.39 .701 -6.44 9.54 
 3-months*genotype -1.20 5.37 -0.22 .824 -11.91 9.51 
 6-months*genotype 0.03 4.76 0.01 .995 -9.39 9.45 
        
 Baseline*CpG3*ChildT 0.02 0.01 3.90 .0002* 0.01 0.03 
 3-months*CpG3*ChildT 0.00 0.01 0.72 .477 -0.01 0.02 
 6-months*CpG3*ChildT -0.00 0.01 -0.61 .542 -0.01 0.01 
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3D Baseline*CpG3 0.14 0.15 0.95 .350 -0.16 0.45 
 3-months*CpG3 -0.21 0.17 -1.22 .230 -0.55 0.14 
 6-months*CpG3 -0.35 0.17 -2.06 .044 -0.68 -0.01 
        
 Baseline*rs1360780*ChildT 0.17 0.23 0.74 .467 -230 0.64 
 3-months* rs1360780*ChildT 0.24 0.30 0.78 .439 -0.37 0.84 
 6-months* rs1360780*ChildT 0.31 0.27 1.13 .264 -0.24 0.86 
        
3E Baseline*rs1360780*ChildT*CpG3 0.01 0.00 4.76 .000004* 0.01 0.01 
 3-months* rs1360780*ChildT*CpG3 -0.00 0.00 -0.90 .368 -0.01 0.00 
 6-months* rs1360780*ChildT*CpG3 -0.01 0.00 -2.86 .005* -0.01 -0.00 
        
 FKBP5 CpG4 methylation       
       
4A Baseline*CpG4 -0.02 0.23 -0.09 .926 -0.49 0.45 
 3-months*CpG4 -0.27 0.28 -0.99 .328 -0.84 0.29 
 6-months*CpG4 -0.41 0.26 -1.59 .116 -0.93 0.10 
        
 Baseline*genotype -3.60 4.31 -0.84 .409 -12.38 5.18 
 3-months*genotype 1.81 6.44 0.28 .780 -11.29 14.92 
 6-months*genotype 6.77 5.44 1.24 .218 -4.11 17.65 
        
 Baseline*ChildT 1.94 0.69 2.86 .007* 0.57 3.30 
 3-months*ChildT 1.03 0.89 1.16 .252 -0.77 2.83 
 6-months*ChildT 0.65 0.73 0.89 .378 -0.71 2.12 
        
4B Baseline*CpG4*rs1360780 -0.01 0.04 -0.30 .765 -0.10 0.07 
 3-months*CpG4*rs1360780 -4.12 0.06 0.00 1.00 -0.11 0.11 
 6-months*CpG4*rs1360780 0.03 0.05 0.52 .604 -0.07 0.13 
        
 Baseline*ChildT 2.64 0.55 4.81 .000004* 1.56 3.73 
 3-months*ChildT 0.78 0.65 1.20 .232 -0.51 2.06 
 6-months*ChildT -0.10 0.57 -0.17 .863 -1.25 1.02 
        
4C Baseline*genotype -0.05 4.04 -0.01 .990 -8.22 8.11 
 3-months*genotype -0.10 5.60 4.52 .866 -15.87 13.87 
 6-months*genotype 2.39 4.83 0.50 .624 -7.46 12.25 
        
 Baseline*CpG4*ChildT 0.02 0.01 4.20 .0002* 0.01 0.04 
 3-months*CpG4*ChildT 0.01 0.01 0.95 .360 -0.01 0.02 
 6-months*CpG4*ChildT -0.00 0.01 -0.66 .521 -0.02 0.01 
        
4D Baseline*CpG4 0.03 0.22 0.13 .896 -0.40 0.46 
 3-months*CpG4 -0.35 0.24 -1.47 .144 -0.82 0.12 
 6-months*CpG4 -0.48 0.23 -2.11 .037* -0.38 0.55 
        
 Baseline*rs1360780*ChildT 0.09 0.23 0.37 .710 -0.38 0.55 
 3-months* rs1360780*ChildT 0.31 0.30 1.01 .317 -0.30 0.91 
 6-months* rs1360780*ChildT 0.37 0.27 1.36 .178 -0.17 0.90 
        
4E Baseline*rs1360780*ChildT*CpG4 0.01 0.00 4.64 .000007* 0.00 0.01 
 3-months* rs1360780*ChildT*CpG4 -0.00 0.00 -0.68 .499 -0.01 0.00 
 6-months* rs1360780*ChildT*CpG4 -0.00 0.00 -2.62 .010* -0.01 0.00 
        
 FKBP5 CpG5 methylation      
       
5A Baseline*CpG5 0.07 0.20 0.37 .712 -0.32 0.46 
 3-months*CpG5 -0.20 0.25 -0.81 .419 -0.70 0.30 
 6-months*CpG5 -0.57 0.22 -2.62 .010* -1.00 -0.14 
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 Baseline*genotype -3.88 4.02 -0.97 .336 -11.84 4.08 
 3-months*genotype 0.65 5.95 0.11 .914 -11.22 12.51 
 6-months*genotype 7.55 5.23 1.44 .152 -2.81 17.90 
        
 Baseline*ChildT 1.78 0.64 2.77 .007* 0.50 3.06 
 3-months*ChildT 0.60 0.80 0.75 .458 -1.00 2.20 
 6-months*ChildT 0.62 0.64 0.96 .341 -0.66 1.89 
        
5B Baseline*CpG5*rs1360780 -0.02 0.06 -0.40 .693 -0.14 0.10 
 3-months*CpG5*rs1360780 0.02 0.08 0.23 .823 -0.14 0.17 
 6-months*CpG5*rs1360780 -0.03 0.07 -0.41 .681 -0.17 0.11 
        
 Baseline*ChildT 2.53 0.55 4.57 .00001* 1.43 3.62 
 3-months*ChildT 0.47 0.62 0.77 .442 -0.74 1.69 
 6-months*ChildT 0.13 0.55 0.24 .808 -0.94 1.21 
        
5C Baseline*genotype 0.61 3.69 0.17 .869 -6.69 7.91 
 3-months*genotype -1.85 5.32 -0.35 .729 -12.45 8.75 
 6-months*genotype 3.75 4.75 0.79 .432 -5.66 13.16 
        
 Baseline*CpG5*ChildT 0.03 0.01 3.87 .0002* 0.01 0.04 
 3-months*CpG5*ChildT 0.00 0.01 0.32 .751 -0.02 0.02 
 6-months*CpG5*ChildT -0.02 0.01 -1.96 .051 -0.03 0.00 
        
5D Baseline*CpG5 0.20 0.17 1.17 .242 -0.14 0.53 
 3-months*CpG5 -0.30 0.20 -1.53 .129 -0.68 0.09 
 6-months*CpG5 -0.57 0.19 -2.99 .003* -0.94 -0.19 
        
 Baseline*rs1360780*ChildT 0.08 0.21 0.36 .716 -0.34 0.50 
 3-months* rs1360780*ChildT 0.18 0.28 0.64 .526 -0.38 0.74 
 6-months* rs1360780*ChildT 0.38 0.25 1.51 .153 -0.12 0.88 
        
5E Baseline*rs1360780*ChildT*CpG5 0.01 0.00 4.51 .00001* 0.01 0.02 
 3-months* rs1360780*ChildT*CpG5 -0.00 0.00 -1.23 .219 -.01 0.00 
 6-months* rs1360780*ChildT*CpG5 -0.01 0.00 -3.46 .001* -0.01 0.00 
        
*p < .05 
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Interaction between methylation and rs1360780 CC vs CT/TT genotype  
The results of the interaction between methylation and rs1360780 genotype are presented in 
Table 5 (models 1B-5B). The interaction between methylation and rs1360780 genotype was 
not a significant predictor of PTSD in any of the models.  
 
Interaction between methylation and childhood trauma  
The results of the interaction between methylation and childhood trauma are presented in Table 
5 (models 1C-5C). The interaction between childhood trauma and methylation was a significant 
predictor of PTSD at baseline for all CpG sites. However, when comparing the correlation 
between methylation and PTSD for the groups with low vs high childhood trauma, there were 
no significant differences (see Supplementary Table 11).  
 
Interaction between childhood trauma and rs1360780 genotype 
The results of the interaction between childhood trauma and rs1360780 genotype are presented 
in Table 5 (models 1D-5D). The interaction between childhood trauma and rs1360780 
genotype was not a significant predictor of PTSD in any of the models. 
 
Interaction between methylation, rs1360780 genotype and childhood trauma  
The results of the interaction between methylation, rs1360780 genotype and childhood trauma 
are presented in Table 5 (models 1E-5E). The interaction between methylation, rs1360780 
genotype and childhood trauma was a significant predictor of PTSD at baseline and 6-months 
post-rape in all models.  
 When comparing the correlations between methylation and PTSD for the groups with 
high childhood trauma and CC genotype vs high childhood trauma and CT/TT genotype, there 
was a significant difference between the correlations for CpG3 (Fisher’s z = -8.70, p < .000) at 
baseline (see Supplementary Table 12). Increased baseline PTSD scores were associated with 
decreased methylation at CpG3 in participants carrying the CC genotype (r = -0.58, p = .040) 
but not in participants carrying the CT/TT genotype (r = -.003, p = .989). The interaction effect 
was no longer significant when adding depression and alcohol use as covariates (see 
Supplementary Table 13). Increased baseline depression was a significant predictor of 
increased PTSD scores at baseline  = 0.72 t(4.87), p < .000. 
 There was a significant difference between the correlations for CpG5 methylation and 
PTSD at baseline (Fisher’s z = -5.89, p < .000). Increased baseline PTSD scores were 
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associated with decreased methylation at CpG5 in participants carrying the CC genotype (r = 
-0.83, p < .001) but not in participants carrying the CT/TT genotype (r = .057, p = .774). The 
interaction effect was no longer significant when adding baseline BMI and medication use as 
control variables (see Supplementary Table 14) as well as baseline depression and alcohol use 
as covariates (see Supplementary Table 15). Increased baseline depression was a significant 
predictor of increased baseline PTSD scores  = 0.74 t(4.90), p < .000. 
When comparing the correlations between methylation and PTSD for the groups with 
low childhood trauma and CC genotype vs low childhood trauma and CT/TT genotype, there 
was a significant difference between the correlations for CpG5 at 6-months post-rape (Fisher’s 
z = 1.80, p = .036). However, the correlation in the group with low childhood trauma and CC 
genotype (r = 0.32, p = .271) was not significant, neither was the correlation in the group with 
low childhood trauma and CT/TT genotype (r = -0.31, p = .103).  
 
DISCUSSION 
The overarching aim of this study was to determine if longitudinal change in FKBP5 intron 7 
methylation was a significant independent predictor of longitudinal change in PTSD scores. 
We also investigated the relationship between childhood trauma, rs1360780 and PTSD and the 
interaction effect between methylation, childhood trauma and rs1360780 as predictors of 
PTSD.  
Decreased CpG1 methylation was a significant independent predictor of increased 
PTSD at 3-months and 6 months post-rape, and decreased CpG2 and CpG5 methylation were 
significant independent predictors of PTSD at 6-months post-rape. These results relate to those 
from the only prior longitudinal study investigating FKBP5 intron 7 methylation 47. They found 
that responders (>10 point reduction in PTSD symptom scores) to a mindfulness-based stress 
reduction intervention showed increased methylation in CpG4 from pre-intervention to post-
intervention, compared to non-responders who showed decreased methylation over time 47. 
Decreased methylation is likely to result in overexpression of FKBP5 which may disrupt the 
ultra-short intracellular negative feedback loop regulated by the interaction between 
glucocorticoid receptor and FKBP5 28,29. Increased expression of FKBP5 will likely result in 
reduced intracellular binding of cortisol to GRs (since FKBP5 inhibits GR functioning) and 
this may result in  delayed activation of the negative feedback loop of the HPA-axis (binding 
of cortisol to GRs signals the activation of the negative feedback loop) and a prolonged stress 
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response 27,30,35,37,80. Prolonged activation of the stress response may underlie or exaggerate 
PTSD symptoms, especially symptoms related to hypervigilance 14,81. 
The rs1360780 genotype (CC vs CT/TT), either independently or in interaction with 
childhood trauma and methylation, was not a significant independent predictor of PTSD. This 
finding is inconsistent with prior cross-sectional studies where the T allele of rs1360780 was 
found to interact with increased childhood trauma in predicting increased PTSD symptom 
severity 30,31,35. The T allele of rs1360980 is generally thought to have a functional effect on 
FKBP5 expression by upregulating FKBP5 transcription through the formation of a TATA box 
and altered chromatin structure 27,35,37. However, the aforementioned studies did not take the 
effect of FKBP5 methylation into account 31,35,82. While the T allele of rs1360780 is likely to 
result in increased expression of FKBP5, decreased FKBP5 promoter methylation may have 
the same effect 18,23,44. The functional effect of methylation may be stronger than that of the 
rs1360780 genotype and may overrule the effect of the T allele on FKBP5 expression, although 
rs1360780 may also contribute to decreased methylation in intronic regions 83,84. The sample 
characteristics of prior studies are also different to the characteristics of our sample since one 
prior study investigated a North American populations with a mixture of trauma types 35 and 
another investigated an older veteran sample 31. Characteristics such as gender, ethnicity and 
trauma type may have an effect on methylation and on the risk of developing PTSD and limits 
the comparison results between studies 85–87. 
Increased childhood trauma was an independent predictor of increased PTSD scores at 
baseline. Childhood trauma is a well-established risk factor for the development of PTSD 
following adulthood revictimization 38–40. Prolonged increased circulating cortisol subsequent 
to childhood trauma may result in neuroendocrinological changes underlying the functioning 
of the HPA-axis 88,89. These neuroendocrinological changes may be more pronounced when 
childhood trauma occurs at developmentally sensitive periods and may include 
methylation/demethylation of FKBP5 CpG sites 35,37. In fact, an interaction effect between 
childhood trauma and methylation at each CpG sites was observed in this study but the effect 
was not significant upon further investigation of the correlations in the childhood trauma vs 
genotype subgroups. It is plausible that an incremental increase in childhood trauma results in 
an incremental decrease in FKBP5 methylation as well as increase in baseline PTSD scores, 
and that this effect may be masked by categorising childhood trauma exposure into low and 
high groups 90. Childhood trauma also has adverse effects on emotional development and may 
result in maladaptive coping, social and emotional skills, which may increase the risk for 
developing PTSD following rape, independent of the effects of methylation 91,92.   
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When considering the interaction between methylation, rs1360780 genotype and 
childhood trauma, we found that increased baseline PTSD scores were associated with 
decreased methylation at CpG3 and CpG5 in participants with high childhood trauma who 
possessed the CC genotype. Conflicting findings related to the association between 
methylation, rs1360780 genotype and childhood trauma have been reported in prior cross-
sectional studies 34,35,46. Some studies report that T allele carriers with increased childhood 
trauma show decreased FKBP5 intron 7 methylation at CpG1 33, CpG3 and CpG4 35, while 
others found that increased childhood trauma and carrying the T allele is associated with 
increased methylation in and around CpG4 34,46. There are currently no longitudinal studies 
investigating both rs1360780 genotype and FKBP5 intron 7 methylation in relation to PTSD 
and the majority of cross-sectional studies have investigated FKBP5 methylation levels in 
relation to PTSD, irrespective of the time since the traumatic event occurred 34,35,46. This limits 
the comparison of our findings with previous findings since we measured methylation change 
in the immediate aftermath of trauma. Our study is also the first investigating participants of 
African ethnicity and rs1360780; therefore it is important to note that the SNP may have an 
ethnicity-dependent functional effect 85,86. 
The independent effects observed for decreased CpG1, CpG2 and CpG5 methylation 
in relation to PTSD symptom severity at 6-months post-rape, as well as the interaction effects 
observed for decreased methylation at CpG3 and CpG5 in participants with high childhood 
trauma and carrying the CC genotype, were no longer significant when adding baseline 
depression as a covariate to the model. Decreased CpG1 methylation as an independent 
predictor of increased PTSD at 3-months post-rape survived the addition of depression as a 
covariate. Although depression was a strong predictor of PTSD and reduced the effect of 
methylation on PTSD symptom severity in most models, the role of depression in the 
development of PTSD must be considered carefully 93. Depression and PTSD comorbidity is 
highly prevalent in survivors of interpersonal trauma 94,95. They are considered distinct 
disorders, but they do also share overlapping symptom components; most notably, both 
disorders are associated with negative affect 93. A study investigating survivors of sexual 
assault reported that PTSD symptom severity decreased in proportion to depression symptom 
severity over time, and that depression scores were fully mediated by PTSD scores 4. 
Depression may explain a significant proportion of variance in PTSD simply based on 
overlapping symptom constructs, in which case it cannot be considered an independent variable 
but rather a variable closely related to the dependent variable 93–95. 
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 Increased baseline alcohol consumption was added to the models along with baseline 
depression scores, and higher alcohol consumption was associated with decreased PTSD 
symptoms at baseline. Although the finding seems counterintuitive, it is not completely 
unsupported 96,97. A retrospective study investigating male and female veterans found that 
female veterans reporting moderate alcohol consumption showed a decreased risk for PTSD 
compared to those who abstained, light drinkers and hazardous drinkers 96. No difference in 
risk for PTSD was observed between light and moderate drinkers in their male subsample 96. 
Another study found that moderate drinkers showed decreased PTSD scores following 
admission to an emergency department for a traumatic injury and at 3-months post-
admission 97. Although further investigation of the relationship between alcohol consumption 
and change in PTSD scores over time is needed, it is plausible that moderate intake of alcohol 
may protect against fear conditioning related to traumatic memories or may provide temporary 
relief from distressing symptoms 97,98. 
The findings reported in this study should be interpreted in light of some limitations. First, 
our sample size was small, thus the study was statistically underpowered. Second, although 
substantial evidence exists linking PTSD to FKBP5 genotype and differential methylation, 
PTSD remains a complex disease and its aetiology and trajectory is likely due to an interaction 
between many genes and biological pathways. Third, whole blood was used to investigate 
differential methylation while differential methylation in brain tissue is more likely to 
contribute to PTSD pathophysiology. However,  FKBP5 intron 7 methylation levels in whole 
blood have been found to correlate with methylation levels in brain tissue in animal 
studies 99,100. Blood is also easily accessible and blood biomarkers of PTSD risk could be used 
to prioritise treatment for individuals most likely to develop PTSD following trauma exposure. 
Fourth, we could not compare post-rape epigenetic changes to pre-rape epigenetic markers 
since we did not have pre-rape data i.e. the baseline assessment was completed within 20 days 
following the rape. This is a limitation for determining whether a cause-effect relationship 
exists between rape exposure and epigenetic changes. Finally, we did not use laboratory 
methods to identify and count specific blood cell types in individual samples. Potential 
confounding in methylation findings, due to cell-type composition and change in blood cell-
type compositions over time, cannot be determined. 
 Despite these limitations, there are notable strengths.  The rs1360980 genotype and the 
CpG sites in and around GREs investigated in this study have been associated with functional 
effects. Investigating these sites thus contributes to the understanding of PTSD aetiology. In 
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addition, we investigated a relatively homogenous sample, both in terms of demographic 
characteristics (young women from low socio-economic position and from the same ethnicity 
group) and trauma exposure, enabling us to control various confounding factors.  
 In summary, the study provides evidence linking FKBP5 methylation to PTSD 
symptoms scores at 3-months and 6-months post-rape. Childhood trauma and FKBP5 
rs1360780 CC genotype influenced the relationship between FKBP5 methylation and PTSD at 
baseline. This is the second study to investigate longitudinal changes in methylation levels in 
intron 7 of the FKBP5 gene, but the first to investigate longitudinal changes in a rape-exposed, 
African sample. Rape carries a high conditional risk for PTSD and identifying the underlying 
molecular mechanisms contributing to the aetiology and course of PTSD in the aftermath of 
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The main aim of this study was to investigate the pre-, peri- and post-trauma risk and protective 
factors related to socio-demographic, psychological and epigenetic mechanisms in the 
aetiology and trajectory of posttraumatic stress disorder (PTSD) following rape-exposure. 
Socio-economic factors included demographic factors such as age, gender, relationship status 
and income/employment status, as well as social factors such as social support and stigma 
associated with rape. Psychological factors included exposure to trauma, resilience, perceived 
stress, alcohol use and depression. Epigenetic mechanisms included epigenome-wide 
differential methylation of genes in relation to PTSD status at 3-months post-rape as well as 
the longitudinal change in brain-specific serine/threonine-protein kinase (BRSK2), pituitary 
adenylate cyclase-activating polypeptide 1 (ADCYAP1) and FK506 binding protein (FKBP5) 
methylation levels in relation to longitudinal changes in PTSD symptom scores. A common 
functional single nucleotide polymorphism (SNP) of the FKBP5 gene was also investigated, 
given that it has been associated with biological changes in the functioning of the stress 
response following childhood trauma exposure and increases the risk for psychiatric disorders 
following adult revictimization 1–3. A systematic review of epigenetic changes in relation to 
childhood trauma across adult onset psychiatric disorders was also conducted given that little 
is known about the shared epigenetic changes resulting from childhood trauma across 
psychiatric disorders 4.  
 The parent study, the Rape Impact Cohort Evaluation (RICE) 5 allowed for the 
successful assessment and collection of peripheral blood DNA samples from rape-exposed 
women. A relatively homogenous cohort (similar socio-demographic background, similar 
history of trauma exposure and aged between 16 and 40 years; n = 852) of rape-exposed women 
were assessed at baseline (within 20 days of the rape), 3-months and 6-months post-rape. The 
large cohort investigated in the parent study allowed us to control for various confounding 
factors associated with DNA methylation including the exclusion of women who were pregnant 
or lactating, women who met criteria for PTSD at the baseline assessment indicating PTSD due 
to a past traumatic event other than the rape, and women who had HIV seroconverted. We also 
matched participants as closely as possible on HIV status, age, education level, income, body 
mass index (BMI), smoking status and lifetime trauma exposure.   
 To the best of our knowledge, this is the first study to compare epigenome-wide DNA 
methylation profiles between rape-exposed women with and without PTSD. It is also the first 
study to investigate epigenome-wide methylation profiles in women of African ethnicity. There 
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are no known studies that have investigated longitudinal change in methylation in relation to 
change in PTSD scores in rape-exposed women exclusively. Longitudinal studies 
comprehensively investigating pre-, peri- and post-rape psychosocial risk and protective 
associated with PTSD do exist but are scarce, especially those investigating PTSD beyond 3-
months post-rape and studies solely investigating rape as opposed to the broader category of 
sexual assault 6. This study therefore makes an important contribution to understanding the 
psychosocial risk and protective factors associated with mental health in the aftermath of rape. 
Identifying epigenetic differences and changes over time in relation to PTSD further improves 
our understanding of the molecular mechanisms mediating the association between 
environmental exposures and mental health outcomes.  
A comprehensive discussion of the findings related to each objective of this study is 
presented in the chapters dedicated to each objective (chapter 2-5). An overview of the key 
findings, contribution of the findings to the knowledge gaps, limitations of the study, 
concluding remarks, recommendations for practice and recommendations for future research 
are discussed below.  
6.2. OVERVIEW OF KEY FINDINGS 
6.2.1. Epigenetic alterations associated with childhood trauma and adult mental health 
outcomes: A systematic review 
Childhood trauma is prevalent across low-, middle- and high-income countries and increases 
the risk for nearly all adult-onset psychiatric disorders as well as suicide 7–11. Differential 
methylation of genes associated with the biological response to stress and trauma may underlie 
a range of phenotypic presentation, including behavioural and affective symptoms 12,13. The 
epigenome is particularly amenable to environmental influences during childhood, given 
heightened brain plasticity during critical developmental periods 14,15. Studies have 
investigated the relationship between differential methylation and childhood trauma in relation 
to adult-onset psychiatric disorders, but little is known about the discrepancies and 
commonalities in pathways affected by differential methylation across psychiatric disorders 
14,16. We conducted a systematic review investigating differential methylation in relation to 
childhood trauma and adult mental health outcomes and determined the following: 
(1) high levels of childhood trauma were associated with increased NR3C1 methylation in 
mood and personality disorders and decreased methylation in anxiety and trauma-
related disorders; 
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(2) high levels of childhood trauma were associated with increased BDNF methylation in 
healthy adult and adults with borderline personality disorder; 
(3) high levels of childhood trauma were associated with increased OXTR methylation in 
healthy adults; 
(4) studies investigating the relationship between differential methylation and childhood 
trauma were generally limited by a lack of statistical power, stemming from small 
sample sizes; 
(5) there was a lack of uniformity in defining childhood trauma and some studies did not 
use standardised measures to assess childhood trauma exposure; 
(6) there was a lack of uniformity in the molecular methods used to investigated 
differential methylation; 
(7) the vast majority of studies followed a candidate gene design and implicated 
differential methylation at single CpG sites in the relationship between childhood 
trauma and psychiatric disorders; 
(8) the vast majority of studies were conducted in American, Canadian and European 
countries on Caucasian individual, only one study was conducted in an Asian country 
and none were conducted in African countries. 
The findings provide evidence for the role of NR3C1, BDNF and OXTR in the association 
between childhood trauma and adult-onset psychiatric disorders. NR3C1, BDNF and OXTR 
have all been implicated in the functioning of the hypothalamic-pituitary-adrenal (HPA) axis 
and the neuroendocrinology of psychiatric disorders 6,17. The findings highlight the need to 
refine the design and methodological strategies used in epigenetic studies to eliminate the noise 
caused by confounding factors 18. Identifying discrepancies and commonalities in pathways 
affected by childhood trauma across psychiatric disorders may aid in identifying biomarkers of 
psychiatric disorders and developing epigenetic therapies 18–20.  
 
6.2.2. Risk and protective factors affecting the symptom trajectory of posttraumatic 
stress disorder post-rape 
The prevalence of PTSD in sexual assault survivors (35% - 45% at 3-months post-rape) is 
higher than those associated with other trauma types 17,21–23. Risk and protective factors for 
PTSD in sexual assault survivors have been found to differ from those associated with non-
sexual trauma types 6,22. Putative risk and protective factors for PTSD following rape include 
pre-assault factors (e.g. age 22,24,25, relationship status 17,25,26, education 24,26 
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employment/income 17,24,25, childhood trauma exposure 26–28 adult cumulative lifetime trauma 
17,22,26 and HIV status29), assault factors (e.g. multiple perpetrators 17, multiple sexual acts 17, 
physical injury inflicted during the rape 17,25 and a longer duration of assault 30) and post-assault 
factors (e.g. resilience22,26,31, social support32, perceived stress 33,34, rape stigma25,26,31,35, 
alcohol use, depression17,24,27,36–41). The aforementioned risk and protective factors may also 
have long-term effects on the trajectory of PTSD symptomatology 6,34,42. Few studies have 
comprehensively investigated pre- and post-assault risk and protective factors for PTSD in a 
longitudinal prospective design, especially beyond the 3-month post-rape period and in low- to 
medium-income countries 6,17. We investigated pre-assault, assault and post-assault risk factors 
as predictors of the trajectory of PTSD symptoms over 6-months (n = 639) and determined the 
following: 
(1) baseline age, education, relationship status, employment status, HIV status, childhood 
trauma and lifetime trauma exposure were not significant predictors of PTSD at any 
timepoint; 
(2) if the perpetrator was known to the rape survivor or was a stranger, being abducted or 
lured somewhere under false pretences or not, the use of a weapon or not, use of bodily 
physical force or not, if the perpetrator or accomplice threatened to kill the rape survivor 
or not, if the rape survivor thought she would be killed or not, if the same perpetrator/s 
had raped the same survivor on a previous occasion or not, the number of different 
sexual acts that occurred during the rape (vaginal/anal/oral/digital/object penetration, 
forced or observed masturbation); and if the rape was reported to the police or not were 
not significant predictors of PTSD at any timepoint; 
(3) rape survivors reporting a single perpetrator had higher PTSD scores at 3-months post-
rape compared to those who reported multiple perpetrators;  
(4) baseline resilience, social support, perceived stress and alcohol use were not significant 
predictors of PTSD scores over time; 
(5) increased baseline depression scores predicted increased PTSD scores at 3-months and 
6-months post-rape; 
(6) increased baseline rape stigma scores predicted increased PTSD scores at 6-months 
post-rape.  
The findings support those reported in previous studies where increased baseline depression 
17,27,43 and rape stigma had a significant adverse effect on PTSD recovery following rape. 
25,26,31,35. The finding that rape involving a single perpetrator (compared to multiple 
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perpetrators) is associated with increased PTSD scores at 3-months post-rape is 
counterintuitive and needs further investigation. Screening for depression and identifying and 
correcting stigmatising views associated with rape soon after the rape occurred may have long-
term beneficial effects.   
 
6.2.3. Genome-wide differentially methylated genes associated with posttraumatic stress 
disorder and longitudinal change in methylation in female rape survivors  
Epigenetic mechanisms, including DNA methylation, are known to respond to environmental 
exposures such as trauma and can lead to stable changes in gene expression 44,45. DNA 
methylation responses may confer risk or protection for PTSD, as they may alter an individual’s 
ability to adapt to traumatic events on a molecular level 46,47 To date, twelve epigenome-wide 
association studies (EWASs) investigating blood DNA methylation differences between PTSD 
cases and controls have been published 48–56, but none of the gene-specific findings have been 
replicated between EWASs. The lack of replication may be due to design limitations and 
demographic differences across studies. We conducted an EWAS (n = 48) in a demographically 
similar group of rape-exposed women and attempted to validate and replicate findings related 
to selected genes associated with PTSD in the EWAS. We determined the following: 
(1) One differentially methylated position (DMP, cg01700569) was associated with PTSD 
after correction for multiple testing; this CpG site was located in an intergenic region 
and has not been associated with any phenotypes or behaviours in previous studies; 
(2) Thirty-four differentially methylation regions (DMRs) were associated with PTSD and 
included CpG regions in BRSK2 and ADCYAP1; BRSK1, a paralog of BRSK2, and 
ADCYAP1 receptor 1 (ADCYAP1R1) have been linked to the development of PTSD 
in prior studies 51,57–59 
(3) The BRSK2 region (chr11:1463541-1463670) identified from the EWAS included five 
CpG sites (CpG1 - cg12186219, CpG2 - cg14064268, CpG3 - cg10590925, CpG4 - 
cg17429870, CpG5 - cg18651858) that showed decreased methylation in participants 
with PTSD; 
(4) The ADCYAP1 region (chr18:905177-905180) identified from the EWAS included 
two CpG sites (CpG1 – cg22388954, CpG2 – cg11773720) that showed increased 
methylation in participants with PTSD. 
(5) In the validation analysis related to BRSK2, methylation levels of CpG3 and CpG4 at 
3-months post-rape were not significantly associated with PTSD status at 3-months 
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post-rape. Decreased methylation of CpG5 at 3-months post-rape was significantly 
associated with a PTSD status at 3-months post-rape, but the association was no longer 
significant when covariates were added to the model. 
(6) In the validation analysis related to ADCYAP1, methylation levels of CpG1&2 was not 
significantly associated with PTSD status at 3-months post-rape. 
(7) In the replication analysis related to BRSK2, methylation levels of BRSK2 CpG3, 
CpG4 and CpG5 were not significantly associated with PTSD status at 3-months post-
rape. 
(8) In the replication analysis related to ADCYAP1, methylation levels of ADCYAP1 
CpG1&2 were not significantly associated with PTSD status at 3-months post-rape. 
The EWAS was followed by a longitudinal investigation of BRSK2 and ADCYAP1 methylation 
levels as predictors of PTSD symptom scores at baseline, 3-months and 6-months post-rape. 
We determined the following: 
(9) decreased baseline BRSK2 CpG3, CpG4 and CpG5 methylation levels were associated 
with increased PTSD scores at 3- and 6-months post-rape. Decreased BRSK2 
methylation at 3-months and 6-months post-rape was associated with increased PTSD 
scores at the same time-points. However, the relationship between decreased BRSK2 
CpG3 methylation at 3-months post-rape and increased PTSD scores at 3-months post-
rape was the only association that remained significant after covariates were added to 
the models. 
(10) decreased baseline ADCYAP1 CpG1&2 methylation was associated with increased 
PTSD scores at 6-months post-rape. Decreased ADCYAP1 methylation at 3-months 
and 6-months post-rape was associated with increased PTSD scores at the same time-
points, while decreased baseline ADCYAP1 CpG1&2 methylation was associated with 
decreased PTSD scores at baseline. The findings did not remain significant after PTSD 
covariates were added to the models.  
 
The findings provide evidence for the role of BRSK2 and ADCYAP1 in the development and 
maintenance of PTSD symptoms over time. Differential methylation of BRSK2 may contribute 
to adverse neuronal development, neuronal maintenance and dysregulated blood glucose 
levels, which may explain the increased risk for diabetes and cardiovascular disease observed 
in prior PTSD studies 60,61. Differential methylation of ADCYAP1 may result in a dysregulated 
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HPA-axis since its protein product PACAP is a master regulator of the HPA-axis 62,63. A 
dysregulated HPA-axis is a well-known phenomenon in PTSD 62–64.  
 
6.2.4. FKBP5 intron 7 methylation and the trajectory of PTSD symptoms in rape-exposed 
women 
Most studies investigating differential methylation in relation to PTSD have focused on genes 
that are directly or indirectly associated with regulation of the HPA-axis 16,47. One of the most 
commonly investigated genes is the FK506 binding protein gene (FKBP5) and a SNP within 
the gene, rs1360780 47,65. The interaction between childhood trauma and the rs1360780 T allele 
has previously been associated with an increased risk for the development of PTSD 1,16,47,66,67 
and with differential FKBP5 intron 7 methylation 3,68–71. Only one study has investigated 
longitudinal change in intron 7 methylation in relation to change in PTSD symptom scores in 
a war veteran sample, without considering the contribution of rs1360780 genotype 70. We 
investigated the association between longitudinal FKBP5 methylation and PTSD symptoms 
(baseline, 3-months and 6-months post-rape) while also considering childhood trauma and 
rs1360780 genotype. We determined the following: 
(1) Decreased methylation of FKBP5 CpG sites was associated with increased PTSD 
scores at 3-months and 6-months post-rape. 
(2) Decreased methylation of one FKBP5 CpG site remained a significant predictor of 
increased PTSD scores at 3-months post-rape after adjusting for depression and alcohol 
use. 
(3) Higher childhood trauma was a predictor of increased PTSD scores at baseline.  
(4) Increased baseline FKBP5 methylation at two CpG sites was associated with increased 
baseline PTSD scores in the group with high childhood trauma and carrying the CC 
genotype of rs1360780, but the interaction effect was no longer significant when 
baseline depression and alcohol use were included as covariates in the model.  
The findings provide evidence for the role of FKBP5 intron 7 methylation in the development 
and course of PTSD over six months. The findings also confirm the strong relationship between 
childhood trauma and PTSD 26–28 as well as the strong relationship between depression and 
PTSD reported in prior studies 72,73. Decreased methylation is likely to result in overexpression 
of FKBP5 which may disrupt the ultra-short intracellular negative feedback loop regulated by 
the interaction between glucocorticoid receptor and FKBP5 74,75. Differential methylation of 
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FKBP5 and other HPA-axis associated genes may mediated the relationship between HPA-
axis dysfunction and increased risk for PTSD 76,77. 
 
6.2. CONTRIBUTION TO THE KNOWLEDGE GAPS 
First, the study provides synthesised evidence for the role of NR3C1 in mediating the 
association between childhood trauma and increased risk for the development of adult onset 
psychiatric disorders. We also identified that the direction of NR3C1 methylation (increased/ 
decreased) is dependent on psychiatric diagnosis 78–85.  
Second, we identified several discrepancies in methodological strategies applied when 
investigating differential methylation in relation to childhood trauma and adult onset 
psychiatric disorders. These discrepancies may hinder the pursuit to finding commonalities in 
pathways affected by childhood trauma across psychiatric disorders 18–20. 
Third, although prior studies have reported a link between depression, rape stigma and 
PTSD in sexual assault survivors, few have investigated their effect on long-term recovery 
following rape 17,23. The majority of longitudinal rape studies have been conducted in high-
income countries that are better equipped to provide psychological and medical support to rape 
survivors suffering from PTSD compared to low-resourced countries 86,87. Identifying risk 
factors for the development and trajectory of PTSD in low- and middle-income countries is 
important since they may differ from those reported in high-income countries and may aid in 
developing context-specific evidence-based health care 88. Early intervention in countries 
characterised by limited resources and overburdened mental health care facilities is also 
important since treatment of severe psychopathology is more resource intensive (e.g. longer 
duration of treatment, medical interventions, hospitalisation, management of comorbid 
disorders) with higher costs and burden for the healthcare system 86,87. 
Forth, the current study is the first to investigate genome-wide differentially methylated 
genes associated with PTSD in an African country. The majority of prior EWASs have 
investigated differential methylation in North American participants 89,90. Studying differential 
methylation in and between different ethnicity groups is important given that shared 
environmental exposures and ethnicity-specific evolution may influence methylation profiles 
91,92.  Differences in methylation profiles between ethnicity groups may also increase the risk 
for comorbid psychiatric disorders and physiological diseases 92,93. 
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Fifth, the current study is also the first to investigate genome-wide differentially methylated 
genes associated with PTSD in a rape-exposed sample. The majority of prior EWASs have 
investigated combat-exposed populations and civilian samples exposed to a mixture of trauma 
types 47,89,90. Rape is associated with a high risk for the development of PTSD compared to 
other trauma types and methylation profiles of rape-exposed women may differ from those 
associated with other trauma types 94,95.  
Sixth, other than ethnicity and trauma exposure, we also controlled for the effect of various 
other variables that may influence methylation profiles. We investigated differential 
methylation associated with rape in women only, since gender may influence methylation 
profiles and differential methylation may explain the increased risk for PTSD observed among 
women 96. Epigenetic differences governing sexual differentiation (e.g. testosterone, estrogen, 
steroid receptors, binding proteins) and their impact on neurological and endocrine functioning 
may mediate the risk for developing PTSD 97,98. 
We investigated methylation profiles in women of similar age (16 – 40 years), thereby 
controlling for differential methylation related to chronological age which may underly the 
phenotypic presentation of aging and age associated increased risk for diseases 99–104.  
Differential methylation governs aspects of pregnancy and lactation 105. To avoid 
confounding, we excluded women who were pregnant or lactating from the methylation 
analyses.   
We investigated methylation differences in blood samples, which reflect methylation in 
brain regions associated with PTSD more accurately than saliva and buccal mucosa samples 
106. All prior EWASs investigating PTSD have used blood samples, which allows collating 
findings and identify potential blood biomarkers (since brain tissue cannot be used to assess 
risk) of psychiatric disorders and using this information to prioritise and individualise treatment 
according to individual risk profiles 107 Blood cell type composition was estimated by applying 
the Houseman algorithm to DNA methylation profiles using a publicly available blood cell 
type reference dataset (Gene Expression Omnibus accession number GSE35069) 108. We 
therefore controlled for differential methylation associated with the cell type composition in 
whole blood 109,110. 
Pharmacotherapy for PTSD, including psychotropic medication, have been found to exert 
their effects through alterations in DNA methylation, chromatin structure, transcription factor 
activity and receptor expression 111. None of the participants included in the methylation 
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analyses were in receipt of psychotropics. A number of participants used antiretrovirals (ARV) 
and medication for sexually transmitted infections (STIs) and a few were on medication for 
hypertension. We included medication use in the methylation analyses to control for the effect 
of medication use on methylation profiles. We did not include contraception as a covariate 
since the majority of women were using hormone contraceptives.  
Cigarette smoke and alcohol dependence have been associated with reduced global 
methylation and genome-wide differential methylation profiles 112–114. The confounding effects 
of smoking and alcohol use was controlled for by included these factors in the methylation 
analyses.  
Differential methylation of genes associated with transcription factors, chromatin 
remodelling, viral binding and viral transport have been associated with HIV infection as well 
as genes associated with the immune, metabolic and endocrine system 115–118. There was a high 
HIV prevalence rate in our sample, and we included HIV status as a confounding variable in 
the methylation analysis. 
PTSD is associated with an increased risk for metabolic disease including obesity, type 2 
diabetes, hypertension, increased triglycerides and decreased high-density lipoprotein (HDL) 
cholesterol 119,120. The link between PTSD and metabolic disease is likely due to differential 
methylation of genes involved in mitochondrial function, metabolic and endocrine processes 
shared by both conditions 121. We included BMI, as a proxy measure for metabolic syndrome, 
as a confounding factor in the methylation analyses. 
Childhood trauma is associated with an increased risk for PTSD and with genome-wide 
differential methylation 122–124. Childhood trauma was included as a covariate when 
investigating psychosocial risk and protective factors for PTSD and in the methylation 
analyses.  
Seventh, the study provides evidence for the role of differential methylation of BRSK2 in 
the development and maintenance of PTSD symptoms over time. Differential methylation of 
BRSK2 may also contribute to the PTSD-associated increased risk for metabolic syndrome 
given that BRSK2 has been linked to metabolic processes and glucose homeostasis 125,126 
Interestingly, BRSK1 a paralog of BRSK2, was found to be differentially methylated in a prior 
EWAS investigating male Vietnam war veterans 51.  
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Eight, the study also provides evidence for the role of differential methylation of ADCYAP1 
in the development and maintenance of PTSD symptoms over time. This finding builds on 
prior studies investigating HPA-axis dysregulation in relation to PTSD, given that ADCYAP1’s  
protein product, PACAP, is an important regulator of the HPA-axis and the stress response 62. 
Our findings are also supported by previous research implicating ADCYAP1/ADCYAP1R1 
methylation and expression (especially in women) in the development of PTSD 57–59,70,127.  
Ninth, the current study is the second study to investigate longitudinal change in FKBP5 
intron 7 methylation in relation to change in PTSD symptom scores 70 and the first to 
investigated FKBP5 intron 7 methylation in a rape-exposed African sample. Our finding 
supports those reported in the prior longitudinal FKBP5 intron 7 methylation studies since 
decreased methylation of FKBP5 CpG sites were associated with increased PTSD scores in our 
study and the prior study 70. Our findings further support prior findings investigating HPA-axis 
dysregulation in relation to PTSD given that FKBP5 is a coregulator of the glucocorticoid 
receptor which signals the activation of the negative feedback loop of the HPA-axis 1–3,128,129. 
 
6.3. LIMITATIONS 
Some limitations were unavoidable in this study and deserve mention. First, all participants 
included in this study disclosed the rape and sought help from rape crisis centres. 
Underreporting of rape is common and may in itself be influenced by sociodemographic and 
psychosocial risk and protective factors. As such, we could not assess risk and protective 
factors associated with PTSD in non-disclosing rape survivors. 
Second, some participants received counselling at the rape crisis centres at which they 
presented and/or at the study site. We could not include counselling as a predictor of PTSD 
scores in the multivariate analyses since we did not have this information for those who were 
lost to follow-up.  
Third, although PTSD and depression are considered distinct disorders, some of the 
symptoms of depression do overlap with the symptoms of PTSD 130. Depression may explain 
a significant proportion of variance in PTSD simply based on overlapping symptom constructs, 
in which case it cannot be considered a predictor of PTSD, but rather a symptom domain of 
PTSD 131–133. 
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Forth, baseline depression and alcohol use were investigated as post-assault risk factors for 
PTSD, assuming that they develop and covary with PTSD symptoms. Although depression and 
alcohol use often covary with PTSD symptoms following rape, they may also be pre-existing 
factors that increase the risk for sexual assault and PTSD post-rape 17,24,135,27,36–41,134. 
Fifth, the Mini International Neuropsychiatric Interview (MINI) was used to exclude 
participants who met criteria for a PTSD diagnosis at baseline, due to an event other than the 
rape. The MINI is a clinician administered diagnostic tool and should ideally be administered 
by a clinical psychologist or a psychiatrist. The baseline MINI interviews were administered 
by a registered trauma counsellor in this study and a lack of diagnostic and clinical skills may 
have resulting in inaccurate diagnoses. Interrater reliability and repeat calibration between the 
trauma counsellor and the psychiatrist who provided training in administering the MINI was 
also not assess and would have been beneficial in establishing the reliability and validity of 
the diagnoses.  
Sixth, we could not compare post-rape epigenetic changes to pre-rape epigenetic markers, 
since we did not have pre-rape data i.e. the baseline assessment was completed within 20 days 
following the rape. This is a limitation for determining whether a cause-effect relationship 
exists between rape exposure and epigenetic changes.  
Seventh, some of epigenetic changes observed may have occurred due to a history of 
childhood trauma. Although we controlled for the effect of childhood trauma in the analyses, 
it is difficult to disentangle the epigenetic changes that occurred as a result of childhood trauma 
from those that occurred as a direct result of the rape.  
Eight, the methylation analyses were likely underpowered given the small sample size. 
Although increasing the sample size in epigenetic studies does not necessarily increased the 
power given that the epigenome is not static like the genome 136. Heterogeneity of the sample 
may be of equal importance to sample size in epigenetic studies 136. 
Ninth, we used whole blood to measure methylation levels while differential methylation 
in brain tissue are more likely to underly PTSD pathophysiology 107. However, studies have 
found that blood-brain methylation levels are often correlated 137,138 and identifying potential 
blood biomarkers of psychiatric disorders may contribute to prioritising and individualising 
treatment according to individual risk profiles 107. Brain tissue cannot be used to identify 
biomarkers of PTSD since it is not accessible in living participants 107.  
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Tenth, we used the Houseman algorithm108 and the publicly available blood cell type 
reference dataset GSE35069139 to estimate, and control for, blood cell-type composition at 3-
months post-rape, in the EWAS. This was implemented within the meffil pipeline. We did not 
use flow cytometry to identify and count specific blood cell types in individual samples 
empirically, and we were therefore unable to control for within-individual change in blood cell 
type composition over time. We also did not have epigenome-wide information for the 
longitudinal analyses and could not implement the Houseman method to determine cell-type 
composition. Potential confounding in methylation findings due to change in blood cell-type 
compositions can therefore not be determined. However, surrogate variable analysis (SVA) 
was also applied and controls for unwanted variance in methylation caused by biological 
differences in the sample which are unrelated to the phenotype of interest i.e. PTSD. The 
surrogate variables were included as covariates in the EWAS models. 
Eleventh, DNA methylation was not assessed in relation to RNA expression in this study 
and conclusions related to the functional effects of methylation are only assumed. 
Twelfth, self-report measures were used to assess PTSD symptoms and other psychosocial 
risk and protective factors. Subjective rating of symptoms may result in over- or under-
reporting compared to clinician administered measure which are considered more objective 140. 
Thirteenth, multiple comparisons may have increased the risk of Type I errors in some of 
the analyses and those findings should be considered preliminary findings.  
Fourteenth, the self-report measure of perceived stress showed poor reliability in the study 
and the results related to this measure should be interpreted with caution. 
 
6.4. CONCLUSION 
This study demonstrated that depression is a significant risk factors for the development and 
trajectory of PTSD symptoms post-rape. This finding is similar to those reported in longitudinal 
rape studies conducted in high-income countries where depression was as prevalent as PTSD 
following rape, if not more prevalent, especially in the immediate aftermath of rape 17,22,23,30.  
Some studies suggest that PTSD and depression remain distinct disorders even though there is 
an overlap in the symptoms reported between the disorders 72,131–133 while others suggest that 
PTSD symptoms mediate the relationship between depression and the effect of time 23,130. 
There seems to be a uniquely amplified relationship between PTSD and depression in the 
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aftermath of rape in low- to medium-income and high-income countries compared to the 
relationship between PTSD and depression related to exposure to other trauma types 17,23,24,72.  
 Similar to prior longitudinal studies, we also found that protective factors, such as 
resilience and social support, lose their protective effect when accounting for the effect of 
depression in relation to PTSD, in the context of rape 22,24. Prior studies suggest that the 
physical and emotional intrusive nature of rape results in severe traumatisation and that the 
severity of the trauma leaves little room for other factors to have an impact on the risk of 
developing PTSD 22,141. This finding emphasises the need for emotional support from 
professional counsellors and mental health facilities given that positive internal coping 
mechanisms are not sufficient in dealing with the adverse effects of rape 142.  
 Rape stigma is less commonly investigated in rape studies conducted in high-income 
countries but those who have investigated elements of rape stigma reported a significant 
relationship between negative social reactions (e.g. victim blaming, self-blaming, shame, 
embarrassment, downplaying the severity of the rape, treating the victim differently) and PTSD 
post-rape 25,26,31,35. It is plausible that the effect of rape stigma is more pronounced in women 
from low socioeconomic backgrounds, given that low socioeconomic status is associated with 
less equitable views of gender roles in both perpetrators and rape survivors 143,144. Less 
equitable gender roles and perceptions of gender roles are likely to result in women blaming 
themselves for the rape and community members downplaying the severity of the rape or 
justifying the rape through perceptions of male sexual entitlement 143,144.  
 With regard to methylation findings, we confirmed that genes associated with the HPA-
axis are implicated in the development and course of PTSD symptoms post-rape 16,47. Both 
ADCYAP1 and FKBP5 are associated with HPA-axis functioning and have been implicated in 
the risk for developing PTSD in prior studies 16,47. The role of HPA-axis genes in the 
development of PTSD seems to be independent of ethnicity and the type of trauma endured, 
given that findings have been replicated in various populations 145. Based on prior findings, the 
effect of ADCYAP1 methylation and expression in relation to PTSD risk in more pronounced 
in women which highlights the need for gender stratification in methylation studies 58,59,146,147.  
 Our finding that BRSK2 in associated with PTSD also builds on a prior finding where 
genome-wide differential methylation of BRSK1, a paralog of BRSK2, was associated with 
PTSD in a study investigating Australian male Vietnam veterans 51. Differential expression of 
both BRSK1 and BRSK2 have been linked to disorganised presynaptic vesicle formation, 
uncoordinated release and reuptake of neurotransmitters, altered axonal development and 
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abnormal neuronal polarisation in animal studies  148–153. BRSK2 has also been associated with 
metabolic processes and glucose homeostasis 125,126. Further investigation of BRSK2 in future 
human studies could potentially increase our understanding of the brain morphology associated 
with PTSD and may also aid in understanding the relationship between PTSD and metabolic 
syndrome observed in prior studies 60,61. 
 In summary, the study builds on the existing literature in highlighting the risk factors 
for the development and course of PTSD in rape-exposed women. Methylation findings also 
builds on the existing literature, although the genome-wide finding implicating differential 
methylation of BRSK2 in the development of PTSD is a novel finding in human studies. The 
study provides evidence that both psychological and biological factors have an impact on the 
symptom trajectory of PTSD post-rape.  
 
6.5. RECOMMENDATIONS FOR PRACTICE  
Although ADCYAP1 and BRSK2 methylation levels were identified as potential biomarkers of 
PTSD risk and symptom trajectory, further research is needed to determine if the differentially 
methylated regions identified in this study are consistently linked to the development of PTSD. 
Replication of our findings and testing for PTSD associated biomarkers may aid in prioritising 
treatment according to individual risk profiles 107. Identifying and replicating findings in studies 
that possess increased power may also aid in developing targeted pharmaceutical interventions 
154. 
 There is a growing body of literature linking differential methylation, expression and 
SNPs in FKBP5 to the altered neurocircuitry and brain morphology observed in PTSD and 
other psychiatric disorders 67. Human studies have shown that higher expression of FKBP5 
increases the risk for psychiatric disorders and manipulating Fkbp5 in rodents has resulted in 
reduced anxiety, increased stress coping, increased glucocorticoid receptor sensitivity and 
enhanced functioning of the negative feedback loop of the HPA-axis 155,156. Increased 
expression of FKBP5 following exposure of adipose tissue to dexamethasone treatment has 
also provided evidence for the for the role of FKBP5 in stress induced metabolic dysregulation 
157. FKBP5 antagonist treatment may therefore have beneficial psychiatric and physiological 
outcomes 1. Although studies investigating peripheral FKBP5 expression have provided 
consistent evidence implicating FKBP5 in psychiatric disorders, less in known about FKBP5 
expression in the brain and further research is needed before human clinical trials involving 
FKBP5 antagonist treatment can commence 1.  
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Our finding that rape stigma is a factor in the development and course of PTSD has 
public health relevance considering that rape stigma is a barrier to disclosure, and receiving 
legal, psychological and medical intervention, including HIV prophylaxis 158. This may have 
downstream individual-level effects such as increased risk for psychiatric disorders, HIV and 
STIs 158. It may also have downstream community and society level effects, increasing the 
likelihood of  reoffending by a perpetrator if the perpetrator is not convicted 144. Reoffending 
without prosecution may instil the belief that rape is a minor offence and that the victim is to 
blame for the rape or could have done more to prevent the rape 159.  
Rape stigma includes internal thoughts and morally rooted emotions (e.g. self-blaming, 
shame and embarrassment) as well as actions from significant others (e.g. downplaying the 
severity of the rape and treating the victim differently) 35,160,161. Increased rape stigma may 
therefore result in a decreased ability to access and rely on social support especially when 
significant other display stigmatising attitudes 35,160,162. Stigmatising attitudes are especially 
prevalent when the perpetrator is known to the victim or is a respected member of the 
community 25,31,35,162,163. Since rape is a violation at an interpersonal level, it is plausible that 
victims develop a sense of distrust in others and when this distrust is not repaired over time 
through positive supportive responses, this may result in more severe emotional distress 22,27. 
Women who report fears of being stigmatised following rape are also more likely to 
have prior sexual traumas and have decreased positive coping mechanisms putting them at 
increased risk for psychiatric disorders 158. Decreased positive coping mechanisms and 
increased negative coping mechanisms such as social isolation and alcohol abuse 162,164,165 may 
sustain PTSD symptoms and result in an upward PTSD symptom trajectory and chronicity.  If 
rape survivors do report the rape, they have access to a counsellor when at a Thuthuzela Care 
Centre and this may be an opportunity to deliver a brief intervention targeting stigmatising 
views of rape 166. Psychoeducation and brief rape stigma-focussed cognitive behavioural 
interventions could be delivered by trained counsellors attending to those reporting the rape for 
the first time 167. 
Addressing stigmatising attitudes and gender-based violence on a societal level is more 
taxing, but programmes based on the ecological systems model do exist and are implemented 
in South Africa 143,168,169. These programmes focus on addressing risk factors for gender-based 
violence which include addressing: inequality between men and women, male sexual 
entitlement, violence as a means to resolve relationship conflicts, lack of education and 
employment opportunities for women, hazardous alcohol consumption and a cycle of familial 
domestic violence 144.  
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Depression should also be assessed and monitored in rape survivors given that it is a 
disabling condition and can have significant adverse effects on quality of life including 
domains related to physical health 170, social interaction 171, parenting 172 and occupational 
functioning 173. There is also an increased risk for suicide if a rape victim meets diagnostic 
criteria for both PTSD and depression 174,175. Longitudinal monitoring of depression and suicide 
risk in rape survivors is a less obtainable goal than brief interventions addressing rape stigma, 
given that it is resource intensive and requires specialised counselling skills 176.  However, there 
is a growing body of literature providing evidence for the effectiveness of web-based mental 
health intervention 177,178. Developing an internet-based intervention for rape survivors 
targeting depression, PTSD and rape stigma may be an effective tool for improving mental 
health in a resource constrained setting such as South Africa 86,87. Internet-based mental health 
interventions that include symptom monitoring tools may be especially helpful in flagging 
individuals experiencing high levels of PTSD, depression and high risk for suicide 179 and 
referring them to counsellors, psychologists or psychiatrists as needed 176. 
 
 
6.5. RECOMMENDATIONS FOR FUTURE RESEARCH 
 Our sample consisted of Black African females from a similar socioeconomic background, of 
similar age and all exposed to rape. While homogeneity of the sample is important when 
investigating differential methylation in relation to PTSD, it does limit the generalisability of 
findings. Replicating the findings related to differential methylation in other ethnicity groups, 
in males and in participants exposed to other trauma types may provide further support for the 
role of differential methylation of ADCYAP1 and BRSK2 in relation to PTSD status and 
symptom severity.  
 The diagnostic criteria for PTSD included distinct symptom clusters related to re-
experiencing the trauma, avoidance of trauma cues and memories, negative cognitions and 
hyperarousal 180. It is plausible that HPA-axis genes (e.g. ADCYAP1 and FKBP5) play a more 
important role in the hyperarousal symptom cluster compared to other symptom clusters given 
that hyperarousal includes HPA-axis associated symptoms such as hypervigilance, a 
heightened startle reaction, difficulty concentrating and difficulty sleeping 180,181. BRSK2 
methylation may play a more important role in intrusion and avoidance symptoms given that 
these symptoms may be rooted in altered brain morphology associated with memory 
functioning 182. Intrusion and avoidance symptoms include unwanted, upsetting memories, 
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nightmares, flashbacks and heightened physical reactivity to trauma-related thoughts, feelings 
and external reminders 180. We aim to explore differential methylation of ADCYAP1, BRSK2 
and FKBP5 in relation to PTSD symptom clusters in the future.  
 The RICE parent study collected a vast amount of additional data and biological 
specimens not mentioned in our study. Additional data gathered included the collection of 
serum samples at all timepoints. Future work that is being considered includes: (1) 
investigating PACAP serum levels over time, as increased PACAP blood levels have been 
associated with increased PTSD symptom severity and an increased acoustic startle reflex 
response in women compared to men 57,127, and (2) exploring ADCYAP1 and ADCYAP1R1 
SNPs, especially the rs2267735 SNP of ADCYAP1R1, given that it has been associated with 
decreased ADCYAP1R1 mRNA expression, increased PTSD symptom severity, increased 
dark-enhanced startle response and increased amygdala and hippocampal activity in response 
to viewing threatening face stimuli 57–59,127.  
 It will be important that other studies investigate BRSK2, ADCYAP1 and FKBP5 
methylation in relation to structural and functional brain changes in rape-exposed women with 
and without PTSD.  
 Several biomarkers and indicators of metabolic syndrome were assessed in the RICE 
study and include: BMI, blood pressure, heart rate, waist circumference, glycated haemoglobin 
(HbA1c), HDL cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, gamma-
glutamyl transferase (GGT), aspartate transaminase (AST), alanine aminotransferase (ALT), 
creatine and C reactive protein (CRP). We aim to investigate the relationship between 
metabolic disease markers and differential methylation of BRSK2 and FKBP5 in relation to 
PTSD in the future, given that BRSK2 and FKBP5 are associated with metabolic processes 
125,126,183. We also have access to adiponectin, leptin and resistin genotyping data, methylation 
data (from our EWAS findings) and serum levels and will investigate the relationship between 
these adipokines, metabolic syndrome and PTSD in the future.  
 The relationship between rape stigma and social support in relation to PTSD will also 
be explored in more detail. Data related to support from the police, legal system, medical 
professionals, psychological counsellors, family members, friends and intimate partners were 
collected in the RICE study. We aim to explore the associations between different domains of 
support and stigmatising thoughts, in relation to PTSD symptom trajectory.  
 We investigated baseline depression and alcohol use as predictors of PTSD symptom 
scores over time in this study, but we did not investigate a history of depression and alcohol 
use as predictors of PTSD scores over time. We will use additional data collected in the RICE 
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study to determine if depression and alcohol use covaries with PTSD symptoms over time 
and/or if a history of depression and alcohol use predicts PTSD symptom trajectories. We will 
also explore the relationship between symptoms of depression and symptoms of PTSD in rape 
survivors, given that depression was a significant predictor of PTSD scores overtime and that 
the symptoms of depression potentially overlaps with the symptoms of PTSD. 
 The age at which childhood trauma occurred and the type of childhood trauma endured 
may contribute to PTSD risk given heightened brain plasticity in critical periods of 
developments 14,15. We will explore the relationship between different childhood trauma types 
and exposure during different developmental periods as a predictor of PTSD. We will also 
determine if differential methylation of BRSK2, ADCYAP1 and FKBP5 mediates the 
relationship between childhood trauma type/age of exposure and PTSD risk.  
 Although we did find epigenome-wide significant findings, our EWAS sample was 
small and replication of the study in a larger sample may implicate additional genes, not 
identified in our EWAS, in the trajectory of PTSD symptoms. Future studies investigating 
longitudinal change in methylation in relation to change in PTSD symptoms in larger samples 
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CHAPTER 3: SUPPLEMENTARY MATERIAL 
 
Supplementary Table 1: Difference is baseline pre- and post-assault characteristics for those who completed all visits vs those who missed one 
or more visit/s 
 Gorup1: 
Completed all visits         
     n               %            M(SD) 
Group 2: 
Intermittent attendance 
     n              %            M(SD) 
Group 3: 
Baseline only 
     n              %            M(SD) 
            
p 
           
PTSD (DTS) 274 100 67.8(25.4) 140 100 67.3(25.4) 225 100 68.9(23.4) .774 
           
Age 274 100 25.4(5.6) 140 100 24.4(5.1) 225 100 24.2(4.8) .091 
           
Basic education completed  274 100  140 100  225 100  .616 
     No 118 43.1  63 45.0  90 40   
     Yes 156 56.9  77 55.0  135 60   
           
Relationship status 274 100  140 100  225 100  .287 
      In a relationship 214 78.1  111 79.3  191 84.9   
      Widowed/separated/divorced 1 0.4  0 0.0  0 0.0   
      Single 59 21.5  29 20.7  34 15.1   
           
Employment status 274 100  140 100  225 100  .531 
      Employed 64 23.4  26 18.6  48 21.3   
      Unemployed 210 76.6  114 81.4  177 78.7   
           
HIV status 274 100  140 100  225 100  .853 
      Positive 126 46.0  68 48.6  103 45.8   
      Negative 148 54.0  72 51.4  122 54.2   
           
Childhood trauma (CTQ-SF)¹  274 100 16.6(3.3) 140 100 15.8(2.5) 225 100 16.4(4.1) .026* 
           
Number of childhood traumas (CTQ-SF)¹ 274 100  140 100  225 100  .059 
      No childhood trauma 93 34.0  62 44.3  89 39.6   
      1 childhood trauma 59 21.5  39 27.9  57 25.3   
      2 childhood traumas 63 23.0  20 14.3  38 16.9   
      3 or more childhood traumas 59 21.5  19 13.6  41 18.2   
           
Lifetime cumulative trauma (LEC)¹ 274 100 2.4(1.5) 140 100 2.5(1.6) 225 100 2.2(1.4) .328 
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Number of lifetime traumas (LEC)¹ 274 100  140 100  225 100  .237 
      No lifetime traumas 54 19.7  29 20.7  36 16.0   
      1 lifetime trauma 56 20.4  29 20.7  54 24.0   
      2 lifetime traumas 75 27.4  32 22.9  54 24.0   
      3 lifetime traumas 42 15.3  35 25.0  46 20.4   
      4 or more lifetime traumas 47 17.2  15 10.7  35 15.6   
           
Resilience (CD-RISC)² 274 100 74.2(6.7) 140 100 74.5(5.3) 225 100 74.9(6.3) .042* 
Social Support (MSPSS)² 274 100 35.0(4.9) 140 100 35.0(5.3) 225 100 35.0(4.9) .944 
Perceived stress (PSS)² 274 100 23.5(5.7) 140 100 21.6(5.9) 225 100 23.5(5.2) .002** 
Rape Stigma (RSS)  274 100 20.5(6.9) 140 100 20.3(6.9) 225 100 21.2(7.0) .424 
Alcohol consumption (AUDIT-C)  274 100 1.8(2.4) 140 100 2.7(2.7) 225 100 2.0(2.4) .003** 
Depression (CES-D) 274 100 32.9(12.8) 140 100 31.8(13.2) 225 100 33.9(12.0) .293 
           
1Modified version ²Modified response option, *p<.05, **p<.01 
Abbreviations: Mean (M); Standard Deviation (SD); Posttraumatic Stress Disorder (PTSD); Davidson Trauma Scale (DTS); Childhood Trauma 
Questionnaire Short Form (CTQ-SF); Life Events Checklist (LEC); The Connor-Davidson Resilience Scale (CD-RISC); Multidimensional Scale 
of Perceived Social Support (MSPSS); Perceived Stress Scale (PSS); Rape Stigma Scale (RSS); Alcohol Use Disorders Identificat ion Test – 
Consumption (AUDIT-C); Center for Epidemiologic Studies Depression Scale (CES-D). 
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Supplementary Table 2: Correlation coefficients for baseline pre- and post-assault continuous variables and PTSD scores over time 
 1 2 3 4 5 6 7 8 9 10 11 
            
1. Baseline PTSD (DTS)            
2. 3-month PTSD (DTS) .44**           
3. 6-month PTSD (DTS) .28** .43**          
4. Age .06 -.04 -.04         
5. Childhood trauma (CTQ-SF)¹ .19** .15** .12** -.04        
6. Lifetime trauma (LEC)¹ .14** .08* .02 .08* .27**       
7. Resilience (CD-RISC)² -.02 .03 .08 -.09* -.06 .01      
8. Social support (MSPSS)² -.05 -.08* .03 -.06 -.13** -.08* .32**     
9. Perceived stress (PSS)² .22** .12** .10** .04 .27** .12** -.14** -.11**    
10. Rape stigma (RSS) .46** .32** .16** .02 .23** .11** -.00 -.11** .20**   
11. Alcohol use (AUDIT-C) .09* .08* .03 .04 .20** .24** -.02 -.01 .09* .11**  
12. Depression (CES-D) .62** .29** .21** .05 .16** .11** -.05 -.10* .20** .35** .06 
            
* p<.05, **p<.001 
1Modified version ²Modified response options 
Abbreviations: Posttraumatic Stress Disorder (PTSD); Davidson Trauma Scale (DTS); Childhood Trauma Questionnaire Short Form (CTQ-SF); 
Life Events Checklist (LEC); The Connor-Davidson Resilience Scale (CD-RISC); Multidimensional Scale of Perceived Social Support 
(MSPSS); Perceived Stress Scale (PSS); Rape Stigma Scale (RSS); Alcohol Use Disorders Identification Test - Consumption (AUDIT-C); 
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Supplementary Table 3: Childhood and lifetime trauma exposure and PTSD score over time 
   Baseline PTSD score 
 
3-month PTSD score 6-month PTSD score 
 n % M(SD) z p M(SD) z p M(SD) z p 
            
Childhood neglect    -3.98 .000**  -3.08 .002**  -1.55 .122 
      No 395 61.8 65.0(25.0)   37.0(23.3)   30.7(20.9)   
      Yes 244 38.2 73.0(23.4)   43.1(25.0)   33.3(25.0)   
            
Childhood domestic violence    -1.75 .080  -2.01 .044*  -1.84 .066 
      No 554 86.7 67.4(25.1)   38.7(24.2)   31.1(22.1)   
      Yes 85 13.3 72.6(21.4)   43.3(23.2)   35.7(25.2)   
            
Childhood emotional abuse    -3.12 .002**  -3.15 .002**  -3.05 .002** 
      No 512 80.1 66.6(24.7)   37.9(23.6)   30.7(22.2)   
      Yes 127 19.9 73.9(23.9)   44.9(25.3)   35.7(23.8)   
            
Childhood physical abuse    -2.71 .007**  -1.91 .057  -1.12 .262 
      No 381 59.6 65.8(25.6)   37.6(23.2)   31.2(22.4)   
      Yes 258 40.4 71.4(23.0)   41.7(25.3)   32.3(22.8)   
            
Childhood sexual abuse    -1.28 .201  -2.61 .009**  -1.73 .084 
     No 530 82.9 67.4(25.2)   38.2(23.6)   31.2(22.6)   
     Yes 109 17.1 71.3(22.0)   44.8(25.8)   34.0(22.5)   
            
Imprisonment     -0.94 .348  -1.92 .054  -0.20 .841 
     No 605 94.7 67.8(24.7)   39.0(24.2)   31.7(22.7)   
     Yes 34 5.3 72.5(25.2)   45.2(22.4)   30.2(20.8)   
            
Civil unrest or war    -2.75 .006**  -1.84 .066  -0.96 .337 
     No 613 95.9 67.6(24.9)   38.9(23.9)   31.5(22.6)   
     Yes 26 4.1 80.1(16.3)   49.0(28.2)   34.5(22.5)   
            
Serious injury    -2.50 .012*  -2.04 .041*  -0.14 .888 
     No 552 86.4 67.1(24.8)   38.5(23.6)   31.7(22.4)   
     Yes 87 13.6 74.1(23.1)   44.6(26.7)   31.4(24.0)   
            
Being close to death    -2.80 .005**  -0.25 .803  -0.87 .384 
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     No 481 75.3 66.4(25.0)   39.3(24.2)   31.2(22.4)   
     Yes 158 24.7 73.2(23.1)   39.4(23.9)   33.0(23.1)   
            
Murder of family/friend    -2.16 .031*  -1.16 .245  -0.29 .769 
     No 546 85.4 67.1(24.6)   38.8(23.7)   31.6(22.5)   
     Yes 93 14.6 73.5(24.8)   42.3(26.2)   31.8(23.0)   
            
Unnatural death of family/friend    -0.71 .480  -0.63 .526  -0.78 .434 
     No 525 82.2 67.6(25.2)   39.0(24.2)   31.4(22.5)   
     Yes 114 17.8 70.2(22.4)   40.5(23.8)   32.8(23.2)   
            
Murder of a stranger    -2.02 .044*  -0.64 .523  -0.70 .482 
     No 570 89.2 67.3(24.9)   39.0(23.8)   31.6(22.7)   
     Yes 69 10.8 74.6(22.5)   41.8(26.8)   32.1(32.2)   
            
Robbed at gunpoint or knifepoint    -1.20 .230  -1.66 .098  -0.28 .777 
     No 380 59.5 67.2(25.0)   37.5(22.7)   31.7(22.5)   
     Yes 259 40.5 69.3(24.3)   42.0(25.9)   31.6(22.7)   
            
Kidnapped    -1.49 .135  -0.66 .511  -0.09 .925 
     No 575 90.0 67.5(24.8)   39.0(23.9)   31.6(22.6)   
     Yes 64 10.0 73.5(23.4)   41.9(26.5)   31.8(22.6)   
            
*p<.05, **p<.01 
Abbreviations: Mean (M); Standard Deviation (SD); Posttraumatic Stress Disorder (PTSD) 
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Supplementary Table 4: Baseline pre- and post-assault categorical variables and PTSD 
score over time 
 Baseline PTSD score 
     M(SD)           p 
3-month PTSD score 
      M(SD)              p 
6-month PTSD score 
       M(SD)              p 
       
PTSD (DTS) 68.1(24.7)  39.3(24.1)  31.7(22.6)  
       
Secondary education completed   .397  .984  .887 
     No 68.9(25.6)  39.3(25.0)  32.3(24.4)  
     Yes 67.4(24.1)  39.3(23.5)  31.2(21.1)  
       
Relationship status  .131  .706  .513 
      In a relationship 67.0(24.7)  39.0(23.8)  31.5(22.1)  
      Widowed/separated/divorced 73.0  48.7  45.0  
      Single 72.3(24.3)  40.4(25.7)  31.7(22.6)  
       
Employment status  .553  .046*  .071 
      Employed 66.9(25.6)  35.9(24.6)  29.1(22.2)  
      Unemployed 68.4(24.5)  40.2(23.9)  32.4(22.6)  
       
HIV status  .122  .035*  .788 
      Positive 69.5(25.0)  40.7(24.2)  32.3(24.7)  
      Negative 66.8(24.4)  38.0(24.0)  31.1(20.6)  
       
Childhood trauma (CTQ-SF)¹  .000**  .002**  .002** 
      No childhood trauma 63.4(25.9)  36.3(23.2)  29.7(50.5)  
      1 childhood trauma 66.7(25.0)  37.3(23.3)  33.8(24.0)  
      2 childhood traumas 72.2(22.8)  41.6(24.4)  29.1(24.1)  
      3 or more childhood traumas 75.1(21.6)  45.7(25.6)  35.6(22.6)  
             
Lifetime traumas (LEC)¹  .025*  .432  .244 
      No lifetime traumas 72.7(25.1)  41.3(25.3)  32.7(23.4)  
      1 lifetime trauma 63.8(26.8)  37.9(24.2)  33.7(25.2)  
      2 lifetime traumas 65.0(25.4)  37.3(22.4)  28.4(21.7)  
      3 lifetime traumas 69.1(22.2)  38.9(24.2)  30.5(18.7)  
      4 or more lifetime traumas 72.2(21.5)  42.8(25.2)  34.3(23.3)  
       
Resilience (CD-RISC)²  .177  .607  .498 
      1st quartile 71.7(24.7)  40.0(25.8)  31.3(25.2)  
      2nd quartile 65.1(24.5)  37.4(25.1)  31.2(23.0)  
      3rd quartile 69.1(24.4)  38.8(22.9)  31.8(19.1)  
      4th quartile 67.3(24.8)  40.0(23.1)  32.1(21.8)  
       
Social Support (MSPSS)²  .177  .607  .498 
       1st quartile 74.3(24.7)  42.2(25.4)  31.7(23.6)  
       2nd/3rd quartile 66.1(26.9)  40.6(23.9)  31.7(22.4)  
       4th quartile 67.1(23.0)  37.5(23.7)  31.6(22.4)  
       
Perceived stress (PSS)²  .000**  .031*  .002** 
        1st quartile 63.9(27.9)  38.2(24.3)  30.9(25.6)  
        2nd quartile 60.2(25.6)  35.9(24.0)  27.4(20.8)  
        3rd quartile 69.4(22.3)  40.0(22.9)  32.5(21.8)  
        4th quartile 76.8(20.5)  42.2(25.2)  34.9(21.5)  
       
Rape Stigma (RSS)  .000**  .000**  .000** 
         1st quartile 51.9(24.4)  28.5(20.8)  27.7(22.0)  
         2nd quartile 61.9(22.5)  36.7(21.4)  32.1(22.1)  
         3rd quartile 72.5(20.7)  42.2(23.7)  35.9(23.2)  
         4th quartile 82.4(21.1)  47.6(25.9)  31.7(22.6)  
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Alcohol use (AUDIT-C)  .036*  .035*  .236 
          No consumption 65.0(25.2)  36.4(23.8)  30.8(22.8)  
          Some consumption 69.8(23.8)  42.7(25.3)  33.6(21.8)  
          Hazardous consumption 70.6(24.4)  40.4(24.1)  31.3(22.9)  
       
Depression (CES-D)  .000**  .000**  .000** 
          1st quartile 47.5(22.1)  30.0(20.7)  24.9(19.8)  
          2nd quartile 61.1(20.2)  38.6(23.4)  31.8(22.2)  
          3rd quartile 76.2(18.6)  40.1(22.0)  32.1(21.8)  
          4th quartile 88.6(18.2)  48.0(26.5)  37.4(24.5)  
       
1Modified version ²Modified response options, *p<.05, **p<.01 
Abbreviations: Mean (M); Standard Deviation (SD); Posttraumatic Stress Disorder (PTSD); 
Davidson Trauma Scale (DTS); Childhood Trauma Questionnaire Short Form (CTQ-SF); 
Life Events Checklist (LEC); The Connor-Davidson Resilience Scale (CD-RISC); 
Multidimensional Scale of Perceived Social Support (MSPSS); Perceived Stress Scale (PSS); 
Rape Stigma Scale (RSS); Alcohol Use Disorders Identification Test - Consumption 
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Supplementary Table 5: Baseline pre-assault and post-assault (converted to categorical 
variables) predictors of PTSD at 6-months post-rape 
 ß Std 
error 
t p 95% CI 
  Lower      Upper 
      
Time (Baseline) ¹       
      3-months -28.77 1.87 -15.38 .000** -32.47 -25.06 
      6-months -36.40 1.86 -19.62 .000** -40.05 -32.73 
       
Age -0.13 0.18 -0.75 .453 -0.48 0.22 
       
Basic education - not completed¹       
      Completed 0.09 1.67 0.06 .955 -3.19 3.38 
       
Employment - Unemployed¹       
      Employed -1.30 2.08 -0.63 .531 -539 2.78 
       
Relationship status - in a relationship¹       
      Separated/divorced/widow -1.06 3.50 -0.30 .761 -7.93 5.80 
      Single -1.67 2.10 -0.79 .427 -5.79 2.46 
       
HIV status - negative¹       
      HIV positive 2.21 1.83 1.21 .229 -1.39 5.80 
       
Childhood trauma (CTQ-SF) 2–none¹       
      1 childhood trauma -0.20 2.17 -0.09 .925 -4.56 4.05 
      2 childhood traumas 2.11 2.51 0.84 .401 -2.82 7.03 
      3 or more childhood traumas 2.34 2.53 0.93 .355 -2.63 7.30 
       
Lifetime trauma (LEC) 2–none¹        
      1 trauma  -0.01 2.81 -0.00 .998 -5.52 5.51 
      2 traumas  -3.53 2.62 -1.35 .178 -8.68 1.62 
      3 traumas -0.77 2.72 -0.28 .778 -6.12 4.59 
      4 or more traumas 1.06 2.89 0.37 .715 -4.62 6.73 
       
Resilience (CD-RISC)³–1st quartile¹       
      2nd quartile 0.43 2.36 0.18 .857 -4.21 5.06 
      3rd quartile 2.40 2.77 0.87 .387 -3.04 7.83 
      4th quartile 0.34 2.16 0.16 .875 -3.90 4.58 
       
Social support (MSPSS)³ – 1st quartile¹       
      2nd/3rd quartile -0.31 2.43 -0.13 .898 -5.08 4.46 
      4th quartile -0.00 2.28 -0.00 1.000 -4.47 4.47 
       
Perceived stress (PSS)³ – 1st quartile¹       
      2nd quartile -2.98 2.41 -1.24 .217 -7.72 1.75 
      3rd quartile -0.59 2.38 -0.25 .805 -5.26 4.09 
      4th quartile 1.01 2.61 0.39 .700 -4.14 6.15 
       
Rape stigma (RSS) – 1st quartile¹        
      2nd quartile 6.57 2.44 2.69 .007** 1.77 11.37 
      3rd quartile 9.67 2.63 3.67 .000** 4.49 14.84 
      4th quartile 14.71 2.70 5.44 .000** 9.39 20.03 
       
Alcohol use (AUDIT-C) – none¹       
       Some consumption 0.14 2.21 0.06 .948 -4.21 4.49 
       Hazardous consumption 0.12 2.05 0.06 .953 -3.72 3.96 
       
Depression (CES-D) – 1st quartile¹       
      2nd quartile 8.37 2.38 3.51 .000** 3.69 13.05 
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      3rd quartile 14.53 2.48 5.85 .000** 9.65 19.42 
      4th quartile 20.87 2.51 8.32 .000** 15.94 25.79 
       
1 Reference categories in regression model ²Modified version ³Modified response options, 
**p<.01 
Abbreviations: Childhood Trauma Questionnaire Short Form (CTQ-SF); Life Events 
Checklist (LEC); The Connor-Davidson Resilience Scale (CD-RISC); Multidimensional 
Scale of Perceived Social Support (MSPSS); Perceived Stress Scale (PSS); Rape Stigma 
Scale (RSS); Alcohol Use Disorders Identification Test (AUDIT); Center for Epidemiologic 
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Supplementary Table 6: Interaction between depression quartiles, rape stigma quartiles and 





z p 95% CI 
Lower     Upper  
      
Baseline x 1st quartile depression (CES-D) 50.50 1.97 25.61 .000 46.63 54.36 
Baseline x 2nd quartile depression  62.41 1.89 32.98 .000 58.70 66.11 
Baseline x 3rd quartile depression  77.74 1.96 39.76 .000 73.91 81.29 
Baseline x 4th quartile depression  83.51 1.93 43.29 .000 79.73 87.29 
3-months x 1st quartile depression  33.51 2.07 16.19 .000 29.46 37.57 
3-months x 2nd quartile depression  39.04 1.99 19.64 .000 35.14 42.93 
3-months x 3rd quartile depression  40.36 2.05 19.65 .000 36.34 44.39 
3-months x 4th quartile depression  45.52 2.02 22.51 .000 41.56 49.49 
6-months x 1st quartile depression  27.57 2.34 11.78 .000 22.98 32.16 
6-months x 2nd quartile depression  32.74 2.25 14.55 .000 28.33 37.15 
6-months x 3rd quartile depression  30.59 2.32 13.16 .000 26.03 35.14 
6-months x 4th quartile depression  36.09 2.28 15.82 .000 31.62 40.56 
      
1st quartile stigma (RSS) x       
Baseline x 1st quartile depression 42.11 2.28 18.48 .000 37.64 46.57 
Baseline x 2nd quartile depression 54.01 2.27 23.75 .000 49.55 58.47 
Baseline x 3rd quartile depression 69.35 2.39 29.05 .000 64.67 74.94 
Baseline x 4th quartile depression  75.12 2.46 30.51 .000 70.29 74.02 
3-months x 1st quartile depression  25.12 2.4 10.63 .000 20.49 29.76 
3-months x 2nd quartile depression  30.64 2.4 13.01 .000 26.03 35.26 
3-months x 3rd quartile depression 31.97 2.5 12.95 .000 27.13 36.81 
3-months x 4th quartile depression 37.13 2.5 14.64 .000 32.16 42.10 
6-months x 1st quartile depression 19.17 2.6 7.36 .000 14.07 24.28 
6-months x 2nd quartile depression 24.35 2.6 9.44 .000 19.29 29.40 
6-months x 3rd quartile depression 22.19 2.7 8.23 .000 16.90 27.48 
6-months x 4th quartile depression  27.70 2.7 10.08 .000 22.32 33.08 
       
2nd quartile stigma x       
Baseline x 1st quartile depression 49.05 2.22 22.05 .000 44.69 53.41 
Baseline x 2nd quartile depression 60.95 2.19 27.78 .000 56.65 65.25 
Baseline x 3rd quartile depression 76.29 2.32 32.92 .000 71.74 80.83 
Baseline x 4th quartile depression  82.06 2.34 35.14 .000 77.48 86.83 
3-months x 1st quartile depression  32.06 2.31 13.87 .000 27.53 36.59 
3-months x 2nd quartile depression  37.59 2.28 16.51 .000 33.12 42.05 
3-months x 3rd quartile depression 38.91 2.40 16.21 .000 34.20 43.61 
3-months x 4th quartile depression 44.07 2.41 18.26 .000 39.34 48.80 
6-months x 1st quartile depression 26.12 2.56 10.22 .000 21.11 31.13 
6-months x 2nd quartile depression 31.29 2.51 12.47 .000 26.37 36.21 
6-months x 3rd quartile depression 29.13 2.64 11.05 .000 23.97 34.30 
6-months x 4th quartile depression  34.64 2.63 13.15 .000 29.48 39.80 
       
3rd quartile stigma x       
Baseline x 1st quartile depression 53.30 2.33 22.90 .000 48.74 57.87 
Baseline x 2nd quartile depression 65.21 2.23 29.22 .000 60.84 69.59 
Baseline x 3rd quartile depression 80.54 2.22 36.33 .000 76.20 84.89 
Baseline x 4th quartile depression  86.32 2.18 39.52 .000 82.04 90.60 
3-months x 1st quartile depression  36.32 2.41 15.06 .000 31.59 41.05 
3-months x 2nd quartile depression  41.84 2.31 18.09 .000 37.31 46.38 
3-months x 3rd quartile depression 43.17 2.30 18.73 .000 38.65 47.68 
3-months x 4th quartile depression 48.33 2.27 21.31 .000 43.88 52.77 
6-months x 1st quartile depression 30.37 2.65 11.48 .000 25.19 35.56 
6-months x 2nd quartile depression 35.55 2.54 13.98 .000 30.56 40.53 
6-months x 3rd quartile depression 33.39 2.55 13.10 .000 28.40 38.39 
6-months x 4th quartile depression  38.90 2.50 15.55 .000 34.00 43.80 
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4th quartile stigma x       
Baseline x 1st quartile depression 57.54 2.41 23.86 .000 52.81 62.27 
Baseline x 2nd quartile depression 69.45 2.27 30.54 .000 64.99 73.90 
Baseline x 3rd quartile depression 84.78 2.26 37.44 .000 80.34 89.22 
Baseline x 4th quartile depression  90.55 2.10 43.10 .000 86.43 94.67 
3-months x 1st quartile depression  40.55 2.49 16.27 .000 35.67 45.44 
3-months x 2nd quartile depression  46.08 2.35 19.58 .000 41.46 50.69 
3-months x 3rd quartile depression 47.10 2.35 20.17 .000 42.79 52.01 
3-months x 4th quartile depression 52.56 2.19 24.03 .000 48.28 56.85 
6-months x 1st quartile depression 34.61 2.72 12.72 .000 29.27 39.94 
6-months x 2nd quartile depression 39.78 2.58 15.42 .000 34.72 44.84 
6-months x 3rd quartile depression 37.62 2.59 14.53 .000 32.55 42.70 
6-months x 4th quartile depression  43.13 2.43 17.76 .000 38.37 47.89 
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A subset of participants (n=96), recruited from a longitudinal cohort study investigating the 
impact of rape on women’s health and their use of health services in South Africa (n = 852), 
was used in this study. The study is also known as the Rape Impact Cohort Evaluation (RICE) 
study 1. Female survivors of rape were recruited from rape centres in and around the city of 
Durban located in the KwaZulu Natal province of South Africa. The rape centres provide 
comprehensive emergency care, including access to police, counselling, and medical and 
forensic care. 
 
Clinical measures  
 The Mini International Neuropsychiatric Interview  
The Mini International Neuropsychiatric Interview (MINI) is a structured psychiatric interview 
that screens for 16 DSM-IV psychiatric disorders including mood disorders, anxiety disorders, 
alcohol and drug dependence, psychosis, eating disorders and personality disorders 2. The 
MINI was used at baseline to screen for PTSD based on prior traumas other than the rape. The 
MINI has shown good reliability and validity in various settings 3,4. 
 
Davidson Trauma Scale  
The Davidson Trauma Scale (DTS) is a self-report questionnaire used to assess seventeen 
PTSD symptoms 5. The DTS was administered at all timepoints and responses were measured 
on a 5-point Likert scale for symptom frequency (ranging from 0 ‘not at all’ to 4 ‘every day’) 
and symptom severity (ranging from 0 ‘not at all distressing’ to 4 ‘extremely distressing’). The 
symptom frequency and severity scores were added together to produce a PTSD total score 
ranging between 0 and 136. A total score of forty or more is considered indicative of PTSD. 
Previous findings indicated that the DTS was excellent at discriminating between participants 
with and without PTSD at a cut-point of 40 5,6. The DTS showed excellent reliability in this 
study at each timepoint with a Cronbach alpha sore of .92 at baseline, .91 at 3-months and .93 
at 6-months post-rape.  
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Childhood Trauma Questionnaire Short Form  
A modified version of the Childhood Trauma Questionnaire Short Form (CTQ-SF) was used 
to measure exposure to childhood trauma before the age of eighteen years 7,8. The fourteen 
items measuring childhood trauma centres around sexual abuse, physical abuse, emotional 
abuse, parental neglect and domestic violence. Responses were measured on a 4-point Likert 
scale ranging from 1 ‘never’ to 4 ‘very often’. The CTQ-SF has shown excellent validity in 
previous studies 9,10 and showed acceptable reliability in this study with a Cronbach alpha score 
of .75 at baseline.  
 
 Life Events Checklist  
A modified version of the Life Events Checklist (LEC) was used to measure lifetime exposure 
to different trauma types at the baseline visit 11,12. The modified version of the LEC measures 
direct exposure to nine trauma types using a dichotomous ‘yes/no’ response. The trauma types 
measured were imprisonment, civil unrest/war, serious injury, being close to death, murder of 
a family member or friend, unnatural death of a family member or friend, murder of a 
stranger/s, robbed at gunpoint or knifepoint and kidnapping. The number of yes responses are 
added together to yield a total score ranging from 0 to 9 and indicating the trauma load or 
number of traumas exposed to during the participant’s lifetime.  
 
 Alcohol Use Disorders Identification Test (AUDIT) 
The original Alcohol Use Disorders Identification Test (AUDIT) is a 10-item, self-report 
questionnaire and responses are recorded on a five-point Likert scale using different response 
options relevant to the different items 13. The AUDIT-C is a sub-scale of the original AUDIT 
and is used to measure alcohol consumption 14. A score of 3 or more on the AUDIT-C indicates 
hazardous drinking in women. The AUDIT was developed by the World Health Organisation 
(WHO) and has shown good reliability and validity in various settings and cultures 15–21. The 
AUDIT-C showed good reliability in this study at each timepoint with a Cronbach alpha sore 
of .83 at baseline, .86 at 3-months post-rape and .83 at 6-months post-rape.  
 
Center for Epidemiologic Studies Depression Scale (CES-D) 
The Center for Epidemiologic Studies Depression Scale (CESD) is a 20-item, self-report 
questionnaire used to screen for current depression in accordance with DSM-IV criteria 22. The 
CESD was completed at all time points. Responses were recorded on a 4-point Likert scale 
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ranging from 0 ‘rarely or none of the time’ to 3 ‘most or all of the time’. The CESD has shown 
good reliability and validity in various cross-cultural samples and in clinic and community 
settings 23–32. The CES-D showed good reliability in this study at each timepoint with a 
Cronbach alpha sore of .89 at baseline, .88 at 3-months and .89 at 6-months post-rape.  
 
Procedure 
Epigenome-wide association study 
The Illumina MethylationEPIC BeadChip array was used to investigated genome-wide 
differences in methylation between participants with and without PTSD (Illumina, California, 
United States). The array interrogates over 850 000 sites at single-nucleotide resolution 
covering 99% of RefSeq genes and including CpG islands, shores and shelves. Results obtained 
from the EPIC are highly reproducible (98%) with a less than 1% false positive rate reported 
Illumina, 2012, 2015a). 
DNA was extracted from peripheral blood samples using the Gentra Puregene DNA 
extraction kit (Qiagen, Germany) and quantified by fluorimetry, using the PicoGreen dsDNA 
quantitation reagent (ThermoFisher Scientific, Massachusetts, United States). Sample 
concentrations were normalised to 50 ng/μl and shipped on dry ice to the Epigenome Centre at 
the University of South California (USC) in Los Angeles, United States. The DNA samples 
were bisulfite-converted using the Zymo EZ DNA Methylation Kit (Zymo Research, 
California, United States) and assayed using the Illumina MethylationEPIC BeadChip 
(Illumina, California, United States). The samples were randomly assigned to one of six arrays 
(8 samples per array) to reduce technical bias. 
 
Internal control probes 
There are 42 internal control probes present on the MethylationEPIC array which were used to 
assess the quality of the sample processing steps e.g. bisulfite conversion, hybridization, 
staining, extension, specificity and target removal 34. There were no outliers detected i.e. none 
of the samples had a mean score > 5 standard deviations from the expected mean on all control 
probes (see Supplementary Figure 1). This indicates that all steps of the sample processing 
procedures were successful for all samples and that the arrays used in this study passed the 
sample processing quality control measures. 
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Supplementary Figure 1: Distribution of probe intensity signals for the MethylationEPIC 
control probes. The x-axis represents samples listed from 1 to 48 and the y-axis represents the 
mean signal intensities on each control probe.  
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Supplementary Figure 1 (continued): Distribution of probe intensity signals for the 
MethylationEPIC control probes. The x-axis represents samples listed from 1 to 48 and the y-
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Negative control probes 
The array also contains 600 negative control probes i.e. randomly permutated sequences that 
should not hybridise to sample DNA 35. However, cross-hybridisation may occur as a result of 
the simplification of the DNA code after bisulfite conversion or due to DNA 
polymorphisms/mutations 36. Nonetheless, the mean fluorescence intensity signal across 
negative control probes is considered to be background noise 37. A detection p-value is 
calculated for every CpG site on the MethylationEPIC array and in every sample using a signal-
to-noise ratio of fluorescence intensities where signal represents target probe intensities and 
noise represents negative probe intensities 35. A small detection p-value (p < 0.01) indicates 
that methylated/unmethylated intensities are likely true intensities and not as a result of 
background noise 34. The null hypothesis is that the sum of methylated and unmethylated 
intensities is equal to background intensities. If p < 0.01 the null hypothesis can be rejected. 
The detection p-value is used to evaluate both the quality of the samples and the technical 
quality of the performance of the array 35. The proportion of samples showing a detection p-
value > 0.01 was less than 5% indicating that all samples passed the quality check (see 
Supplementary Figure 3). There were 3521 probes showing a detection p-value > 0.01 in more 
than 5% of the samples indicating that the data resulting from these probes were unreliable (see 
Supplementary Figure 2). 
 The array also contains multiple beads containing hundreds to thousands of 
oligonucleotides designed to target the same CpG site in sample DNA 35. Basing findings on 
the average intensities across multiple beads increases the reliability of the findings since the 
procedure is essentially repeated several times 34. The beads are randomly distributed across 
the array to minimise batch effects associated with the position of a bead on the array. A 
‘number of beads threshold’ of < 3 (i.e. number of beads detecting methylated/unmethylated 
signal intensities) is used to evaluate both the quality of the samples and the technical quality 
of the performance of the array 35. Less than 5% of the samples showed a high proportion of 
probes with a number of beads threshold < 3 indicating that all samples passed this quality 
check (see Supplementary Figure 4). There were 26415 probes with a number of beads 
threshold < 3 in more than 5% of the samples (see Supplementary Figure 5). The 3521 CpG 
probes showing a detection p-value > 0.01 and the 26415 CpG probes with a number of bead 
threshold < 3 were excluded from the downstream analysis. 
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Supplementary Figure 2: All samples showed a detection p-value > 0.01 indicating that the 
methylated/unmethylated intensities are likely true intensities and not the result of background 
noise. The x-axis represents samples ordered from 1 to 48 and the y-axis represents the 
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Supplementary Figure 3: Distribution of the probes indicating that 3521 probes showed a 
detection p-value > 0.01 in more than 5% of the samples. The x-axis represents the 
















Supplementary Figure 4: Less than 5% of the samples showed a high proportion of probes with 
a number of beads threshold < 3 indicating that all samples passed this quality check. The x-
axis represents samples ordered from 1 to 48 and the y-axis represents the proportion of probes 
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Supplementary Figure 5: There were 26415 probes with a number of beads threshold < 3 in 
more than 5% of the samples. The x-axis represents the chromosomal position of the probes 
and the y-axis represents the proportion samples for which a given probe failed to be detected 















To further assess the quality of sample DNA, median methylated intensities were compared to 
the median unmethylated intensities across the array and a sample was considered an outlier if 
the median methylated/unmethylated intensities were more than 3 standard deviations from the 
expected median (see Supplementary Figure 6). A sample may show increased 
methylated/unmethylated signals if it is contaminated or if the DNA concentration was too low 
for sufficient binding to probes therefore indicating poor quality of the sample DNA 38. There 
were no outliers for the methylated vs unmethylated intensity comparison. No samples were 










Supplementary Figure 6: Distribution of median methylation intensities for each sample. The 
solid red line represents the regression line and the solid blue line represents the loess-smoothed 
line resulting from the observed intensities. The upper and lower dotted red lines enclose the 
points at most 3 standard deviations from the expected mean. The shaded region denotes the 
95% confidence interval around the loess-smoothed line. The x-axis represents the median 
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Functional normalisation and batch effects 
The array includes two different assay types, the first being the Infinium I assay which contains 
two probes (one for methylated intensities and one for unmethylated intensities) to target a 
CpG site. The second assay type, the Infinium II, contains only one probe to distinguish 
between methylated and unmethylated alleles using green and red dye colours 35. The different 
technological designs used in Infinium I and II assays could potentially introduce technical bias 
since an upwards shift in β-values for unmethylated intensities and a downwards shift for 
methylated intensities have been associated with the Infinium II assay when comparing the two 
assays with each other 34.  
Differences in methylation intensities have been associated with batch effects in 
previous studies e.g. the assignment of a sample to a given plate or array and positioning the 
sample in a given row or column 39. Column assignment was not considered as a potential batch 
effect in this study since the MethylationEPIC array does not contain columns like its 
predecessors. All samples in this study were located on the same plate. Six arrays were used to 
accommodate the 48 samples analysed in this study (8 samples per array). Each sample was 
assigned to one of eight rows on each array. 
Functional normalisation was used in an effort to reduce the technical bias associated 
with batch effects by using the information obtained from the 42 control probes on the 
MethylationEPIC array 37. This method removes the variance associated with technical 
variation without compromising the variance associated with methylation differences between 
PTSD cases and controls since none of the control probes are designed to detect a biological 
signal 37. Five principal components (PCs) were found to explain most of the technical variance 
in the sample (see Supplementary Figure 7) and were regressed against the batch variables 
array and row position before and after functional normalisation 40.  
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Supplementary Figure 7: Estimating the number of principal components (PCs) to regress 
against batch variables. The first five PCs explained most of the technical variance observed 
from the methylated (M) and unmethylated (U) intensities. Variance explained was estimated 
using cross-validation. The x-axis represents the number of PCs and the y-axis represents the 
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Batch effects before functional normalisation 
Each control probe PC was regressed against each level of each batch variable (see 
Supplementary Figures 8a-8b and Supplementary Figures 9a-9e) to determine the extent to 
which control variation accounted for batch variation. There were six slide batch variables 
representing the six arrays used in the epigenome-wide association study (EWAS; slide 
201904850009, slide 201959740048, slide 201959750230, slide 201990430029, slide 
201985320017, slide 201995320078) and eight row batch variables representing the sentrix 
row on an array to which a sample was assigned (sentrix row 01 – sentrix row 08). The 
significant findings resulting from ANOVAS and post-hoc t-tests comparing PC values 
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Supplementary Table 1: Association between principal components and batch variables 



















Lower            Upper 
        
Slide  PC1 3.54  .009   
 210904650009 PC1  6.56 .0002 2.81 10.32 
Row  PC1 7.91  .000005   
 Sentrix row 01 PC1  -7.38 .00006 -11.21 -3.55 
 Sentrix row 02 PC1  -4.64 .017 -8.95 -0.33 
 Sentrix row 06 PC1  4.22 .045 -0.49 8.93 
 Sentrix row 07 PC1  4.62 .018 0.31 8.93 
Slide  PC2 5.06  .001   
 201959750236 PC2  2.25 .005 0.50 4.01 
 201985320017 PC2  -3.89 .000002 -5.53 -2.26 
Row Sentrix row 08 PC2  -3.39 .004 -5.95 -0.84 
Slide  PC4 6.35  .0002   
 210904650009 PC4  1.87 .000002 1.09 2.66 
 201985320017 PC4  -0.78 .028 -1.56 0.01 
Row Sentrix row 01 PC4  1.12 .016 0.01 2.15 
 Sentrix row 08 PC4  -0.98 .027 -1.97 0.00 
Slide 201959750236 PC5  0.90 .022 0.03 1.76 
Row  PC5 3.31  .007   
 Sentrix row 05 PC5  -1.18 .007 -2.14 -0.23 
 Sentrix row 08 PC5  1.59 .0007 0.58 2.60 














Supplementary Figures 8a & 8b: Principal component (PC) plots for the six slides used in the 
EWAS and the eight rows to which samples were assigned. The figure is divided into three 
parts representing the first three PCs. Each dot represents one of the 48 samples included in the 
EWAS and each colour represents one of the six arrays used in the EWAS in Supplementary 







































Supplementary Figures 9a-e: Forrest plots representing regression coefficients and 95% 
confidence intervals (x-axis) before functional normalisation for each slide (bar 1 to 6) and 
each row (bar 7 to 14) divided into five figures representing principal component 1 (PC1) 
(Supplementary Figure 9a), PC2 (Supplementary Figure 9b), PC3 (Supplementary Figure 9c), 
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Batch effects after functional normalisation 
Principal components analysis was then applied to the normalized DNA methylation matrix. 
Each top PC was regressed against each level of each batch variable following functional 
normalisation (see Supplementary Figures 10a-10b and Supplementary Figures 11a-11e) to 
evaluate the extent of technical variation remaining in the normalized data. None of the 
ANOVAS comparing PC values with slide and row batch variables were statistically 
significant, but post-hoc t-test comparisons did reveal some significant findings between PC 
values and slide/row numbers. The results of the significant t-tests are presented in 
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95% Confidence Interval 
(CI) 
Lower            Upper 
       
Row Sentrix row 03 PC1 2.40 .027 -0.01 4.82 
 Sentric row 04 PC1 -2.30 .035 -4.73 0.13 
 Sentrix row 05 PC1 2.57 .018 0.17 4.96 
Slide 201959740046 PC2 -2.42 .023 -4.78 -0.06 
 201980430029 PC2 1.94 .048 -0.25 4.12 
 201980430029 PC4 2.45 .011 0.33 4.56 
 201985320017 PC4 -2.05 .023 -4.05 .0.05 
Row Sentrix row 06 PC4 2.73 .014 0.29 5.18 
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Supplementary Figures 10a & 10b: Principal component (PC) plots following functional 
normalisation for the six slides used in the EWAS and the eight rows to which samples were 
assigned. The figure is divided into three parts representing the first three PCs. Each dot 
represents one of the 48 samples included in the EWAS and each colour represents one of the 
six arrays used in the EWAS in Supplementary Figure 10a and each of the eight rows in 
























Supplementary Figures 11a-e: Forrest plots representing regression coefficients and 95% 
confidence intervals (x-axis) after functional normalisation for each slide (bar 1 to 6) and each 
row (bar 7 to 14) divided into five figures representing principal component 1 (PC1) 
(Supplementary Figure 11a), PC2 (Supplementary Figure 11b), PC3 (Supplementary Figure 
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Surrogate variable analysis  
Since all batch effects were not be fully removed using functional normalisation, we also 
performed surrogate variable analysis (SVA) 41. In addition to addressing the variance 
explained by batch effects and other technical sources, SVA can also account for unknown 
unwanted variance caused by biological differences in the samples which are unrelated to the 
phenotype of interest e.g. covariates such as age, body mass index (BMI), smoking, HIV status, 
medication use, childhood trauma exposure, lifetime trauma exposure, alcohol use and 
depression may have an impact on methylation levels irrespective of PTSD status 41,42.  The 
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Blood cell type composition 
Blood cell type composition is another source of bias often introduced when using whole blood 
to investigate methylation profiles. Whole blood contains several different cell types  and each 
type has its own methylation profile 43. SVA has been shown to be successful in removing the 
unwanted variance introduced by cell-type distribution, but as a precautionary measure we also 
estimated cell type composition using the Houseman algorithm and the publicly available blood 
cell type reference dataset GSE35069 (available on the Gene Expression Omnibus) 44 and 
included cell type compositions for B lymphocytes, CD4 T-cells, CD8 T-cells, eosinophils, 
monocytes, neutrocytes and natural killer cells in the final analysis (see Supplementary Figure 




















Supplementary Figure 12: Boxplots illustrating the estimated cellular composition for each 
reference cell type across all samples. The x-axis represents the cell type (eosinophils, B 
lymphocytes, natural killer cells, monocytes, CD4 T-cells, CD8 T-cells and neutrophils). The 
y-axis represents the estimated cell proportions.  
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Differentially methylated regions (DMRs) 
Differentially methylated regions (DMRs) were identified using the dmrff R package 45. DMR 
analysis improves statistical power given that the EWAS CpG sites can be subdivided into 
clusters and associations assessed as a group rather than individually. There are often strong 
dependencies between CpG sites, especially those clustering around the same gene or those in 
close genomic proximity to each other 45,46. The default setting applied by the dmrff package 
for qualification as a DMR was used in this study with the exception of the distance between 
CpG sites. The default value in the dmrff package is 500 bp apart, but we applied a more 
stringent criteria of 100 bp apart since CpG sites are more likely to co-methylate if they are in 
closer proximity to each other 47,48. 
 The more conservative Bonferonni adjustment was used to correct for multiple testing 
in the DMR analysis as opposed to false discovery rate (FDR), which was used in the 
differentially methylated position (DMP) analysis 49. FDR was deemed suitable for the DMP 
analysis since intercorrelation of CpG sites on the MethylationEPIC array is highly likely and 
a Bonferonni correction (especially when several thousands of tests are conducted at once) 
would most likely result in inflated false negatives (type 2 errors) 50,51. FDR reduces false 
positives (type 1 errors) by adjusting p-values according to their number ranking (ranked from 
most significant/smallest p-value to least significant/largest p-value) and are less stringent 
compare to a Bonferonni correction which defines the new significance level as p < .05 / by 
the number of tests completed 49,52,53.  
A Bonferroni correction was deemed appropriated for the DMP analysis because the it 
assumes that each test is independent of the others, which is more likely to be true in the DMR 
analysis since it identifies CpGs covarying within a region in an individual gene 46. A 
Bonferroni correction was also deemed appropriate for the DMR analysis since it is a 
confirmative approach rather than an explorative approach like the DMP analysis and more 
stringent criteria are often applied in confirmative analyses 45,50.  
 
Annotation  
Coordinates resulting from the DMP and DMR analyses were annotated using the 
MethylationEPIC_v-1-0_B4 manifest. All genomic coordinates reported in this study is in 
reference to the Hg19/GRCh37 human genome assembly. The location of a CpG site was 
determined using the ‘University of California Santa Cruz (UCSC) reference gene group’ (see 
Supplementary Figure 13). TSS200 indicates that the CpG site is located 0 to 200 bp upstream 
of the transcription start site (TSS), TSS1500 indicates that the CpG site is located 200-1500bp 
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upstream of the TSS, 5’UTR indicates that the CpG site is located within the 5’ untranslated 
region between the TSS and ATG (the protein coding start site), body indicates that the CpG 
site is located between the ATG and the stop codon (protein coding end site), irrespective of 
introns, exons, TSS or promoters in the region, 3’UTR indicates that the CpG site is located 
between the stop codon and the polyadenylation signal. The ‘regulatory feature group’ 
provided by the Methylation Consortium was used to determine if a CpG site is located in a 
regulatory sequence (region associated with increasing or decreasing expression of genes). 
CpG sites located in a regulatory sequence are labelled as promoter associated 34. 
 The location of individual CpG sites in relation to a CpG island in the gene were 
determined using the ‘UCSC CpG island location classification’ (see Supplementary Figure 
13). A CpG island was defined as a region with more than 50% of the nucleotide sequence 
consisting of CpG sites and at least 200pb in length. A CpG island shore was defined as a 
region 0 to 2000bp from a CpG island and a CpG island shelf was defined as a region 2000 to 
4000 bp from the island. North (N) and South (S) indicates the direction of the shore/shelf with 
N indicating the shore/shelf is upstream (5’) form the CpG island and S indicating the 
shore/shelf is downstream (3’) from the CpG island. OpenSea indicates that the region the CpG 
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Supplementary Figure 13: Region in a gene in which a CpG site is located according to the 
University of California Santa Cruz (UCSC) reference gene group. Location of an individual 
CpG sites in relation to a CpG island in the gene according to UCSC CpG Island location 
classification. Reprinted from "High density DNA methylation array with single CpG site 
resolution" by M Bibikova, B Barnes, C Tsan, V Ho, B Klotzle, JM Le, D Delano, L Zhang, 
GP Schroth, KL Gunderson, JB Fan, R Shen, 2011, Genomics, 98, p. 291, Copyright 2011 by 




Validation, replication and longitudinal analysis 
Sample concentrations were normalised to 50 ng/ul and shipped on ice to Inqaba Biotec in 
Pretoria, South Africa for bisulfite conversion and analysis using EpiTYPER Sequenom 
MassARRAY (Agena Bioscience, California, United States) technology. The method 
involved: (1) PCR primer design using Sequenom Epidesigner software 
(www.epidesigner.com); (2) bisulfite conversion using the Zymo EZ DNA methylation kit 
(Zymo Research, California, United States); (3) PCR amplification of the target region using 
t7-promoter tagged primers; (4) RNA transcription and base-specific RNA cleavage; (5) 
quantification of DNA methylation based on the size and mass of  RNA fragments using the 
SpectroCHIP Array, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) 
mass spectrometry and EpiTYPER software. The samples were randomly assigned to one of 
three plates (96 samples per plate). The EpiTYPER procedure is highly reproducible and has 
been found to detect methylation levels as low as 5% 89,90.  
 
The primer designs used in the EpiTYPER analysis for BRSK2 and ADCYAP1 are provided 
below: 




BRSK2: forward primer, 5’-aggaagagagGAAGGAGTTTGTTAGGGTGTAGGAG-3’ and reverse 
primer, 5’- cagtaatacgactcactatagggagaaggctAAACAAAACCAATCTCTACCTTAAA-3’ 
ADCYAP1: forward primer, 5’- aggaagagagGGTTTTTTGAGTTGAATAGTATTTGG-3’ and reverse 
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Supplementary Figure 14: Manhattan plot indicating the top twenty CpG sites significantly associated with PTSD prior to correction for multiple 
testing (p < .05). CpG sites are organised according to their chromosomal position on the horizontal axis. CpG sites above the upper red line 
indicates that the site showed increased methylation in the group without PTSD and CpG sites below the lower red line indicates that the site 
showed decreased methylation in the group without PTSD
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Figure 15a-t: Boxplots illustrating the difference in methylation levels between participants 
with and without PTSD at 3-months post-rape for the top twenty CpG sites resulting from the 
epigenome-wide association study. 
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Figure 15a-t continued: Boxplots illustrating the difference in methylation levels between 
participants with and without PTSD at 3-months post-rape for the top twenty CpG sites 
resulting from the epigenome-wide association study. 
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Figure 15a-t continued: Boxplots illustrating the difference in methylation levels between 
participants with and without PTSD at 3-months post-rape for the top twenty CpG sites 
resulting from the epigenome-wide association study. 
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Figure 15a-t continued: Boxplots illustrating the difference in methylation levels between 
participants with and without PTSD at 3-months post-rape for the top twenty CpG sites 
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Supplementary Table 3: Genome-wide differentially methylated positions (DMPs) and regions (DMRs) associated with PTSD  




β SE t/z p Adj. p Other exposures/ 
phenotypes associated with the CpG 
site5 
           
Differentially methylated positions (DMPs)         
           
NA, SLC16A96  Chr10:61385771 cg01700569 OpenSea NSF 0.031 0.004 7.119 6.187e-08 0.049233 None 
 
NA, IRF46 Chr6:429318 cg06868375 OpenSea NSF -0.009 0.002 -5.846 2.067e-06 0.777284 None 
 
FEZ1 Chr11:125365803 cg06309855 Island 5'UTR 0.022 0.004 5.727 2.930e-06 0.777284 Gestational age 
 
CGLC Chr6:53371893 cg05277169 OpenSea Body 0.013 0.002 5.468 6.043e-06 0.999998 None 
 
 
BEGAIN Chr14:101036470 cg05730092 S_Shore TSS1500 0.032 0.006 5.401 7.352e-06 0.999998 Gestational age 
 
CRTC3-AS1 Chr15:91193536 cg16207883 OpenSea Body 0.021 0.004 5.233 1.183e-05 0.999998 None 
 
LINC01006 Chr7:156267149 cg01020356 OpenSea Body 0.025 0.005 5.224 1.216e-05 0.999998 Ethnicity; osteonecrosis of the 
femoral head 
 
EPB41L1 Chr20:34818105 cg20355257 OpenSea 3'UTR 0.017 0.003 5.204 1.286e-05 0.999998 Down syndrome 
 
ADCYAP1 Chr18:905177 cg22388954 Island 5'UTR; 
TSS200 
-0.025 0.005 -5.181 1.371e-05 0.999998 B acute lymphoblastic leukemia 
BRSK2 Chr11:1431833 cg09450823 Island Body 0.036 0.007 5.115 1.653e-05 0.999998 None 
 
NA, MIR42906 Chr9:92782655 cg04299914 OpenSea NSF -0.049 0.010 -5.091 1.769e-05 0.999998 None 
 
USP49 Chr6:41790313 cg11943190 OpenSea 5'UTR -0.010 0.002 -5.050 1.970e-05 0.999998 Rheumatoid arthritis; exercise 
 
DOK5 Chr20:53127455 cg01998039 OpenSea 5'UTR; 
Body 
0.040 0.008 5.049 1.994e-05 0.999998 Down syndrome; aging 
MCEE Chr2:71338735 cg08848660 OpenSea Body -0.011 0.002 -5.012 2.205e-05 0.999998 None 
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Chr7:44965393 cg01855601 OpenSea NSF 0.010 0.002 4.975 2.436e-05 0.999998 None 
PARD3 Chr10:35016204 cg18026072 OpenSea Body -0.009 0.002 -4.961 2.534e-05 0.999998 None 
 
NA, BRSK26 Chr11:1401914 cg22820726 N_Shelf NSF -0.063 0.013 -4.963 2.544e-05 0.999998 None 
 
TMEM52B Chr12:10322100 cg05617790 OpenSea Body; 
TSS1500 
0.015 0.003 4.953 2.619e-05 0.999998 None 
TRMO Chr9:100662939 cg13109115 OpenSea NSF -0.103 0.021 -4.915 2.915e-05 0.999998 None 
 
           
Differentially methylated regions (DMRs)         
           
LRRC34 Chr3:169530817-
169530920 
   0.071 0.007 9.631 5.910e-22 4.897e-16  
  cg160242147 S_Shore TSS1500      None 
 
  cg274672347 S_Shore TSS1500      None 
 
  cg047149947 S_Shore TSS1500      Ethnicity 
 




   0.091 0.010 9.101 8.960e-20 7.424e-14  
  cg123241447 S_Shore TSS1500      None 
 
  cg033699657 S_Shore TSS1500      Follicular thyroid carcinoma; type 2 
diabetes; ethnicity 
 
  cg133370957 S_Shore TSS1500      None 
 




   0.026 0.003 9.316 1.214e-20 1.006e-14  
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  cg032922137 Island 5'UTR      Ankylosing spondylitis 
 
  cg113928587 Island TSS200      Ankylosing spondylitis 
 
  cg236613447 Island TSS200      Ankylosing spondylitis 
 
  cg265398187 Island TSS200      Ankylosing spondylitis 
 
  cg005725867 N_Shore TSS200      Juice consumption 
 










   0.093 0.011 8.166 3.191e-16 2.644e-10  
  cg01238395 OpenSea NSF      None 
 




   -0.022 0.003 -7.718 1.178e-14 9.762e-09  
  cg03464655 OpenSea 5'UTR      Adrenocortical carcinoma; Nicolaides 
Baraitser syndrome (NCBRS); 
neurodevelopmental presentations 
and congenital anomalies; Gulf War 
illness 
 
  cg20641955 OpenSea TSS200      None 
 
 
  cg16376155 OpenSea TSS200      None 
  cg05339727 NSF TSS200      Age; sex; ethnicity; SETD1-B-related 
syndrome 
 
  cg05090759 OpenSea TSS200      Clear cell renal carcinoma; sex; 
SETD1-B-related syndrome 
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  cg12301695 OpenSea TSS200      Oral squamous cell carcinoma; 
colorectal cancer; SETD1-B-related 
syndrome; Gulf War illness 
 




   0.015 0.002 7.856 3.964e-15 3.285e-09  
  cg21329975 OpenSea TSS1500      Smoking status; 
air population exposure; 
gestational age 
 
  cg16509355 OpenSea TSS1500      Fetal vs adult liver; 
smoking status; 
gestational age; Down syndrome 
 
  cg21123203 NSF NSF      Smoking status; 
fruit consumption 
 
  cg02964094 OpenSea TSS200      Gingivobuccal oral squamous cell 
carcinoma; Gulf War illness 
 
  cg18470593 OpenSea TSS200      Fetal vs adult liver; 
smoking status; obesity 
 




   -0.042 0.004 -9.746 9.935e-13 8.233e-07  
  cg21180956 OpenSea TSS200      None 
 
 
  cg13106512 OpenSea TSS200      Myalgic encephalomyelitis / chronic 
fatigue syndrome 
  cg24403549 OpenSea TSS200      Myalgic encephalomyelitis / chronic 
fatigue syndrome; ethnicity 
 
  cg10631947 OpenSea TSS1500      Height 
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  cg20059697 OpenSea TSS1500      Down syndrome 
 
  cg16462183 OpenSea TSS1500      Gestational age; Down syndrome; 
hepatocellular carcinoma; colorectal 





   0.047 0.006 7.452 9.180e-14 7.607e-08  
  cg12309668 OpenSea 5'UTR; 
TSS1500 
     Down syndrome; early childhood 
development 
  cg04392082 OpenSea 5'UTR; 
TSS1500 
     Down syndrome; gestational age 
  cg02790305 OpenSea 5'UTR; 
TSS1500 
     Down syndrome; aging; gestational 
age 
 




  cg01933073 OpenSea 5'UTR; 
TSS1500 
     Down syndrome; gestational age 
  cg18342119 NSF NSF      Down syndrome; aging 
 
  cg13921444 OpenSea 5'UTR; 
TSS1500 
     Down syndrome; aging; respiratory 
allergies; early childhood 
development; gestational age 
 
  cg04348265 OpenSea 5'UTR; 
TSS1500 





   0.030 0.004 7.499 6.442e-14 5.338e-08  
  cg12053065 OpenSea TSS200      None 
 
  cg19974223 OpenSea TSS200      None 
 
  cg09755932 OpenSea TSS200      None 
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  cg10384244 OpenSea TSS200      None 
 
  cg19948393 OpenSea 5'UTR      Down syndrome 
 
  cg26279928 OpenSea 5'UTR      None 
 
  cg04349021 OpenSea 5'UTR      None 
 
  cg17424856 OpenSea 5'UTR      None 
 




   0.029 0.004 7.373 1.671e-13 1.385e-07  
  cg24201814 N_Shore TSS200; 
Body 
     None 
  cg06552850 N_Shore TSS200; 
Body 
     None 
  cg07279557 N_Shore TSS200; 
Body 
     Down syndrome; fetal vs adult liver; 
early childhood development; 
gestational age; 
maternal smoking; sex; 
neurodevelopmental presentations 
and congenital anomalies 
 
  cg04401043 N_Shore TSS200; 
Body 
     None 
  cg11029358 N_Shore 5'UTR; 
Body 
     Gestational age; neurodevelopmental 
presentations and congenital 
anomalies 
 




   0.112 0.016 7.131 9.935e-13 8e-07  
  cg12186219 N_Shore Body      Childhood stress; ethnicity 
 
  cg14064268 N_Shore Body      Aging; childhood stress; ethnicity 
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  cg10590925 N_Shore Body      Aging, childhood stress, ethnicity 
 
  cg17429870 N_Shore Body      Aging, childhood stress, ethnicity 
 




   -0.053 0.008 -6.864 6.686e-12 5.5e-06  
  cg274595917 N_Shore NSF      Down syndrome 
 




 N_Shore NSF      Down syndrome 
 




   -0.021 0.003 -6.857 7.040e-12 5.8e-06  
  cg08309747 N_Shore TSS1500      None 
 
  cg26255604 N_Shore TSS1500      None 
 
  cg12085698 N_Shore TSS200      Pancreatic ductal adenocarcinoma; 




  cg25486824 N_Shore TSS200      Pancreatic ductal adenocarcinoma; 
gestational age; sex; inflamed 
Crohn’s disease 
 
  cg11028624 N_Shore TSS200      Pancreatic ductal adenocarcinoma; 
gestational age; inflamed Crohn’s 
disease 
 
  cg22805485 N_Shore TSS200      Pancreatic ductal adenocarcinoma; 
gestational age; maternal smoking; 
inflamed Crohn’s disease 
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  cg24258347 N_Shore TSS200      Pancreatic ductal adenocarcinoma; 
gestational age; aging; preterm birth; 
maternal hypertensive disorder; 
inflamed Crohn’s disease 
 
  cg10153349 N_Shore TSS200      Gestational age; sex; prenatal 
paracetamol exposure; aging; 
inflamed Crohn’s disease 
 
  cg09191626 N_Shore 5'UTR      Gestational age; maternal smoking; 
follicular thyroid carcinoma 
 




   -0.041 0.006 -6.827 8.662e-12 7.2e-06  
  cg14972155 OpenSea NSF      Italian ethnicity; sex; maternal 
plasma folate; chronic obstructive 
pulmonary disease 
 
  cg06837426 OpenSea NSF      Maternal plasma folate 
 
  cg20451680 OpenSea NSF      Chronic obstructive pulmonary 
disease; type 2 diabetes 
 
  cg20673840 OpenSea 5'UTR      Chronic obstructive pulmonary 




   -0.022 0.003 
 
-6.761 1.370e-11 1.13e-05  
  cg22388954 Island 5'UTR; 
TSS200 
     B Acute lymphoblastic leukemia 
  cg11773720 Island 5'UTR; 
TSS200 
     None 
INPP5A Chr10:134549665
-134549800 
   0.016 0.002 6.700 2.081e-11 1.72e-05 B Acute lymphoblastic leukemia 
  cg18305652 Island Body      B Acute lymphoblastic leukemia 
 
  cg16311946 Island Body      B Acute lymphoblastic leukemia 
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   0.021 0.003 6.345 2.219e-10 1.839e-4  
  cg03803086 OpenSea 5'UTR      Fetal vs adult liver; early childhood 
development; gestational age; sex; air 
pollution; body mass index; Down 
syndrome; follicular thyroid 
carcinoma; thyroid lesion 
 
  cg27427104 OpenSea 5'UTR      Werner syndrome; Gulf War illness 
 
  cg00780604 OpenSea 5'UTR      Gulf War illness 
 
  cg23163200 OpenSea TSS200      Fetal vs adult liver; early childhood 
development; gestational age; 




   0.050 0.008 6.184 6.268e-10 0.001  
  cg028602407 S_Shore TSS1500      Hepatocellular carcinoma; ethnicity 
 
  cg246550167 S_Shore TSS200      Ethnicity 
 




   0.023 0.004 6.146 7.946e-10 0.001  
  cg10247374 OpenSea       None 
 
  cg11668797 OpenSea       None 
 




   0.036 0.006 6.115 9.646e-10 0.001  
  cg05005821 OpenSea Body      None 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
357 
 




   0.042 0.007 6.029 1.650e-09 
 
0.001  
  cg04270401 N_Shore       Fetal vs adult liver; early childhood 
development; gestational age; alcohol 
consumption; aging; follicular thyroid 
carcinoma; obesity 
 
  cg24067118 N_Shore       Fetal vs adult liver; early childhood 
development; gestational age; alcohol 
consumption; absolute fat mass; 
aging; body mass index; fat free mass 




   0.026 0.004 5.996 2.019e-09 0.002  
  cg02101355 OpenSea Body; 
TSS200 
     Clear cell renal carcinoma; psoriasis 
  cg03891346 NSF NSF      Clear cell renal carcinoma 
 
  cg24213115 OpenSea Body; 
TSS200 
     Down syndrome 
  cg07281370 OpenSea TSS1500; 
Body 





   0.019 0.003 5.975 2.301e-09 0.002  
  cg18042081 OpenSea NSF      None 
 
  cg13502252 OpenSea NSF      Gestational age; fetal alcohol 
spectrum disorder 
 
  cg11710659 OpenSea NSF      Clear cell renal carcinoma; 
rheumatoid arthritis; maternal 






   0.025 0.004 5.881 4.068e-09 0.003  
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  cg26182859 OpenSea NSF      Fetal vs adult liver; early childhood 
development; gestational age; 
smoking status; sex; acute myelocytic 
leukemia; aging; Crohn’s disease 
 
  cg09762021 OpenSea NSF      Smoking status; gestational age 
 




   0.011 0.002 5.829 5.589e-09 0.005  
  cg11469026 Island TSS200; 
5'UTR 
     None 
  cg12887021 Island TSS200; 
5'UTR 
     None 
FSCN2 Chr17:79504142-
79504180 
   0.006 0.001 5.820 5.874e-09 0.005  
  cg07707031 Island 3'UTR      HIV infection 
 




   -0.020 0.004 -5.734 9.805e-09 0.008  
  cg12375158 S_Shore TSS1500; 
TSS200 
     SETD1B-related syndrome 
  cg04049626 NSF NSF      SETD1B-related syndrome 
 
  cg18174678 S_Shore TSS1500      Fetal vs adult liver; smoking status; 
maternal smoking; gestational age; 





   -0.014 0.003 -5.693 1.250e-08 0.010  
  cg05778943 S_Shore 5'UTR      None 
 
  cg19668951 S_Shore 5'UTR      Fetal vs adult liver; gestational age; 
sex; multiple sclerosis 
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   0.054 0.009 5.685 1.305e-08 0.011  
  cg22879098 OpenSea Body      Fetal vs adult liver; maternal smoking 
 
  cg24082121 OpenSea Body      Fetal vs adult liver; maternal 
smoking; aging 
 





   0.030 0.005 5.577 2.450e-08 0.020  
  cg02456406 OpenSea       Rheumatoid arthritis 
 
  cg14624451 OpenSea Body      None 
 
  cg11791444 OpenSea Body      None 
 




   -0.052 0.009 -5.535 3.115e-08 0.026  
  cg143409287 N_Shore 5'UTR      Fetal vs adult liver 
 





   0.036 0.007 5.465 4.632e-08 0.038  
  cg08269485 Island Body; 
TSS200 
     Early childhood development; 
prostate cancer 
 
  cg03846408 Island Body; 
TSS200 
     Early childhood development; 
prostate cancer 
 
  cg08966208 Island Body; 
TSS200 
     Early childhood development; 
preterm birth; prostate cancer 
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  cg02916272 Island Body; 
TSS200 
     Early childhood development; 
gestational age; preterm birth; 
prostate cancer 
 
  cg20272155 Island Body; 
TSS200 




   -0.030 0.005 -5.452 4.973e-08 0.041  
  cg19776589 N_Shore TSS1500      None 
 
  cg07747220 Island TSS200      Early childhood development; 
gestational age; aging; childhood 
stress; multiple sclerosis; preterm 
birth; antiphospholipid syndrome; 
neurodevelopmental presentations 
and congenital anomalies; SETD1B-
related syndrome 
 
  cg16887334 Island TSS200      Aging; sex; childhood stress; short-
term diesel exhaust inhalation 
 
  cg13285174 Island TSS200      Early childhood development; 
gestational age; aging; cleft palate cs 
cleft lip; HIV infection; childhood 
stress; multiple sclerosis; preterm 
birth; Alzheimer’s disease; SETD1B-
related syndrome 
 
  cg26267561 Island TSS200      Gestational age; cleft palate vs cleft 
lip; aging; childhood stress multiple 
sclerosis; preterm birth; epithelial 
ovarian cancer; SETD1B-related 
syndrome; Gulf War illness 
 
  cg01644611 Island TSS200      Early childhood development; 
gestational age; cleft palate vs cleft 
lip; aging; childhood stress; multiple 
sclerosis; preterm birth; 
Stellenbosch University  https://scholar.sun.ac.za




and congenital anomalies 
 
  cg13725599 Island TSS200      Early childhood development; 
gestational age 





   0.018 0.003 5.424 5.830e-08 0.048  
  cg01419539 N_Shore TSS1500      Early childhood development; 
smoking status; aging; alcohol 
consumption 
 
  cg07697276 NSF NSF      Early childhood development; 
alcohol consumption 
 
  cg26385085 N_Shore TSS200      Early childhood development 
 
           
1 Identified using the GENECODE database; 2 identified using the Human Genome 19 (HG19) build from the Genome Reference Consortium; 3 
identified using the University of California Santa Cruz (UCSC) Genomic Institute/Genome Browser; 4 multiple listings indicate splice variants; 
5 identified using the Medical Research Council Integrative Epidemiology Unit (MRC-IEU) catalog of epigenome-wide association studies54 and 
the China National Center for Bioinformation National Genomics Data Center epigenome-wide association studies (EWAS) atlas55; 6 CpG sites 
located in a region not attributed to a gene, the gene closest to the CpG site is provided; 7 The site is associated with a promoter region - identified 
using the Methylation Consortium project. 
Abbreviations: Standard error (SE); adjusted (Adj); not applicable (NA); solute carrier family 16 member 9 (SLC16A9); not specified (NSF); 
interferon regulatory factor 4 (IRF4); fasciculation and elogation protein zeta 1 (FEZ1); 5’ untranslated region (5’UTR); glutamate-cysteine ligase 
catalytic subunit (GCLC); brain-enriched guanylate kinase-associated protein (BEGAIN); transcription start site 1500 (TSS1500); South shore 
(S_Shore); CRTC3 antisense RNA 1 (CRTC3-AS1); long intergenic non-protein coding RNA 1006 (LINC01006); erythrocyte membrane protein 
band 4.1 Like 1 (EPB41L1); 3’ untranslated region (3’UTR);  adenylate cyclase activating polypeptide 1 (ADCYAP1); transcription start site 200 
(TSS200); brain-specific serine/threonine-protein kinase 2 (BRSK2); microRNA 4290 (MIR4290); ubiquitin specific peptidase 49 (USP49); 
docking protein 5 (DOK5); methylmalonyl-CoA epimerase (MCEE); catenin alpha 3 (CTNNA3); novel transcript antisense to purine rich element 
binding protein B (AC004854.2); PAR-3 family cell polarity regulator (PARD3); North shelf (N_Shelf); transmembrane protein 52B (TMEM52B); 
TRNA methyltransferase O (TRMO); leucine-rich repeat-containing protein 34 (LRRC34); phospholipase D family member 6 (PLD6); North shore 
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(N_Shore); solute carrier family 38 member 11 (SLC38A11); coiled-coil and C2 domain-containing protein 2A (CC2D2A); endothelial cell specific 
molecule 1 (ESM1); sorbin and SH3 domain-containing protein 2 (SORBS2); ankyrin repeat domain-containing protein 33 (ANKRD33); collagen 
type XVIII alpha 1 chain (COL18A1); spondin 1 (SPON1); inositol polyphosphate-5-phosphatase A (INPP5A); chromosome 21 open reading 
frame 62 (C21orf62); thrombospondin type laminin G domain and EAR repeats antisense RNA 2 (TSPEAR-AS2), microRNA 125b-1 (MIR125B1); 
chromosome 5 open reading frame 66 antisense RNA (C5orf66AS1); fascin actin-bundling protein 2 (FSCN2); forkhead box J3 (FOXJ3); solute 
carrier family 39 member 13 (SLC39A13); tubulin polymerization promoting protein (TPPP); long intergenic non protein coding RNA 1529 
(LINC01529); chromosome 5 open reading frame 63 (C5orf63); hepatocellular carcinoma-associated gene 2 (HCCA2), oxytocin/neurophysin I 
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Blood-brain methylation comparison 
Co-variation in methylation levels between blood and brain tissue was explored using the 
online Blood Brain DNA Methylation Comparison Tool 56. Blood methylation of the BRSK2 
CpG sites were highly correlated with methylation in the prefrontal cortex, superior temporal 
gyrus and the cerebellum (see Supplementary Figures 17a-17d). The blood-brain methylation 
correlation for BRSK2 CpG5 is not provided since the correlations provided by the Blood Brain 
DNA Methylation Comparison Tool is based on the Illumina 450K array and CpG5 was not 
included on this array. There were no significant correlations between blood and brain 
methylation for the ADCYAP1 CpG sites (see Supplementary Figures 18a and 18b). 
 
 































Figure 16a: Correlation between methylation levels observed in blood and methylation levels 
observed in the prefrontal cortex (PFC), entorhinal cortex (EC), superior temporal gyrus (STG) 








Figure 16b: Correlation between methylation levels observed in blood and methylation levels 
observed in the prefrontal cortex (PFC), entorhinal cortex (EC), superior temporal gyrus (STG) 




































Figure 16c: Correlation between methylation levels observed in blood and methylation levels 
observed in the prefrontal cortex (PFC), entorhinal cortex (EC), superior temporal gyrus (STG) 




































Figure 16d: Correlation between methylation levels observed in blood and methylation levels 
observed in the prefrontal cortex (PFC), entorhinal cortex (EC), superior temporal gyrus (STG) 




































Figure 17a: Correlation between methylation levels observed in blood and methylation levels 
observed in the prefrontal cortex (PFC), entorhinal cortex (EC), superior temporal gyrus (STG) 









Figure 17b: Correlation between methylation levels observed in blood and methylation levels 
observed in the prefrontal cortex (PFC), entorhinal cortex (EC), superior temporal gyrus (STG) 
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Supplementary Table 4: Genomic coordinates of the BRSK2 CpG sites investigated 





chr11:1463561 TGATTGGCTGCCTATGACATCACCAGGCTGGGCTGCTATTGG   
 
chr11:1463603 CCCTTATGTGTGATTGGCGTTTGGAGAGGCAGTGGGCTCTG    
                                             CpG3       
chr11:1463644 GGCAGGGGGTCTCCAGGGCGGGGAGGCGCTCAAGGCAGA    
                                                  CpG4                    CpG5 
chr11:1463683 GACTGGCCCTGTTCAGCCTCACCACCCTCCTCCCCAGCCACA     
 
chr11:1463725 GGGATCTGAAACCTGAAAACCTCCTGCTGGACGAGAAGAAC     
 
Genomic coordinates are based on the Human Genome Build 37 (GRCh37/hg19).           
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Supplementary Table 5: Univariate relationship between baseline confounding/covarying factors, PTSD, BRSK2 and ADCYAP1 methylation in the 
discovery/validation set 
Abbreviations: 


































use (no vs yes) 
 r/z p z/x2 p r/z p z/x2 p r/z p r/z p r/z p r/z p z/x2 p 
                   
PTSD status (3-months) -1.05 .296 0.02 .900 -1.11 .268 0.18 .672 -1.66 .098 -1.86 .063 -0.85 .394 -1.36 .173 0.17 .680 
                   
BRSK2 CpG3 (3-months) 0.02 .881 -0.44 .657 -0.04 .810 -0.07 .944 -0.16 .282 -0.16 .301 0.02 .889 0.17 .259 -0.56 .573 
BRSK2 CpG4 (3-months) -0.07 .650 -0.17 .868 -0.10 .516 -0.23 .818 -0.14 .354 -0.19 .210 0.12 .443 0.17 .263 -0.82 .935 
BRSK2 CpG5 (3-months) 0.01 .946 -0.34 .731 -0.10 .516 -0.12 .902 -0.10 .527 -0.12 .429 0.10 .505 0.19 .208 -0.52 .606 
                   
ADCYAP1 CpG5.6 (3-months) -0.15 .341 -1.47 .141 -0.13 .400 -1.32 .188 0.17 .273 0.07 .648 0.26 .083 0.10 .512 -0.22 .823 
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Supplementary Table 6: Univariate relationship between baseline confounding/covarying factors, PTSD, BRSK2 and ADCYAP1 methylation in the 
replication set 
Abbreviations: 

























use (no vs yes) 
 r/z p z/x2 p r/z p z/x2 p r/z p r/z p r/z p r/z p z/x2 p 
                   
PTSD status (3-months) -0.50 .616 0.57 .451 -0.33 .745 0.17 .899 -1.04 .299 -2.47 .014* -1.04 .299 -1.45 .149 0.62 .433 
                   
BRSK2 CpG3 (3-months) -0.04 .769 -0.61 .545 -0.05 .725 -0.14 .989 -0.22 .133 -0.14 .329 0.15 .302 0.08 .587 -0.96 .339 
BRSK2 CpG4 (3-months) -0.06 .702 -1.11 .267 0.13 .360 -0.82 .415 0.14 .324 -0.14 .349 0.10 .497 0.17 .240 -1.42 .156 
BRSK2 CpG5 (3-months) -0.08 .571 -1.23 .220 0.05 .726 -0.67 .501 -0.10 .495 -0.15 .305 0.03 .836 0.08 .579 -1.67 .094 
                   
ADCYAP1 CpG5.6 (3-months) 0.04 .785 -1.85 .064 0.09 .557 -0.54 .586 0.09 .551 0.08 .576 -0.24 .095 0.04 .796 -1.43 .154 
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Supplementary Table 7: Validation of the BRSK2 and ADCYAP1 findings resulting from the 
epigenome-wide association study and the discovery set 
Model  β SE Wald’s 
χ2 
p  OR Lower Upper 
         
 BRSK2 CpG3 methylation        
         
1A CpG3 (3-months) -0.04 0.02 3.84 .050 0.96 0.92 1.00 
         
1B CpG3 (3-months) -0.04 0.02 3.20 .074 0.96 0.92 1.00 
 Childhood trauma (baseline) 0.11 0.09 1.54 .215 1.11 0.94 1.31 
         
 BRSK2 CpG4 methylation        
         
2A CpG4 (3-months) -0.04 0.02 3.78 .052 0.96 0.92 1.00 
         
2B CpG4 (3-months) -0.04 0.02 3.25 .072 0.96 0.92 1.00 
 Childhood trauma (baseline) 0.11 0.08 1.66 .198 1.11 0.95 1.31 
         
 BRSK2 CpG5 methylation        
         
3A CpG5 (3-months) -0.04 0.02 3.90 .048 0.96 .928 1.00 
         
3B CpG5 (3-months) -0.04 0.02 3.32 .069 0.97 0.93 1.00 
 Childhood trauma (baseline) 0.11 0.09 1.58 0.21 1.11 0.94 1.32 
         
 ADCYAP1 CpG1&2 
methylation 
       
         
4A ADCYAP1 CpG5.6 (3-months) -0.09 0.10 0.76 .382 0.92 0.76 1.11 
         
4B ADCYAP1 CpG5.6 (3-months) -0.13 0.11 1.25 .263 0.88 0.71 1.10 
 Childhood trauma (baseline) 0.14 0.08 2.66 .103 1.15 0.97 1.35 
         
Abbreviations: standard error (SE); odds ration (OR), brain-specific serine/threonine-protein 










Stellenbosch University  https://scholar.sun.ac.za
374 
 
Supplementary Table 8: Replication of the BRSK2 and ADCYAP1 findings resulting from the 
epigenome-wide association study and the discovery set 
Model  β SE Wald’s 
χ2 
p  OR Lower Upper 
         
 BRSK2 CpG3 methylation        
         
1A CpG3 (3-months) -0.00 0.02 0.02 .889 1.00 0.96 1.04 
         
1B CpG3 (3-months) -0.01 0.02 0.11 .736 0.99 0.95 1.04 
 Childhood trauma (baseline) -0.12 0.14 0.84 .360 0.88 0.68 1.15 
         
 BRSK2 CpG4 methylation        
         
2A CpG4 (3-months) -0.01 0.02 0.19 .667 0.99 0.95 1.04 
         
2B CpG4 (3-months) -0.01 0.02 0.32 .570 0.99 0.94 1.03 
 Childhood trauma (baseline) -0.13 0.14 0.87 .350 0.88 0.68 1.15 
         
 BRSK2 CpG5 methylation        
         
3A CpG5 (3-months) 0.00 0.02 0.03 .866 1.00 0.97 1.04 
         
3B CpG5 (3-months) 0.00 0.02 0.01 .944 1.00 0.96 1.04 
 Childhood trauma (baseline) -0.13 0.14 0.88 .347 0.88 0.68 1.15 
         
 ADCYAP1 CpG1&2 
methylation 
       
         
4A ADCYAP1 CpG5.6 (3-months) -0.06 0.13 0.22 .639 0.94 0.73 1.21 
         
4B ADCYAP1 CpG5.6 (3-months) -0.5 0.13 0.15 .700 0.95 0.74 1.22 
 Childhood trauma (baseline) -0.12 0.13 0.83 .362 0.89 0.68 1.15 
         
Abbreviations: standard error (SE); odds ration (OR), brain-specific serine/threonine-protein 
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Supplementary Table 10: Comparison of BRSK2 methylation levels obtained from the 
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Supplementary Table 11: Comparison of ADCYAP1 methylation levels obtained from the 
MethylationEPIC array and the EpiTYPER analysis 
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Supplementary Table 12: Summary of genes and CpG sites investigated in candidate gene studies alongside findings in the current epigenome-wide 
study 




Main finding p-value Study specific 
identifier 
         
ADCYAP1         
 Current EWAS chr18:905101 TSS200; TSS1500; 
5’UTR 
Island NSF ↑Methylation in group with PTSD p=.034 cg17059658 
 Current EWAS chr18:905127 TSS200; TSS1500; 
5’UTR 
Island NSF ↑ Methylation in group with PTSD p=.006 cg15194943 
 Current EWAS chr18:905177 TSS200; TSS1500; 
5’UTR 
Island NSF ↑ Methylation in group with PTSD p=.00008 cg22388954 
 Current EWAS chr18:905180 TSS200; TSS1500; 
5’UTR 
Island NSF ↑ Methylation in group with PTSD p=.0008 cg11773720 
 Current EWAS chr18:905245 TSS200;  
5’UTR 
Island NSF ↑ Methylation in group with PTSD p=.044 cg09172003 
 Ressler et al., 201157 chr18:905450 NSF NSF NSF Not significant  p>.05 cg07376535 
         
ADCYAP1R1         
 Ressler et al., 201157 chr7:31091718 TSS1500 Island NSF ↑ Methylation ↑ PTSD symptom severity p<.0005* cg27076139 
 Current EWAS chr7:31092854 5’UTR Island NSF ↓ Methylation in group with PTSD p=.012 cg11218385 
         
AIM2         
 Miller et al., 201858 chr1:159046973 TSS1500 NSF Yes ↓ Methylation ↑ PTSD symptom severity p=.009* cg10636246 
         
BDNF         
 Current EWAS chr11:27681475 TSS1500; 3’UTR; 
5’UTR 
Island NSF ↑ Methylation in group with PTSD p=.017 cg07238832 
 Current EWAS chr11:27722889 TSS1500; 3’UTR; 
5’UTR 
S_Shore NSF ↓ Methylation in group with PTSD p=.029 cg04672351 
 Current EWAS chr11:27732958 3’UTR; 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.029 cg11806762 
 Moser et al., 201559 chr11:277440226 Exon IV NSF Yes Not significant p>.05 CpG4 
 Current EWAS chr11:27744049 TSS1500; 3’UTR Island NSF ↓ Methylation in group with PTSD p=.021 cg15462887 
 Kim et al., 201760 chr11:277442796 Exon I NSF Yes ↑ Methylation in group with PTSD p=.009* CpG4 
 Kim et al., 201760 chr11:277442866 Exon I NSF Yes ↑ Methylation in group with PTSD p=.021* CpG3 
 Kim et al., 201760 chr11:277442906 Exon I NSF Yes ↑ Methylation in group with PTSD p=.039* CpG2 
 Kim et al., 201760 chr11:277442926 Exon I  NSF Yes ↑ Methylation in group with PTSD p=.053 CpG1 
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 Moser et al., 201559 chr11:277449636 Exon IV NSF Yes Not significant p>.05 CpG1 
 Moser et al., 201559 chr11:277449716 Exon IV NSF Yes Not significant p>.05 CpG2 
 Moser et al., 201559 chr11:277449756 Exon IV NSF Yes Not significant p>.05 CpG3 
         
COMT         
 Norrholm et al., 201361 chr22:19950040 NSF NSF Yes ↑ Methylation in group with PTSD p<.01* cg23601416  
 Current EWAS chr22:19956281 3’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.040 cg19930203 
 Current EWAS chr22:19938096 TSS1500; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.002 cg09926649 
 Current EWAS chr22:19928616 TSS1500; 3’UTR; 
5’UTR 
N_Shore NSF ↑ Methylation in group with PTSD p=.015 cg27399558 
 Current EWAS chr22:19928667 TSS1500; 3’UTR; 
5’UTR 
N_Shore NSF ↑ Methylation in group with PTSD p=.044 cg11712482 
 Current EWAS chr22:19928740 TSS1500; 3’UTR; 
5’UTR 
N_Shore NSF ↑ Methylation in group with PTSD p=.039 cg24547396 
 Current EWAS chr22:19928445 TSS1500; 3’UTR; 
5’UTR 
N_Shore NSF ↑ Methylation in group with PTSD p=.0004 cg15926585 
 Current EWAS chr22:19949585 TSS1500; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.028 cg21905167 
         
FKBP5         
  chr6:355583866 Intron 7; TSS NSF NSF    
 Bishop et al., 201862     Not significant  p>.05 CpG35558386 
 Yehuda et al., 201663     Not significant p>.05 Bin1-CpG1 
  chr6:355584386 Intron 7; TSS NSF NSF    
 Bishop et al., 201862     Not significant p>.05 CpG35558438 
 Yehuda et al., 201663     Not significant p>.05 Bin1-CpG2 
  chr6:35558488 Intron 7; TSS NSF NSF    
 Bishop et al., 201862     Not significant p>.05 CpG35558488 
 Yehuda et al, 201663     Not significant p>.05 Bin2-CpG3 
 Kang et al., 201964     ↑ Methylation in group with PTSD p=.037* CpG1 
  chr6:355585136 Intron 7; TSS NSF NSF    
 Bishop et al., 201862 
    
↑ Methylation in MBSR non-responders 
post-treatment 
p=.029* CpG35558513 
 Yehuda et al., 201663 
    
Not significant p>.05 Bin2-CpG4-
GRE 




chr6:355585666 Intron 7; TSS NSF NSF 
   
 Bishop et al., 201862     Not significant  p>.05 CpG35558566 
 Yehuda et al., 201663     Not significant p>.05 Bin2-CpG5 
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chr6:355587106 Intron 7; TSS NSF NSF 
   
 Bishop et al., 201862     Not significant  p>.05 CpG35558710 
 Yehuda et al., 201663     ↑ Methylation in group with PTSD p=.046* Bin3-CpG6 
 Bishop et al., 201862 chr6:355587216 Intron 7; TSS NSF NSF Not significant p>.05 CpG35558721 
 Yehuda et al., 201663 chr6:35656916-
35656633 exon1 NSF 
Yes ↑ Methylation (across 38 CpG sites) ↑ 
PTSD symptom severity  
p=.044* CpG1-CpG38 
 Current EWAS chr6:35681420 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.046 cg24295963 
         
HTR3A         
 Schechter et al., 201765  chr11:1138279176 GRE NSF Yes Not significant p>.05 CpG1_I 
 Schechter et al., 201765  chr11:1138445296 TSS NSF Yes Not significant p>.05 CpG4_II 
 Schechter et al., 201765  chr11:113844828 TSS NSF Yes Not significant p>.05 CpG1_II 
 Schechter et al., 201765  chr11:1138448646 TSS NSF Yes Not significant  p>.05 CpG2_II 
 Schechter et al., 201765  chr11:1138449426 TSS NSF Yes Not significant  p>.05 CpG3_II 
 Schechter et al., 201765  chr11:113845939 5'UTR NSF Yes Not significant p>.05 CpG1_III 
 Schechter et al., 201765  chr11:113846004 5'UTR NSF Yes ↓ Methylation in group with PTSD p=.009* CpG2_III 
 Current EWAS chr11:113846004 TSS200; 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.028 cg20621129 
 Schechter et al., 201765  chr11:113846017 5'UTR NSF Yes Not significant p>.05 CpG3_III 
 Schechter et al., 201765  chr11:1138460446 Coding Sequence NSF Yes ↑ Methylation in group with PTSD p=.002* CpG4_III 
 Schechter et al., 201765  chr11:1138460706 Coding Sequence NSF Yes ↑ Methylation in group with PTSD p=.004* CpG5_III 
 Schechter et al., 201765  chr11:1138460776 Coding Sequence NSF Yes Not significant p>.05 CpG6_III 
 Current EWAS chr11:113860607 3’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.036 cg20178075 
         
IL12B         
 Bam et al., 201666 chr5:159314783-
159330473 
TSS Island Yes ↓ Methylation in group with PTSD NSF NA 
         
MAN2C1         
 Current EWAS chr15:75660215 TSS1500; 3’UTR N_Shore Yes ↓ Methylation in group with PTSD p=.024 cg05432169 
 Uddin et al., 201167 chr15:75661449 NSF Island Yes ↑ Methylation x ↑ trauma load in group 
with PTSD 
p=.04* cg04008455 
 Current EWAS chr15:75661532 TSS1500; 5’UTR S_Shore Yes ↑ Methylation in group with PTSD p=.029 cg04095413 
         
MAOA         
 Current EWAS chrX:43515349 TSS200 Island NSF ↑ Methylation in group with PTSD p=.048 cg19441691 
 Ziegler et al., 201868 chrX:435156136 Exon1/Intron1 NSF NSF Not significant p>.05 CpG1 
 Ziegler et al., 201868 chrX:435156246 Exon1/Intron1 NSF NSF Not significant p>.05 CpG2 
 Ziegler et al., 201868 chrX:435156586 Exon1/Intron1 NSF NSF ↑ Methylation in group with PTSD p=.029* CpG3 
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 Ziegler et al., 201868 chrX:435156656 Exon1/Intron1 NSF NSF Not significant  p>.05 CpG4 
 Ziegler et al., 201868 chrX:435156676 Exon1/Intron1 NSF NSF Not significant p>.05 CpG5 
 Ziegler et al., 201868 chrX:435156806 Exon1/Intron1 NSF NSF Not significant p>.05 CpG6 
 Ziegler et al., 201868 chrX:435156836 Exon1/Intron1 NSF NSF Not significant p>.05 CpG7 
 Ziegler et al., 201868 chrX:435156896 Exon1/Intron1 NSF NSF Not significant p>.05 CpG8 
 Ziegler et al., 201868 chrX:435156956 Exon1/Intron1 NSF NSF Not significant p>.05 CpG9 
 Ziegler et al., 201868 chrX:435157246 Exon1/Intron1 NSF NSF Not significant  p>.05 CpG10 
 Ziegler et al., 201868 chrX:435157296 Exon1/Intron1 NSF NSF Not significant p>.05 CpG11 
 Ziegler et al., 201868 chrX:435158116 Exon1/Intron1 NSF NSF ↑ Methylation in group with PTSD p=.011* CpG12 
 Ziegler et al., 201868 chrX:435158406 Exon1/Intron1 NSF NSF Not significant  p>.05 CpG13 
         
NR3C1         
 Current EWAS chr5:142729377 3’UTR; 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.029 cg22233604 
 Current EWAS chr5:142729913 3’UTR; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.031 cg03857453 
 Current EWAS chr5:142735238 3’UTR; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.008 cg14621978 
 Labonte et al., 201469 chr5:1427830956 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG54 
 Labonte et al., 201469 chr5:1427831016 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG53 
 Labonte et al., 201469 chr5:1427831046 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG52 
 Labonte et al., 201469 chr5:1427831126 5'UTR, exon 1C NSF Yes ↑ Methylation in group with PTSD p<.05* 1C-CpG51 
 Labonte et al., 201469 chr5:1427831206 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG50 
 Labonte et al., 201469 chr5:1427831286 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG49 
 Labonte et al., 201469 chr5:1427831396 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG48 
 Labonte et al., 201469 chr5:1427831456 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG47 
 Labonte et al., 201469 chr5:1427831616 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG46 
 Labonte et al., 201469 chr5:1427831646 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG45 
 Labonte et al., 201469 chr5:1427831676 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG44 
 Labonte et al., 201469 chr5:1427831816 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG43 
 Labonte et al., 201469 chr5:1427831836 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG42 
 Labonte et al., 201469 chr5:1427831896 5'UTR, exon 1C NSF Yes ↓ Methylation in group with PTSD p<.05* 1C-CpG41 
 Labonte et al., 201469 chr5:1427831916 5'UTR, exon 1C NSF Yes ↓ Methylation in group with PTSD p<.05* 1C-CpG40 
 Labonte et al., 201469 chr5:1427832046 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG39 
 Labonte et al., 201469 chr5:1427832136 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG38 
 Labonte et al., 201469 chr5:1427832176 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG37 
 Labonte et al., 201469 chr5:1427832216 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG36 
 Labonte et al., 201469 chr5:1427832276 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG35 
 Labonte et al., 201469 chr5:1427832316 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG34 
 Labonte et al., 201469 chr5:1427832386 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG33 
 Labonte et al., 201469 chr5:1427832486 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG32 
 Labonte et al., 201469 chr5:1427832516 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG31 
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 Labonte et al., 201469 chr5:1427832566 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG30 
 Labonte et al., 201469 chr5:1427832596 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG29 
 Labonte et al., 201469 chr5:1427832616 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG28 
 Labonte et al., 201469 chr5:1427832716 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG27 
 Labonte et al., 201469 chr5:1427832796 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG26 
 Labonte et al., 201469 chr5:1427832816 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG25 
 Labonte et al., 201469 chr5:1427832986 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG24 
 Labonte et al., 201469 chr5:1427833026 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG23 
 Labonte et al., 201469 chr5:1427833096 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG22 
 Labonte et al., 201469 chr5:1427833136 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG21 
 Labonte et al., 201469 chr5:1427833216 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG20 
 Labonte et al., 201469 chr5:1427833236 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG19 
 Labonte et al., 201469 chr5:1427833256 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG18 
 Labonte et al., 201469 chr5:1427833286 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG17 
 Labonte et al., 201469 chr5:1427833326 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG16 
 Labonte et al., 201469 chr5:1427833346 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG15 
 Labonte et al., 201469 chr5:1427833416 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG14 
 Labonte et al., 201469 chr5:1427833606 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG13 
 Labonte et al., 201469 chr5:142783379 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG12 
 Labonte et al., 201469 chr5:142783383 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG11 
 Labonte et al., 201469 chr5:142783385 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG10 
 Labonte et al., 201469 chr5:1427834006 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG9 
 Labonte et al., 201469 chr5:1427834076 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG8 
 Labonte et al., 201469 chr5:1427834096 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG7 
 Labonte et al., 201469 chr5:1427834116 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG6 
 Labonte et al., 201469 chr5:1427834186 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG5 
 Labonte et al., 201469 chr5:1427834266 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG4 
 Labonte et al., 201469 chr5:1427834326 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG3 
 Labonte et al., 201469 chr5:1427834356 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG2 
 Labonte et al., 201469 chr5:1427834386 5'UTR, exon 1C NSF Yes Not significant p>.05 1C-CpG1 
  chr5:1427835286 5'UTR, exon 1F Island Yes    
 Schechter et al., 201570      Not significant p>.05 CpG13 
 Schur et al., 201771     Not significant  p>.05 CpG52 
  chr5:1427835316 5'UTR, exon 1F Island Yes    
 Schechter et al., 201570      Not significant p>.05 CpG12 
 Schur et al., 201771     Not significant  p>.05 CpG51 
  chr5:1427835376 5'UTR, exon 1F Island Yes    
 Schechter et al., 201570      Not significant p>.05 CpG11 
 Schur et al., 201771     Not significant  p>.05 CpG50 
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  chr5:1427835406 5'UTR, exon 1F Island Yes    
 Schechter et al., 201570      Not significant p>.05 CpG10 
 Schur et al., 201771     Not significant  p>.05 CpG49 
  chr5:1427835476 5'UTR, exon 1F Island Yes    
 Schechter et al., 201570      Not significant p>.05 CpG9 
 Schur et al., 201771     Not significant  p>.05 CpG48 
  chr5:1427835666 5'UTR, exon 1F Island Yes    
 Schechter et al., 201570     Not significant  p>.05 CpG8 
 Vukojevic et al., 201472     Not significant p>.05 CpG8 
 Schur et al., 201771     Not significant  p>.05 CpG47 
  chr5:142783569 5'UTR, exon 1F Island Yes    
 Schechter et al., 201570     Not significant  p>.05 CpG7 
 Vukojevic et al., 201472     Not significant p>.05 CpG7 
 Schur et al., 201771     Not significant  p>.05 CpG46 
  chr5:1427835846 5'UTR, exon 1F Island Yes    
 Schechter et al., 201570     Not significant  p>.05 CpG6 
 Vukojevic et al., 201472     Not significant p>.05 CpG6 
 Schur et al., 201771     Not significant  p>.05 CpG45 
 Yehuda et al., 201373 chr5:142783607-
142783883 5'UTR, exon 1F Island Yes 
↑ Methylation (across 39 CpG sites) ↓ 





  chr5:142783607 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201373     ↓ Methylation in group with PTSD p=.022* CpG39 
 Schechter et al., 201570     Not significant  p>.05 CpG5 
 Mcnerney et al., 201874     Not significant p>.05 CpG26 
 Vukojevic et al., 201472     Not significant p>.05 CpG5 
  
Schur et al., 201771 
    Not significant  p>.05 CpG44 
  chr5:142783621 5'UTR, exon 1F, 
NGFI-A binding 
site Island Yes 
   
 Yehuda et al., 201575     Not significant  p>.05 CpG38 
 Schechter et al., 201570     Not significant p>.05 CpG4 
 Mcnerney et al., 201874     Not significant p>.05 CpG25 
 Vukojevic et al., 201472     Not significant  p>.05 CpG4 
 Schur et al., 201771     Not significant p>.05 CpG43 
  
chr5:1427836276 
5'UTR, exon 1F, 
NGFI-A binding 
site Island Yes 
   
 Yehuda et al., 201575     Not significant  p>.05 CpG37 
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 Schechter et al., 201570     Not significant p>.05 CpG3 
 Mcnerney et al., 201874     Not significant p>.05 CpG24 
 Vukojevic et al., 201472     ↓ Methylation ↑ PTSD symptom severity p<.05* CpG3 
 Schur et al., 201771     Not significant p>.05 CpG42 
  chr5:1427836376 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG36 
 Schechter et al., 201570     Not significant p>.05 CpG2 
 Mcnerney et al., 201874     Not significant p>.05 CpG23 
 Vukojevic et al., 201472     Not significant  p>.05 CpG2 
 Schur et al., 201771     Not significant p>.05 CpG41 
  chr5:142783639 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG35 
 Schechter et al., 201570     Not significant p>.05 CpG1 
 Mcnerney et al., 201874     Not significant p>.05 CpG22 
 Vukojevic et al., 201472     Not significant  p>.05 CpG1 
 Schur et al., 201771     Not significant p>.05 CpG40 
  chr5:1427836556 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG34 
 Mcnerney et al., 201874     Not significant p>.05 CpG21 
 Schur et al., 201771     Not significant p>.05 CpG39 
  chr5:1427836636 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG33 
 Mcnerney et al., 201874     Not significant p>.05 CpG20 
 Schur et al., 201771     Not significant p>.05 CpG38 
  chr5:1427836786 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG32 
 Mcnerney et al., 201874     Not significant p>.05 CpG19 
 Schur et al., 201771     Not significant p>.05 CpG37 
  chr5:1427836856 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG31 
 Mcnerney et al., 201874     Not significant p>.05 CpG18 
 Schur et al., 201771     Not significant p>.05 CpG36 
  chr5:1427836886 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG30 
 Mcnerney et al., 201874     Not significant p>.05 CpG17 
 Schur et al., 201771     Not significant p>.05 CpG35 
  chr5:1427837026 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG29 
 Mcnerney et al., 201874     Not significant p>.05 CpG16 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
385 
 
 Schur et al., 201771     Not significant p>.05 CpG34 
  chr5:1427837126 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG28 
 Mcnerney et al., 201874     Not significant p>.05 CpG15 
 Schur et al., 201771     Not significant p>.05 CpG33 
  chr5:1427837166 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG27 
 Mcnerney et al., 201874     Not significant p>.05 CpG14 
 Schur et al., 201771     Not significant p>.05 CpG32 
  chr5:1427837306 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG26 
 Mcnerney et al., 201874     Not significant p>.05 CpG13 
 Schur et al., 201771     Not significant p>.05 CpG31 
  chr5:1427837356 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG25 
 Mcnerney et al., 201874     Not significant p>.05 CpG12 
 Schur et al., 201771     Not significant p>.05 CpG30 
  chr5:1427837426 5'UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG24 
 Mcnerney et al., 201874     Not significant p>.05 CpG11 
 Schur et al., 201771     Not significant p>.05 CpG29 
  chr5:1427837446 5'UTR, exon 1F Island Yes     
 Yehuda et al., 201575     ↓ Methylation in group with PTSD p=.021* CpG23 
 Mcnerney et al., 201874     Not significant p>.05 CpG10 
 Schur et al., 201771     Not significant p>.05 CpG28 
  chr5:1427837556 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG22 
 Mcnerney et al., 201874     Not significant p>.05 CpG9 
 Schur et al., 201771     Not significant p>.05 CpG27 
  chr5:1427837666 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG21 
 Mcnerney et al., 201874     Not significant p>.05 CpG8 
 Schur et al., 201771     Not significant p>.05 CpG26 
  chr5:1427837686 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG20 
 Mcnerney et al., 201874     Not significant p>.05 CpG7 
 Schur et al., 201771     Not significant p>.05 CpG25 
  chr5:1427837716 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG19 
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 Mcnerney et al., 201874     Not significant p>.05 CpG6 
 Schur et al., 201771     Not significant p>.05 CpG24 
  chr5:1427837746 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG18 
 Mcnerney et al., 201874     Not significant p>.05 CpG5 
 Schur et al., 201771     Not significant p>.05 CpG23 
  chr5:1427837776 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG17 
 Mcnerney et al., 201874     Not significant p>.05 CpG4 
 Schur et al., 201771     Not significant p>.05 CpG22 
  chr5:1427837806 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG16 
 Mcnerney et al., 201874     Not significant  p>.05 CpG3 
 Schur et al., 201771     Not significant p>.05 CpG21 
  chr5:1427837856 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG15 
 Mcnerney et al., 201874     Not significant p>.05 CpG2 
 Schur et al., 201771     Not significant p>.05 CpG20 
  chr5:1427837926 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG14 
 Mcnerney et al., 201874     Not significant p>.05 CpG1 
 Schur et al., 201771     Not significant p>.05 CpG19 
  chr5:1427838096 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG13 
 Schur et al., 201771     Not significant p>.05 CpG18 
  chr5:1427838216 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG12 
 Schur et al., 201771     Not significant p>.05 CpG17 
  chr5:1427838316 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG11 
 Schur et al., 201771     Not significant p>.05 CpG16 
  chr5:1427838376 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG10 
 Schur et al., 201771     Not significant p>.05 CpG15 
  chr5:1427838436 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG9 
 Schur et al., 201771     Not significant p>.05 CpG14 
  chr5:1427838486 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG8 
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 Schur et al., 201771     Not significant p>.05 CpG13 
  chr5:1427838536 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG7 
 Schur et al., 201771     Not significant p>.05 CpG12 
  chr5:1427838576 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG6 
 Schur et al., 201771     Not significant p>.05 CpG11 
  chr5:1427838596 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG5 
 Schur et al., 201771     Not significant p>.05 CpG10 
  chr5:1427838636 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG4 
 Schur et al., 201771     Not significant p>.05 CpG9 
  chr5:1427838696 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG3 
 Schur et al., 201771     Not significant p>.05 CpG8 
  chr5:1427838736 5’UTR, exon 1F Island Yes    
      Not significant  p>.05 CpG2 
 Schur et al., 201771     Not significant p>.05 CpG7 
  chr5:1427838836 5’UTR, exon 1F Island Yes    
 Yehuda et al., 201575     Not significant  p>.05 CpG1 
 Schur et al., 201771     Not significant p>.05 CpG6 
 Schur et al., 201771 chr5:1427839126 5’UTR, exon 1F Island Yes Not significant  p>.05 CpG5 
 Schur et al., 201771 chr5:1427839206 5’UTR, exon 1F Island Yes Not significant p>.05 CpG4 
 Schur et al., 201771 chr5:1427839276 5’UTR, exon 1F Island Yes Not significant  p>.05 CpG3 
 Schur et al., 201771 chr5:1427839306 5’UTR, exon 1F Island Yes Not significant p>.05 CpG2 
 Schur et al., 201771 chr5:1427839366 5’UTR, exon 1F Island Yes Not significant  p>.05 CpG1 
 Labonte et al., 201469 chr5:1427840716 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG29 
 Labonte et al., 201469 chr5:1427840746 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG28 
 Labonte et al., 201469 chr5:1427840786 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG27 
 Labonte et al., 201469 chr5:1427840826 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG26 
 Labonte et al., 201469 chr5:1427841026 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG25 
 Labonte et al., 201469 chr5:1427841106 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG24 
 Labonte et al., 201469 chr5:1427841156 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG23 
 Labonte et al., 201469 chr5:1427841186 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG22 
 Labonte et al., 201469 chr5:1427841216 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG21 
 Labonte et al., 201469 chr5:1427841246 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG20 
 Labonte et al., 201469 chr5:1427841366 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG19 
 Labonte et al., 201469 chr5:1427841396 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG18 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
388 
 
 Labonte et al., 201469 chr5:142784168 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG17 
 Labonte et al., 201469 chr5:142784187 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG16 
 Labonte et al., 201469 chr5:1427842016 5’UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG15   
 Labonte et al., 201469 chr5:142784222 5’UTR, exon 1B NSF Yes ↓ Methylation in group with PTSD p=.05* 1B-CpG14 
 Labonte et al., 201469 chr5:1427842426 5'UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG13 
 Labonte et al., 201469 chr5:142784278 5'UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG12 
 Labonte et al., 201469 chr5:1427843046 5'UTR, exon 1B NSF Yes ↓ Methylation in group with PTSD p<.05* 1B-CpG11 
 Labonte et al., 201469 chr5:142784323 5'UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG10 
 Labonte et al., 201469 chr5:1427843696 5'UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG9 
 Labonte et al., 201469 chr5:1427843806 5'UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG8 
 Labonte et al., 201469 chr5:142784382 5'UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG7 
 Current EWAS chr5:142784382 TSS1500; 5’UTR Island Yes ↑ Methylation in group with PTSD p=.036 cg18849621 
 Labonte et al., 201469 chr5:1427843946 5'UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG6 
 Labonte et al., 201469 chr5:1427844126 5'UTR, exon 1B NSF Yes Not significant  p>.05 1B-CpG5 
 Labonte et al., 201469 chr5:1427844356 5'UTR, exon 1B NSF Yes ↓ Methylation in group with PTSD p<.005* 1B-CpG4 
 Labonte et al., 201469 chr5:1427844456 5'UTR, exon 1B NSF Yes ↓ Methylation in group with PTSD p<.005* 1B-CpG3 
 Labonte et al., 201469 chr5:1427844626 5'UTR, exon 1B NSF Yes ↓ Methylation in group with PTSD p<.005* 1B-CpG2 
 Labonte et al., 201469 chr5:1427845226 5'UTR, exon 1B NSF Yes Not significant p>.05 1B-CpG1 
 Current EWAS chr5:142815463 TSS1500 OpenSea NSF ↓ Methylation in group with PTSD p=.003 cg07589972 
         
OXTR         
 Nawijn et al., 201976 chr3:88094646 Exon 3 Island NSF Not significant  p>.05 CpG1 
 Nawijn et al., 201976 chr3:88094426 Exon 3 Island NSF Not significant  p>.05 CpG2 
 Nawijn et al., 201976 chr3:88094376 Exon 3 Island NSF ↑ Methylation in females with PTSD  p=.022* CpG3 
 Nawijn et al., 201976 chr3:88094336 Exon 3 Island NSF Not significant p>.05 CpG4 
 Nawijn et al., 201976 chr3:88094286 Exon 3 Island NSF Not significant  p>.05 CpG5 
 Nawijn et al., 201976 chr3:88094256 Exon 3 Island NSF Not significant  p>.05 CpG6 
 Nawijn et al., 201976 chr3:88094226 Exon 3 Island NSF Not significant p>.05 CpG7 
 Nawijn et al., 201976 chr3:88094176 Exon 3 Island NSF Not significant p>.05 CpG8 
 Nawijn et al., 201976 chr3:88094136 Exon 3 Island NSF ↑ Methylation in females with PTSD  p=.015* CpG9 
 Nawijn et al., 201976 chr3:88093996 Exon 3 Island NSF Not significant p>.05 CpG10 
 Nawijn et al., 201976 chr3:88093946 Exon 3 Island NSF Not significant p>.05 CpG11 
 Nawijn et al., 201976 chr3:88093876 Exon 3 Island NSF Not significant p>.05 CpG12 
         
SKA2  chr17:57187728 3'UTR NSF NSF    
 Sadeh et al., 201677     ↑ Methylation ↑ PTSD symptom severity p=.021* cg13989295 
 Boks et al., 201678     ↓ Methylation ↑ PTSD symptom severity  p=.00006* cg13989295 
 Current EWAS chr17:57232722 TSS1500; 5’UTR S_Shore Yes ↑ Methylation in group with PTSD p=.012 cg20104110 
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SLC6A3         
 Current EWAS chr5:1443460 TSS200; TSS1500; 
5’UTR 
N_Shore NSF ↑ Methylation in group with P TSD p=.017 cg04088992 
 Current EWAS chr5:1444395 TSS1500; 5’UTR Island NSF ↑ Methylation in group with PTSD p=.023 cg13723431 
 Current EWAS chr5:1444333 TSS1500; 5’UTR Island NSF ↑ Methylation in group with PTSD p=.033 cg08713711 
 Current EWAS chr5:1445542 1stExon; 5’UTR Island NSF ↑ Methylation in group with PTSD p=.035 cg04598517 
 Change et al., 201279 chr5:1446443 TSS1500 Island Yes ↑ Methylation x SLC6A3 VNTR 9R in 
group with PTSD 
p=.008* cg13202751 
         
SLC6A4         
 Koenen et al., 201180 chr17:28562220 5'UTR; 1stIntron N Shore NSF ↓ Methylation in group with PTSD x ↑ 
lifetime trauma exposure 
p=.036* cg22584138 
 
         
1 Identified using the GENECODE database; 2 identified using the Human Genome 19 (HG19) build from the Genome Reference Consortium;  
3 identified using the University of California Santa Cruz (UCSC) Genomic Institute/Genome Browser; 4 Multiple listings indicate splice variants;  
5 identified using the Methylation Consortium project; 6 CpG site not included on the MethylationEPIC beadchip. 
*p < .05 after correction for multiple testing 
 
Abbreviations:  
Pituitary adenylate cyclase-activating polypeptide 1 (ADCYAP1); epigenome-wide association study (EWAS); transcription start site 200 (TSS200); 
transcription start site 1500 (TSS1500); 5’ untranslated region (5’UTR); not specified (NSF); posttraumatic stress disorder (PTSD); ADCYAP1 
receptor 1 (ADCYAP1R1);  interferon-inducible protein / absent in melanoma 2 (AIM2); brain-derived neurotropic factor (BDNF); 3’ untranslated 
region (3’UTR); South shore (S_Shore); catechol-O-methyltransferase (COMT); North shore (N_Shore); FK506 binding protein (FKBP5); 
transcription start site (TSS); mindfulness based stress reduction (MBSR); glucocorticoid response element (GRE); 5-hydroxytryptamine receptor 3A 
(HTR3A); interleukin 12B (IL12B); mannosidase, alpha class 2c member 1 (MAN2C1); monoamine oxidase A (MAOA); nuclear receptor subfamily 3, 
group C (NR3C1); transcription factor nerve growth factor-inducible protein A (NGFI-A); oxytocin receptor (OXTR); spindle and kinetochore-
associated protein 2 (SKA2); 3’ untranslated region (3’UTR); solute carrier family 6, member 3 (SLC6A3); variable number tandem repeat nine repeats 
(VNTR 9R); solute carrier family 6, member 4 (SLC6A4). 
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Supplementary Table 13: Summary of genes and CpG sites associations with PTSD observed in prior epigenome-wide studies alongside associations 
observed in the current study 
Gene1 Reference Genomic 
position2 





         
ACO11899.9         
 Smith et al., 201981 Chr7:157294357 cg26801037 Intergenic NSF NSF ↓ Methylation in group with PTSD p=.000000308 
         
ACP5         
 Smith et al., 201182 Chr19:11688246 cg07967308 NSF NSF NSF ↑ Methylation in group with PTSD p=.0000080 
 Current EWAS chr19:11685647 cg14188508 3’UTR N_Shelf NSF ↓ Methylation in group with PTSD p=.046 
 Current EWAS chr19:11689855 cg03302259 TSS200/1500 S_Shore Yes ↓ Methylation in group with PTSD p=.049 
         
AHRR         
 Current EWAS Chr5:306699 cg21813876 TSS200; 3'UTR; 
5'UTR 
N_Shore NSF ↓ Methylation in group with PTSD p=.001 
 Current EWAS Chr5:314553 cg18584368 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.024 
 Current EWAS Chr5:321320 cg11554391 TSS1500; 5'UTR Island NSF ↓ Methylation in group with PTSD p=.044 
 Current EWAS Chr5:369088 cg12202185 5'UTR N_Shore NSF ↓ Methylation in group with PTSD p=.039 
  Chr5:373378 cg05575921 5'UTR N_Shore NSF   
 Smith et al., 201981      ↓ Methylation in group with PTSD p=.0000000000472 
 Current EWAS      ↓ Methylation in group with PTSD p=.033 
 Current EWAS Chr5:374425 cg22356527 5'UTR Island NSF ↑ Methylation in group with PTSD p=.015 
  Chr5:377358 cg26703534 5'UTR S_Shelf NSF   
 Smith et al., 201981      ↓ Methylation in group with PTSD p=.0000000225 
 Current EWAS      ↓ Methylation in group with PTSD p=.031 
 Current EWAS Chr5:378854 cg01097768 5'UTR OpenSea NSF ↓ Methylation in group with PTSD p=.048 
 Current EWAS Chr5:388196 cg01958142 5'UTR OpenSea NSF ↓ Methylation in group with PTSD p=.030 
 Smith et al., 201981 Chr5:395444 cg25648203 Body NSF NSF ↓ Methylation in group with PTSD p=.0000000107 
 Smith et al., 201981 Chr5:399360 cg21161138 Body NSF NSF ↓ Methylation in group with PTSD p=.000000000439 
 Current EWAS Chr5:405488 cg12207033 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.044 
 Current EWAS Chr5:405567 cg01141993 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.007 
         
ANXA2         
 Smith et al., 201182 Chr15:60690219 cg08081036 NSF NSF NSF ↓ Methylation in group with PTSD p=.0000093 
         
ATP9A         
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 Current EWAS Chr20:50224119 cg08403379 Body OpenSea NSF ↓ Methylation in group with PTSD p=.035 
 Smith et al., 201981 Chr20:50312490 cg07339236 Body NSF NSF ↓ Methylation in group with PTSD p=.000000239 
         
BRSK1         
 Current EWAS Chr19:55798650 cg24351452 Body Island NSF ↓ Methylation in group with PTSD p=.004 
 Current EWAS Chr19:55798477 cg22577385 Body Island NSF ↓ Methylation in group with PTSD p=.030 
 Mehta et al., 201783 Chr19:55813339 cg02357741 Body N_Shore Yes ↓ Methylation in group with PTSD p=.00000224 
         
CDH15         
 Snijders et al., 202084 Chr16:89251975 cg05901543 Body NSF NSF ↓ Methylation in group with PTSD p=.0000025 
         
CLEC9A         
 Current EWAS Chr12:10183167 cg13830870 TSS200; 3’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.038 
 Current EWAS Chr12:10183220 cg26262442 TSS200 OpenSea NSF ↓ Methylation in group with PTSD p=.010 
 Current EWAS Chr12:10183234 cg02930518 TSS200 OpenSea NSF ↓ Methylation in group with PTSD p=.046 
 Smith et al., 201182 Chr12:10183364 cg20098659 NSF NSF NSF ↑ Methylation in group with PTSD p=.0000043 
 Current EWAS Chr12:10184399 cg03900817 TSS1500; 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.035 
         
COL1A2         
 Rutten et al., 201885 Chr7:93740160 cg22676075 NSF NSF NSF ↓ Methylation ↑ PTSD symptom severity p=.0000000129 
 Rutten et al., 201885 Chr7:94023308 cg24406898 TSS1500 N_Shore NSF ↓ Methylation ↑ PTSD symptom severity p=.00000179 
 Current EWAS Chr7:94059900 cg20943251 3'UTR; 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.013 
         
CTRC         
 Snijders et al., 202084 Chr1:15764093 cg18917957 TSS1500 NSF NSF ↓ Methylation in group with PTSD p=.00000050 
 Current EWAS Chr1:15773099 cg13551783 3’UTR; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.023 
         
DOCK2         
 Current EWAS Chr5:169064897 cg23184477 5'UTR S_Shore NSF ↑ Methylation in group with PTSD p=.032 
 Mehta et al., 201783 Chr5:169068404 cg16277944 5'UTR S_shelf Yes ↓ Methylation in group with PTSD p=.00000495 
 Current EWAS Chr5:169083252 cg14784010 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.015 
 Current EWAS Chr5:169146570 cg26982433 5'UTR OpenSea NSF ↓ Methylation in group with PTSD p=.002 
 Current EWAS Chr5:169416192 cg10849016 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.021 
         
DUSP22         
  Chr6:291882 cg21548813 TSS1500 N_Shore Yes   
 Rutten et al., 201885      ↓ Methylation ↑ PTSD symptom severity p=.0000000140 
 Current EWAS      ↓ Methylation in group with PTSD p=.032 
 Rutten et al., 201885 Chr6:291903 cg03395511 TSS200 N_Shore Yes ↓ Methylation ↑ PTSD symptom severity p=.000000234 
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 Rutten et al., 201885 Chr6:292329 cg18110333 5'UTR Island Yes ↓ Methylation ↑ PTSD symptom severity p=.00000000689 
 Rutten et al., 201885 Chr6:292522 cg11235426 5'UTR Island Yes ↓ Methylation ↑ PTSD symptom severity p=.000000665 
 Rutten et al., 201885 Chr6:292596 cg01516881 Body Islan Yes ↓ Methylation ↑ PTSD symptom severity p=.000000452 
         
FLJ46321         
 Smith et al., 201981 Chr9:84609982 cg14405344 Body NSF NSF ↓ Methylation in group with PTSD p=.000000786 
         
G0S2         
 Logue et al., 202086 Chr1:209849006 cg19534438 5'UTR Island NSF ↑ Methylation in group with PTSD p=.000000119 
         
HDAC4         
 Current EWAS chr2:240062051 cg25828346 3’UTR; 5’UTR S_Shore NSF ↓ Methylation in group with PTSD p=.033 
 Current EWAS chr2:240066248 cg06107260 3’UTR; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.046 
 Maddox et al., 201887 chr2:240168862 cg22937172 5’UTR NSF NSF ↑ Methylation in group with PTSD p=.000000127 
 Current EWAS chr2:240196171 cg16348668 3’UTR; 5’UTR N_Shore Yes ↑ Methylation in group with PTSD p=.017 
 Current EWAS chr2:240205260 cg00116699 3’UTR; 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.013 
 Current EWAS chr2:240205602 cg20453985 3’UTR; 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.039 
 Current EWAS chr2:240218482 cg09664216 3’UTR; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.022 
 Current EWAS chr2:240288826 cg06381933 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.004 
 Current EWAS chr2:240309587 cg02812817 3’UTR; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.021 
 Current EWAS chr2:240313052 cg00811555 3’UTR; 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.008 
         
HEXDC         
 Current EWAS Chr17:80375674 cg07050946 TSS1500 N_Shore Yes ↓ Methylation in group with PTSD p=.020 
 Current EWAS Chr17:80376872 cg12655836 TSS1500; 5’UTR S_Shore Yes ↓ Methylation in group with PTSD p=.012 
 Snijders et al., 202084 Chr17:80394529 cg20756026 Body S_Shore NSF ↓ Methylation in group with PTSD p=.000000013 
         
HGS         
 Uddin et al., 201888 Chr17:79658554 cg19577098 Body S_Shelf NSF ↓ Methylation in group with PTSD p=.000000147 
         
HIST1H2APS2         
 Rutten et al., 201885 chr6:25882590 cg03517284 NSF S_Shore NSF ↓ Methylation ↑ PTSD symptom severity p=.013 
         
HOOK2         
 Current EWAS Chr19:12874033 cg07798386 3'UTR N_Shelf NSF ↑ Methylation in group with PTSD p=.002 
 Rutten et al., 201885 Chr19:12876846 cg06417478 Body N_Shore NSF ↓ Methylation ↑ PTSD symptom severity p=.000000000288 
 Rutten et al., 201885 Chr19:12876947 cg04657146 Body Island NSF ↓ Methylation ↑ PTSD symptom severity p=.0000000345 
 Rutten et al., 201885 Chr19:12877000 cg11738485 Body Island NSF ↓ Methylation ↑ PTSD symptom severity p=.0000000129 
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LCN8         
 Current EWAS Chr9:139652023 cg16004906 TSS200/1500 N_Shelf NSF ↓ Methylation in group with PTSD p=.016 
 Current EWAS Chr9:139653461 cg13839917 TSS1500 N_Shore NSF ↓ Methylation in group with PTSD p=.031 
 Mehta et al., 201783 Chr9:139653533 cg09325682 TSS1500 N_Shore NSF ↓ Methylation in group with PTSD p=.00000328 
         
LINC00599         
 Smith et al., 201981 Chr8:9742024 cg18217048 Intergenic NSF NSF ↓ Methylation in group with PTSD p=.000000961 
         
LRRC3B         
 Current EWAS Chr3:26663805 cg10332616 TSS1500; 3’UTR N_Shore NSF ↓ Methylation in group with PTSD p=.021 
 Current EWAS Chr3:26664115 cg13787438 TSS200/1500; 
3'UTR 
Island NSF ↓ Methylation in group with PTSD p=.029 
 Current EWAS Chr3:26688128 cg12975201 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.013 
 Mehta et al., 201783 Chr3:26753752 cg26499155 NSF OpenSea NSF ↑ Methylation in group with PTSD p=.000000794 
         
MAD1L1         
 Snijders et al., 202084 Chr7:1923695 cg12169700 Body NSF NSF ↓ Methylation in group with PTSD p=.00000000081 
 Current EWAS Chr7:2020501 cg17633015 TSS200 S_Shore NSF ↓ Methylation in group with PTSD p=.015 
 Current EWAS Chr7:2250274 cg01859191 3’UTR Island NSF ↓ Methylation in group with PTSD p=.036 
 Current EWAS Chr7:2256023 cg00420390 TSS1500; 3’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.028 
 Current EWAS Chr7:2257611 cg17718984 3’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.044 
 Current EWAS Chr7:2274072 cg11571856 TSS1500; 3’UTR S_Shore NSF ↑ Methylation in group with PTSD p=.015 
         
MIR3179         
 Smith et al., 201981 Chr13:98749760 cg17284326 Intergenic NSF NSF ↓ Methylation in group with PTSD p=.0000000893 
         
MYT1L         
  Chr2:1817351 cg10075506 Body OpenSea NSF   
 Rutten et al., 201885      ↓ Methylation ↑ PTSD symptom severity p=.00000128 
 Current EWAS      ↑ Methylation in group with PTSD p=.036 
         
NGF         
 Current EWAS Chr1:115829856 cg12647496 5'UTR OpenSea  ↓ Methylation in group with PTSD p=.020 
 Mehta et al., 201783 Chr1:115844232 cg17750109 5'UTR NSF NSF ↓ Methylation in group with PTSD p=.00000306 
 Current EWAS Chr1:115877962 cg01804281 5'UTR N_Shelf  ↓ Methylation in group with PTSD p=.011 
         
NINJ2         
 Rutten et al., 201885 Chr12:739980 cg14911689 Body NSF Yes ↓ Methylation ↑ PTSD symptom severity p=.00000000861 
 Rutten et al., 201885 Chr12:740100 cg26654770 Body NSF Yes ↓ Methylation ↑ PTSD symptom severity p=.000000610 
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 Current EWAS Chr12:751121 cg11552370 TSS200/1500; 
3'UTR; 5'UTR 
N_Shore NSF ↓ Methylation in group with PTSD p=.004 
 
 Current EWAS Chr12:751317 cg21334546 TSS1500; 3'UTR; 
5'UTR 
N_Shore NSF ↓ Methylation in group with PTSD p=.012 
 Current EWAS Chr12:772861 cg00237010 TSS200; 5'UTR OpenSea NSF ↓ Methylation in group with PTSD p=.020 
NRG1         
 Uddin et al., 201888 Chr8:31996079 cg23637605 5’UTR OpenSea NSF ↓ Methylation in group with PTSD p=.0000000753 
 Current EWAS Chr8: 32577951 cg10157574 TSS1500; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.009 
 Current EWAS Chr8:32504400 cg05861515 TSS1500; 5’UTR OpenSea NSF ↑ Methylation in group with PTSD p=.014 
         
 Current EWAS Chr12:772966 cg15884713 TSS200 OpenSea NSF ↓ Methylation in group with PTSD p=.038 
         
PAX8         
 Current EWAS Chr2:113991662 cg19081868 TSS1500; 3'UTR; 
5'UTR 
N_Shore NSF ↓ Methylation in group with PTSD p=.026 
 Current EWAS Chr2:113992694 cg23122642 TSS1500; 3'UTR; 
5'UTR 
N_Shore NSF ↑ Methylation in group with PTSD p=.048 









 Rutten et al., 201885      ↓ Methylation ↑ PTSD symptom severity p=.00000129 
 Current EWAS      ↑ Methylation in group with PTSD p=.030 
 Current EWAS Chr2:113992930 cg21550016 TSS200/1500; 
3'UTR; 5'UTR 
N_Shore NSF ↑ Methylation in group with PTSD p=.047 
 Current EWAS Chr2:113994578 cg00422909 TSS200 /1500; 
3'UTR; 5'UTR 
S_Shore NSF ↑ Methylation in group with PTSD p=.0009 
 Current EWAS Chr2:113998034 cg17774569 TSS1500; 5'UTR S_Shelf NSF ↓ Methylation in group with PTSD p=.028 
 Current EWAS Chr2:114036444 cg05194362 TSS1500; 3'UTR; 
5'UTR 
S_Shore NSF ↑ Methylation in group with PTSD p=.036 
         
RNF6         
 Smith et al., 201981 Chr13:26795862 cg25415650 5'UTR NSF NSF ↑ Methylation in group with PTSD p=.0000000738 
 Current EWAS Chr13:26796956 cg27472353 TSS200/1500 S_Shore Yes ↓ Methylation in group with PTSD p=.015 
 Current EWAS Chr13:26797157 cg03033508 TSS1500 S_Shore NSF ↓ Methylation in group with PTSD p=.013 
 Current EWAS Chr13:26797279 cg23140290 TSS1500 S_Shore NSF ↓ Methylation in group with PTSD p=.032 
         
SDK1         
 Current EWAS Chr7:3343581 cg11998431 TSS1500; 5'UTR S_Shore NSF ↓ Methylation ↑ PTSD symptom severity p=.006 
 Current EWAS Chr7:3343830 cg19871079 5'UTR S_shelf NSF ↑ Methylation in group with PTSD p=.034 
 Current EWAS Chr7:3470434 cg02716317 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.043 
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 Current EWAS Chr7:3478077 cg25451765 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.008 
 Current EWAS Chr7:3920006 cg18620306 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.002 
 Current EWAS Chr7:3920082 cg05812582 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.014 
 Current EWAS Chr7:3920297 cg05896377 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.012 
 Current EWAS Chr7:3920534 cg18022346 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.042 
 Current EWAS Chr7:3989167 cg01923516 TSS1500; 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.045 
 Current EWAS Chr7:4018931 cg14950237 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.016 
 Current EWAS Chr7:4049819 cg24851600 5'UTR OpenSea NSF ↓ Methylation ↑ PTSD symptom severity p=.037 
 Current EWAS Chr7:4052042 cg09274366 5'UTR OpenSea NSF ↓ Methylation ↑ PTSD symptom severity p=.011 
 Current EWAS Chr7:4056929 cg11082847 5'UTR OpenSea NSF ↓ Methylation ↑ PTSD symptom severity p=.028 
 Current EWAS Chr7:4146971 cg27215475 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.047 
 Current EWAS Chr7:4152976 cg14682731 5'UTR N_Shore NSF ↑ Methylation in group with PTSD p=.009 
 Current EWAS Chr7:4167822 cg12801000 TSS1500; 5'UTR N_Shore NSF ↑ Methylation in group with PTSD p=.030 
 Current EWAS Chr7:4175403 cg01667575 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.047 
 Current EWAS Chr7:4183976 cg04612959 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.002 
 Current EWAS Chr7:4191467 cg21108029 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.028 
 Current EWAS Chr7:4213731 cg06610094 TSS200; 5'UTR OpenSea NSF ↓ Methylation ↑ PTSD symptom severity p=.008 
 Current EWAS Chr7:4228775 cg23357832 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.039 
 Current EWAS Chr7:4228948 cg26800883 5'UTR OpenSea NSF ↑ Methylation in group with PTSD p=.034 
 Rutten et al., 201885 Chr7:4244643 cg07249765 Body NSF NSF ↓ Methylation ↑ PTSD symptom severity p=.0000000541 
 Current EWAS Chr7:4276193 cg03010092 5'UTR OpenSea NSF ↓ Methylation ↑ PTSD symptom severity p=.006 
 Snijders et al., 202084 Chr7:4304779 cg16956686 Body NSF NSF ↓ Methylation in group with PTSD p=.00000020 
 Current EWAS Chr7:4306321 cg22611217 3'UTR; 5'UTR S_Shore NSF ↑ Methylation in group with PTSD p=.001 
 Current EWAS Chr7:4308120 cg21853331 3'UTR; 5'UTR S_shelf NSF ↑ Methylation in group with PTSD p=.009 
         
SPRY4         
 Snijders et al., 202084 Chr5:141660565 cg05656210 NSF NSF NSF ↓ Methylation in group with PTSD p=.000000010 
         
TLR8         
 Smith et al., 201182 ChrX:12924783 cg07759587 NSF NSF NSF ↑ Methylation in group with PTSD p=.000011 
         
TPR         
  Chr1:186344558 cg24577137 TSS200/1500 Island Yes   
 Smith et al., 201182      ↓ Methylation in group with PTSD p=.0000019 
 Current EWAS      ↓ Methylation in group with PTSD p=.0008 
         
1 Identified using the GENECODE database; 2 identified using the Human Genome 19 (HG19) build from the Genome Reference Consortium;  
3 identified using the University of California Santa Cruz (UCSC) Genomic Institute/Genome Browser; 4 Multiple listings indicate splice 
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variants; 5 identified using the Methylation Consortium project. 
 
Abbreviations: 
Anaphase promoting complex subunit 5 (APC5); not specified (NSF); posttraumatic stress disorder (PTSD); untranslated region (3’UTR); North shelf 
(N_Shelf); transcription start site 200 (TSS200); transcription start site 1500 (TSS1500); South shore (S_Shore); human aryl hydrocarbon receptor 
repressor (AHRR); 5’ untranslated region (5’UTR); North shore (N_Shore); South shelf (S_Shelf); annexin A2 (ANXA2); ATPase phospholipid 
transporting 9A (ATP9A); brain-specific serine/threonine-protein kinase 1 (BRSK1); cadherin 15 (CDH15); C-type lectin domain family 9, member A 
(CLEC9A); collagen type I alpha 2 chain (COL1A2); chymotryosin C (CTRC); dedicator of cytokinesis 2 (DOCK2); dual specificity phosphatase 22 
(DUSP22); family with sequence similarity 75, member D1 (FLJ46321); putative lymphocyte G0/G1 switch (G0S2); histone deacetylase 4 (HDAC4); 
hexosaminidase glycosyl hydrolase family 20 catalytic domain containing (HEXDC); hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) 
H2A histone family, member T, pseudogene (HIST1H2APS2); hook microtubule tethering protein 2 (HOOK2); lipocalin 8 (LCN8); long intergenic non-
protein coding RNA 599 (LINC00599); leucine rich repeat containing 3B (LRRC3B); mitotic arrest deficient 1 like 1 (MAD1L1); microRNA 3170 
(MIR3170); myelin transcription factor 1 like (MYT1L); nerve growth factor (NGF); ninjurin 2 (NINJ2); neuregulin 1 (NRG1); paired box 8 (PAX8); 
ring finger protein 6 (RNF6); sidekick cell adhesion molecule 1 (SDK1); sprouty RTK signalling antagonist 4 (SPRY4); toll-like receptor 8 (TLR8); 
translocated promoter region (TPR). 
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Supplementary Table 14: Univariate relationship baseline confounding/covarying factors, PTSD, BRSK2 and ADCYAP1 methylation 

























use (no vs yes) 
 r/z p z/x2 p r/z p z/ x2 p r/z p r/z p r/z p r/z p z/x2 p 
                   
PTSD total score (baseline) -0.20 .052 -1.07 .284 0.08 .455 -.487 .626 0.25 .013* 0.06 .550 -0.07 .514 0.50 .000* -1.46 .144 
PTSD total score (3-months) -0.12 .252 -.139 .889 -0.04 .720 .000 1.00 0.16 .118 0.06 .552 -0.05 .650 0.06 .568* -1.08 .282 
PTSD status (3-months) 0.12 .908 0.93 .336 0.99 .323 0.01 .937 0.70 .482 0.14 .889 0.38 .706 0.14 .890 0.78 .378 
PTSD total score (6-months) 0.11 .286 -.631 .528 -0.02 .884 -.288 .773 0.04 .723 0.05 .646 -0.20 .049* 0.22 .029* -.513 .608 
PTSD status (6-months) 1.93 .054 0.50 .478 0.51 .609 0.27 .602 0.86 .389 1.80 .071 1.41 .158 2.01 .044* 0.42 .516 
                   
BRSK2 CpG3 (baseline) -0.01 .918 -1.01 .313 -0.05 .662 -.316 .752 -0.19 .070 -0.19 .061 0.10 .332 0.11 .287 -.540 .589 
BRSK2 CpG4 (baseline) -0.04 .725 -1.01 .313 -0.09 .382 -.543 .587 -0.26 .011* -0.31 .003* 0.09 .405 0.11 .269 -.933 .351 





        
  
BRSK2 CpG3 (3-months) -0.01 .905 -.332 .740 0.02 .844 -.062 .951 -0.16 .114 -0.14 .169 0.08 .466 0.13 .208 -.307 .759 
BRSK2 CpG4 (3-months) -0.07 .508 -1.15 .249 0.08 .451 -.471 .638 -0.15 .149 -0.21 .040* 0.11 .292 0.18 .086 -1.05 .295 





        
  
BRSK2 CpG3 (6-months) -0.02 .866 -.607 .544 -0.00 .990 -.291 .771 -0.15 .141 -0.26 .012* 0.09 .385 0.20 .058 -.272 .786 
BRSK2 CpG4 (6-months) 0.00 .967 -.898 .369 0.02 .860 -.768 .443 -0.10 .335 -0.22 .034* 0.08 .434 0.24 .020* -.232 .816 





        
  
ADCYAP1 CpG1&2 (baseline) -0.40 .698 -1.43 .154 0.02 .834 -1.34 .179 0.04 .670 -0.07 .513 0.14 .163 0.19 .063 -.548 .583 
                   
ADCYAP1 CpG1&2 (3-months) -0.15 .314 -2.13 .034* 0.11 .488 -1.22 .221 0.28 .066 0.09 .559 0.00 .967 0.12 .269 -.703 .482 
                   
ADCYAP1 CpG1&2 (6-months) -0.14 .162 -.060 .952 -0.11 .306 -1.22 .223 0.02 .815 0.04 .698 0.15 .136 -0.10 .314 -.380 .704 
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CHAPTER 5: SUPPLEMENTARY MATERIAL 
 
Supplementary tables for the main effect of FKBP5 methylation 
Supplementary Table 1: CpG1 methylation levels and covariates predicting PTSD at 3-months 
post-rape 
 ß Std 
error 
t p 95% CI 
   Lower               Upper 
      
CpG1 (3-months) -0.68 0.32 -2.14 .035* -1.32 -0.05 
rs1360780 6.38 6.47 0.99 .327 -6.50 19.26 
Childhood trauma (baseline) 1.58 0.95 1.66 .102 -0.32 3.47 
Depression (baseline) -0.10 0.24 -0.42 .678 -0.57 0.38 
Alcohol consumption (baseline) -0.89 1.28 -0.70 .487 -3.43 1.65 
       
* p < .05 
 
Supplementary Table 2: CpG1 methylation levels and covariates predicting PTSD at 6-months 
post-rape 
 ß Std 
error 
t p 95% CI 
   Lower               Upper 
      
CpG1 (6-months) -0.04 0.30 -0.14 .889 -0.65 0.56 
rs1360780 7.69 6.71 1.15 .255 -5.67 21.04 
Childhood trauma (baseline) 0.46 0.94 0.49 .628 -1.42 2.34 
Depression (baseline) 0.55 0.24 2.24 .028* 0.06 1.04 
Alcohol consumption (baseline) -2.07 1.32 -1.57 .121 -4.71 0.56 
       
* p < .05 
 
Supplementary Table 3: CpG2 methylation levels and covariates predicting PTSD at 6-months 
post-rape 
 ß Std 
error 
t p 95% CI 
   Lower               Upper 
      
CpG2 (6-months) -0.15 0.42 -0.36 .718 -0.99 0.69 
rs1360780 7.85 6.60 1.19 .238 -5.29 21.00 
Childhood trauma (baseline) 0.41 0.93 0.44 .664 -1.45 2.26 
Depression (baseline) 0.55 0.24 2.27 .026* 0.07 1.04 
Alcohol consumption (baseline) -2.03 1.32 -1.53 .130 -4.66 0.61 
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Supplementary Table 4: CpG5 methylation levels and confounding variables predicting PTSD at 
6-months post-rape 
 ß Std 
error 
t p 95% CI  
   Lower               Upper 
      
CpG5 (6-months) -0.82 0.36 -2.29 .025* -1.53 -0.11 
rs1360780 5.98 6.53 0.92 .363 -7.02 18.97 
Childhood trauma (baseline) 0.39 0.90 0.43 .668 -1.40 2.17 
BMI (baseline) -0.04 0.53 -0.07 .945 -1.10 1.02 
Medication use (baseline) 14.12 6.89 2.05 .044* 0.40 27.83 
       
* p < .05 
Abbreviations: body mass index (BMI) 
 
 
Supplementary Table 5: CpG5 methylation levels and covariates predicting PTSD at 6-months 
post-rape 
 ß Std 
error 
t p 95% CI 
   Lower              Upper 
      
CpG5 (6-months) -0.70 0.35 -1.98 .051 -1.40 0.00 
rs1360780 7.04 6.36 1.11 .272 -5.62 19.70 
Childhood trauma (baseline) 0.31 0.90 0.34 .734 -1.49 2.11 
BMI (baseline) -0.34 0.53 -0.65 .521 -1.40 0.72 
Medication use (baseline) 14.06 6.78 2.07 .042* 0.55 27.57 
Depression (baseline) 0.47 0.24 1.92 .059 -0.02 0.95 
Alcohol consumption (baseline) -2.28 1.30 -1.76 .083 -4.86 0.30 
       
* p < .05 
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Supplementary tables for the main effect of childhood trauma 
Supplementary Table 6: Childhood trauma and covariates (including CpG1 methylation) 
predicting PTSD at baseline 
 ß Std 
error 
t p 95% CI 
   Lower               Upper 
      
CpG1 (baseline) -0.01 0.19 -0.03 .977 -0.37 0.36 
rs1360780 -2.58 4.17 -0.62 .539 -10.89 5.73 
Childhood trauma (baseline) 1.66 0.70 2.37 .021* 0.26 3.05 
Depression (baseline) 0.67 0.15 4.52 .00002* 0.38 0.97 
Alcohol consumption (baseline) -1.68 0.83 -2.02 .047* -3.34 -0.02 
       
* p < .05 
 
Supplementary Table 7: Childhood trauma and covariates (including CpG2 methylation) 
predicting PTSD at baseline 
 ß Std 
error 
t p 95% CI 
   Lower               Upper 
      
CpG2 (baseline) -0.33 0.24 -1.40 .166 -0.80 0.14 
rs1360780 -3.67 4.09 -0.90 .372 -11.81 4.47 
Childhood trauma (baseline) 1.43 0.68 2.08 .041* 0.06 2.79 
Depression (baseline) 0.63 0.14 4.43 .00003* 0.35 0.92 
Alcohol consumption (baseline) -1.05 0.84 -1.25 .215 -2.72 0.62 
       
* p < .05 
 
Supplementary Table 8: Childhood trauma and covariates (including CpG3 methylation) 
predicting PTSD at baseline 
 ß Std 
error 
t p 95% CI 
   Lower              Upper 
      
CpG3 (baseline) -0.22 0.18 -1.21 .230 -0.58 0.14 
rs1360780 -2.37 4.07 -0.58 .563 -10.48 5.74 
Childhood trauma (baseline) 1.68 0.69 2.43 .018* 0.30 3.05 
Depression (baseline) 0.68 0.15 4.67 .00001* 0.39 0.97 
Alcohol consumption (baseline) -1.70 0.81 -2.09 .040* -3.33 -0.08 
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Supplementary Table 9: Childhood trauma and covariates (including CpG4 methylation) 
predicting PTSD at baseline 
 ß Std 
error 
t p 95% CI 
   Lower              Upper 
      
CpG4 (baseline) -0.40 0.28 -1.44 .154 -0.95 0.15 
rs1360780 -2.84 4.04 -0.70 .485 -10.88 5.21 
Childhood trauma (baseline) 1.62 0.69 2.34 .021* 0.25 2.99 
Depression (baseline) 0.69 0.14 4.77 .000008* 0.40 0.98 
Alcohol consumption (baseline) -1.71 0.81 -2.11 .038* -3.32 -0.10 
       
* p < .05 
 
Supplementary Table 10: Childhood trauma and covariates (including CpG5 methylation) 
predicting PTSD at baseline 
 ß Std 
error 
t p 95% CI 
   Lower              Upper 
      
CpG5 (baseline) 0.07 0.23 0.30 .765 -0.38 0.52 
rs1360780 -2.58 4.19 -0.62 .539 -10.93 5.76 
Childhood trauma (baseline) 1.66 0.70 2.36 .021* 0.26 3.05 
Depression (baseline) 0.68 0.15 4.62 .00002* 0.39 0.98 
Alcohol consumption (baseline) -1.64 0.82 -1.99 .050 -3.28 0.00 
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Supplementary table for the interaction effect between methylation and childhood trauma 
Supplementary Table 11: Comparison of correlations between methylation and PTSD for the 
groups with low vs high childhood trauma 
 n % r p PTSD 
M             SD 
z p 
         
CpG1 & PTSD (baseline) 84 100     -0.36 .359 
     Low childhood trauma 42 50 -.132 .405 61.96 3.06   
     High childhood trauma 42 50 -.051 .750 71.17 3.06   
         
CpG2 & PTSD (baseline) 84 100     -0.20 .419 
     Low childhood trauma 42 50 -.189 .230 62.06 2.93   
     High childhood trauma 42 50 -.144 .365 71.53 2.94   
         
CpG3 & PTSD (baseline) 84 100     0.64 .263 
     Low childhood trauma 42 50 -.033 .835 61.77 3.07   
     High childhood trauma 42 50 -.175 .269 71.23 3.07   
         
CpG4 & PTSD (baseline) 85 100     0.54 .295 
     Low childhood trauma 43 50.6 .002 .990 61.66 3.05   
     High childhood trauma 42 49.4 -.119 .451 71.17 3.08   
         
CpG5 & PTSD (baseline) 85 100     0.59 .277 
     Low childhood trauma 43 50.6 .069 .658 61.62 3.05   
     High childhood trauma 42 49.4 -.064 .688 71.37 3.09   
















Stellenbosch University  https://scholar.sun.ac.za
413 
 
Supplementary tables for the interaction effect between methylation, rs1360780 genotype and 
childhood trauma 
Supplementary Table 12: Correlation between methylation and PTSD: comparison of childhood trauma 
and genotype subgroups 
 N % r p PTSD 
M           SD 
z p 
        
CpG1 & PTSD (baseline) 42 100     0.32 .376 
     Low childhood trauma & CC genotype 14 33.3 -.040 .892 65.82 5.33   
     Low childhood trauma & CT/TT genotype 28 66.7 -.153 .436 59.88 3.77   
CpG1 & PTSD (baseline) 41 100     -0.40 .345 
     High childhood trauma & CC genotype 13 31.7 -.187 .541 72.51 5.68   
     High childhood trauma & CT/TT genotype 28 68.3 -.040 .838 70.04 3.79   
         
CpG2 & PTSD (baseline) 43 100     0.90 .183 
     Low childhood trauma & CC genotype 14 32.6 .180 .557 67.87 5.94   
     Low childhood trauma & CT/TT genotype 29 67.4 -.142 .462 59.77 3.52   
CpG2 & PTSD (baseline) 41 100     -1.00 .160 
     High childhood trauma & CC genotype 13 31.7 -.434 .138 74.75 5.26   
     High childhood trauma & CT/TT genotype 28 68.3 -.092 .641 69.66 3.56   
         
CpG3 & PTSD (baseline) 42 100     0.61 .271 
     Low childhood trauma & CC genotype 14 33.3 .180 .538 65.24 5.40   
     Low childhood trauma & CT/TT genotype 28 66.7 -.039 .846 60.04 3.80   
CpG3 & PTSD (baseline) 41 100     -8.70 .000* 
     High childhood trauma & CC genotype 13 31.7 -.575 .040* 74.30 5.58   
     High childhood trauma & CT/TT genotype 28 68.3 -.003 .989 69.37 3.79   
         
CpG4 & PTSD (baseline) 43 100     -0.01 .497 
     Low childhood trauma & CC genotype 14 32.6 .031 .916 65.62 5.34   
     Low childhood trauma & CT/TT genotype 29 67.4 .034 .861 59.58 3.74   
CpG4 & PTSD (baseline) 41 100     0.40 .345 
     High childhood trauma & CC genotype 13 31.7 -.075 .808 74.09 5.54   
     High childhood trauma & CT/TT genotype 28 68.3 -.221 .259 69.22 3.80   
         
CpG5 & PTSD (baseline) 43 100     1.40 .081 
     Low childhood trauma & CC genotype 14 32.6 .347 .224 65.84 5.35   
     Low childhood trauma & CT/TT genotype 29 67.4 -.139 .471 59.21 3.73   
CpG5 & PTSD (baseline) 41 100     -5.89 .000* 
     High childhood trauma & CC genotype 13 31.7 -.825 .001** 73.87 5.72   
     High childhood trauma & CT/TT genotype 28 68.3 .057 .774 69.60 3.79   
         
CpG1 & PTSD (6-months) 42 100     -0.98 .164 
     Low childhood trauma & CC genotype 14 33.3 -.362 .204 21.05 7.70   
     Low childhood trauma & CT/TT genotype 28 66.7 -.026 .894 26.70 5.95   
CpG1 & PTSD (6-months) 41 100     0.10 .461 
     High childhood trauma & CC genotype 13 31.7 .117 .703 20.54 8.16   
     High childhood trauma & CT/TT genotype 28 68.3 .081 .681 29.57 5.71   
         
CpG2 & PTSD (6-months) 42 100     0.17 .432 
     Low childhood trauma & CC genotype 13 31.0 -.066 .829 20.22 7.74   
     Low childhood trauma & CT/TT genotype 29 69.0 -.129 .505 27.95 6.20   
CpG2 & PTSD (6-months) 41 100     -1.27 .103 
     High childhood trauma & CC genotype 13 31.7 -.165 .590 23.10 7.73   
     High childhood trauma & CT/TT genotype 28 68.3 .298 .124 28.25 5.70   
         
         
CpG3 & PTSD (6-months) 41 100     1.44 .075 
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     Low childhood trauma & CC genotype 13 31.7 .382 .178 20.54 7.99   
     Low childhood trauma & CT/TT genotype 28 68.3 -.136 .489 26.54 5.98   
CpG3 & PTSD (6-months) 41 100     -1.36 .087 
     High childhood trauma & CC genotype 13 31.7 -.047 .878 23.05 7.82   
     High childhood trauma & CT/TT genotype 28 68.3 .432 .022* 28.64 5.66   
         
CpG4 & PTSD (6-months) 43 100     -0.13 .448 
     Low childhood trauma & CC genotype 14 32.6 .196 .503 19.66 7.77   
     Low childhood trauma & CT/TT genotype 29 67.4 .241 .207 26.44 5.96   
CpG4 & PTSD (6-months) 41 100     -0.80 .212 
     High childhood trauma & CC genotype 13 31.7 -.269 .375 23.87 7.76   
     High childhood trauma & CT/TT genotype 28 68.3 .023 .909 29.77 5.74   
         
CpG5 & PTSD (6-months) 43 100     1.80 .036* 
     Low childhood trauma & CC genotype 14 32.6 .316 .271 23.05 7.62   
     Low childhood trauma & CT/TT genotype 29 67.4 -.309 .103 26.80 5.82   
CpG5 & PTSD (6-months) 41 100     -0.04 .483 
     High childhood trauma & CC genotype 13 31.7 -.140 .648 20.19 7.64   
     High childhood trauma & CT/TT genotype 28 68.3 -.124 .530 28.59 5.50   
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Supplementary Table 13: Methylation, rs1360780 genotype and childhood trauma interaction 
with covariates predicting PTSD at baseline 
 ß Std 
error 
t p 95% CI 
   Lower                Upper 
      
CpG3 (baseline) 
*rs1360780*childhood trauma 
-0.00 0.00 -0.39 .698 -0.01 0.00 
Depression (baseline) 0.72 0.15 4.87 .000006* 0.43 1.02 
Alcohol consumption (baseline) -1.14 0.82 -1.40 .167 -2.77 0.49 
       
* p < .05 
 
Supplementary Table 14: Methylation, rs1360780 genotype and childhood trauma interaction 
with confounding variables predicting PTSD at baseline 
 ß Std 
error 
t p 95% CI 
   Lower                Upper 
      
CpG5 (baseline) 
*rs1360780*childhood trauma 
0.00 0.00 -0.58 .564 -0.01 0.01 
BMI (baseline) 0.29 0.37 0.80 .428 -0.44 1.03 
Medication use (baseline) -5.88 4.60 -1.28 .205 -15.04 3.28 
       
* p < .05 
Abbreviations: body mass index (BMI) 
 
 
Supplementary Table 15: Methylation, rs1360780 genotype and childhood trauma interaction 
with covariates predicting PTSD at baseline 
 ß Std 
error 
t p 95% CI 
   Lower                Upper 
      
CpG5 (baseline) 
*rs1360780*childhood trauma 
0.00 0.00 -0.15 .885 -0.01 0.01 
BMI (baseline) -0.03 0.33 -0.09 .925 -0.69 0.63 
Medication use (baseline) -6.03 4.08 -1.48 .143 -14.15 2.09 
Depression (baseline) 0.74 0.15 4.90 .000005* 0.44 1.04 
Alcohol consumption (baseline) -0.98 0.82 -1.20 .235 -2.62 0.65 
       
* p < .05 














































A STUDY ON WOMEN’S HEALTH AND 
WELL-BEING  
INFORMED CONSENT 
RECRUITED AT ______________________ 
INTRODUCTION 
Hello, welcome to our clinic.  You are being invited to take part in the women’s health and well-being 
study.  It is a study that the Medical Research Council is conducting with women in Durban on women’s 
health and wellbeing.   We want to learn more about women’s health so we can help the Government 
in better planning of their services so that they can meet women’s health needs.  
We also want to have a better understanding about women’s physical and mental health problems, 
how long these problems last, what causes them, and what social factors and life experiences affect 
them, whether the problems persist and if the problems require treatment. We are also very 
interested to know how experiences of violence affect women’s health. In addition, we want to get a 
better understanding on how women heal after being hurt.  
This is an information and consent form, and we are inviting women between the ages of 18 – 40 years 
who attend Thuthuzela Care Centre/Rape Centres after they have been sexual assaulted. One of the 
primary reasons for doing this research is to understand the health problems that women who have 
been raped experience. Your participation in our research will not influence the health care that you 
receive at the Thuthuzela Care Centre/Rape Centres or your case. We will not ask you questions about 
the rape experience or the circumstances of the incident. We will ask about other sexual violence 
experiences. We understand that these questions might bother you and we will stop and can always 
ask these same questions at a later interview. However, we will also be prepared to help you if you 
need to speak to someone.  
This study will be done over a period of three years and we will speak to women on repeat occasions. 
This means that you will be invited to come to the research clinic and have interviews done every 3 
months.  At each study visit we will ask you some interview questions, we will also ask you to give us 
permission to do some blood tests and tests on your urine as well as to provide a swab. We will explain 
more about this later. This means we will have to remain in contact so that we can invite you to return 
for the follow-up interviews over the three years.   
 
IS MY PARTICIPATION VOLUNTARY IN THIS STUDY  
This form gives you information about the study and what will be expected of you. Once you have 
read and understood and agree to participate, you will then be asked to sign your name on this 
form. You will be given a copy of this form to keep. It is important that you know that your 
participating is voluntary, and you are free to withdraw from the study at any point, even after you 
have agreed to take part.  
 
 WHAT HAPPENS IF I DECIDE TO PARTICPATE IN THE STUDY? 
If you agree to participate in the study, then we will start with your baseline visit today. You will see 
and talk to both of us (nurse and research assistant) today.  We will start by explaining in more detail 
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about the procedures that will take place today and we will answer questions before you sign the 
informed consent for us to continue. The nurse will see you first and will do health assessments 
including the understanding of how you cope, taking of your blood pressure, your pulse, your weight 
and provide advice on healthy living. You will then be seen by the other researcher and she will ask 
questions about yourself, your relationships with husbands and boyfriends and other health questions 
sexual and reproductive health matters, as well as questions about experiences of violence.  There will 
be some questions about things which are often thought of as secrets. Let us know if you feel 
uncomfortable about these questions. At the end the nurse will take blood, urine and hair samples 
and will give you the answers to the tests as soon as we get them and will discuss your health with 
you.  Everything that you tell the interviewer will be kept secret and you have the right not to answer 
any questions that you do not wish to answer. The answers to the questions will be entered on a 
computer and we expect the interviews with the two of us to take about 2 hours. We will also refer 
you to the health clinics if we think it is necessary.   
 
WHAT ARE THE PROCEDURES IN THIS STUDY? 
If you are interested in being part of this study, the following will take place: 
The Research assistant start by using a biometric system to log her on the study data entry system.  A 
biometric system allows researchers to use her fingerprint to identify her every time she returns to 
the clinic. Her fingerprint will be linked to a number and this number will be used to store the 
information and this will ensure her information remains safe and confidential.  The reason why we 
need to identify her fingerprint each time she visit the clinic is the study is over a long period of time, 
the patients’ information can get mixed up so by entering your details with your study number it 
prevents your information getting mixed up with another participant’s information.   We will ask you 
to give us permission to use the biometric system in a separate informed consent that you will sign.   
A study nurse will do a mental health assessment as well as a screen for high blood pressure as we 
explained earlier.  
The research assistant will then do an interview asking the questions as we explained earlier, and she 
will enter this on the computer as she speaks with you.  
Hair sample- We will ask you to allow us to collect about 6-8 strands of hair between 3-6 cm.  We will 
take it from the back of the head, close to the scalp and we will do it at each visit. We aware that this 
might upset your hairstyle and we have a person here that will ensure that your hair is not disarranged. 
She will make sure that your hair looks exactly the same again after we taken the hair sample. The hair 
samples will be sent to a special laboratory in Germany where they will be examined and will provide 
us information about levels of stress we experience. The reason why it must be done in Germany is 
because we in South Africa do not have the machines and the equipment to examine it here. Because 
our hair grows slowly it will allow us to examine the levels of stress over the previous 2 months. Finding 
the levels of stress is very useful as it will assist us in coping better with stressful events in our lives. 
We will provide you with the test result as soon as we get it. We will be very careful about how we 
take the hair. In order to take a hair sample, the following will be important: 
• Your hair must be longer than 3 cm 
• You must not have any signs of hair loss or baldness 
• You do not have had a severe physical disease in the last 5 years 
• You have not been taking anti-depressants in the last 6 months 
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We will then collect some samples to screen your health as part of the study to answer the questions 
we have about women’s health at each time when you are interviewed. The following are tests and 
samples that we plan to collect at the screening visit as well as all study visits thereafter:  
• Urine test- we will require a sample of your urine to test for pregnancy. We will give you the 
result as soon as it has been tested in the lab here at the clinic. This test will be done every 
time you visit.  
• Swab from your vulva – this is to test for infections passed through sex. This test is done by 
taking a smear from vagina. This is similar to a pap smear test, but we do not use instruments 
and the nurse will assist you and show you how to do it. You will do it in private. The results 
will be given and discussed with you as soon as it comes back from the laboratory. This test 
will be done every time you visit. 
• Blood tests- Blood will be collected from you for various tests.   This will be done by the nurse 
and we will collect about 4-5 teaspoons of blood at each study visit.  
We will collect the blood for the following:  
• To test for diabetes, cholesterol levels, kidney and heart diseases in blood. Women who 
experience stress and mental problems may be more likely to develop heart cardiovascular 
disease risk factors such as diabetes, high cholesterol and related kidney problems. We 
would like to test for diabetes and cholesterol (fat) levels in blood as well as any related 
kidney problems. We would also like to test for other indicators (signs) of heart disease in 
the blood. This is a very common illness and it is often hidden. We will also test for fat in 
your blood which can contribute to heart disease. We will also give you the test results once 
we receive it from the laboratory. This test only be done on 3 of the visits.  
• To test for infections that passed through sex, including herpes infection and HIV. We will 
inform you of your STI test results and whether any treatment is needed.  If treatment is 
needed, we will assist you in receiving treatment.  
• HIV test: you will receive counselling before the HIV test and also after the test.  You will be 
told the HIV result as soon as it is available. The nurse will speak to you about the meaning 
of the results, how you feel, and ways to prevent HIV and other sexually transmitted 
infections. Sometimes the HIV test is not clear and in this case, we will do an additional test 
until we confirm your results for sure. We will discuss the repeat test with you and what this 
means. The result will be kept secret. The information will be kept by the Medical Research 
Council and the people who see it will not know your name. The information will not be 
given to anyone else who may come to learn that we have it. We will ask you to give us 
permission to do the HIV test at each study visit in a separate informed consent. This test 
will be done every 3 months. 
• If you are HIV positive, we will also do a CD4 test.  By measuring the CD4 cells in your body 
we can determine the progression of the HIV.  CD4 cells are cells that give us information on 
how well our immune system is working and they tell us when a person should start with 
anti-retroviral therapy (HIV treatment). If you are on HIV treatment, we will also measure 
the viral load as this tells us how well the treatment is working. We will measure these every 
six months during the research, and we will give you the outcome of the test result and help 
you to understand what it means.   We will also refer you to your local health care clinic to 
get the necessary treatment. This test will be done at each visit depending on if you are HIV 
positive. 
• P24 Antigen Test: If you seroconvert during the study- this means you become HIV positive 
during the period of this study then we will do a special test called a p24 antigen test which 
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will tell us information on how long ago the infection happened. This May mean that we have 
to prick you again as we only know that your HIOV status has changed after testing the blood.  
 
• Herpes test: We will also test the blood for herpes (1 teaspoon), which is a virus that can cause 
you to have painful ulcers around your vagina, although in many people who are infected 
there is little pain. This is an important virus as people who have it are at greater risk of 
catching HIV if they have sex with a person who is HIV positive. We want to test to see if you 
have this. We will give you the test result as soon as we get it back from the laboratory and 
we will help you to understand the result. This test will be done every time you visit. 
• Genetic research - We will take a blood sample (about 2 teaspoons) to examine the genes in 
your blood.  
What is Genetic research?  Genetic material, also called DNA or RNA, is usually obtained from 
a small blood sample. Genes are found in every cell in the human body.  Our genes determine 
what we look like, such as the colour of our eyes or how tall we will grow.  Sometimes, genes 
also give us information about what kind of diseases we may be susceptible to, such as heart 
disease or diabetes.  Worldwide, researchers in the field of genetics are continuously 
discovering new information that may be of great benefit to future generations and also that 
may benefit people today, who suffer from particular diseases or conditions. Some factors in 
our environment can bring about changes in our genes and we are particularly interested to 
know about changes in the genes that will affect our ability to cope. We will ask you to give 
us permission to take a sample of blood for genetic testing at each study visit in a separate 
informed consent. This test will not be done on every visit.  
• Storage of left-over specimens – If you agree to participate in the study and agree to have the 
above blood specimens taken we will ask you to allow us to store the left over samples such 
as left over blood. These left-over samples might be useful for future related studies and we 
will use it to look for additional evidence of disease progression. For example, we may further 
look at your genes.  We will store this in a safe place called a repository.  Nobody will have 
access to this left-over blood sample other than the study researchers and it will not be used 
unless the blood can be used in a study approved by the Ethics committee. We plan to keep 
this left-over blood sample for 10 years and it will be destroyed after 10 years if it is not used.  
There are no names on any of the specimens, only a special study number. The people who 
run the repository and the scientists who later use the specimens will not know your name or 
any other information about you that might identify you.  You may decide that you do not 
want your left-over blood samples stored for future research studies.  You can still participate 
in this study even if you make this decision, any leftover specimens from you will be destroyed 
at the end of the study.  People always have the right to stop participating in research. So, if 
you decide that you do not want researchers to be able to use the left-over specimens in the 
repository, you can contact the clinic staff. They will tell the repository that the specimens 
with your study code number should not be studied, and these specimens will be destroyed. 
There are no direct benefits to you from storing your left-over specimens.  You may be helping 
people in the future from the results of studies using the stored specimens. All these 
specimens are being collected as part of the RICE study in which you are participating.  We are 
not asking you to give any additional specimens for storage, so there is no additional risk 
associated with collection.  The specimens are stored only by code number (not your name) 
so there is no risk of loss of privacy. 
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Will you get told your results? 
You will not normally get the result of the genetic testing as these tests are experimental. Also, the 
blood samples from all participants will be de-identified and analysed together and not individually. 
While the genetic test will not benefit you directly, the research may benefit people who have 
experienced a traumatic event in the future. In addition, the tests done on the samples of blood 
stored may not be ready for many years.  Your personal results will be made known to you only 
under special circumstances and only if they indicate that you may: 
• have a definite risk for developing a particular disorder 
• have a condition or predisposition to developing a condition that is treatable or avoidable, 
e.g. by a lifestyle modification 
• need genetic counseling. 
When this happens, you will be supported by the staff at the genetic clinic who are experts in helping 
people understand these diseases. It is however very unlikely that this will happen as such diseases 
are rare.  
The same apply for results from tests done on the stored blood samples. If the researcher’s findings 
could provide important information for your medical care, then they will contact the research staff 
at your site with the results, and the staff at your clinic can link the code with your name and notify 
you of the results.  If you would like to be contacted with this sort of information, you must notify 
the study staff of any changes in your address or phone number.  
 
We will ask you to give us permission to store the blood at each study visit in a separate informed 
consent.  
WHAT ARE THE BENEFITS TO ME IF I PARTICIPATE IN THIS STUDY 
The main benefit will be in gaining information about your physical and mental health. If we detect 
that you have any mental or physical health problems, with your permission, we will refer you to 
your local health care facility for treatment. It is very beneficial for you to learn your HIV status, if 
you are negative you can make decisions to protect yourself to make sure you remain negative. If 
you are positive it is important to know so you can get on treatment as soon as you need it and can 
look after yourself. If you have sexually transmitted infections, we will find this out on the day of 
your visit and we will treat you for this infection, it is important to know so these can be treated as 
otherwise you may develop other health problems or become infertile. It is also very useful to know 
early if you are pregnant so you can receive early care.   
 
Benefits for society 
It is very important for South Africa women that we understand their health better and can plan 
health services that can properly meet their physical and mental health needs. In order to do this 
effectively it is necessary to have information about what places at women at risk of health 
problems and how great this risk is. By participating in this study, you will be playing an important 
role in helping us build this knowledge. 
WHAT ARE THE RISKS? 
There are no major medical risks involved with participating in this study.  Some of the questions 
may make you feel sad, especially when we ask about experiences of violence, but the study staff 
will give you support if this happens. There should not be a risk that your private information 
becomes known to anyone because the study staff will use a special project ID number to identify 
you and the information you provide. All the staff involved in this study have been given special 
training on the importance of confidentiality. Some of the women in the study have been invited for 
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the interviews because they experienced trauma and violence in their lives and some of them have 
not. Only the interviewer will know whether you have been invited because of violence in your life, 
no one else will know this.  
 
WHAT ARE THE COSTS TO ME? 
There is no cost to you for participating in this study.  Y You will be given R80 at the baseline visit and 
at every visit thereafter you will receive an increment of R20 to compensate for time spent 
completing the questionnaire and giving the samples. You will also be given money to cover travel 
costs for each of the visits and we will provide you with a snack every time you come for the 
interviews. 
 
WHAT IF I CHANGE MY MIND AFTER JOINING THE STUDY? 
At any stage you may change your mind and no longer participate. You can then stop participating 
and will not be punished in any way for this. 
 
INSURANCE FOR THE STUDY PROVIDED BY THE MEDICAL RESEARCH COUNCIL 
If you fall ill, suffer any side effects or if you are injured in any study related manner, contact the 
researchers immediately at the numbers provided below. The MRC, as sponsors of this study has taken 
out the necessary insurance to cover you as a research participant.  
 
WHO CAN I ASK IF THERE ARE ANY PROBLEMS WITH THE STUDY? 
Principal Investigator 
Dr Naeemah Abrahams 
Deputy Director 
Gender & Health Research Unit, Medical Research Council 
Cape Town Office  
TEL: 021 9380823 
FAX: 021 9380310 
CELL 082 461 7542 
Email: naeemah.abrahams@mrc.ac.za 
 
Project Coordinator  
Alesha Sewnath 
Gender & Health Research Unit, Medical Research Council 
Gender & Health Research Unit, Medical Research Council 
RICE study- RK Khan Hospital, Chatsworth, Durban 
TEL: 031 242 3721 
Email: alesha.sewnath@mrc.ac.za 
Study Office: Tel: 031 2423720 
 
For questions about your rights as the research participant, contact: 
Chairperson: The MRC Research Ethics Committee 
Prof. Danie du Toit 





Email: adri.labuschagne@mrc.ac.za  




MAIN STUDY SIGNATURE PAGE 
I declare that: - 
 
•    I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. I have had a chance to ask questions and all my questions 
have been adequately answered. 
 
•    I understand that taking part in this study is voluntary and I have not been pressurised to take 
part.  
 
I DO AGREE to join the study.   
_________________________   




I DO NOT AGREE to join the study.   
_________________________ 
Participant’s Signature /Initial  
  
 
_________________________  __________________________  ________ 
Participant’s Signature    Signature         Date 
                                  
 
__________________________  __________________________  ________ 




__________________________   __________________________            _________ 
  Witness Name                   Signature                       Date 
 





STORAGE OF LEFT OVER BLOOD SPECIMEN SIGNATURE PAGE 
I declare that: - 
 
•   I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. I have had a chance to ask questions and all my questions 
have been adequately answered. 
•   I understand that taking part in this study is voluntary and I have not been pressurized to take 
part. 
 
I DO AGREE for the left over blood specimens to be stored and used for future tests as discussed in 
this consent form.  
_________________________ 




I DO NOT AGREE to have any of my left over blood specimens to be stored in the repository for use 
in studies in future. 
 
__________________________ 




__________________________  __________________________               _________ 
 Participant’s Name   Signature                   Date 
 
 
__________________________  __________________________  ________ 




__________________________  __________________________           _________ 
Witness Name                  Signature                        Date 
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I declare that: - 
 
•   I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. I have had a chance to ask questions and all my questions 
have been adequately answered. 
 
•   I understand that taking part in this study is voluntary and I have not been pressurized to take 
part. 
 
I DO AGREE to the collection of my hair sample as discussed in this consent form. 
 _________________________ 









_________________________  __________________________                 _________ 




_________________________  __________________________       ________ 





__________________________         __________________________          _________ 
   Witness Name                                 Signature                       Date 
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A STUDY ON WOMEN’S HEALTH AND WELL-BEING  





 You have decided to participate in the Women’s Health and Well Being Study.  In addition to the tests 
taken as part of the study, we are now asking you permission to take a fingerprint scans for our 
biometric systems. We have two systems the one is to ensure that there is no duplication of your 
results in our study and the second scan is to check if you are not participating in another study. It is 
important for us to know if you are with another study as it is not always safe to do so. 
 
You are free to ask questions about this study at any time and, if you agree, you will be asked to sign 
this consent form.  You will get a copy to keep. Your participation is entirely voluntary, and you are 
free to decline to participate. If you say no, this will not affect you negatively in any way whatsoever. 
Remember you are also free to withdraw from the study at any point, even if you do agree to take 
part initially.  
 
This research study has been approved by the Medical Research Council of South Africa (MRC) Ethics 
Committee. 
 
WHAT PROCEDURES WILL BE INVOLVED IN THIS RESEARCH? 
We are asking you if we can do two scans of your fingerprints.  This procedure is harmless and will not 
hurt you in any way.  For the fingerprint scan, we will check to see if you are already on another study. 
The second fingerprint scan will be saved, and it will be linked to your unique identifier on the 
computer for the study. There will not be a picture of your thumbprint, but the computer will change 
the thumb print into a code. The code will then be printed into barcodes and this will be linked to your 
unique identifier number. These barcodes will then be placed on all your blood samples and your study 
file.  In addition, whenever you return for follow-up visits, we will use the scanning of your thumb 
print to ensure we do not mix you up with someone else and also to make sure you are not with 
another study.  
 
This is a longitudinal study, meaning that this study will be taking place over a long period of time, and 
sometimes studies that take place over a long period of time, patient samples and information gets 
misplaced. Using this system, we are making sure we link you to the samples without using your name. 
This is a precautionary measure that we will be taking in this study.     
 
WHAT ABOUT CONFIDENTIALITY? 
There will never be a picture of your thumb print. All fingerprints done for each participant will be 
stored as a code and under a unique identifier number.  No one will know what your unique identifier 
is except the researchers working on the study.  
 
WHAT IF I DO NOT WANT TO USE THE BIOMETRIC SYSTEM?  
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WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
 
For questions about this study, contact: 
Principal Investigator 
Dr Naeemah Abrahams 
Deputy Director, Gender & Health Research Unit, Medical Research Council 
Cape Town: Office: 031 242 3688, CELL 082 461 7542 
Email: naeemah.abrahams@mrc.ac.za 
 
Project Coordinator  
Alesha Sewnath 
Gender & Health Research Unit, Medical Research Council 
RICE study: RK Khan Hospital, Chatsworth, Durban 
TEL: 031 242 3721 
Email: alesha.sewnath@mrc.ac.za 
 
For questions about your rights as the research participant, contact: 
Chairperson: The MRC Research Ethics Committee 
Prof. Moodley 
Medical Research Council,  





































I declare that: - 
 
•    I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. I have had a chance to ask questions and all my questions 
have been adequately answered. 
 
 
•    I understand that taking part in this study is voluntary and I have not been pressurized to take part.  
 
 
I DO AGREEE  to have my fingerprint used for the two biometric systems. 
 
_______________________ 







I DO NOT AGREE to have my fingerprint used for the two biometric systems.   
  
_______________________ 
Participant’s Signature/Initial  
 
 
_________________________  __________________________  _________ 
Participant’s Name    Signature               Date 
 
 
__________________________  __________________________  ________ 
Name of Study Staff Conducting   Signature    Date 
Consent Discussion 
 
__________________________  __________________________           _______ 
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A STUDY ON WOMEN’S HEALTH AND WELL-BEING 




You have decided to participate in the Women’s Health and Well Being Study.  As part of the study 
procedures, you will be asked to do an HIV Test. Like all the other tests that will be done in this study, 
there will be no names on any of the specimens, only a special study number.   
You are free to ask questions about this study at any time and, if you agree, you will be asked to sign 
this consent form.  You will get a copy to keep. Your participation is entirely voluntary and you are 
free to decline to participate. If you say no, this will not affect you negatively in any way whatsoever. 
Remember you are also free to withdraw from the study at any point, even if you do agree to take 
part initially.  
This research study has been approved by the Medical Research Council of South Africa (MRC) Ethics 
Committee. 
 
 WHAT ARE MY RIGHTS? 
You have the following rights: 
1. Not to be tested for the AIDS virus without your free and informed consent. 
2. To be given all relevant information on the harms, risks and benefits of taking, or not taking,  
 the HIV test. 
3.  To receive pre-test counselling which is private and confidential, and which will inform you 
 more about the test and its implications before you give consent.   
5. To have your test result treated confidentially 
6. To receive post-test counselling  
 
IS THE TEST ALWAYS CORRECT?  CAN THERE BE MISTAKES? 
Even though the tests are very accurate, if your test result shows that you may be infected with the 
AIDS virus, we will have this confirmed by doing some additional tests. 
Sometimes, a false positive result may occur in a small number of cases.  A false positive means that 
the test shows positive when the person is not infected with the virus, by doing further tests we can 
see if the test is really a positive.  The clinic staff and the laboratories follow a strict procedure to 
prevent these potential mistakes. In order to minimize false positive results, two different tests are 
performed. 
 
WHAT DOES IT MEAN IF THE TEST IS NEGATIVE? 
If your test result is negative, it means that you are not currently infected, but it does not mean that 
you may not become infected in the future.   
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WHAT DOES IT MEAN IF THE TEST IS POSITIVE? 
If your test result is positive, it means that you may be infected with the AIDS. However, to be sure, 
we will do an additional two tests to confirm the result.  You will be called back to the research clinic 
and our research nurse will discuss the information with you so that you can understand clearly 
what the test result means.  You will be given your CD4 and viral load and referred to your local clinic 
for further HIV management.   
 
WHAT ABOUT TESTING AT HOME 
When you struggle to attend the clinic, we will try and visit you at home to hear how we can assist 
you to come to the clinic. If you unable to attend the clinic we will ask you if we can do a finger prick 
HIV test at your home. We will follow all the confidential procedures as explained above. 
 
WHAT ARE THE COSTS TO ME? 
There is no direct cost to you for having an HIV test done. 
 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
 
For questions about this study, contact: 
Principal Investigator 
Dr Naeemah Abrahams 
Deputy Director, Gender & Health Research Unit, Medical Research Council 
Cape Town: Office: 031 242 3688, CELL 082 461 7542 
Email: naeemah.abrahams@mrc.ac.za 
 
Project Coordinator  
Alesha Sewnath 
Gender & Health Research Unit, Medical Research Council 
RICE study: RK Khan Hospital, Chatsworth, Durban 
TEL: 031 242 3721 
Email: alesha.sewnath@mrc.ac.za 
 
For questions about your rights as the research participant, contact: 
Chairperson: The MRC Research Ethics Committee 
Prof. Moodley 
Medical Research Council,  









HIV TESTING SIGNATURE PAGE(Adult) 
 
 
I declare that: - 
 
•    I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. I have had a chance to ask questions and all my questions 
have been adequately answered. 
 




I DO AGREEE to have a HIV test 
 
_______________________ 









_________________________  __________________________         _________ 
Participant Name   Signature                         Date 
 
__________________________  __________________________         _________ 




_________________________                __________________________           _________ 
       Witness Name                 Signature                           Date 
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 A STUDY ON WOMEN’S HEALTH AND WELL-BEING  




 You have decided to participate in the Women’s Health and Wellbeing study.  In addition to the tests 
taken as part of the study, we are now asking you permission to collect some of your blood for a study 
that involves DNA (Genetic) analysis.   
You are free to ask questions about this study at any time and, if you agree, you will be asked to sign 
this consent form.  You will get a copy to keep. Your participation is entirely voluntary and you are 
free to decline to participate. If you say no, this will not affect you negatively in any way whatsoever. 
You are also free to withdraw from the study at any point, even if you do agree to take part initially.  
This research study has been approved by the ethics Committee of the Medical Research Council of 
South Africa (MRC). 
 
WHAT PROCEDURES WILL BE INVOLVED IN THIS RESEARCH? 
A small blood sample (about 10-20 ml, equivalent to 1-2 tablespoons) will be taken from you by a 
trained nurse. Bloods will not be taken every time you visits us.  The blood will be transported to a 
laboratory, where researchers will examine and identify your DNA from the blood sample. This sample 
will not be stored for later use but will be processed for immediate analysis and destroyed. The DNA 
sample will then help us to look for genetic differences and changes in your DNA. Findings these 
changes could tell us a lot about the development of stress-related mental health problems. 
 
WHAT ABOUT CONFIDENTIALITY? 
All blood samples collected will be identified only by a coded number and not your name to ensure to 
maintain confidentiality. The research records for this study will be kept in a secured area only 
accessible to the research team involved. 
 
WHAT DOES THIS PARTICULAR RESEARCH STUDY INVOLVE? 
In this study, we hope to be able to find genes that put a person at a higher risk for developing 
stress-related mental health problems, such as post-traumatic stress disorder (PTSD), depression 
and anxiety. We will do this by looking for changes in the genes and this will give us clues to the 
various factors that contribute to the development of these mental health problems.  
 
WHAT IS DNA ANALYSIS OR GENETIC RESEARCH? 
Genes are part of genetic material, also called DNA or RNA.  Genes can be found by looking at a small 
blood sample and can be found in every cell our bodies.  Our genes determine what we look like and 
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sometimes what kind of diseases we may be at risk in getting.  Worldwide, researchers who do genetic 
research are continuously discovering new information that may be of great benefit to future 
generations and to people who suffer from different types of diseases or conditions. Our study will 
therefore assist in bringing about this new information to show how changes in our genes may affect 
our health and ability cope. 
 
WHAT ARE THE RISKS TO ME IF I AGREE TO JOIN THIS STUDY? 
• You may experience minor pain or bruising at the site where blood is taken. Occasionally, 
some people experience fleeing dizziness or feel faint when their blood is drawn.    
• The samples collected will only be for this study and will not be shared with anyone. 
 
WHAT ARE THE BENEFITS TO ME IF I DECIDE TO JOIN THIS STUDY 
Your personal results will be made known to you only if they indicate that you may:-  
• Have a definite risk for developing a particular disorder. 
• Have a condition or predisposition to developing a condition that is treatable or avoidable e.g. 
by a lifestyle modification. 
 
There are no direct benefits to you taking part in this study.  However, the findings may benefit 
future patients with stress-related mental health problems.  This new information will provide us 
with a better understanding of the development of stress-related mental health problems and may 
result in the development of ways to lower the risk for these disorders, as well as helping us find 
new treatments.  
 
WHAT ARE THE COSTS TO ME? 
As explained earlier you will not be paid to take part in this study although you will be given R80 at 
each of the interviews to compensate for time spent completing the questionnaire and providing 
samples. You will also be given money to cover travel costs for each of the visits and we will provide 
you with a snack every time you come for the interviews. 
 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS? 
 




Dr Naeemah Abrahams 
Deputy Director, Gender & Health Research Unit, Medical Research Council 
Cape Town: Office: 031 242 3688, CELL 082 461 7542 
Email: naeemah.abrahams@mrc.ac.za 
 
Project Coordinator  




Gender & Health Research Unit, Medical Research Council 
RICE study: RK Khan Hospital, Chatsworth, Durban 
TEL: 031 242 3721 
 
For questions about your rights as the research participant, contact: 
 
Chairperson: The MRC Research Ethics Committee 
Prof. Danie du Toit 
Medical Research Council 
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GENETIC STUDIES SIGNATURE PAGE (adult)  
 
 
I declare that: - 
• I have read or had read to me this information and consent form and it is written in a language 
with which I am fluent and comfortable. I have had a chance to ask questions and all my questions 
have been adequately answered. 
•   I understand that taking part in this study is voluntary and I have not been pressurized to take 
part. 
 













__________________________  __________________________  _________ 
Participant’s Name                Signature                       Date 
 
 
_________________________  __________________________  _________ 
Name of Study Staff Conducting                 Signature   Date 
Consent Discussion 
 
__________________________  __________________________  __________ 
Witness Name                        Signature   Date 





Demographic and clinical characteristics of the rape impact cohort evaluation (RICE) 
group compared to the data subsets used in this study 
In Chapter 3 of this dissertation (risk and protective factors affecting the symptom trajectory 
of posttraumatic stress disorder post-rape) we present the findings from the RICE cohort with 
the exclusion of participants with posttraumatic stress disorder (PTSD) at baseline, due to a 
trauma other than the rape. When comparing the Chapter 3 subset to the entire RICE cohort, 
we found a number of significant differences in baseline demographic and clinical 
characteristics. The participants included in the subset had a slightly lower score on 
childhood trauma (mean difference = 0.04), social support (mean difference = 0.05), 
perceived stress (mean difference = 0.05), rape stigma (mean difference = 0.06) and PTSD 
score (mean difference = 4.4). Al of the aforementioned variables were measure on a Likert 
scale and given the small differences observed it is unlikely that they will be of clinical 
significance. The larger difference in PTSD scores may be of clinical significance and is 
likely the result of excluding participants with PTSD at baseline (due to an event other than 
the rape) from the Chapter 3 subset. The findings of the comparisons between the RICE 
cohort and the Chapter 3 subset is presented in Table 1. 
 In Chapter 4 of this dissertation (genome-wide differentially methylated genes 
associated with posttraumatic stress disorder and longitudinal change in methylation in rape 
survivors) we present the findings from a case-control subgroup (discovery/validation subset) 
selected by matching consecutive cases of PTSD to controls, based on baseline demographic 
and clinical characteristics. We also included a replication set selected based on the quality 
and availability of DNA samples (replication subset). Participants included in the 
discovery/validation subset were less likely to use chronic medication at baseline (mean 
difference = 2.7%) and showed decrease alcohol consumption at baseline (mean difference = 
0.04) compared to the entire RICE cohort (see Table 2). There were no significant differences 
in demographic and clinical characteristics between the replication sample and the entire 
RICE cohort (see Table 3). 
 In Chapter 4 and 5 (FKBP5 intron 7 methylation and the trajectory of PTSD 
symptoms in rape-exposed women) of this dissertation we present the findings from the 
combined discovery/validation and replication subsets. We found that participants included in 
the combined subset showed decreased alcohol consumption (mean difference = 0.07) at 
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baseline compared to the participants include in the entire RICE cohort. No other differences 
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Table 1: Baseline demographic and clinical characteristics of the RICE cohort compared to the 
chapter 3 subset 
 RICE cohort 
set (n=852) 
Chapter 3 subset 
(n=639) 
Comparison of RICE cohort 
to chapter 3 subset  
 n (%) M (SD) n (%) M (SD) χ2 z p 
        
Age¹ 852(100) 25.0(5.3) 639(100) 24.7(5.3)  -0.95 .344 
Secondary education completed² 484(56.8)  368(57.6)  0.09  .763 
Employed² 185(21.7)  138(21.6)  0.00  .957 
In a relationship/married² 664(78.0)  512(80.1)  0.91  .340 
BMI¹ 852(100) 26.0(6.3) 639(100) 25.9(5.3)  -0.02 .988 
Smoker² 125(14.7)  88(13.8)  0.25  .617 
HIV positive² 411(48.2)  297(46.5)  0.34  .558 
Chronic medication use²,3 475(55.8)  353(55.2)  0.04  .851 
        
Childhood trauma score¹ 852(100) 16.7(3.9) 639(100) 16.3(3.5)  -1.98 .047* 
Number of lifetime traumas¹,3 852(100) 1.5(1.5) 639(100) 1.4(1.4)  -1.22 .222 
Resilience score¹ 850(100) 50.8(6.4) 638(100) 50.5(6.3)  -0.76 .447 
Social support score¹ 850(100) 25.5(5.1) 638(100) 25.0(5.0)  -6.98 .000* 
Perceived stress score¹ 850(100) 24.1(4.9) 638(100) 23.6(4.6)  -9.70 .000* 
Rape stigma score¹ 850(100) 21.3(7.0) 638(100) 20.7(7.0)  -33.07 .000* 
Alcohol use severity¹ 852(100) 2.1(2.5) 639(100) 2.1(2.5)  -0.76 .446 
Depression symptom score¹ 852(100) 34.0(12.6) 639(100) 33.0(12.6)  -1.46 .146 
PTSD symptom score¹ 852(100) 71.9(31.7) 639(100) 67.5(31.0)  -2.18 .029* 
        
¹Continous variables; ²categorical variables; 3lifetime traumas refer to directly experiencing the 
trauma; *p < .05 
Abbreviations: Rape impact cohort study (RICE); mean (M); standard deviation (SD); body mass 
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Table 2: Baseline demographic and clinical characteristics of the RICE cohort compared to the 
chapter 4 discovery/validation subset 





Comparison of RICE  
cohort to chapter 4 
discovery/validation set 
 n (%) M (SD) n (%) M (SD) χ2 z p 
        
Age¹ 852(100) 25.0(5.3) 96(100) 25.2(5.4)  -1.23 .218 
Secondary education completed² 484(56.8)  57(59.4)  0.23  .630 
Employed² 185(21.7)  22(22.9)  0.92  .338 
In a relationship/married² 664(78.0)  76(79.2)  0.02  .896 
BMI¹ 852(100) 26.0(6.3) 96(100) 25.9(6.1)  -0.48 .633 
Smoker² 125(14.7)  12(12.5)  0.59  .442 
HIV positive² 411(48.2)  46(47.9)  2.02  .155 
Chronic medication use²,3 475(55.8)  51(53.1)  4.26  .039* 
Childhood trauma score¹ 852(100) 16.7(3.9) 96(100) 16.7(3.4)  -0.46 .644 
Number of lifetime traumas¹,3 852(100) 1.5(1.5) 96(100) 1.4(1.4)  -0.67 .501 
Resilience score¹ 850(100) 50.8(6.4) 96(100) 49.4(7.5)  -1.52 .129 
Social support score¹ 850(100) 25.5(5.1) 96(100) 24.6(5.1)  -1.17 .243 
Perceived stress score¹ 850(100) 24.1(4.9) 96(100) 23.7(4.3)  -0.98 .330 
Rape stigma score¹ 850(100) 21.3(7.0) 96(100) 20.9(7.2)  -0.74 .462 
Alcohol use severity¹ 852(100) 2.1(2.5) 96(100) 1.7(2.4)  -2.21 .027* 
Depression symptom score¹ 852(100) 34.0(12.6) 96(100) 32.0(13.0)  -0.68 .495 
PTSD symptom score¹ 852(100) 71.9(31.7) 96(100) 66.0(32.4)  -1.30 .195 
        
¹Continous variables; ²categorical variables; 3lifetime traumas refer to directly experiencing the 
trauma; *p < .05 
Abbreviations: Rape impact cohort study (RICE); mean (M); standard deviation (SD); body mass 
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Table 3: Baseline demographic and clinical characteristics of the RICE cohort compared to the 
chapter 4 replication subset 
 RICE cohort 
(n=852) 
Chapter 4 replication 
set (n=49) 
Comparison of RICE cohort 
to chapter 4 replication set 
 n (%) M (SD) n (%) M (SD) χ2 z p 
        
Age¹ 852(100) 25.0(5.3) 49(100) 24.6(5.5)  -0.75 .454 
Secondary education completed² 484(56.8)  25(51)  0.71  .400 
Employed² 185(21.7)  9(18.4)  0.34  .560 
In a relationship/married² 664(78.0)  38(77.6)  0.01  .934 
BMI¹ 852(100) 26.0(6.3) 49(100) 25.8(5.7)  -0.25 .801 
Smoker² 125(14.7)  7(14.3)  0.01  .935 
HIV positive² 411(48.2)  19(38.8)  1.87  .172 
Chronic medication use²,3 475(55.8)  32(65.3)  1.90  .168 
Childhood trauma score¹ 852(100) 16.7(3.9) 49(100) 16.2(2.5)  -0.62 .534 
Number of lifetime traumas¹,3 852(100) 1.5(1.5) 49(100) 1.1(1.2)  -1.66 .098 
Resilience score¹ 850(100) 50.8(6.4) 49(100) 50.1(6.9)  -0.03 .980 
Social support score¹ 850(100) 25.5(5.1) 49(100) 24.6(4.7)  -1.14 .253 
Perceived stress score¹ 850(100) 24.1(4.9) 49(100) 24.2(3.7)  -0.19 .850 
Rape stigma score¹ 850(100) 21.3(7.0) 49(100) 21.4(7.1)  -0.01 .994 
Alcohol use severity¹ 852(100) 2.1(2.5) 49(100) 1.9(2.5)  -0.67 .501 
Depression symptom score¹ 852(100) 34.0(12.6) 49(100) 31.6(12.1)  -1.26 .208 
PTSD symptom score¹ 852(100) 71.9(31.7) 49(100) 67.1(30.3)  -1.20 .230 
        
¹Continous variables; ²categorical variables; 3lifetime traumas refer to directly experiencing the 
trauma; *p < .05 
Abbreviations: Rape impact cohort study (RICE); mean (M); standard deviation (SD); body mass 
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Table 4: Baseline demographic and clinical characteristics of the RICE cohort compared to the 
chapter 4 and 5 combined subset 
 RICE cohort 
set (n=852) 
Chapter 4&5 
combined set (n=96) 
Comparison of RICE  
cohort to chapter 4&5 
combined set 
 n (%) M (SD) n (%) M (SD) χ2 z p 
        
Age¹ 852(100) 25.0(5.3) 47(100) 25.9(5.4)  -0.32 .750 
Secondary education completed² 484(56.8)  32(68.1)  0.23  .630 
Employed² 185(21.7)  13(27.7)  0.07  .787 
In a relationship/married² 664(78.0)  38(80.9)  0.07  .798 
BMI¹ 852(100) 26.0(6.3) 47(100) 26.0(6.5)  -0.50 .616 
Smoker² 125(14.7)  5(10.6)  0.33  .563 
HIV positive² 411(48.2)  27(57.4)  0.00  .952 
Chronic medication use²,3 475(55.8)  19(40.4)  0.25  .615 
        
Childhood trauma score¹ 852(100) 16.7(3.9) 47(100) 17.2(4.1)  -0.12 .906 
Number of lifetime traumas¹,3 852(100) 1.5(1.5) 47(100) 1.6(1.5)  -0.69 .488 
Resilience score¹ 850(100) 50.8(6.4) 47(100) 48.8(8.2)  -1.09 .278 
Social support score¹ 850(100) 25.5(5.1) 47(100) 24.7(5.5)  -1.64 .101 
Perceived stress score¹ 850(100) 24.1(4.9) 47(100) 23.2(4.9)  -0.36 .716 
Rape stigma score¹ 850(100) 21.3(7.0) 47(100) 20.3(7.3)  -0.27 .785 
Alcohol use severity¹ 852(100) 2.1(2.5) 47(100) 1.4(2.2)  -2.21 .027* 
Depression symptom score¹ 852(100) 34.0(12.6) 47(100) 32.4(13.9)  -1.37 .172 
PTSD symptom score¹ 852(100) 71.9(31.7) 47(100) 64.9(34.7)  -1.59 .112 
        
¹Continous variables; ²categorical variables; 3lifetime traumas refer to directly experiencing the 
trauma; *p < .05 
Abbreviations: Rape impact cohort study (RICE); mean (M); standard deviation (SD); body mass 
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